ChinaNationalAccordMedicinesCorporationLtd.
Semi-AnnualReport2021
August2021
SectionI.ImportantNotice,ContentsandInterpretationBoardofDirectors,SupervisoryCommittee,alldirectors,supervisorsandseniorexecutivesofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)herebyconfirmthattherearenoanyfictitiousstatements,misleadingstatements,orimportantomissionscarriedinthisreport,andshalltakeallresponsibilities,individualand/orjoint,forthereality,accuracyandcompletionofthewholecontents.LinZhaoxiong,PrincipaloftheCompany,GuGuolin,personinchargerofaccountingworksandWangYing,personinchargeofaccountingorgan(accountingprincipal)herebyconfirmthattheFinancialReportofSemi-AnnualReport2021isauthentic,accurateandcomplete.AlldirectorsareattendedtheBoardMeetingforreportdeliberation.TheCompanyplansnottopaycashdividends,bonusandcarryoutcapitalizingofcommonreserves.
Contents
SectionIImportanNotice,ContentsandInterpretation ...... 2
SectionIICompanyProfileandMainFinancialIndexes ...... 6
SectionIIIManagementDiscussionandAanalysis ...... 9
SectionIVCorporateGovernance ...... 31
SectionVEnviornmentalandSocialResponsibility ...... 33
SectionVIImportantEvents ...... 37
SectionVIIChangesinSharesandParticularaboutShareholders ...... 70
SectionVIIIPreferredStock ...... 76
SectionIXCorporateBonds ...... 77
SectionXFinancialReport ...... 78
DocumentsAvailableforReference
I.Thefinancialstatementscarriedwiththesignatureandsealsoflegalrepresentative,personinchargerofaccountingworksandpersoninchargeofaccountingorgan;II.OriginaltextofalldocumentsoftheCompanyaswellasthemanuscriptoftheannouncementdisclosedinthereportingperiodonJuchaoWebsite.III.TextoftheSemi-AnnualReport2021bearingthesignatureofthelegalrepresentative.
Interpretation
Items | Refersto | Contents |
ListedCompany,Company,theCompany,SinopharmAccord,theGroup | Refersto | ChinaNationalAccordMedicinesCorporationLtd. |
SINOPHARM | Refersto | ChinaNationalAccordMedicinesCorporationLtd. |
SinopharmHolding | Refersto | SinopharmGroupCo.,Ltd,ControllingshareholderoftheCompany |
CompanyLaw | Refersto | CompanyLawofthePeople’sRepublicofChina |
SecuritiesLaw | Refersto | SecuritiesLawofthePeople’sRepublicofChina |
Yuan,10thousandYuan,100millionYuan | Refersto | RMB,RMB10thousand,RMB100million |
Terminology: | Refersto | |
4Dbusiness | Refersto | SPDhospitallogisticssupplychainextensionbusiness,IVDdiagnosticreagentbusiness,CSSDdisinfectionservice,andMWDequipmentlifecyclemanagementbusiness |
GPO | Refersto | Grouppurchasingorganizations |
Abbreviation: | Refersto | |
SinopharmHoldingGuangzhou | Refersto | SinopharmHoldingGuangzhouCo.,Ltd. |
GuodaDrugstore | Refersto | SinopharmHoldingGuodaDrugstoreCo.,Ltd. |
SinopharmHoldingGuangxi | Refersto | SinopharmHoldingGuangxiCo.,Ltd. |
ChinaNationalZhijun | Refersto | ChinaNationalZhijun(Shenzhen)PharmaceuticalCo.,Ltd. |
ZhijunPharmacyTrade | Refersto | ShenzhenZhijunPharmacyTradeCo.,Ltd. |
ZhijunPingshan | Refersto | ChinaNationalZhijun(Shenzhen)PingshanPharmaceuticalCo.,Ltd. |
MainLuckPharmaceuticals | Refersto | ShenzhenMainLuckPharmaceuticalsInc. |
SectionIICompanyProfileandMainFinancialIndexesI.Companyprofile
Shortformofthestock | SinopharmAccord,AccordB | Stockcode | 000028,200028 |
Stockexchangeforlisting | ShenzhenStockExchange | ||
NameoftheCompany(inChinese) | 国药集团一致药业股份有限公司 | ||
ShortformoftheCompany(inChineseifapplicable) | 国药一致 | ||
ForeignnameoftheCompany(ifapplicable) | ChinaNationalAccordMedicinesCorporationLtd. | ||
ShortformofforeignnameoftheCompany(ifapplicable) | SinopharmAccord | ||
Legalrepresentative | LinZhaoxiong |
II.Person/Waytocontact
SecretaryoftheBoard | |
Name | ChenChangbing |
Contactadd. | AccordPharm.Bldg.,No.15,BaGuaSiRoad,FutianDistrict,Shenzhen,GuangdongProvince |
Tel. | +(86)75525875195 |
Fax. | +(86)75525195435 |
gyyzinvestor@sinopharm.com |
III.Others
1.WayofcontactWhetherregistrationsaddress,officesaddressandcodesaswellaswebsiteandemailoftheCompanychangedinreportingperiodornot
□Applicable√NotapplicableRegistrationsaddress,officesaddressandcodesaswellaswebsiteandemailoftheCompanyhasnochangeinreportingperiod,foundmoredetailsinAnnualReport2020.
2.InformationdisclosureandpreparationplaceWhetherinformationdisclosureandpreparationplacechangedinreportingperiodornot
□Applicable√NotapplicableThenewspaperappointedforinformationdisclosure,websiteforsemi-annualreportpublishappointedbyCSRCandpreparationplaceforsemi-annualreporthavenochangeinreportingperiod,foundmoredetailsinAnnualReport2020IV.MainaccountingdataandfinancialindexesWhetherithasretroactiveadjustmentorre-statementonpreviousaccountingdata
□Yes√No
Currentperiod | Sameperiodoflastyear | Increase/decreaseinthisreporty-o-y(+,-) | |
Operatingrevenue(RMB) | 33,163,091,887.39 | 27,169,940,188.52 | 22.06% |
NetprofitattributabletoshareholdersofthelistedCompany(RMB) | 741,445,013.25 | 643,451,580.59 | 15.23% |
NetprofitattributabletoshareholdersofthelistedCompanyafterdeductingnon-recurringgainsandlosses(RMB) | 720,954,408.22 | 627,017,019.45 | 14.98% |
Netcashflowarisingfromoperatingactivities(RMB) | 1,229,373,283.57 | 1,438,204,043.35 | -14.52% |
Basicearningspershare(RMB/Share) | 1.73 | 1.50 | 15.33% |
Dilutedearningspershare(RMB/Share) | 1.73 | 1.50 | 15.33% |
WeightedaverageROE | 5.22% | 4.91% | Increase0.31percentagepoints |
Endofcurrentperiod | Endoflastperiod | Increase/decreaseinthisreport-endoverthatoflastperiod-end(+,-) | |
Totalassets(RMB) | 44,190,878,403.95 | 39,594,533,471.65 | 11.61% |
NetassetsattributabletoshareholderoflistedCompany(RMB) | 14,346,870,065.79 | 13,948,322,652.33 | 2.86% |
V.DifferenceoftheaccountingdataunderaccountingrulesinandoutofChina
1.Differenceofthenetprofitandnetassetsdisclosedinfinancialreport,underbothIAS(InternationalAccountingStandards)andChineseGAAP(GenerallyAcceptedAccountingPrinciples)
□Applicable√NotapplicableTheCompanyhadnodifferenceofthenetprofitornetassetsdisclosedinfinancialreport,undereitherIAS(InternationalAccountingStandards)orChineseGAAP(GenerallyAcceptedAccountingPrinciples)intheperiod.
2.Differenceofthenetprofitandnetassetsdisclosedinfinancialreport,underbothforeignaccountingrulesandChineseGAAP(GenerallyAcceptedAccountingPrinciples)
□Applicable√Notapplicable
TheCompanyhadnodifferenceofthenetprofitornetassetsdisclosedinfinancialreport,undereitherforeignaccountingrulesorChineseGAAP(GenerallyAcceptedAccountingPrinciples)intheperiod.VI.Itemsandamountsofextraordinaryprofit(gains)/loss
√Applicable□Notapplicable
InRMB
Item | Amount | Note |
Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets) | -802,029.11 | Mainlyprobabilityofgainandlossesfromtheendoflease. |
Governmentalsubsidycalculatedintocurrentgainsandlosses(whilecloselyrelatedwiththenormalbusinessoftheCompany,excludingthefixed-amountorfixed-proportiongovernmentalsubsidyaccordingtotheunifiednationalstandard) | 35,363,341.68 | MainlyprobabilityofexemptionandothergovernmentgrantsforspecialpurposeandfinanceDiscount. |
Investmentcostswhileacquiringsubsidiaries,jointventuresandassociatedenterprise,lessthanfairvalueoftheidentifiablenetassetsfrominvestedenterprisewhichshouldbeenjoined | 578,610.41 | |
Switchbackofprovisionfordepreciationofaccountreceivableandcontractualassetsthatareindividuallytestedforimpairment | 88,994.76 | |
Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems | 7,540,783.96 | Mainlyprobabilityofthenonoperatingincomegeneratedfromthewriteoffoffundsthatdonotneedtobepaidinthecurrentperiod. |
Othergains/lossessatisfyadefinitionofextraordinarygains/losses | 1,717,435.90 | |
Less:Impactonincometax | 12,962,326.01 | |
Impactonminorityshareholders’equity(post-tax) | 11,034,206.56 | |
Total | 20,490,605.03 | -- |
Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss
SectionIIIManagementDiscussionandAnalysisI.MainbusinessesofthecompanyinthereportingperiodInthereportingperiod,themainbusinessofSinopharmAccordincludespharmaceuticaldistributionandpharmaceuticalretail,specificallyasfollows:
(i)Inthepharmaceuticaldistributionfield,thecompanycontinuestointegratethedistributionandlogisticsbusiness,deeplypenetratesintotheendmarkets,improvesthesteppeddistributionnetwork,createsintelligentsupplychain,anddevotestobecomeaproviderforpharmaceuticalandhealthcareproductsandserviceswiththestrongestinfluence,thehighestshare,themostcompletevariety,thebestservice,andthefastestdeliveryinsouthdistrictofChina.
1.TheCompany’spharmaceuticaldistributionbusinessisestablishedinGuangdongandGuangxi,thecompanyhascompletedthenetworkconstructionofGuangdongandGuangxiin2013,andthebusinesshasextendedtothecounty-levelregions;in2014,weacceleratingtheintegrationofthree-tiercompaniesandtheCompanyachievedanoperationalloverthenetworkin2015.Thenetworkfurtherexpandedin2019andmaindevelopmentdirectionisretailterminals.AsofJune30,2021,in2021,thereare1,061secondaryandtertiarymedicalinstitutionsinoperation;6,564primarymedicalcarecustomersinoperation;and4,947retailterminalcustomers(includingchaindrugstores,singlestoresandhospitalself-payingpharmacies)inoperation.
2.TheCompany’spharmaceuticaldistributionbusinesshasachievedthefirstscaleinGuangdongandGuangxi;TheGuangdongandGuangxiregionshavesubdividedtheformatmarkets,pharmaceuticaldistributionandapparatusconsumables,retaildirectsalesandretaildiagnosisandtreatment,medicalinstrumentlinkage,retaildevelopment,andtheentireindustrybusinessmaintainsarelativelyleadingpositionintheindustry;innovativebusinesscontinuestodevelopnewcustomercooperationmodelsandbecomeamedicalsupplychainmanagementsolutionandserviceproviders;improvenationallogisticsplanningandconstruction,providethird-partylogisticsprofessionalservices,andcreateleadinglogisticsandsupplychainservicecapabilities.(ii)Inthepharmaceuticalretailfield,GuodaDrugstoreisaleadingpharmaceuticalretailenterpriseinsalesscalethroughoutthecountry,andisoneofthefewenterprisesinChinawithnationaldirectsalesdrugretailnetwork.AsofJune30,2021,GuodaDrugstorehasoperated8,439stores,covering20provinces,autonomousregionsandmunicipalities,enteringnearly155largeandmediumsizedcities,whichhasformedadrugstorenetworkscoveringnortheast,easternChina,northernChinaandsoutherncoastalcities,andgraduallyexpandedintonorthwest,centralplainsandinlandcities;Guodadrugstore,thebusinessofwhichweremainlyrelyingonsocialretaildrugstores,hasbeenputtinggreatattentiononthedevelopmentofprofessionalservicesystemwithmedicalresourcesascorecompetitiveness,buildingagroupofstoreswithprofessionalcommercialactivities,whichare
abletoprovideretailsandtherapyservicesthatintegratingmedicalserviceandhealth-careproductssalesandcooperatewithhospitals;atthesametime,theCompanyhasbeenvigorouslydevelopingnewbusiness,exploringandexpandingnewsaleschannels,improvingprofessionalservices,beingdedicatedtotransitfromatraditionalmedicalretailintoaninnovativeserviceenterprise.Bymeansofconventionalproductsretailmanagement,improvingmajorbrandsandexploringbusinesscooperationwithsupplier,acceleratingtheestablishmentandimprovementofDTPbusinessandcontinuationofhealthcareservicesystem,Guodahasbuiltindustry-leadingprofessionalserviceability.TheCompanycomplieswiththedisclosurerequirementofInformationDisclosureGuidelinesfortheShenzhenStockExchangeNo.8-ListingCompanyEngagedinRetailingIndustry(i)BusinessmodeofGuodaDrugstoreThemainbusinessofGuodaDrugStoreisthepharmaceuticalretailchainandthedrugwholesaleanddistributionbusinessforthefranchisestoresandthememberstores,amongwhichthepharmaceuticalretailchainisthecompany'scorebusiness.
(1)Retailbusinessismainlydividedintotwobusinessmodels,i.e.directoperationandfranchiseoperation.ThemainbusinessscopeincludesChineseandWesternpatentmedicines,healthfood,Chineseherbalmedicines,medicaldevicesandothercommodities,amongwhichthepharmaceuticalsalesrevenueofdirectchainstoresisthemainincomesource.Specifically,thecompanypurchasesanddeliversthecommoditiestodirectchainstores,andthestoressellthecommoditiestoend-consumersundertheunifiedpricingpoliciesandmarketingstrategiesformulatedbythecompany.Inaddition,inordertobroadenthesaleschannelsandexpandtherangeofstoreservices,thecompanymeetsconsumers'demandsforonlinedrugpurchasethroughthecombinationofB2CandO2O.Franchisechainoperationisthattheleadingenterpriseauthorizesthefranchiseestouseitsowntrademark,tradename,businessmodel,etc.intheformoffranchisecontract.Thefranchiseeengagesinbusinessactivitiesundertheunifiedbusinessmodelsoftheleadingenterpriseandpayscorrespondingcoststotheleadingenterprise.
(2)Wholesaleanddistributionbusinessoffranchisestores:Thecompanyadoptsthemodelof"centralizedpurchasefromsuppliers,wholesaletosubsidiariesandthirdparties".Thecompany'swholesalebusinesscanfurtherutilizethecompany'scommodityagentadvantages,logisticsanddistributioncapacity,strengthenthecompany'sbusinesscontactswithsmallandmedium-sizedpharmaceuticalwholesalecompanies,smallandmedium-sizedchainpharmacies,drugstores,whichisahelpfulsupplementtothecompany'sretailbusiness.(ii)Thebusinesssituationofretailstoresduringthereportingperiod:
1.AsofJune30,2021,GuodaDrugStorehas8,439stores,including6,890direct-salestores,salesrevenuereaching(excludingtaxes)7862millionyuan;1,549franchisestores,distributionincomereaching(excludingtaxes)651millionyuan.
Region | Direct-salestore | Franchisedoutlet | ||
Numbers | Salesrevenue(in10thousand | Numbers | Distributionrevenue(in10 |
Yuan) | thousandYuan) | |||
North | 4,428 | 488,113 | 640 | 30,263 |
EastChina | 1,014 | 122,450 | 607 | 27,825 |
SouthChina | 497 | 76,422 | 158 | 3,802 |
CentralChina | 310 | 28,277 | 142 | 3,232 |
Northwest | 322 | 49,521 | 2 | 24 |
Southwest | 319 | 21,436 | - | - |
Total | 6,890 | 786,219 | 1,549 | 65,146 |
Note:North:Liaoning,Shanxi,InnerMongolia,Beijing,Tianjin,Hebei,Jiling;EastChina:Shanghai,Jiangsu,Anhui,Shandong,Fujian,Zhejiang;SouthChina:Guangdong,Guangxi;CentralChina:Henan,Hunan;Northwest:Ningxia,Xinjiang;Southwest:Yunnan
2.Infirsthalfof2021,therewere632direct-salestoresopenedand168storesclosed,anetincreaseofdirect-salestoresof464.
Region | Direct-salestore | Franchisedoutlet | |||
Numberofstoreincreased | Totalarea(squaremeters) | Numberofstoresshutdown | Numberofstoreincreased | Numberofstoresshutdown | |
North | 421 | 44,735 | -87 | 106 | -10 |
EastChina | 81 | 8,064 | -41 | 24 | -16 |
SouthChina | 41 | 4,272 | -20 | 17 | -27 |
CentralChina | 23 | 2,276 | -11 | 7 | -2 |
Northwest | 35 | 3,758 | -8 | 2 | - |
Southwest | 31 | 3,829 | -1 | - | - |
Total | 632 | 66,933 | -168 | 156 | -55 |
3.MedicalinsurancequalificationofthestoresAsofJune30,2021,theCompanyhas6,890chainstoreswithdirectlyselling,and5,958pharmacystoresobtainedthequalificationof“Designatedretailpharmaciesofmedicalinsurance”,representing86%ofthetotalpharmaciesoftheCompany.
Region | Numberofstores | Storesobtainedthequalificationof“Designatedretailpharmaciesofmedical | Ratiointotalpharmaciesin |
insurance” | regions | ||
North | 4,428 | 3,955 | 89% |
EastChina | 1,014 | 779 | 77% |
SouthChina | 497 | 427 | 86% |
CentralChina | 310 | 246 | 79% |
Northwest | 322 | 275 | 85% |
Southwest | 319 | 276 | 87% |
Total | 6,890 | 5,958 | 86% |
4.Top10storesintermsofoperatingrevenueThecumulativeoperatingrevenuefromtop10storestakes8.7%intheCompany’soveralloperatingrevenue.
Nameofthestore | Address | Dateofopening | Operationmode | Propertyownership |
SinopharmHebeiLerentangMedicineChainCo.,Ltd.(GeneralStore) | Shijiazhuang | September2010 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstoreInnerMongoliaCo.,Ltd.(GeneralStore) | Hohhotcity | March2003 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstoreShanxiYiyuanChainCo.,Ltd.(ZhongliStore) | Taiyuan | September2002 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstoreShanxiYiyuanChainCo.,Ltd.(EryuanStore) | Taiyuan | February2011 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstore(Shenzhen)ChainCo.,Ltd.(ShowroomStore) | Shenzhen | December2006 | Directlyoperated | Rentalproperties |
BeijingJinxiangPharmacyChainCo.,Ltd.(XidanJinxiangPharmacy) | Beijing | May1997 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstoreYangzhouDadeshengChainCo.,Ltd.(YangzhouBaiyulanMedicineShop) | Yangzhou | September1991 | Directlyoperated | Rentalproperties |
FujianGuodaDrugstoreChainCo.,Ltd.(XiamenNewSpecialDrugStore) | Xiamen | March2005 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstore(Shenzhen)ChainCo.,Ltd.(Buxinvillagebranch) | Shenzhen | April2017 | Directlyoperated | Rentalproperties |
SinopharmHoldingGuodaDrugstore(Shenzhen)ChainCo.,Ltd.(LianhuaNorthBranch) | Shenzhen | December2003 | Directlyoperated | Rentalproperties |
5.Operatingefficiencyofdirect-salestoresinreportingperiod
Region | Numberofstores | Operatingareaofthestores(squaremeters) | Dailyaverageefficiency(tax-included,Yuan/SquareMeters) | Rentalefficiency(tax-included,annualsalesvolume/rental) |
North | 4,428 | 555,915 | 49 | 14 |
EastChina | 1,014 | 127,251 | 53 | 13 |
SouthChina | 497 | 55,310 | 76 | 16 |
CentralChina | 310 | 36,215 | 43 | 13 |
Northwest | 322 | 38,396 | 71 | 27 |
Southwest | 319 | 38,861 | 30 | 15 |
Note:Dailyaverageefficiency=Averagedailyoperatingincome/Operatingareaofthestores;Averagedailyoperatingrevenue=Operatingrevenue(tax-included)ofthestoreintheYear/OperatingdaysofstoreintheYear.Rentalefficiency=Annualsalesvolume/Yearlyrental
6.Structureofthecategoryatretailterminal
Category | Firsthalfof2021 | Firsthalfof2020 |
Healthcareproducts | 4.7% | 6.5% |
Conveniencefood | 0.8% | 0.9% |
RxDrug | 54.5% | 52.9% |
OTC | 25.3% | 27.2% |
TraditionalChinesemedicine | 3.9% | 5.7% |
Personalcare | 1.1% | 1.2% |
Homeconvenience | 0.2% | 0.3% |
Householdhealthproducts | 5.3% | 5.0% |
Proportionofothercategories | 4.1% | 0.2% |
7.Purchasingandsupplies:
GoodssuppliersofGuodaDrugstorearemainlyexternalsuppliersandassistaffiliatedenterpriseofSINOPHARMandprivatebrands.Topfivesuppliersforyearof2021:
Ranking | Purchaseamount(taxincluded)(10thousandyuan) | Procurementratio |
No.1 | 10,300 | 7.5% |
No.2 | 6,753 | 4.9% |
No.3 | 6,109 | 4.4% |
No.4 | 4,530 | 3.3% |
No.5 | 4,345 | 3.2% |
8.MembermanagementandservicebusinessThesalesfrommembershipaccountedfor67%inthefirsthalfof2021,increase6%fromfirsthalfyearof2020.Meanwhile,inthefirsthalfof2021,numberoftransactionshave53%uponay-o-ybasis.Theproportionofmembertransactionsintotaltransactionsincreasedfrom55%lastyearto64%.Thenumberofmembertransactionsmaintainsasteadygrowthintheprocessofcontinuousimprovementinsales,whichplayedakeysupportingroleinthesteadyimprovementofthecompany'sperformance.
9.WarehousingandlogisticsduringthereportingperiodBythefirsthalfof2021,GuodaDrugstorehas33logisticsdistributioncentersacrossthecountry,withatotalconstructionareaofmorethan180,000squaremeters,whichisusedforthestorageandcirculationofnormaltemperature,cool,andrefrigeratedgoods.Thereare176transportvehicles,withanaveragedailyoperationofmorethan280,000items,and27,000customerboxes,thedeliveryamountismorethan52million,andthecompany'soveralllogisticsannualdistributionboxesexceed9millionpieces.
10.On-linesalesinthePeriodInthefirsthalfof2021,theO2Orevenuefromdirectlysalesstoreswas255millionyuan,ay-o-yincreaseof122%.
II.Corecompetitivenessanalysis
1.StrongnetworkcoverageandlayoutRelyingontheperfectnetworkandrichvarietyresources,SinopharmAccordhascompletedrugdistributionnetworksinGuangdongandGuangxiProvincesbasedonwholesaleandretailintegration,andthesaleshaveresultedinsolidgrowthovertheyears.andallagesaleshavegrownintheyears.Duetothenationalretailnetworklayout,thescalecontinuestobeinthelead.DrugdistributionbusinesscoversbothGuangdongandGuangzhou,including44distributionbusinesssubsidiariesin35prefecture-levelcitiesinGuangdongandGuangzhou(excludingGuangdongLogistics,ShenzhenLogisticsandGuangxiLogistics),whichfullycoversmedicalinstitutionsatalllevels,smallsocialhospitalsandretailchainsinglestoreterminals;RetaildiagnosisandtreatmentbusinesscoverstheDTPandpharmaciesnexttothehospitals(GuodaDrugStore),reaching109stores.Nationwidelayoutofretailbusiness:SinopharmAccordhasthelarge-scaleGuodaDrugStoreretailchainnetwork,covering20provinces,autonomousregionsandmunicipalities,enteringnearly155largeandmedium-sizedcities,formingapharmacynetworkcoveringNortheast,EastChina,NorthChina,SouthChinaandgraduallyexpandingintothenorthwest,centralplainsandtheinlandurbanagglomeration.
2.Richvarietyresources
Afteryearsofcultivation,thecompany'sdistributionbusinesshasrichvarietyresourcesinvariousfieldssuchasdrugs,andconsumables,andhasestablishedextensivecooperativerelationswiththousandsofdomesticmanufacturersandcommercialenterprises,andestablishedstablebusinessrelationshipswithhundredsofimportandjointventuremanufacturers,withoverallbusinessrangeofmorethan50,000productspecifications.GuodaDrugstoreoperatesnearly160,000merchandises.Withitsrelativelycomprehensivepurchasingnetworkandyearsofexperienceincommoditymanagement,GuodaDrugstorehasestablishedamerchandisesystemwithwidecoverage,highprofessionalization,andrichvarieties.
3.CompletelogisticsanddistributionsystemSinopharmAccorddistributionadoptssupplychainmanagementandwarehousemanagementsolutionssystem,equippedwith5large-scaleautomatedlogisticscenter,includingGuangzhou,Shenzhen,Foshan,NanningandLiuzhou,and15regionaldistributioncenters,andbecomingaladderlogisticsanddistributionnetworks.InGuangdongandGuangxi,itisthefirstenterprisethathasachievedthethird-partylogisticqualification,andhastheprofessionalpharmaceuticallogisticscapabilitieswiththelargestscale,themostextensivenetwork,andthemostcompletemodesinsouthdistrictofChina.GuodaDrugstoreownsanationwidemodernlogisticsanddistributionsystem,andthelogisticswarehousesarelocatedin20provinces,has33large-and-smalllogisticswarehouses,coveringmorethan180,000squaremeterswarehousesintotal.ThecompanyplanstocontinuetopromotethelogisticsintegrationinShanghaiandtheWanminmodernlogisticstransformationandupgradinginLiaoningandShanxisoastomeetthebusinessneedsofthe"14
th
Five-YearPlan"planningofGuodaDrugStore.
4.Unique-influenceSinopharmbrandBrandoftheCompanyanddistribution,industrychild-brandandcontrollingshareholderandactualcontroller’sbrandcomedowninonecontinuousline,dependingonpowerfulforceofcentralenterprises,theCompany’spopularityandinfluenceareprominentdaybydayintheindustry.
6.AdvantagesofwholesaleandretailintegrationSinopharmAccorddistributionhasavarietysalesnetworkdistributingtomedicalinstitutionsandretailpharmaciesinallcitiesandareasinGuangdongandGuangxiprovinces,realizingthemedicalinstrumentretaildevelopmentofretaildirectsales,retaildiagnosisandtreatment;carriesoutnationalchainexpansioncategorycooperationunderthe"Internet+"mode,promotestheresourcesupgradeandcooperationofchainO2Omode;promotesthesinglestoreterminaltoreplicate"MemberStoreMode"inGuangdongprovince;vigorouslyexpandstheDTPpharmacy+storesnexttohospitals,andbuildsacustomernetworktoundertakeprescriptionoutflowbyrelyingontheintroductionofhigh-valuespecialdrugs,prescriptiondrugsforchronicdiseasesandotheradvantages.
7.TechnologyenablingDrivenbydigitaltransformation,andbasedoninformationmanagementandcontrolsystemcooperatingsupplychainmanagement,SinopharmAccordcloselycombinesthebusiness,controlandlogisticsinformationsystemtoachieveseamlessconnectionsofeachlink,formingthefullchainconnectionofbusinessflow,logistics,capitalflowandinformationflow.
8.Createa4DbusinessservicemodelSinopharmAccorddistributioniscommittedtothetransformationinnovation,andvigorouslypromotestheSPDprojectlanding,formsregionaladvantagesandcoverageinGuangzhouandShenzhenandradiatesGuangdongandGuangxiprovinces,andtakesthelaunchedSPDprojectasabreakthrough,realizesthejointlaunchofSPD+IVDprojects,linksMEDandCSSDinnovationbusiness,takesadvantageofintegration,meanwhile,promotesthejointdevelopmentofsubsidiariesinGuangdongandGuangxiprovinces,andbecomesanindustry-leadingproviderofmedicalsupplychainmanagementsolutionsandservices.III.Mainbusinessanalysis
Introduction:
Inthefirsthalfof2021,undertheinfluenceoftheCOVID-19pandemic,centralizedprocurementofdrugs,andpricereductionofnegotiationdrugs,businessstructurehadin-depthchanges,andprofitmarginoftraditionalbusinesscontinuedtobereduced.SinopharmAccordtookvariousmeasuresunderthepressure,unswervinglypromotedthelandingof"14thFive-YearPlan"planning,focusedonwholesaleandretailintegrationtobuildbusinesscorecompetitiveness,technologyenergizedandbuiltsmartsupplychain,serviceupgradeacceleratedthetransformationtoleadinnovation-drivendevelopment,andcomprehensivelybuiltanewpatternofhigh-qualitydevelopment.Inthefirsthalfof2021,theCompanyhasaccumulatedoperatingrevenueof33163millionyuan,ay-o-ygrowthof22.06%;operatingprofitachieved1137millionyuanwith12.13%uponay-o-ybasis;thenetprofitamountedas908millionyuan,ay-o-yincreaseof12.62%andthenetprofitattributabletoshareholdersoflistedcompanywas741millionyuan,anincreaseof15.23%fromayearearlier.Inthefirsthalfof2021,SinopharmAccorddistributionbusinessachievedacumulativeoperatingincomeof
22.824billionyuan,withayear-on-yeargrowthof20.24%.Byovercomingtheimpactofthepandemiconmedicalinstitutions,ithasconsolidatedtheadvantagesofdirectsellingbusiness,andfurtherenhancedthecoverageofprimarymedicalinstitutions.Multiplebusinessformshaveachievedrapidgrowth,amongwhichdirectsalesrevenueofhospitalsreached14.415billionyuan,anincreaseof23.81%onayear-on-yearbasis;directsalesrevenueofothermedicalinstitutionsreached1.738billionyuan,anincreaseof20.98%onayear-on-yearbasis;directsalesrevenueofretailreached3.236billionyuan,anincreaseof10.21%onayear-on-yearbasis;instrumentconsumablesbusinessrevenuewas2.864billionyuan,withayear-on-yeargrowthof30.04%;andtherevenueofretaildiagnosisandtreatmentbusinesswas934millionyuan,anincreaseof23.27%onayear-on-year
basis.SinopharmAccorddistributionbusinessachievednetprofitof462millionyuaninthefirsthalfof2021,anincreaseof14.26%onayear-on-yearbasis.Inthefirsthalfof2021,GuodaDrugstorecompletedanoperatingrevenueof10841millionyuanintotal,ay-o-ygrowthof25.87%.Varioustypesofbusinesshavedevelopedrapidly,amongthem,thedirectnon-DTPrevenuewas6557millionyuan,29%uponay-o-ybasis;directDTPrevenuewas1305millionyuan,ay-o-ygrowthof34%;wholesale&distributionrevenuewas1987millionyuan,ay-o-yincreaseof25%;revenuefromO2Owas255millionyuan,ay-o-yincreaseof122%.GuodaDrugstoreachievedanetprofitof263millionyuaninthefirsthalfof2021withagrowthof6.14%fromayearearlier;thenetprofitattributabletoparentcompanyamountedas199millionyuan,ay-o-yincreaseof10.62%.Infirsthalfof2021,theaccumulativeinvestmentincomefromassociateswas158millionyuan,ay-o-yincreaseof18.03%.(i)"FightagainstCOVID-19"underthenormalizationofthepandemicAccordingtotherepeatedoutbreaksincertainregions,SinopharmAccordheldspecialmeetingsonpandemicpreventionandcontrolinatimelymanner,implementedrelevantarrangements,anditssubsidiariesatalllevelsstrivedforandundertookthereservesofpandemicmaterials.SinopharmpharmaciesandGuodaDrugStoresatthequarantineareascomprehensivelyrespondedtodemandandlaunchedtheemergencymodelofonline"wechat-enterprisecustomerserviceguide+storestakingorders+logisticsvehicledelivery",openedasusual,especiallyGuangdongGuodaFangcunStoreopenedfor576hours,providingprofessionalconsultation,medicinedeliveryservicesforpatientswithchronicdiseasesinthequarantineareas.Allbusinessdepartmentscoordinatedandsupportedthepreparationofnucleicacidtestingmaterialsforallstafforganizedbythegovernment.SinopharmGuangdongLogisticsinvestednearly2000squaremetersofcoldstoragehouse,120refrigeratedtrucks,morethan2000setsoftemperaturecontrolboxes,companyemployeesinGuangdongandShenzhenquicklyformedvolunteerteamstocooperatewithotherstaffsoastoensurethequality,safety,efficiencyandorderofthevaccinewarehousinganddeliveryservicesinthewarehouse.Thecompany'ssubsidiaries,SinopharmGuangdongLogistics,SinopharmZhanjiang,SinopharmShaoguan,ShenyangGuoDa,NanjingGuoDa,NingxiaGuoDa,JiangmenGuoDaandmanyothersubsidiarieshavewonthegovernment'santi-pandemicawards.(ii)Focusonhighqualitydevelopment,publicizeandimplementthe"14thFive-YearPlan"strategyEffectivelyorganizedandcarriedoutthepublicityandimplementationworkofthe14thFive-YearPlanofSinopharmAccord,sortedoutandformedtheplanningstudypublicitydraft,andpublicizedandimplementedtheplanthroughvarioustypesofmeetings,trainingandactivitiessuchasthePartyandtheYouthLeague,laborunionandhumanresources.SinopharmAccorddistributionpromotedtheimplementationofthe"14thFive-YearPlan"strategy,andcompletedtheformulationof11thematicsub-plansofthe"14thFive-YearPlan"fordistribution;GuodaDrugStorehadanin-depthdiscussiononstrategicgoals,industrytrends,strategicpathsandresourceallocation,andmadeclearstrategicgoalsanddirections.(III)SinopharmAccorddistributionbusiness:strategicguidanceandqualityandefficiencyimprovementstartedanewjourneyofhigh-qualitydevelopment.
1.Strategicdriveacceleratesthenewpatternofonebodywithtwowings
(1)Consolidatedandtappedthepotentialoftraditionalbusiness,andstrengthenedthemarketshareleadingadvantages.ActivelyrespondedtothechallengesofthenewroundofCOVID-19pandemicandthechangesinpoliciesandmarkets,andtraditionalbusinesscontinuedtobreaktheice.Arrangedbiddingandcentralizedprocurementinadvance,andlinkedpurchaseandsalestogethertoseizetheshare,eachbatchofcentralizedprocurementvarietiesheldtheleadincommissiondeliveryrate.Seizedtheopportunityofmulti-platformoperation,grabbedtheshareofcentralizedprocurementresources,andnewlyincreased2exclusivevarietiesofcentralizedprocurementintheprovince.Coordinatedwholesaleandretail,strivedfornewproducts,andincreased4,802newproductspecificationsinGuangdongandGuangxiprovinces,utilizedtheexclusivechannelofretailDTPShutanming,expandedthetopfourchainagreementsofXishumei,hierarchicalmanagement,shareincrease.Themarketshareofkeyvarietiescontinuestobreaktheice.Amongthem,domesticandintegrativemanufacturersarerankedinthetop10respectively,and5Guangdongmanufacturershaveamarketshareofmorethan50%.Matchedthegradingservicepackage,focusedonpromotingprojectcooperation,continuedtobreakiceformarketsharesofkeyvarieties,amongwhichdomesticandjointventuremanufacturersrespectivelyrankedinthetopten,and5manufacturershadmorethan50%ofmarketsharesinGuangdong.
(2)Consolidatedandtappedthepotentialoftraditionalbusiness,multi-businessfeaturesgraduallyemerged,marketingabilitycontinuouslyimproved,andgrowthpotentialcontinuouslyreleased.Intermsofinstruments,SPDcontinuedtoexpand,followedupprojectsofprovincialmaternityandchildhealthcarehospital,andcoordinatedthemanagementoftheprojectsofthecompanyandYuexingCompany.Establishedpartialfilesofintegratedinstruments,collectedthemarketsituationofconsumables,thekeycategoriesofdistributionandtheproductdevelopmentplanofallcitiesintheprovince.Thewinningrateofhospitaldecoctionpiecesincreased,andthecustomizedcooperativesalesofdecoctionpiecesincreased,forexample,thecordycepssinensissalesofGuodaDrugStoreincreased115%yearoveryear.Themarketexpansionofrefineddecoctionpieceshasachievedinitialresults,andthesalesofPobidecoctionpieceshaveincreased.Intermsofimport,wehaveobtainedtheimportdistributionchannelofDinoprostone,andtheimportquantity,importamountandsalesvolumehaveallincreased.ActivelyexpandedCSOproductprojects,integratedthewholesaleandretailnetworkresources,andpromotedmarketingsystemandteambuilding.
(3)Retaildirectsellingfocusedonthedevelopmentmeasuresof"wholesaleandretailintegration",focusedontheshareincrease,vigorouslydevelopedretaildirectsellingnetwork,promotedmodelinnovationandserviceupgrade,andstrengthenedthecorecompetitivenessofbusiness.Continuedtodevelopretailpuresalesbusiness,withasalesgrowthof42%.UnitedGuodaheadquarters,branchesandmanufacturerscloselyforlinkage,precisionmarketingpromotedthenumberofprojects,increasedthedepthoftop100chaincooperation,increasedproductintroduction,andproductspecificationspromotedtheincreaseoftheshare.B2BprojectandHengxingsiteenrichedthemarketingmode,realizedonlinedailypromotion,andimprovedtheonlinerate;Guangzhousite
increasedthenumberofonlineproductspecifications,anddevelopedDTPspecialzone.Formemberstoreproject,therewereover1,000memberstores.Provincialretailintegrationprojectrealized9,014customersinoperationinasingleterminalstore,andtheimplementationofmarketingpolicycombinationcontinuouslypromotedtheonlineorderpurchasingandreal-timepayment.Keyvarieties/manufacturersjointlypromotedprojects,increasedthenumberofproductspecificationsforendcustomercooperation.Front,middleandbackgrounddivisionoflaborandcoordinationimprovedthecustomermulti-touchcommunicationefficiency.
(4)Retaildiagnosisandtreatmentacceleratedthenetworklayout,integratedthemedicaltreatment,medicalinsuranceandmedicalresources,improvedtheprofitabilityofsinglestores,andgraduallybuiltuptheadvantagesofmulti-levelandthree-dimensionalretaildiagnosisandtreatmentserviceswithcharacteristiccompetitiveness.ThenetworkinGuangdongandGuangxiprovinceshasfullycovered109hospitals,including82inGuangdongProvinceand27inGuangxiProvince,outpatientspecificprojectsandcommercialinsuranceprojectsbecamethedrivingforceforthekeyperformance.Atotalof31prescriptioncirculationprojectshavebeenlaunched,thereweremorethan45,000prescriptionsinvolvinghospitaloutpatientserviceandInternetfurtherconsultationprojectcirculation.
(5)Rapidlycultivatedinnovativebusiness,andcreatedaseriesofinnovativeserviceproductsystem.Focusingontheguidanceofmedicalreformpolicyandcorporatestrategy,weacceleratedthebuildingofnewbusinesscorecompetitivenessandmarketscale.4Dbusinessandthird-partylogisticsserviceshadrapidgrowth,servicefeerevenueincreased54%yearoveryear.
2.Improvequalityandefficiency,andincreaseefficiencythroughcontinuoushigh-qualityoperation
(1)Profit-oriented,benefitsofresourceallocationconstantlyhavebeenimprovedthroughmeasuressuchastalentallocation,incentivescheme,supplychainoptimization,industry-financedualdrive,processoptimizationandsoon,andtheoperationqualityandbenefitshavebeenimproved.
(2)Furtherpromoteintegratedmanagementandcontrol,integratebusinessacrossregions,strengthenresourceintegration,andimproveoperationalefficiencyandincreasebenefits.
3.DigitaltransformationandtechnologypromotessupplychainupgradeTakedigitaltransformationasanimportantstartingpoint,furtherenhancethedigitalcapabilityofsupplychain,promotesupplychainupgrade,andimproveoperationalefficiency.Consolidatethefoundationofdigitaltransformation,deeplyoptimizetheorganizationalstructure,realizeintegratedmanagement,andestablishthefirstsharingplatform.Integrationenabling,externalserviceimprovement,internalefficiencyimprovement;SPDprovidesin-depthservicestocreatesampleproductsandimprovethereplicationcapability;Digitallogisticsoptimizesupplychain,andachieveefficiencyandcostreduction;Logisticsthird-partybusinessesfocusonbusinessdevelopment,acceleratenewbusinesssupport;Theretailendenablestoeffectivelyrespondtoandexpandthedualchannelsofmedicalinsurance.
4.Riskpreventionandcontrol,consolidatebusinessdevelopmentandcontrollineofdefenseConsolidateriskmanagementandcontrolsystemsandmechanisms,strengthenriskpreventionandcontrolwarningandrefinedmanagementandcontrol,furtheroptimizethequalityofoperations,andensurebusinessdevelopment.(iv)GuodaDrugStorebusiness:grabopportunities,innovation-driven,andbuildnewpatternforthecompany’shighqualitydevelopment
1.Acceleratethefullnetworklayout,andthecompany'sscalecontinuestoexpand.
(1)Externalextension:MakefulluseofSinopharmresourcestoactivelypromotetheimplementationofinvestmentandmergerprojects.Inthefirsthalfof2021,therewere257newinvestmentprojectsandstores;activelysearchedfornewprojects,andacceleratedthepromotionoftheinvestmentprojects.
(2)Endogenousgrowth:GuodaDrugStorehas8,439directsales+franchisestoresintotal.Duringthereportperiod,788newstoreswereopenedand223storeswereclosed,withanetincreaseof565stores,reachinganewhigh;newlyopened632direct-salestores,achievingsalesof117millionyuan,amongwhichtherewere48newlyopenedstoresnexttothehospitals,arecordhighinrecentyears.Atpresent,Guodahas697direct-salestoresnexttothehospitalswithatotalsalesof2.03billionyuaninthefirsthalfoftheyear,contributingprofitof101millionyuan.Thetotalsalesofnewstoresreached452millionyuan.Atthesametime,theheadquarterscooperatedwiththesubsidiariestodeepenthenetworklayout,8subsidiarieshavesetup63storesin6prefecture-levelcitiesand55storesin10county-levelcities/counties.Atpresent,thecity-levelcitiesinShanxiandNingxiahaveachievedfullcoverage.
2.Strengthenthecooperationofthewholesupplychainandimprovetheoperationandmanagementefficiency
(1)Productoptimization:Throughtheintroductionofnewproducts,optimizedthecompany'scommoditystructure.Inthefirsthalfoftheyear,wecompletedtheauditformorethan40,000newproducts,andcompletedplanningevaluationof475newproducts,andcompletedevaluationof260commoditiesofitsownbrand.Optimizedthecostofgoodsthroughthedevelopmentofitsownbrandvarieties,andimprovedthecompany'sgrossprofit.Inthefirsthalfoftheyear,thecompanycompletedthedevelopmentproposalsontheself-ownedbrandvarietythroughtheanalysisofthecommodityline.
(2)Optimizedandimprovedtheprovincial-levelplatformbuilding,wholesaleandretailintegration,andmultiplewarehousesinoneregion.Inthefirsthalfofthisyear,logisticsintegrationprojectsinLiaoning,Yangzhou,XinjiangandShanghaihavebeenlaunched.
(3)Carriedoutmarketingincrementalactivities,addingeffectivemembershipof3.933million,ayear-on-yearincreaseof27%.Thenationwideeffectivememberwas21.81million,rising6%yearoveryear.
3.Stepupomni-channelpenetrationandinnovatebusinesstransformationandupgradingInthefirsthalfof2020,thecompanyachievedsalesof255millionyuan,rising122%yearonyear.OrdinarycommercialinsurancehasintroducedPinganmedicineanddiagnosiscard,medtreehealth,etc.;MajordiseasecommercialinsurancehasintroducedZhonganHealthDTPandHainanShangzeDTP.Theself-operatedplatformhad161livebroadcastsinthefirsthalfofthisyear,andtheonlinemembersofthee-commerceplatformexceeded6million.Newstoretypeattempt:CombiningwithsomeelementsofWBA,GuodaDrugStoresuccessfullybuiltthefirstSPS+healthnewconceptstore--SinopharmGuodaDrugStoreLonghuaEastRoadStore.Thestoreintegrateshealth,beauty,profession,convenienceandwisdomintoaone-stopshoppingstore,creatinga"comprehensive,professional,andtop"newmodel.
Y-o-ychangesofmainfinancialdata
InRMB
Currentperiod | Sameperiodoflastyear | Y-o-yincrease/decrease | Reasonsforchanges | |
Operatingrevenue | 33,163,091,887.39 | 27,169,940,188.52 | 22.06% | Ay-o-yincreaseof22.06%;intheyear,rapidgrowthofrevenuefromvarytypesofdistribution,andunderthevigorousdevelopmentofretailbusiness,operatingrevenueincreasedy-o-y. |
Operatingcosts | 29,216,837,201.07 | 23,971,029,719.44 | 21.88% | Ay-o-ygrowthof21.88%;thegrowthtrendisbasicallyinlinewiththerevenue. |
Sellingexpenses | 2,307,485,529.77 | 1,728,738,818.60 | 33.48% | Ay-o-ygrowthof33.48%;insecondof2020,subsidiaryoftheCompany-GuodaDrugstoreacquiretheChengdaFangyuanPharmaceuticalGroupCo.,Ltd,thanthesalesexpenseshavegreatlygrowthoversameperiodlastyear. |
Administrativeexpenses | 492,536,936.71 | 443,287,144.92 | 11.11% | Nomajorchanges |
Financecosts | 107,243,003.15 | 65,313,829.62 | 64.20% | Ay-o-ygrowthof64.20%;inthesecondhalfof2020,alargeamountofequity |
acquisitionconsiderationhavebeenpaid,balanceofbanksavingsdeclined,thantheinterestincomefromsavingsdecreasedonay-o-ybasis,andtheinterestonsupplychainfinancingincreasedinthePeriod | ||||
Incometaxexpenses | 238,426,259.04 | 210,106,764.35 | 13.48% | Nomajorchanges |
Netcashflowsfromoperatingactivities | 1,229,373,283.57 | 1,438,204,043.35 | -14.52% | Nomajorchanges |
Netcashflowsfrominvestingactivities | -291,260,821.37 | -666,346,816.87 | 56.29% | Ay-o-ygrowthof56.29%;theamountpaidfortheacquisitionofsubsidiariesbysubsidiary-GuodaDrugstoreinthecurrentperioddecreasedfromthesameperiodlastyear |
Netcashflowsfromfinancingactivities | -806,011,505.39 | -1,197,318,438.51 | 32.68% | Ay-o-ygrowthof32.68%;thepaymentstonon-financialinstitutionsfelly-o-y,andatsameperiodlastyear,theinvestmentamountpaidforacquisitionoftheenterprise(PudongNewAreaofShanghaiPharmaceuticalMedicineLtd)underthesamecontrolbysubsidiaryoftheCompany-GuodaDrugstore |
Netincreaseincashandcashequivalent | 132,492,959.44 | -425,509,148.00 | 131.14% | Ay-o-ygrowthof131.14%;paymentsfromsubsidiary-GuodaDrugstoreforacquisitiondecreasedoverthatoflastyear |
Majorchangesonprofitcompositionorprofitresourcesinreportingperiod
□Applicable√NotapplicableNomajorchangesonprofitcompositionorprofitresourcesoccurredinreportingperiod.Constitutionofoperationrevenue
InRMB
Currentperiod | Sameperiodlastyear | Increase/decreasey-o-y(+,-) | |||
Amount | Ratioinoperationrevenue | Amount | Ratioinoperationrevenue | ||
Totalofoperationrevenue | 33,163,091,887.39 | 100% | 27,169,940,188.52 | 100% | 22.06% |
Accordingtoindustries | |||||
Pharmaceuticaldistribution | 23,157,094,599.17 | 69.83% | 19,185,884,075.68 | 70.61% | 20.70% |
Retailpharmacy | 9,853,255,644.48 | 29.71% | 7,876,117,404.69 | 28.99% | 25.10% |
Other | 152,741,643.74 | 0.46% | 107,938,708.15 | 0.40% | 41.51% |
Accordingtoproducts | |||||
Pharmaceuticals | 30,006,046,182.11 | 90.48% | 24,375,725,625.65 | 89.71% | 23.10% |
Medicaldevicesanddisposables | 2,210,930,715.28 | 6.67% | 2,185,440,182.47 | 8.04% | 1.17% |
Diagnosticreagents | 515,191,908.40 | 1.55% | 335,716,038.17 | 1.24% | 53.46% |
Medicalequipment | 278,181,437.86 | 0.84% | 165,119,634.08 | 0.61% | 68.47% |
Other | 152,741,643.74 | 0.46% | 107,938,708.15 | 0.40% | 41.51% |
Accordingtoregion | |||||
China | 33,163,091,887.39 | 100.00% | 27,169,940,188.52 | 100.00% | 22.06% |
Abouttheindustries,products,orregionsaccountingforover10%ofthecompany’soperatingincomeoroperatingprofit
√Applicable□Notapplicable
InRMB
Operatingrevenue | Operatingcost | Grossprofitratio | Increase/decreaseofoperatingrevenuey-o-y | Increase/decreaseofoperatingcosty-o-y | Increase/decreaseofgrossprofitratioy-o-y | |
Accordingtoindustries | ||||||
Pharmaceuticaldistribution | 23,157,094,599.17 | 21,760,517,286.11 | 6.03% | 20.70% | 20.73% | -0.03% |
Retailpharmacy | 9,853,255,644.48 | 7,355,870,065.11 | 25.35% | 25.10% | 24.21% | 0.54% |
Accordingtoproducts | ||||||
Pharmaceuticals | 30,006,046,182.11 | 26,306,817,487.33 | 12.33% | 23.10% | 22.20% | 0.65% |
Accordingtoregion | ||||||
China | 33,163,091,887.39 | 29,216,837,201.07 | 11.90% | 22.06% | 21.88% | 0.13% |
Undercircumstancesofadjustmentinreportingperiodforstatisticscopeofmainbusinessdata,adjustedmainbusinessbasedonlatestoneyear’sscopeofperiod-end
□Applicable√NotapplicableReasonsfortheabove30%changesinrelevantdataonay-o-ybasis
√Applicable□Notapplicable
1.Inthisperiod,DiagnosticreagentsandMedicalequipmentincreasedby53.46%and68.47%respectivelycomparedwiththesameperiodoflastyear,mainlyduetotheimplementationofthecompany'sdevelopmentstrategy,theadjustmentofbusinessstructuretransformation,andthepromotionofinnovativebusinessdevelopment.
2.Otherbusinessinthisperiodincreasedby41.51%comparedwiththesameperiodoflastyear,mainlyduetotheincreaseinincomefromdrugwarehousinganddeliveryservice.
IV.Analysisofthenon-mainbusiness
□Applicable√Notapplicable
V.Analysisofassetsandliabilities
1.Majorchangesofassetscomposition
InRMB
Endofcurrentperiod | Endoflastyear | Ratiochanges | Notesofmajorchanges | |||
Amount | Ratiointotalassets | Amount | Ratiointotalassets | |||
Cashandbankbalances | 5,876,638,427.56 | 13.30% | 5,998,204,295.87 | 15.15% | -1.85% | Nomajorchanges |
Accountsreceivable | 17,761,176,449.25 | 40.19% | 13,799,971,014.22 | 34.85% | 5.34% | Nomajorchanges |
Contractassets | 17,066,105.53 | 0.04% | 15,177,731.64 | 0.04% | 0.00% | Nomajorchanges |
Inventories | 7,219,658,618.62 | 16.34% | 6,285,010,674.46 | 15.87% | 0.47% | Nomajorchanges |
Investmentproperties | 123,389,130.71 | 0.28% | 127,444,379.94 | 0.32% | -0.04% | Nomajorchanges |
Long-termequityinvestment | 2,427,605,792.21 | 5.49% | 2,287,019,627.99 | 5.78% | -0.29% | Nomajorchanges |
Fixassets | 840,386,519.64 | 1.90% | 854,191,083.27 | 2.16% | -0.26% | Nomajorchanges |
Constructioninprocess | 64,636,735.93 | 0.15% | 46,631,190.23 | 0.12% | 0.03% | Nomajorchanges |
Right-of-useassets | 2,523,874,174.71 | 5.71% | 2,356,952,392.99 | 5.95% | -0.24% | Nomajorchanges |
Short-termborrowings | 4,632,933,904.39 | 10.48% | 1,612,187,020.12 | 4.07% | 6.41% | ThesupplychainfinancingincreasedinthePeriod |
Contractliabilities | 316,827,151.78 | 0.72% | 368,600,357.14 | 0.93% | -0.21% | Nomajorchanges |
Long-termborrowings | 61,633,794.44 | 0.14% | 31,637,173.89 | 0.08% | 0.06% | Nomajorchanges |
Leaseliabilities | 1,361,131,352.80 | 3.08% | 1,303,054,163.90 | 3.29% | -0.21% | Nomajorchanges |
2.Mainforeignassets
□Applicable√Notapplicable
2.Assetsandliabilitymeasuredbyfairvalue
√Applicable□Notapplicable
InRMB
Item | Openingamount | Gain/lossofchangesinfairvalue | Cumulativechangesoffairvaluereckonedintoequity | ImpairmentaccrualinthePeriod | AmountpurchasedinthePeriod | AmountsoldinthePeriod | Otherchanges | Endingamount |
Financialassets | ||||||||
Otherequityinstrumentinvestment | 99,488,340.28 | 99,488,340.28 | ||||||
Othernon- | 120,972,350.24 | -2,997,441.73 | 117,974,908 |
currentfinancialassets | .51 | |||
Receivablefinancing | 1,404,987,700.38 | -1,059,080,812.83 | 345,906,887.55 | |
Totalofabove | 1,625,448,390.90 | -1,062,078,254.56 | 563,370,136.34 | |
Financialliability | 0.00 | 0.00 |
Contentofotherchanges
1.Othernon-currentfinancialassetsarethefairvalueofthesharesofSinopharmZhongjinMedicalIndustryFund(hereinafterreferredtoasthe"IndustryFund")subscribedbytheCompany.Otherchangesarethewithdrawalofinvestmentprojectsofthefund,andtheinvestmentcostofthewithdrawnprojectsisreturnedinaccordancewiththeagreement.
2.Inthefinancingofreceivables,otherchangeswerecausedbychangesinbankacceptancebillsheldinthecurrentperiod.WhetherthemeasurementattributeformainassetsoftheCompanyhavechangedsignificantlyinthereportingperiod
□Yes√No
4.Assetsrightrestrictiontillendofreportingperiod
2021-6-30 | 2020-12-31 | Note |
Cashandbankbalances | 338,186,269.94 | 593,091,037.88 | (1) |
Endorsednotesreceivableandreceivablefinancing | 20,196,089.49 | 27,939,151.58 | (2) |
Pledgedreceivablefinancing | - | 2,620,000.00 | (3) |
358,382,359.43 | 623,650,189.46 |
(1)On30June2021,theCompanyhasrestrictedmonetaryfundswithbookvalueof338,186,269.94Yuan(on31December2020:
593,091,037.88Yuan),mainlyincludesthedepositsofbankacceptancebill,frozenfundsandspecialreservefundsetc.
(2)On30June2021,theCompanyhasareceivablefinancingwithabookvalueof20,070,999.69Yuanandnotereceivablewithabookvalueof125,089.80yuan(on31December2020:23,843,867.66yuanreceivablefinancingand4,095,283.92Yuannotereceivable),whichhasendorsedbutnotyetdue.
(3)On30June2021,theCompanyhasabookvalueof0.00Yuan(31December2020:2,620,000Yuan)receivablefinancingpledged.
(4)On30June2021,theCompanyhasabookvalueof0.00Yuan(31December2020:N/A)notereceivablediscountedbutnotyetdue.
VI.Investment
1.Overallsituation
√Applicable□NotapplicableDuringthereportingperiod,thecompanypaidcashtoacquiretheequityofYunnanGuodaDishengPharmaceuticalCo.,Ltd.(70%)andYunnanGuodaDishengDrugstoreChainCo.,Ltd.(70%),realizingthebusinesscombinationnotunderthesamecontrolofthesetwocompaniesDuringthereportingperiod,theCompanycompletedtheinvestmentcontributionforthenewcompanyin2020-GuodaWanminHuiminkangweiDrugstoreLvliangCo.,Ltd,andcontributedpartoftheinvestmentforLiaoningHuludaoGuodaDrugstoreCo.,Ltd,newestablishedin2020.Duringthereportingperiod,theCompanypaidcashtoacquiretheassetsof15directly-salesstoresundertheSinopharmHoldingNantongPujiPharceuticalChainCo.,Ltdand32directly-salesstoresunderShanxiHuiminKangweiDrugstoreChainCo.,Ltd.Forspecificinvestment,pleaserefertonote(VI)and(VII)oftheSectionX.FinancialReport.
2.Themajorequityinvestmentobtainedinthereportingperiod
□Applicable√Notapplicable
3.Themajornon-equityinvestmentdoinginthereportingperiod
□Applicable√Notapplicable
4.Financialassetsinvestment
(1)Securitiesinvestment
□Applicable√NotapplicableTheCompanyhadnosecuritiesinvestmentinthereportingperiod.
(2)Derivativeinvestment
□Applicable√NotapplicableTheCompanyhasnoderivativesinvestmentinthePeriod
VII.Salesofmajorassetsandequity
1.Salesofmajorassets
□Applicable√NotapplicableTherearenomajorassetssellintheperiod
2.Salesofmajorequity
□Applicable√Notapplicable
VIII.AnalysisofmainholdingCompanyandstock-jointlycompanies
√Applicable□NotapplicableParticularaboutmainsubsidiariesandstock-jointlycompaniesnetprofitover10%
InRMB
Companyname | Type | Mainbusiness | Registercapital | Totalassets | Netassets | Operatingrevenue | Operatingprofit | Netprofit |
SinopharmHoldingGuangzhouCo.,Ltd. | Subsidiary | "Salesofdrugs,medicalapparatusandinstruments,cargotransport,storage,loadingandunloading,glasswares,cosmeticsanddailymerchandise;otherbusinessservices,otherprofessionalconsultation,variousgoodsagencyandforself-operation,import&exportoftechnology,housesleasing" | 3,553,249,393.17 | 17,918,202,144.73 | 4,512,441,243.75 | 17,320,141,510.68 | 446,580,622.00 | 330,710,871.11 |
SinopharmHoldingGuodaDrugstoreCo.,Ltd. | Subsidiary | "Chinesetraditionalpatentmedicine,chemicalpreparations,antibiotics,bio-chemical | 1,683,333,333.00 | 16,344,255,324.13 | 5,846,823,975.89 | 10,841,326,194.08 | 339,519,962.59 | 263,262,365.37 |
medicine,biologicalmedicine,diagnosismedicine,biologicalmedicinewithfeaturesoftreatmentanddiagnosis,shapedpackingfood,chemicalproducts,andvariouscommodityandtechniqueholdbyself-supportandagencyaswellasimport&exportoftechnology" | ||||||||
SinopharmHoldingGuangxiCo.,Ltd. | Subsidiary | "Retailanddistributioninrespectofpharmaceuticalproductsandmedicalapparatusandinstruments,wholesaleandretailsofhealthproducts" | 521,407,965.79 | 5,054,481,196.10 | 1,141,609,797.48 | 3,232,583,872.71 | 101,502,050.12 | 87,430,862.81 |
Particularaboutsubsidiariesobtainedordisposedinreportperiod
√Applicable□Notapplicable
Company | Themethodofobtainingandhandlingsubsidiariesduringthereportperiod | Theinfluencetothewholeproductionandperformance |
YunnanGuodaDishengPharmaceuticalCo.,Ltd. | Acquisition | Expandlocalmedicinewholesalebusinesslayout,andwithoutmajorinfluenceonperformanceoftheCompany |
YunnanGuodaDishengDrugstoreChainCo.,Ltd. | Acquisition | Expandlocalmedicineretailbusinesslayout,andwithoutmajorinfluenceonperformanceoftheCompany |
NotesofmainholdingCompanyandstock-jointlycompanies
IX.StructuredvehiclecontrolledbytheCompany
□Applicable√NotapplicableX.Risksandcountermeasures
1.RisksofchangesinindustrypolicyWiththecontinuousdeepeningofnewmedicalreform,thepharmaceuticalindustryfrequentlyreleasespolicies,andtheoperatingenvironmentoftheindustryhasmajorchanges,affectedbythe“4+7”centralizedprocurementlinkageandexpansion,theGPOinGuangdongandGuangxiprovinces,andthecontinuousexpansionofthenationaltalks,andotherpolicies,thedrugpricehascontinuedtodropsharply,andthecompany’sprofitmarginisfacingtheriskoffurthercompression.Thesupervisionhasbeencontinuouslyupgraded,theintroductionofthenewDrugAdministrationLawandtheimplementationofthe“fourstrictest”putforwardhigherrequirementsforthecomplianceoperationofpharmaceuticalenterprises,thepharmaceuticalcirculationindustryfacesincreasedrisksofuncertaincompliance.Thecompanywillrespondtotheimpactsofindustrypoliciesbytransformingandupgradingitsbusinessstructure,exploringnewprofitmodels,andimprovingitsriskmanagementandcontrolcapabilities.
2.ManagementrisksofthecontinuousexpansionofmarketingnetworkofGuodaDrugstoreThroughthecontinuousopeningofnewstoresandextendedM&A,themarketingnetworkofGuodaDrugstorehasmaintainedasteadygrowthtrendinrecentyears.Theexpansionsofthesalesareasandtheincreaseinthenumberofstoreshaveputpressureonthestorelocation,distribution,cashmanagement,marketingandhumanresourcemanagementofGuodaDrugstore.Thecompanywillstrengthenmanagementandconstructioninthecommodityprocurement,logisticsanddelivery,salesandotherlinks,andformulatecorrespondingmanagementmeasuresineachlinktoensureunifiedstandardsandmanagementqualityforstoreexpansion,andatthesametimestrengthenintegrationandcontrolofnewmergedstores.
3.RisksofintensifyingmarketcompetitionAsthecountrycontinuestointroducecorrespondingpoliciestoencouragetheintegrationofpharmaceuticalretailindustry,themajorpharmaceuticalretailenterprisesintheindustryhaveacceleratedthepaceofmergersandacquisitions,andcontinuedtoexpandthemarketingnetworks,improvethelogisticscenterconstructions,andinnovatethebusinessandprofitmodelssothatthesalesscaleandcomprehensivestrengthcontinuouslystrengthen.Atthesametime,withtheupgradingofconsumptionandthegradualopeningofmarket,theforeignpharmaceuticaldistributionenterpriseswithpowerfulstrengthareenteringthedomesticpharmaceuticaldistributionmarketsthroughavarietyofways,sotheindustrycompetitionisfurtherintensifying.Inaddition,thecross-bordercompetitorswithinternetgeneshavequicklypenetratedintothecompany’straditionalbusinessfields,whichbroughtnewandgreaterchallengestothecompany’sbusinessmodel.Thecompanywillcontinuetointegrateexistingresources,deepenthestrategicdevelopmentinitiativeswithwholesale-retailintegrationasthecore,anddeeplygiveplaytothesynergies,directlyfacetheterminalpatientsandconsumersthroughcomplementaryvarieties,capitalcollaboration,supplychaincollaboration,and
internationalpromotion,atthesametime,itwillrealizebrandglobalizationbycapitaloperation,andcontinuouslyincreaseinvestmentinscientificandtechnologicalinnovation,andactivelyrespondtocross-bordercompetition.
4.RisksoffacingthehorizontalcompetitionInthepharmaceuticalretailfield,SinopharmHolding’saffiliateddistributionsubsidiarieshavealsoopenedsomesocialretailpharmacies,whichconstituteacertaindegreeofhorizontalcompetitionwiththesubordinateGuodaDrugstore.SinopharmHoldingandSINOPHARMhavepledgedtotakeeffectivemeasurestoresolvethepossiblehorizontalcompetition.
5.TheriskofgoodwillimpairmentsOn30June2021,thebookvalueofgoodwillinconsolidatefinancialstatementlistedas2,932,001,316.63Yuan,anddistributedtotheassetsgroupofdistributionbusinessandretailbusiness.InaccordancewiththeAccountingStandardsforBusinessEnterprises,theCompanycarriedoutannualimpairmenttestforthegoodwill.ImpairmentofgoodwillwillreleasedontheNoteIII.-24andNoteV-18listedundertheSectionX.FinancialReport
SectionIVCorporateGovernanceI.Inthereportperiod,theCompanyheldannualshareholders’generalmeetingandextraordinaryshareholders’generalmeeting
1.Shareholders’GeneralMeetinginthereportperiod
Sessionofmeeting | Type | Ratioofinvestorparticipation | Dateofmeeting | Dateofdisclosure | Resolutions |
AnnualGeneralMeetingof2020 | AGM | 64.31% | 2021-04-28 | 2021-04-29 | JuchaoWebsite—(http://www.cninfo.com.cn)"ResolutionNoticeofAGMof2020No.:2021-19 |
FirstExtraordinaryShareholdersGeneralMeeting2021 | ExtraordinaryShareholdersGeneralMeeting | 63.27% | 2021-06-25 | 2021-06-26 | JuchaoWebsite—(http://www.cninfo.com.cn)"ResolutionNoticeofFirstExtraordinaryShareholdersGeneralMeeting2021No.:2021-25 |
2.Requestforextraordinarygeneralmeetingbypreferredstockholderswhosevotingrightsrestore
□Applicable√Notapplicable
II.Changesofdirectors,supervisorsandseniorexecutives√Applicable□Notapplicable
Name | Title | Type | Date | Reasons |
LiDongjiu | Director | Officeleaving | 2021-03-01 | Workscheduleadjustment |
ZhaoXiaochuan | DeputyGM | Dismissal | 2021-05-21 | Workscheduleadjustment |
JiangXiuchang | Director | Resignaftertermofoffice | 2021-06-25 | RenewaloftheBOD |
LiXiaojuan | Director | Beelected | 2021-06-25 | RenewaloftheBOD |
ZhouSong | Director | Beelected | 2021-06-25 | RenewaloftheBOD |
III.ProfitdistributionplanandcapitalizingofcommonreservesplanforthePeriod
□Applicable√NotapplicableTheCompanyhasnoplansofcashdividenddistributed,nobonussharesandhasnoshareconvertedfromcapitalreserveeitherforthesemi-annualyear.
IV.ImplementationoftheCompany’sstockincentiveplan,employeestockownershipplanorotheremployeeincentives
□Applicable√NotapplicableTheCompanyhasnoequityincentiveplan,employeestockownershipplansorotheremployeeincentivesinPeriod.
SectionVEnvironmentalandSocialResponsibility
1.Majorenvironmentprotection
ThelistedCompanyanditssubsidiarywhetherbelongtothekeysewageunitsreleasedfromenvironmentalprotectiondepartment
□Yes√Novoluntarydisclosure
Company/subsidiary | NameofMajorPollutantsandParticularPollutants | EmissionMethod | QuantityofDischargeOutlet | DistributionofDischargeOutlet | EmissionConcentration | ExecutedPollutantDischargeStandards | TotalEmissions | ApprovedTotalEmissions | ExcessiveDischarge |
MainLuckPharmaceuticals | COD | TubeDischarge | 1 | DischargeOutletofWasteWater | 13mg/L | DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008 | 0.012ton/year | 0.05ton/year | N/A |
MainLuckPharmaceuticals | AmmoniaNitrogen | TubeDischarge | 1 | DischargeOutletofWasteWater | 0.5mg/L | DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008 | 0.0005ton/year | 0.009ton/year | N/A |
MainLuckPharmaceuticals | Phosphate | TubeDischarge | 1 | DischargeOutletofWasteWater | 0.05mg/l | DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory- | 0.00005ton/year | 0.0005ton/year | N/A |
GB21908-2008 | |||||||||
MainLuckPharmaceuticals | BOD | TubeDischarge | 1 | DischargeOutletofWasteWater | 3mg/L | DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008 | 0.003ton/year | 0.014ton/year | N/A |
MainLuckPharmaceuticals | SS | TubeDischarge | 1 | DischargeOutletofWasteWater | 2mg/L | DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008 | 0.002ton/year | 0.03ton/year | N/A |
ChinaNationalZhijun(Shenzhen)PharmaceuticalCo.,Ltd. | COD | TubeDischarge | 1 | DischargeOutletofWasteWater | 29㎎/L | Table-2in“DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008” | 0.6995ton/year | 7.306ton/year | N/A |
ChinaNationalZhijun(Shenzhen)PharmaceuticalCo.,Ltd. | AmmoniaNitrogen | TubeDischarge | 1 | DischargeOutletofWasteWater | 1.3738㎎/L | Table-2in“DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008” | 0.0331ton/year | 0.812ton/year | N/A |
ChinaNationalZhijun | Totalphosphorus | TubeDischarge | 1 | DischargeOutletofWaste | 0.038㎎/L | Table-2in“DischargeStandards | 0.0009ton/year | 0.041ton/year | N/A |
(Shenzhen)PharmaceuticalCo.,Ltd. | Water | ofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory-GB21908-2008” | |||||||
ChinaNationalZhijun(Shenzhen)PingshanPharmaceuticalCo.,Ltd. | COD | TubeDischarge | 1 | DischargeOutletofWasteWater | 21.83㎎/L | Thestricteronebetween“DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory(GB21908-2008)”and“EnvironmentalQualityStandardsforSurfaceWater”(GB3838-2002)forClassIVwater(AmmoniaNitrogenuptoClassV) | 0.609ton/year | 2.16ton/year | N/A |
ChinaNationalZhijun(Shenzhen)PingshanPharmaceuticalCo.,Ltd. | AmmoniaNitrogen | TubeDischarge | 1 | DischargeOutletofWasteWater | 0.287㎎/L |
0.008ton/year | 0.144ton/year | N/A |
2002)forClassIVwater(AmmoniaNitrogenuptoClassV) | |||||||||
ChinaNationalZhijun(Shenzhen)PingshanPharmaceuticalCo.,Ltd. | Totalphosphorus | TubeDischarge | 1 | DischargeOutletofWasteWater | 0.018㎎/L | Thestricteronebetween“DischargeStandardsofWaterPollutantsforPharmaceuticalindustryMixing/CompoundingandFormulationCategory(GB21908-2008)”and“EnvironmentalQualityStandardsforSurfaceWater”(GB3838-2002)forClassIVwater(AmmoniaNitrogenuptoClassV) | 0.0005ton/year | 0.0216ton/year | N/A |
ConstructionandoperationofpollutionpreventionandcontrolfacilitiesAtpresent,theabove-mentionedenvironmentalpollutionkeymonitoringunitsinwhichtheCompanyhasashareholdinghaveestablishedpollutionpreventionandcontrolfacilitiesforwastewater.Inthedailymanagementprocess,enterprisesestablishmanagementproceduresandoperatinginstructionsforenvironmentalprotectionfacilities,andensurethenormalandcompliantoperationofanti-pollutionfacilitiesthroughsystemimplementationandresponsibilityimplementation.Allenterprisesarecontinuouslyinvestingfundsandsteppingupthetransformationandimprovementofpollutionpreventionandcontrolfacilitiestoensurethestableoperationofpollutionpreventionfacilitiesandimprovethedisposalcapacityofenvironmentalprotectionfacilities.EnvironmentalimpactassessmentofconstructionprojectsandotherenvironmentalprotectionadministrativelicensesAtpresent,theprojectsofallkeymonitoringunitshavecarriedoutenvironmentalimpactassessmentsandobtainedapprovals.Theprojectstobebuiltalsocarryouttherelevantadministrativereviewproceduresaccordingtothe“threesimultaneous”requirementsoftheenvironmentalprotectionfacilitiesoftheconstructionproject.EmergencyplanforenvironmentalemergenciesAtpresent,theabove-mentionedenvironmentalpollutionkeymonitoringunitsinwhichtheCompanyhasashareholdinghaveformulatedtheEmergencyPlanforEnvironmentalEmergenciesandreportedthemaccordingtotheregulatoryrequirementsofthelocalregulatoryauthorities.Accordingtothemanagementrequirementsoftheemergencyplan,thekeyunitsregularlycarryoutemergencyplandrillstofurtherprovidetheenterprises’emergencyresponsecapability.
Environmentalself-monitoringschemeAtpresent,theabove-mentionedenvironmentalpollutionkeymonitoringunitsinwhichtheCompanyhasashareholdinghaveestablishedenvironmentalself-detectionschemeandplan,andimplementedself-inspection,third-partydetectionandothermonitoringmethodsaccordingtothegovernmentrequirements.Relevantmonitoringdataandreportshavebeenarchivedandsaved.AdministrativepenaltiesduetotheenvironmentalissuesduringthereportingperiodN/AOtherenvironmentalinformationthatshouldbedisclosedTheabovetwocompaniesarejointstockcompaniesoftheCompany.TheCompanyanditsholdingsubsidiariesarenotlistedaskeypollutantdischargeunitsannouncedbytheenvironmentalprotectiondepartment.RelevantinformationonenvironmentprotectionN/A
II.Socialresponsibility
TheCompanyhasnotyetcarriedoutthepovertyalleviationandruralrevitalizationworks
SectionVI.ImportantEventsI.Undertakingsthattheactualcontroller,shareholders,relatedparty,buyersandtheCompanyhavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendofreportingperiod
□Applicable√NotapplicableNoundertakingsthattheactualcontroller,shareholders,relatedparty,buyersandtheCompanyhavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendoftheperiodII.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty
□Applicable√NotapplicableNonon-operationalfundoccupationfromcontrollingshareholdersanditsrelatedpartyinperiod.III.Externalguaranteeoutoftheregulations
□Applicable√NotapplicableNoexternalguaranteeoutoftheregulationsoccurredintheperiod.
IV.Appointmentandnon-reappointment(dismissal)ofCPAWhetherthefinancialreportofsemi-annualreporthasbeenaudited
□Yes√NoThesemi-annualreportoftheCompanyisunaudited.
V.ExplanationfromBoardofDirectorsandSupervisoryCommitteefor“Non-standardauditreport”thatissuedbyCPA
□Applicable√Notapplicable
VI.ExplanationfromtheBODonthepreviousyear’s“non-standardauditreport”
□Applicable√NotapplicableVII.Bankruptcyreorganization
□Applicable√NotapplicableNobankruptcyreorganizationoccurredduringthereportingperiod.VIII.Litigation
Majorlitigationandarbitration
□Applicable√NotapplicableNomajorlitigationandarbitrationoccurredinthePeriod.OtherlitigationAsofJune30,2021,therewere20economiccontractdisputesindailyoperation,withatotalamountof18.1318millionyuaninvolved;1anti-unfaircompetitioncasewith3millionyuaninvolved;1equitytransferdispute,involvingatotalamountof0.5718millionyuan;2intellectualpropertydisputes,involvingatotalamountof15.3006millionyuan;2laborcontractdisputes,involvingatotalamountof0.3284millionyuan;1privatelendingdispute,withanamountof49.398millionyuaninvolved;1medicalproductliabilitydispute,involvingatotalamountof21.5888millionyuanand1criminalcase,involvinganamountof11.5634millionyuan.Therewere20casesintotalabove-mentioned,atotalamountof119.8828millionyuaninvolvedwithoutaccrualliabilityoccurred,andwillnothaveanyimpactonthenormaloperationandmanagementoftheCompany.
IX.Penaltyandrectification
□Applicable√NotapplicableNopenaltyandrectificationfortheCompanyinreportingperiod.
X.Integrityofthecompanyanditscontrollingshareholdersandactualcontrollers
√Applicable□NotapplicableInreportingperiod,controllingshareholderandactualcontrolleroftheCompanyhasasoundintegrity,andtherearenocasesoffailuretoimplementtheeffectivejudgmentofthecourtandthelargeamountofdebtdueandunliquidatedXI.Majorrelatedpartytransaction
1.Day-to-dayrelatedpartytransaction
√Applicable□Notapplicable
(1)Relatedtransactionwithroutineoperationconcernedcanbefoundin“X.Relatedpartyandrelatedtransaction”carriedinSectionX.FinancialReport;
(2)Therelatedtransactionsaresettledincashandbynotes,accordingtotheProposalofExpectedRoutineRelatedTransactionswithSubordinateEnterpriseforYearof2021deliberatedandapprovedby23
th
sessionof8
thBODheldon31March2021andtheNoticeonExpectedRoutineRelatedTransactionforYearof2021(NoticeNo.:2021-09)releasedon2April2021,therelatedsalestakes34.55%intotalexpectedamountforthewholeyear,andrelatedprocurementtakes38.11%intotalexpectedamountforthewholeyear.
2.Relatedpartytransactionsofassetsacquisitionandsold
□Applicable√NotapplicableNorelatedpartytransactionsofassetsacquisitionandsoldoccurredduringthereportingperiod
3.Relatedpartytransactionsofmutualinvestmentoutside
□Applicable√NotapplicableNorelatedpartytransactionsofmutualinvestmentoutsideoccurredduringthereportingperiod.
4.Contactofrelatedpartycreditanddebt
□Applicable√NotapplicableTheCompanyhadnocontactofrelatedpartycreditanddebtinthereportingperiod.
5.ContactwiththerelatedfinancecompaniesandfinancecompaniesthatcontrolledbytheCompany
√Applicable□NotapplicableDepositbusiness
Relatedparty | Relationship | Maximumdailydepositlimit(in10thousandyuan) | Depositinterestraterange | Openingbalance(in10thousandyuan) | Amountoccurred(in10thousandyuan) | Endingbalance(in10thousandyuan) |
SinopharmGroupFinanceCo.,Ltd | Thesameultimatecontrolling | 30,000.00 | 0.35%-1.15% | 10,177.99 | -10,014.31 | 163.68 |
Loanbusiness
shareholderRelatedparty
Relatedparty | Relationship | Loanline(in10thousandyuan) | Loaninterestraterange | Openingbalance(in10thousandyuan) | Amountoccurred(in10thousandyuan) | Endingbalance(in10thousandyuan) |
SinopharmGroupFinanceCo.,Ltd | Thesameultimatecontrollingshareholder | 100,000.00 | 3.6%-3.7% | 1,432.28 | 56,734.41 | 58,166.69 |
Creditextensionorotherfinancialbusiness
Relatedparty | Relationship | Typeofbusiness | Totalamount(in10thousandyuan) | Actualamount(in10thousandyuan) |
SinopharmGroupFinanceCo.,Ltd | Thesameultimatecontrollingshareholder | Credit | 100,000.00 | 58,166.69 |
SinopharmGroupFinanceCo.,Ltd | Thesameultimatecontrollingshareholder | Bankacceptancebilldiscount | 32,376.15 | 32,376.15 |
SinopharmGroupFinanceCo.,Ltd | Thesameultimatecontrollingshareholder | Entrustedloan | 3,160.00 | 3,160.00 |
6.Othermaterialrelatedpartytransactions
□Applicable√NotapplicableThecompanyhadnoothermaterialrelatedpartytransactionsinreportingperiod.XII.Significantcontractandimplementations
1.Trusteeship,contractandleasing
(1)Trusteeship
□Applicable√NotapplicableNotrusteeshipoccurredduringthereportingperiod
(2)Contract
□Applicable√NotapplicableNocontractoccurredduringthereportingperiod
(3)Leasing
□Applicable√NotapplicableNoleasingoccurredduringthereportingperiod
2.Materialguarantees
√Applicable□Notapplicable
Unit:10’000yuan
ParticularsabouttheexternalguaranteeoftheCompanyandthesubsidiaries(Barringtheguaranteeforsubsidiaries) | ||||||||||
NameoftheCompanyguaranteed | RelatedAnnouncementdisclosuredate | Guaranteelimit | Actualdateofhappening | Actualguaranteelimit | Guaranteetype | Collateral(ifapplicable) | Counter-guaranteesituation(ifapplicable) | Guaranteeterm | Implemented(Y/N) | Guaranteeforrelatedparty(Y/N) |
N/A | ||||||||||
GuaranteebetweentheCompanyandthesubsidiaries | ||||||||||
NameoftheCompanyguaranteed | RelatedAnnouncementdisclosuredate | Guaranteelimit | Actualdateofhappening | Actualguaranteelimit | Guaranteetype | Collateral(ifapplicable) | Counter-guaranteesituation(ifapplicable) | Guaranteeterm | Implemented(Y/N) | Guaranteeforrelatedparty(Y/N) |
SinopharmHoldingGuangzhouCo.,Ltd. | April2,2021 | 30,000 | May20,2021 | 30,000 | Jointliabilityassurance | 2021.05.20-2022.05.20 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April2,2021 | 70,000 | May10,2021 | 70,000 | Jointliabilityassurance | 2021.05.10-2022.05.09 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April22,2020 | 60,000 | December8,2020 | 30,499.62 | Jointliabilityassurance | 2020.12.08-2021.12.03 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April2,2021 | 15,000 | June28,2021 | 15,000 | Jointliabilityassurance | 2021.06.28-2022.06.27 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April2,2021 | 95,000 | May20,2021 | 64,038.5 | Jointliabilityassurance | 2021.05.20-2022.05.20 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April22,2020 | 20,000 | October20,2020 | 2,197.68 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April22,2020 | 47,000 | August31,2020 | 28,423.37 | Jointliabilityassurance | 2020.08.31-2021.08.31 | N | Y | ||
SinopharmHoldingGuangzhouCo.,Ltd. | April22,2020 | 5,000 | August6,2020 | Jointliabilityassurance | 2020.08.06-2021.08.05 | N | Y | |||
SinopharmHolding | April2,2021 | 5,000 | May20,2021 | 657.98 | Jointliability | 2021.05.20- | N | Y |
GuangdongYuexingCo.,Ltd. | assurance | 2022.05.20 | |||||||
SinopharmHoldingGuangdongYuexingCo.,Ltd. | April22,2020 | 12,000 | October20,2020 | 4,090.08 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingGuangdongYuexingCo.,Ltd. | April2,2021 | 15,000 | May10,2021 | 11,313.14 | Jointliabilityassurance | 2021.05.10-2022.05.09 | N | Y | |
SinopharmHoldingGuangdongYuexingCo.,Ltd. | April22,2020 | 3,000 | January10,2021 | 2,545.93 | Jointliabilityassurance | 2021.01.10-2022.01.09 | N | Y | |
SinopharmHoldingGuangdongYuexingCo.,Ltd. | April22,2020 | 5,000 | November20,2020 | Jointliabilityassurance | 2020.11.20-2021.11.19 | N | Y | ||
SinopharmHoldingGuangdongHengxingCo.,Ltd. | April22,2020 | 15,000 | September27,2020 | 7,176.7 | Jointliabilityassurance | 2020.09.27-2021.09.27 | N | Y | |
SinopharmHoldingGuangdongHengxingCo.,Ltd. | April2,2021 | 3,000 | April28,2021 | 467.34 | Jointliabilityassurance | 2021.04.28-2022.04.27 | N | Y | |
SinopharmHoldingFoshanCo.,Ltd. | April22,2020 | 500 | October20,2020 | 149.29 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingFoshanCo.,Ltd. | April2,2021 | 2,000 | May10,2021 | Jointliabilityassurance | 2021.05.10-2022.05.10 | N | Y | ||
SinopharmHoldingFoshanCo.,Ltd. | April22,2020 | 2,500 | March23,2021 | 153.41 | Jointliabilityassurance | 2021.03.23-2022.03.22 | N | Y | |
SinopharmHoldingZhaoqingCo.,Ltd. | April22,2020 | 2,500 | October20,2020 | 1,303.45 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingZhaoqingCo.,Ltd. | April2,2021 | 2,000 | June1,2021 | 762.47 | Jointliabilityassurance | 2021.06.01-2022.05.11 | N | Y | |
SinopharmHoldingZhaoqingCo.,Ltd. | April2,2021 | 3,000 | June30,2021 | 500.48 | Jointliabilityassurance | 2021.06.30-2022.06.29 | N | Y | |
GuangdongNanfangPharmaceut | April22,2020 | 19,500 | July1,2020 | 5,942.14 | Jointliability | 2020.07.01-2021.06.3 | N | Y |
icalForeignTradeCo.,Ltd. | assurance | 0 | |||||||
GuangdongNanfangPharmaceuticalForeignTradeCo.,Ltd. | April22,2020 | 15,000 | October16,2020 | 9,009.66 | Jointliabilityassurance | 2020.10.16-2021.10.15 | N | Y | |
GuangdongNanfangPharmaceuticalForeignTradeCo.,Ltd. | April22,2020 | 20,000 | September27,2020 | 10,264.71 | Jointliabilityassurance | 2020.09.27-2021.09.27 | N | Y | |
GuangdongNanfangPharmaceuticalForeignTradeCo.,Ltd. | April22,2020 | 3,000 | October20,2020 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
GuangdongNanfangPharmaceuticalForeignTradeCo.,Ltd. | April22,2020 | 10,000 | November12,2020 | 4,703.63 | Jointliabilityassurance | 2020.11.12-2021.11.03 | N | Y | |
GuangdongNanfangPharmaceuticalForeignTradeCo.,Ltd. | April22,2020 | 5,000 | September25,2020 | Jointliabilityassurance | 2020.09.25-2021.09.24 | N | Y | ||
FoshanNanhaiMedicineCo.,Ltd. | April22,2020 | 1,500 | October20,2020 | 1,091.78 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
FoshanNanhaiMedicineCo.,Ltd. | April22,2020 | 10,000 | March22,2021 | 5,259.87 | Jointliabilityassurance | 2021.03.22-2022.03.21 | N | Y | |
FoshanNanhaiMedicineCo.,Ltd. | April22,2020 | 7,000 | March1,2021 | 4,214.8 | Jointliabilityassurance | 2021.03.01-2022.02.28 | N | Y | |
FoshanNanhaiMedicineCo.,Ltd. | April2,2021 | 3,000 | June24,2021 | Jointliabilityassurance | 2021.06.24-2022.05.11 | N | Y | ||
FoshanNanhaiUptodate&SpecialMedicinesCo.Ltd. | April22,2020 | 2,000 | October20,2020 | 573.55 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
FoshanNanhaiUptodate&SpecialMedicines | April22,2020 | 10,000 | March22,2021 | 5,505.71 | Jointliabilityassurance | 2021.03.22-2022.03.21 | N | Y |
Co.Ltd. | |||||||||
FoshanNanhaiUptodate&SpecialMedicinesCo.Ltd. | April22,2020 | 7,000 | March1,2021 | 1,490.57 | Jointliabilityassurance | 2021.03.01-2022.02.28 | N | Y | |
FoshanNanhaiUptodate&SpecialMedicinesCo.Ltd. | April2,2021 | 3,000 | June24,2021 | Jointliabilityassurance | 2021.06.24-2022.05.11 | N | Y | ||
SinopharmHolding(Jiangmen)Co.,Ltd. | April22,2020 | 1,500 | October20,2020 | 121.33 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHolding(Jiangmen)Co.,Ltd. | April2,2021 | 5,000 | May26,2021 | 1,791.69 | Jointliabilityassurance | 2021.05.26-2022.05.11 | N | Y | |
SinopharmHolding(Jiangmen)Co.,Ltd. | April22,2020 | 3,000 | September21,2020 | 1,864.86 | Jointliabilityassurance | 2020.09.21-2021.09.20 | N | Y | |
SinopharmHolding(Jiangmen)Co.,Ltd. | April2,2021 | 4,000 | May31,2021 | 3,447.41 | Jointliabilityassurance | 2021.05.31-2022.05.31 | N | Y | |
SinopharmHoldingMeizhouCo.,Ltd. | April22,2020 | 1,000 | October20,2020 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingMeizhouCo.,Ltd. | April22,2020 | 4,000 | June29,2020 | 1,000 | Jointliabilityassurance | 2020.06.29-2021.06.28 | N | Y | |
SinopharmHoldingMeizhouCo.,Ltd. | April2,2021 | 5,000 | June3,2021 | 4,387.21 | Jointliabilityassurance | 2021.06.03-2022.05.11 | N | Y | |
SinopharmHoldingMeizhouCo.,Ltd. | April2,2021 | 6,000 | June21,2021 | 3,000 | Jointliabilityassurance | 2021.06.21-2022.03.19 | N | Y | |
SinopharmHoldingZhongshanCo.,Ltd. | April22,2020 | 1,000 | October20,2020 | 900 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingZhongshanCo.,Ltd. | April22,2020 | 2,000 | November18,2020 | 1,628.39 | Jointliabilityassurance | 2020.11.18-2021.11.17 | N | Y | |
SinopharmHoldingZhongshanCo.,Ltd. | April2,2021 | 3,000 | May26,2021 | Jointliabilityassurance | 2021.05.26-2022.05.11 | N | Y | ||
SinopharmHolding | April2,2021 | 1,000 | May31,2021 | Jointliability | 2021.05.31- | N | Y |
ZhongshanCo.,Ltd. | assurance | 2022.05.30 | |||||||
SinopharmHoldingShantouCo.,Ltd. | April22,2020 | 500 | October20,2020 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingShantouCo.,Ltd. | April22,2020 | 3,000 | August31,2020 | 1,450 | Jointliabilityassurance | 2020.08.31-2021.08.30 | N | Y | |
SinopharmHoldingShantouCo.,Ltd. | April2,2021 | 2,000 | June3,2021 | 1,100 | Jointliabilityassurance | 2021.06.03-2022.05.11 | N | Y | |
SinopharmHoldingShantouCo.,Ltd. | April22,2020 | 2,000 | March31,2021 | Jointliabilityassurance | 2021.03.31-2022.03.30 | N | Y | ||
SinopharmHoldingHuizhouCo.,Ltd. | April22,2020 | 1,000 | October20,2020 | 790.16 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingHuizhouCo.,Ltd. | April22,2020 | 3,000 | October20,2020 | 469.36 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingHuizhouCo.,Ltd. | April22,2020 | 1,000 | September3,2020 | 854.16 | Jointliabilityassurance | 2020.09.03-2021.09.02 | N | Y | |
SinopharmHoldingHuizhouCo.,Ltd. | April2,2021 | 4,000 | June3,2021 | 494.52 | Jointliabilityassurance | 2021.06.03-2022.05.11 | N | Y | |
SinopharmHoldingZhanjiangCo.,Ltd. | April22,2020 | 2,000 | October20,2020 | 1,380 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingZhanjiangCo.,Ltd. | April22,2020 | 5,000 | August10,2020 | 4,376.38 | Jointliabilityassurance | 2020.08.10-2021.08.09 | N | Y | |
SinopharmHoldingZhanjiangCo.,Ltd. | April2,2021 | 8,000 | May19,2021 | 3,361.79 | Jointliabilityassurance | 2021.05.19-2022.05.19 | N | Y | |
SinopharmHoldingZhanjiangCo.,Ltd. | April22,2020 | 3,000 | September18,2020 | Jointliabilityassurance | 2020.09.18-2021.09.17 | N | Y | ||
SinopharmHoldingZhuhaiCo.,Ltd. | April22,2020 | 1,000 | October20,2020 | 999.93 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingZhuhaiCo.,Ltd. | April22,2020 | 3,000 | August5,2020 | 2,855.15 | Jointliabilityassurance | 2020.08.05-2021.08.04 | N | Y | |
Sinopharm | April2, | 4,000 | June1, | 2,716.27 | Joint | 2021.06.0 | N | Y |
HoldingZhuhaiCo.,Ltd. | 2021 | 2021 | liabilityassurance | 1-2022.05.11 | ||||||
SinopharmHoldingZhuhaiCo.,Ltd. | April22,2020 | 2,000 | May15,2020 | 1,173.51 | Jointliabilityassurance | 2020.05.15-2021.05.15 | N | Y | ||
SinopharmHoldingDongguanCo.,Ltd. | April2,2021 | 3,000 | June3,2021 | Jointliabilityassurance | 2021.06.03-2022.05.11 | N | Y | |||
SinopharmHoldingDongguanCo.,Ltd. | April22,2020 | 2,000 | October20,2020 | 1,500 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingDongguanCo.,Ltd. | April22,2020 | 3,000 | June24,2020 | 1,500 | Jointliabilityassurance | 2020.06.24-2021.06.23 | N | Y | ||
SinopharmHoldingGuangdongDongfangNewSpecialMedicineCo.,Ltd. | April2,2021 | 10,000 | May10,2021 | 9,842 | Jointliabilityassurance | 2021.05.10-2022.05.09 | N | Y | ||
SinopharmHoldingGuangdongDongfangNewSpecialMedicineCo.,Ltd. | April2,2021 | 5,000 | April2,2021 | 4,973.42 | Jointliabilityassurance | 2021.04.02-2022.04.01 | N | Y | ||
SinopharmHoldingGuangdongDongfangNewSpecialMedicineCo.,Ltd. | April22,2020 | 9,000 | October19,2020 | 8,649.36 | Jointliabilityassurance | 2020.10.19-2021.10.18 | N | Y | ||
SinopharmHoldingGuangdongDongfangNewSpecialMedicineCo.,Ltd. | April22,2020 | 4,000 | October20,2020 | 1,840.56 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingGuangdongDongfangNewSpecialMedicineCo.,Ltd. | April2,2021 | 3,000 | May19,2021 | 2,996.1 | Jointliabilityassurance | 2021.05.19-2022.05.11 | N | Y | ||
SinopharmHolding | April22,2020 | 1,000 | October20,2020 | 747.21 | Jointliability | Theminorit | 2020.10.20- | N | Y |
ShaoguanCo.,Ltd. | assurance | yshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.10.19 | |||||||
SinopharmHoldingShaoguanCo.,Ltd. | April2,2021 | 3,000 | June11,2021 | 948.71 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.11-2022.05.11 | N | Y | |
SinopharmHoldingMaomingCo.,Ltd. | April2,2021 | 4,500 | May31,2021 | 315.98 | Jointliabilityassurance | 2021.05.31-2022.05.11 | N | Y | ||
SinopharmHoldingMaomingCo.,Ltd. | April22,2020 | 3,000 | July28,2020 | 370.58 | Jointliabilityassurance | 2020.07.28-2021.07.27 | N | Y | ||
SinopharmHoldingGuangzhouHuaduCo.,Ltd. | April22,2020 | 3,000 | September27,2020 | 549.56 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.09.27-2021.09.27 | N | Y | |
SinopharmHoldingGuangzhouHuaduCo.,Ltd. | April22,2020 | 3,000 | February24,2021 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequity | 2021.02.24-2022.02.23 | N | Y |
pledgecontractandregisteredtheirequitypledges | ||||||||||
SinopharmHoldingHeyuanCo.,Ltd. | April2,2021 | 5,000 | June3,2021 | 4,069.64 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.03-2022.05.11 | N | Y | |
SinopharmHoldingHeyuanCo.,Ltd. | April2,2021 | 3,000 | May6,2021 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.05.06-2022.03.19 | N | Y | ||
SinopharmHoldingFoshanMedicalSuppliesSupplyChainCo.,Ltd. | April22,2020 | 1,000 | March1,2021 | 3.59 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.03.01-2022.02.28 | N | Y | |
SinopharmAccord(Guangzhou)MedicineCo.,Ltd. | April2,2021 | 2,000 | May18,2021 | Jointliabilityassurance | Theminorityshareholdershavesignedthe | 2021.05.18-2022.05.11 | N | Y |
equitypledgecontractandregisteredtheirequitypledges | ||||||||||
SinopharmAccord(Guangzhou)MedicineCo.,Ltd. | April22,2020 | 1,000 | August17,2020 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.08.17-2021.08.16 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April2,2021 | 30,000 | May25,2021 | 29,239.38 | Jointliabilityassurance | 2021.05.25-2022.05.25 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April22,2020 | 16,000 | October20,2020 | 9,589.29 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April22,2020 | 20,000 | June16,2020 | 8,000 | Jointliabilityassurance | 2020.06.16-2021.06.15 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April22,2020 | 10,000 | May28,2020 | 5,792.22 | Jointliabilityassurance | 2020.05.28-2021.05.28 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April2,2021 | 25,000 | June28,2021 | 998.02 | Jointliabilityassurance | 2021.06.28-2022.06.28 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April22,2020 | 10,000 | September1,2020 | 4,992.2 | Jointliabilityassurance | 2020.09.01-2021.08.31 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April2,2021 | 20,000 | May20,2021 | 12,085.89 | Jointliabilityassurance | 2021.05.20-2022.05.20 | N | Y | ||
SinopharmHoldingGuangxiCo.,Ltd. | April22,2020 | 15,000 | September11,2020 | Jointliabilityassurance | 2020.09.11-2021.09.10 | N | Y | |||
SinopharmHoldingLiuzhouCo.,Ltd. | April22,2020 | 5,000 | October20,2020 | 1,000.97 | Jointliabilityassurance | Theminorityshareholders | 2020.10.20-2021.10.19 | N | Y |
havesignedthecounter-guaranteecontract | ||||||||||
SinopharmHoldingLiuzhouCo.,Ltd. | April22,2020 | 10,000 | June21,2020 | 1,997.56 | Jointliabilityassurance | Theminorityshareholdershavesignedthecounter-guaranteecontract | 2020.06.21-2021.06.20 | N | Y | |
SinopharmHoldingLiuzhouCo.,Ltd. | April22,2020 | 10,000 | March4,2021 | 2,276.4 | Jointliabilityassurance | Theminorityshareholdershavesignedthecounter-guaranteecontract | 2021.03.04-2022.02.08 | N | Y | |
SinopharmHoldingLiuzhouCo.,Ltd. | April22,2020 | 5,000 | July1,2020 | 4,393.51 | Jointliabilityassurance | Theminorityshareholdershavesignedthecounter-guaranteecontract | 2020.07.01-2021.06.30 | N | Y | |
SinopharmHoldingLiuzhouCo.,Ltd. | April2,2021 | 9,000 | May17,2021 | 3,000 | Jointliabilityassurance | Theminorityshareholdershavesignedthecounter-guaranteecontract | 2021.05.17-2022.05.16 | N | Y | |
SinopharmHoldingLiuzhouCo.,Ltd. | April22,2020 | 10,000 | December21,2020 | 5,469.88 | Jointliabilityassurance | Theminorityshareholdershavesignedthe | 2020.12.21-2021.12.21 | N | Y |
counter-guaranteecontract | ||||||||||
SinopharmHoldingGuilinCo.,Ltd. | April22,2020 | 200 | October20,2020 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |||
SinopharmHoldingGuilinCo.,Ltd. | April2,2021 | 2,000 | May26,2021 | 2,000 | Jointliabilityassurance | 2021.05.26-2022.05.25 | N | Y | ||
SinopharmHoldingWuzhouCo.,Ltd. | April22,2020 | 300 | October20,2020 | 145.95 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingWuzhouCo.,Ltd. | April2,2021 | 3,000 | May26,2021 | Jointliabilityassurance | 2021.05.26-2022.05.25 | N | Y | |||
SinopharmHoldingWuzhouCo.,Ltd. | April22,2020 | 2,000 | August7,2020 | 2,000 | Jointliabilityassurance | 2020.08.07-2021.08.07 | N | Y | ||
SinopharmHoldingBaiseCo.,Ltd. | April22,2020 | 500 | October20,2020 | 384.15 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingBaiseCo.,Ltd. | April2,2021 | 3,000 | May26,2021 | Jointliabilityassurance | 2021.05.26-2022.05.25 | N | Y | |||
SinopharmHoldingYulinCo.,ltd. | April22,2020 | 1,000 | October20,2020 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |||
SinopharmHoldingYulinCo.,ltd. | April2,2021 | 3,000 | May26,2021 | 2,000 | Jointliabilityassurance | 2021.05.26-2022.05.25 | N | Y | ||
SinopharmHoldingBeihaiCo.,Ltd. | April22,2020 | 500 | October20,2020 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | |||
SinopharmHoldingBeihaiCo.,Ltd. | April2,2021 | 2,000 | May20,2021 | 800 | Jointliabilityassurance | 2021.05.20-2022.05.20 | N | Y | ||
SinopharmHoldingBeihaiCo.,Ltd. | April2,2021 | 3,000 | May26,2021 | 3,000 | Jointliabilityassurance | 2021.05.26-2022.05.25 | N | Y | ||
SinopharmHoldingGuigangCo.,Ltd. | April22,2020 | 1,000 | January29,2021 | 1,000 | Jointliabilityassurance | 2021.01.29-2022.01.28 | N | Y | ||
SinopharmHoldingGuigang | April2,2021 | 2,000 | May26,2021 | 2,000 | Jointliabilityassurance | 2021.05.26-2022.05.2 | N | Y |
Co.,Ltd. | 5 | |||||||||
SinopharmHoldingShenzhenYanfengCo.,Ltd. | April22,2020 | 4,000 | October20,2020 | 4,000 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.10.20-2021.10.19 | N | Y | |
SinopharmHoldingShenzhenYanfengCo.,Ltd. | April22,2020 | 8,000 | May28,2020 | 7,363.96 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.05.28-2021.05.28 | N | Y | |
SinopharmHoldingShenzhenYanfengCo.,Ltd. | April22,2020 | 4,000 | January10,2021 | 1,405.81 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.01.10-2022.01.09 | N | Y | |
SinopharmHoldingShenzhenYanfengCo.,Ltd. | April22,2020 | 5,000 | November2,2020 | 5,000 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheir | 2020.11.02-2021.07.13 | N | Y |
equitypledges | ||||||||||
SinopharmHoldingShenzhenJianminCo.,ltd. | April22,2020 | 3,000 | October20,2020 | 2,036.14 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingShenzhenJianminCo.,ltd. | April22,2020 | 2,000 | March17,2021 | Jointliabilityassurance | 2021.03.17-2021.11.05 | N | Y | |||
SinopharmHoldingShenzhenJianminCo.,ltd. | April22,2020 | 3,000 | January10,2021 | 998.48 | Jointliabilityassurance | 2021.01.10-2022.01.09 | N | Y | ||
SinopharmHoldingShenzhenJianminCo.,ltd. | April2,2021 | 3,000 | June22,2021 | Jointliabilityassurance | 2021.06.22-2022.05.11 | N | Y | |||
SinopharmHoldingShenzhenMedicinalMaterialsCo.,Ltd. | April22,2020 | 500 | October20,2020 | 77.14 | Jointliabilityassurance | 2020.10.20-2021.10.19 | N | Y | ||
SinopharmHoldingShenzhenMedicinalMaterialsCo.,Ltd. | April2,2021 | 1,500 | June22,2021 | Jointliabilityassurance | 2021.06.22-2022.05.11 | N | Y | |||
SinopharmAccordMedicalDevices(Shenzhen)Co.,Ltd. | April22,2020 | 5,000 | June18,2020 | 824 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.06.18-2021.05.18 | N | Y | |
SinopharmAccordMedicalDevices(Shenzhen)Co.,Ltd. | April22,2020 | 3,000 | November10,2020 | 546.99 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractand | 2020.11.10-2021.11.09 | N | Y |
registeredtheirequitypledges | ||||||||||
SinopharmAccordMedicalDevices(Shenzhen)Co.,Ltd. | April22,2020 | 3,000 | March24,2021 | 267 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.03.24-2021.08.13 | N | Y | |
Totalamountofapprovingguaranteeforsubsidiariesinreportperiod(B1) | 501,500.00 | Totalamountofactualoccurredguaranteeforsubsidiariesinreportperiod(B2) | 801,052.89 | |||||||
Totalamountofapprovedguaranteeforsubsidiariesattheendofreportingperiod(B3) | 941,500.00 | Totalbalanceofactualguaranteeforsubsidiariesattheendofreportingperiod(B4) | 520,489.63 | |||||||
Guaranteesofsubsidiariestosubsidiaries | ||||||||||
NameoftheCompanyguaranteed | RelatedAnnouncementdisclosuredate | Guaranteelimit | Actualdateofhappening | Actualguaranteelimit | Guaranteetype | Collateral(ifapplicable) | Counter-guaranteesituation(ifapplicable) | Guaranteeterm | Implemented(Y/N) | Guaranteeforrelatedparty(Y/N) |
BeijingJinxiangDrugstoreMedicineChainCo.,Ltd | April22,2020 | 4,200 | December21,2020 | 2,491.52 | Jointliabilityassurance | 2020.12.21-2021.12.20 | N | Y | ||
FujianGuodaDrugstoreChainCo.,Ltd. | April22,2020 | 1,200 | July29,2020 | Jointliabilityassurance | 2020.07.29-2021.07.30 | N | Y | |||
FujianGuodaDrugstoreChainCo.,Ltd. | April22,2020 | 1,800 | October21,2020 | 1,299.14 | Jointliabilityassurance | 2020.10.21-2021.10.20 | N | Y | ||
FujianGuodaMedicinesCo.,Ltd. | April22,2020 | 600 | August13,2020 | 210.57 | Jointliabilityassurance | 2020.08.13-2021.08.13 | N | Y | ||
Guoda | April2, | 1,200 | June10, | 547.06 | Joint | The | 2021.06.1 | N | Y |
Drugstore(Pu'er)SongmaoCo.,Ltd. | 2021 | 2021 | liabilityassurance | minorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 0-2022.05.12 | |||||
GuodaDrugstore(Pu'er)SongmaoCo.,Ltd. | April22,2020 | 1,200 | September1,2020 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.09.01-2021.08.31 | N | Y | ||
GuodaYiheDrugstoreJilinCo.,Ltd. | April22,2020 | 4,080 | September23,2020 | 2,915.18 | Jointliabilityassurance | 2020.09.23-2021.09.22 | N | Y | ||
GuodaYiheDrugstoreJilinCo.,Ltd. | April22,2020 | 3,000 | July15,2020 | Jointliabilityassurance | 2020.07.15-2021.07.15 | N | Y | |||
ChinaNationalHebeiLerentangMedicineChainCo.,Ltd. | April22,2020 | 3,000 | December21,2020 | 2,996.31 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
ChinaNationalHebeiLerentangMedicineChainCo.,Ltd. | April22,2020 | 1,800 | October21,2020 | 1,181.47 | Jointliabilityassurance | Theminorityshareholdershavesignedthe | 2020.10.21-2021.10.20 | N | Y |
equitypledgecontractandregisteredtheirequitypledges | ||||||||||
ChinaNationalHebeiLerentangMedicineChainCo.,Ltd. | April2,2021 | 9,000 | June8,2021 | 8,953.63 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.08-2022.05.12 | N | Y | |
SinopharmHoldingGuodaShanxiMedicinesCo.,Ltd. | April22,2020 | 15,000 | May21,2020 | 8,063.64 | Jointliabilityassurance | 2020.05.21-2021.05.14 | N | Y | ||
SinopharmHoldingGuodaShanxiMedicinesCo.,Ltd. | April22,2020 | 1,200 | October21,2020 | 900 | Jointliabilityassurance | 2020.10.21-2021.10.20 | N | Y | ||
SinopharmHoldingGuodaDrugstore(Shenzhen)ChainCo.,Ltd. | April22,2020 | 1,800 | December21,2020 | 894.45 | Jointliabilityassurance | 2020.12.21-2021.12.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreBayanNurCo.,Ltd. | April2,2021 | 600 | June4,2021 | 418.46 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.04-2022.05.12 | N | Y | |
SinopharmHoldingGuodaDrugstore | April22,2020 | 6,000 | October21,2020 | 1,978.87 | Jointliabilityassurance | 2020.10.21-2021.10.2 | N | Y |
GuangdongCo.,Ltd. | 0 | |||||||||
SinopharmHoldingGuodaDrugstoreGuangdongCo.,Ltd. | April22,2020 | 1,800 | December21,2020 | 515.87 | Jointliabilityassurance | 2020.12.21-2021.12.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreGuangdongCo.,Ltd. | April2,2021 | 6,000 | June22,2021 | 3,586.44 | Jointliabilityassurance | 2021.06.22-2022.05.12 | N | Y | ||
SinopharmHoldingGuodaDrugstoreGuangxiChainCo.,Ltd. | April22,2020 | 1,800 | October21,2020 | 274.77 | Jointliabilityassurance | 2020.10.21-2021.10.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreGuangxiChainCo.,Ltd. | April22,2020 | 600 | December21,2020 | 582.07 | Jointliabilityassurance | 2020.12.21-2021.12.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreHenanChainCo.,Ltd. | April22,2020 | 1,200 | December21,2020 | 918.64 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreHenanChainCo.,Ltd. | April22,2020 | 1,800 | June11,2020 | 677.38 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.06.11-2021.05.14 | N | Y | |
SinopharmHolding | April2,2021 | 600 | June4,2021 | 595.45 | Jointliability | 2021.06.04- | N | Y |
GuodaDrugstoreHulunBuirCo.,Ltd. | assurance | 2022.05.12 | ||||||||
SinopharmHoldingGuodaDrugstoreHulunBuirCo.,Ltd. | April22,2020 | 300 | October21,2020 | 299.19 | Jointliabilityassurance | 2020.10.21-2021.10.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreJiangmenChainCo.,Ltd. | April22,2020 | 1,800 | October21,2020 | 1,127.75 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.10.21-2021.10.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreJiangmenChainCo.,Ltd. | April2,2021 | 1,200 | April2,2021 | 549.33 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.04.02-2022.04.01 | N | Y | |
SinopharmHoldingGuodaDrugstoreJiangmenChainCo.,Ltd. | April22,2020 | 1,800 | December21,2020 | 642.06 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreJiangmen | April22,2020 | 3,000 | December28,2020 | 904.54 | Jointliabilityassurance | Theminorityshareholders | 2020.12.28-2021.12.27 | N | Y |
ChainCo.,Ltd. | havesignedtheequitypledgecontractandregisteredtheirequitypledges | |||||||||
SinopharmHoldingGuodaDrugstoreNanjingChainCo.,Ltd. | April22,2020 | 600 | December21,2020 | 474.23 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreInnerMongoliaCo.,Ltd | April22,2020 | 1,800.00 | September23,2020 | 1,109.97 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.09.23-2021.08.19 | N | Y | |
SinopharmHoldingGuodaDrugstoreInnerMongoliaCo.,Ltd | April22,2020 | 1,800 | July21,2020 | 1,215.9 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.07.21-2021.07.21 | N | Y | |
SinopharmHoldingGuodaDrugstore | April22,2020 | 6,000 | October21,2020 | 4,267.06 | Jointliabilityassurance | Theminorityshareho | 2020.10.21-2021.10.20 | N | Y |
InnerMongoliaCo.,Ltd | ldershavesignedtheequitypledgecontractandregisteredtheirequitypledges | |||||||||
SinopharmHoldingGuodaDrugstoreInnerMongoliaCo.,Ltd | April22,2020 | 4,800 | December21,2020 | 1,928.6 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreInnerMongoliaCo.,Ltd | April2,2021 | 1,800 | June7,2021 | 1,531.37 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.07-2022.05.12 | N | Y | |
SinopharmHoldingGuodaDrugstoreInnerMongoliaCo.,Ltd | April2,2021 | 3,600 | April28,2021 | 3,363.63 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.04.28-2021.12.31 | N | Y | |
SinopharmHoldingGuoda | April22,2020 | 4,800 | December25,2020 | 3,551.98 | Jointliabilityassurance | Theminority | 2020.12.25-2021.04.2 | N | Y |
DrugstoreShanxiYiyuanChainCo.,Ltd. | shareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 1 | ||||||||
SinopharmHoldingGuodaDrugstoreShanxiYiyuanChainCo.,Ltd. | April2,2021 | 5,040 | May6,2021 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.05.06-2022.05.05 | N | Y | ||
SinopharmHoldingGuodaDrugstoreShanxiYiyuanChainCo.,Ltd. | April22,2020 | 3,600 | November28,2020 | 72.39 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.11.28-2021.11.27 | N | Y | |
SinopharmHoldingGuodaDrugstoreShanxiYiyuanChainCo.,Ltd. | April22,2020 | 9,000 | October21,2020 | 7,581.6 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.10.21-2021.10.20 | N | Y | |
SinopharmHolding | April2,2021 | 4,200 | June8,2021 | 3,437.3 | Jointliability | Theminorit | 2021.06.08- | N | Y |
GuodaDrugstoreShanxiYiyuanChainCo.,Ltd. | assurance | yshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2022.05.12 | |||||||
SinopharmHoldingGuodaDrugstoreShanghaiChainCo.,Ltd. | April22,2020 | 1,800 | November27,2020 | 1,390.97 | Jointliabilityassurance | 2020.11.27-2021.11.27 | N | Y | ||
SinopharmHoldingGuodaDrugstoreShanghaiChainCo.,Ltd. | April2,2021 | 2,400 | June20,2021 | 810.57 | Jointliabilityassurance | 2021.06.20-2022.06.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreShanghaiChainCo.,Ltd. | August24,2019 | 2,400 | April13,2020 | 115.48 | Jointliabilityassurance | 2020.04.13-2021.04.12 | N | Y | ||
SinopharmHoldingGuodaDrugstoreShanghaiChainCo.,Ltd. | April22,2020 | 3,000 | June29,2020 | 547.41 | Jointliabilityassurance | 2020.06.29-2021.06.28 | N | Y | ||
SinopharmHoldingGuodaDrugstoreShenyangChainCo.,Ltd. | April22,2020 | 6,000 | December21,2020 | 4,752.98 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreShenyang | April22,2020 | 6,000 | November4,2020 | 2,312.34 | Jointliabilityassurance | Theminorityshareholders | 2020.11.04-2021.11.04 | N | Y |
ChainCo.,Ltd. | havesignedtheequitypledgecontractandregisteredtheirequitypledges | |||||||||
SinopharmHoldingGuodaDrugstoreShenyangChainCo.,Ltd. | April22,2020 | 12,000 | October21,2020 | 11,999.51 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.10.21-2021.10.20 | N | Y | |
SinopharmHoldingGuodaDrugstoreShenyangChainCo.,Ltd. | April2,2021 | 13,800 | June1,2021 | 13,746.37 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.01-2022.05.12 | N | Y | |
SinopharmHoldingGuodaDrugstoreUlanqabCo.,Ltd. | April2,2021 | 600 | June4,2021 | 23.69 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.04-2022.05.12 | N | Y | |
SinopharmHoldingGuodaDrugstore | April22,2020 | 3,000 | December8,2020 | 1,804.79 | Jointliabilityassurance | 2020.12.08-2021.12.08 | N | Y |
XinjiangNewSpecialMedicineChainCo.,Ltd. | ||||||||||
SinopharmHoldingGuodaDrugstoreXinjiangNewSpecialMedicineChainCo.,Ltd. | April2,2021 | 4,800 | May26,2021 | 3,271.49 | Jointliabilityassurance | 2021.05.26-2022.05.12 | N | Y | ||
SinopharmHoldingGuodaDrugstoreYangzhouDadeshengChainCo.,Ltd. | April22,2020 | 1,200 | October21,2020 | 921.83 | Jointliabilityassurance | 2020.10.21-2021.10.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreYangzhouDadeshengChainCo.,Ltd. | April22,2020 | 1,200 | December21,2020 | 1,139.33 | Jointliabilityassurance | 2020.12.21-2021.12.20 | N | Y | ||
SinopharmHoldingGuodaDrugstoreZhengzhouChainCo.,Ltd. | April22,2020 | 300 | December21,2020 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | ||
SinopharmHoldingTianheJilinMedicinesCo.,Ltd. | April22,2020 | 6,000 | November24,2020 | 3,762.85 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequity | 2020.11.24-2021.11.23 | N | Y |
pledges | ||||||||||
SinopharmHoldingTianheJilinMedicinesCo.,Ltd. | April22,2020 | 3,000 | October21,2020 | 2,674.68 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.10.21-2021.10.20 | N | Y | |
SinopharmHoldingTianheJilinMedicinesCo.,Ltd. | April22,2020 | 6,000 | November30,2020 | 607.42 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.11.30-2021.11.29 | N | Y | |
SinopharmHoldingTianheJilinMedicinesCo.,Ltd. | April2,2021 | 6,000 | April28,2021 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.04.28-2022.04.27 | N | Y | ||
HunanGuodaMinshentangDrugstoreChainCo.,Ltd. | April22,2020 | 1,800 | October21,2020 | 1,432.55 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheir | 2020.10.21-2021.10.20 | N | Y |
equitypledges | ||||||||||
HunanGuodaMinshentangDrugstoreChainCo.,Ltd. | April22,2020 | 1,200 | December21,2020 | 76.92 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.12.21-2021.12.20 | N | Y | |
LiaoningChengdaFangyuanMedicineChainCo.,Ltd. | April2,2021 | 15,000 | June22,2021 | 10,897.58 | Jointliabilityassurance | 2021.06.22-2022.06.21 | N | Y | ||
LiaoningChengdaFangyuanMedicineChainCo.,Ltd. | October22,2020 | 6,000 | December21,2020 | 5,370.28 | Jointliabilityassurance | 2020.12.21-2021.12.20 | N | Y | ||
LiaoningChengdaFangyuanMedicineChainCo.,Ltd. | April2,2021 | 4,800 | June1,2021 | 1,288.3 | Jointliabilityassurance | 2021.06.01-2022.05.12 | N | Y | ||
LiaoningChengdaFangyuanMedicineChainCo.,Ltd. | October22,2020 | 6,000 | October22,2020 | 5,838.3 | Jointliabilityassurance | 2020.10.22-2021.10.20 | N | Y | ||
LiaoningGuodaMedicinesCo.,Ltd. | April22,2020 | 600 | October21,2020 | 600 | Jointliabilityassurance | 2020.10.21-2021.10.20 | N | Y | ||
LiaoningGuodaMedicinesCo.,Ltd. | April2,2021 | 3,000 | June1,2021 | 2,993.3 | Jointliabilityassurance | 2021.06.01-2022.05.12 | N | Y | ||
InnerMongoliaGuodaMedicineCo.,Ltd. | April2,2021 | 2,400 | June7,2021 | Jointliabilityassurance | 2021.06.07-2022.05.12 | N | Y | |||
NingxiaGuodaDrugstoreChainCo.,Ltd. | April22,2020 | 2,400 | September7,2020 | 1,593.6 | Jointliabilityassurance | 2020.09.07-2021.09.06 | N | Y | ||
Ningxia | April22, | 1,200 | December | 10.45 | Joint | 2020.12.2 | N | Y |
GuodaDrugstoreChainCo.,Ltd. | 2020 | 21,2020 | liabilityassurance | 1-2021.12.20 | ||||||
ShanxiGuodaWanminDrugstoreChainCo.,Ltd. | April22,2020 | 3,600 | October28,2020 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.10.28-2021.10.27 | N | Y | ||
ShanxiGuodaWanminDrugstoreChainCo.,Ltd. | April22,2020 | 3,600 | July9,2020 | 1,332.00 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2020.07.09-2021.07.09 | N | Y | |
ShanxiGuodaWanminDrugstoreChainCo.,Ltd. | April2,2021 | 15,000 | June8,2021 | 12,120.00 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.08-2022.05.12 | N | Y | |
ShanxiGuodaWanminDrugstoreChainCo.,Ltd. | April22,2020 | 5,400 | October21,2020 | 5,400 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontract | 2020.10.21-2021.10.20 | N | Y |
andregisteredtheirequitypledges | ||||||||||
ShanxiGuodaWanminDrugstoreChainCo.,Ltd. | April2,2021 | 3,000 | April29,2021 | 720 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.04.29-2022.04.15 | N | Y | |
PudongNewAreaofShanghaiPharmaceuticalMedicineCo.,Ltd. | April22,2020 | 3,000 | July24,2020 | Jointliabilityassurance | 2020.07.24-2021.07.23 | N | Y | |||
YanjiXiangheMedicinesCo.,Ltd. | April2,2021 | 1,800 | June8,2021 | 120 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.08-2022.05.12 | N | Y | |
YushuDinghePharmaceuticalTechnologyCo.,Ltd. | April2,2021 | 1,800 | June8,2021 | 840 | Jointliabilityassurance | Theminorityshareholdershavesignedtheequitypledgecontractandregisteredtheirequitypledges | 2021.06.08-2022.05.12 | N | Y | |
Totalamountofapprovingguaranteeforsubsidiaries | 107,640.00 | Totalamountofactualoccurredguaranteefor | 344,749.89 |
inreportperiod(C1) | subsidiariesinreportperiod(C2) | |||
Totalamountofapprovedguaranteeforsubsidiariesattheendofreportingperiod(C3) | 285,720.00 | Totalbalanceofactualguaranteeforsubsidiariesattheendofreportingperiod(C4) | 172,572.81 | |
TotalamountofguaranteeoftheCompany(totalofthreeabovementionedguarantee) | ||||
Totalamountofapprovingguaranteeinreportperiod(A1+B1+C1) | 609,140.00 | Totalamountofactualoccurredguaranteeinreportperiod(A2+B2+C2) | 1,145,802.78 | |
Totalamountofapprovedguaranteeattheendofreportperiod(A3+B3+C3) | 1,227,220.00 | Totalbalanceofactualguaranteeattheendofreportperiod(A4+B4+C4) | 693,062.44 | |
TheproportionofthetotalamountofactuallyguaranteeinthenetassetsoftheCompany(thatisA4+B4+C4) | 48.31% | |||
Including: | ||||
Amountofguaranteeforshareholders,actualcontrolleranditsrelatedparties(D) | Notapplicable | |||
Thedebtsguaranteeamountprovidedfortheguaranteedpartieswhoseassets-liabilityratioexceed70%directlyorindirectly(E) | Notapplicable | |||
ProportionoftotalamountofguaranteeinnetassetsoftheCompanyexceed50%(F) | Notapplicable | |||
Totalamountoftheaforesaidthreeguarantees(D+E+F) | Notapplicable | |||
Explanationsonpossiblybearingjointandseveralliquidatingresponsibilitiesforundueguarantees(ifapplicable) | Notapplicable | |||
Explanationsonexternalguaranteeagainstregulatedprocedures(ifapplicable) | Notapplicable |
ExplanationonguaranteeusingthecompositewayNil
3.Trustfinancing
□Applicable√NotapplicableTheCompanyhadnotrustfinancinginthereportingperiod.
4.Significantcontractsfordailyoperation
□Applicable√Notapplicable
5.Othersignificantcontract
□Applicable√NotapplicableThecompanyhadnoothersignificantcontractinthereportingperiod.
XIII.Descriptionofothersignificantmatters
□Applicable√NotapplicableThecompanyhadnoothersignificantmattersthatneeddescriptioninthereportingperiod.XIV.Importanteventofthesubsidiaries
□Applicable√Notapplicable
SectionVII.ChangesinSharesandParticularsaboutShareholders
I.ChangesinShareCapital
1.ChangesinShareCapital
Unit:share
BeforetheChange | Increase/DecreaseintheChange(+,-) | AftertheChange | |||||||
Amount | Proportion | Newsharesissued | Bonusshares | Publicreservetransferintosharecapital | Others | Subtotal | Amount | Proportion | |
I.Restrictedshares | 5,508,883 | 1.29% | 5,508,883 | 1.29% | |||||
1.State-ownedshares | |||||||||
2.State-ownedlegalperson’sshares | 5,505,770 | 1.29% | 5,505,770 | 1.29% | |||||
3.Otherdomesticshares | 3,113 | 0.00% | 3,113 | 0.00% | |||||
Including:Domesticlegalperson’sshares | 0 | 0.00% | 0 | 0.00% | |||||
Domesticnaturalperson’sshares | 3,113 | 0.00% | 3,113 | 0.00% | |||||
4.Foreignshares | |||||||||
Including:Foreignlegalperson’sshares | |||||||||
Foreignnaturalperson’sshares | |||||||||
II.Unrestrictedshares | 422,618,100 | 98.71% | 422,618,100 | 98.71% | |||||
1.RMBordinaryshares | 367,733,625 | 85.89% | 367,733,625 | 85.89% | |||||
2.Domesticallylistedforeignshares | 54,884,475 | 12.82% | 54,884,475 | 12.82% | |||||
3.Overseaslistedforeignshares | |||||||||
4.Others | |||||||||
III.Totalshares | 428,126,983 | 100.00% | 428,126,983 | 100.00% |
Reasonsforsharechanged
□Applicable√NotapplicableApprovalofsharechanged
□Applicable√NotapplicableOwnershiptransferofsharechanged
□Applicable√NotapplicableProgressofsharesbuy-back
□Applicable√NotapplicableImplementationprogressofreducingholdingsofsharesbuy-backbycentralizedbidding
□Applicable√NotapplicableInfluenceonthebasicEPSanddilutedEPSaswellasotherfinancialindexesofnetassetspershareattributabletocommonshareholdersofCompanyinlatestyearandperiod
□Applicable√NotapplicableOtherinformationnecessarytodiscloseorneedtodisclosedunderrequirementfromsecurityregulators
□Applicable√Notapplicable
2.Changesoflock-upstocks
□Applicable√NotapplicableII.Securitiesissuanceandlisting
□Applicable√Notapplicable
III.AmountofshareholdersoftheCompanyandparticularsaboutsharesholding
Unit:share
Totalcommonstockshareholdersinreportingperiod-end | 43,600 | Totalpreferenceshareholderswithvotingrightsrecoveredatendofreportingperiod(ifapplicable) | 0 | |||||||
Particularsaboutcommonsharesheldabove5%byshareholdersortoptencommonshareholders | ||||||||||
FullnameofShareholders | Natureofshareholder | Proportionofsharesheld | Amountofcommonsharesheldattheendofreportingperiod | Changesinreportperiod | Amountofrestrictedcommonsharesheld | Amountofcommonsharesheldwithoutrestriction | Informationofsharespledged,taggedorfrozen | |||
Stateofshare | Amount | |||||||||
SinopharmGroupCo.,Ltd. | State-ownedCorporation | 56.06% | 239,999,991 | 5,505,770 | 234,494,221 | |||||
FIRSTSENTIERINVESTORSGLOBALUMBRELLAFUNDPLC-FSSACHINAGROWTHFUND | ForeignCorporation | 2.68% | 11,469,644 | 11,469,644 | ||||||
HongKongSecuritiesClearingCompanyLtd | ForeignCorporation | 2.58% | 11,033,948 | 11,033,948 | ||||||
ChinaNationalPharmaceuticalForeignTrade | State-ownedCorporation | 1.24% | 5,323,043 | 5,323,043 |
Corp. | ||||||||
NationalSocialSecurityFund413Portfolio | Domesticnonstate-ownedCorporation | 0.98% | 4,200,032 | 4,200,032 | ||||
BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | ForeignCorporation | 0.78% | 3,358,761 | 3,358,761 | ||||
ChinaConstructionBankCorporation-ChinaEuropeValueDiscoveryEquityFund | Domesticnonstate-ownedCorporation | 0.73% | 3,111,875 | 3,111,875 | ||||
CPICFund-ChinaPacificLifeInsuranceCo.,Ltd.-with-profitinsurance-CPICFundChinaPacificLifeEquityRelativeIncome(GuaranteedDividend)singleassetsmanagementplan | Domesticnonstate-ownedCorporation | 0.66% | 2,822,801 | 2,822,801 | ||||
FidelityInvestmentManagement(HongKong)Limited-Client’sfund | ForeignCorporation | 0.54% | 2,308,237 | 2,308,237 | ||||
VANGUARDEMERGINGMARKETSSTOCKINDEXFUND | ForeignCorporation | 0.41% | 1,756,387 | 1,756,387 | ||||
Explanationonassociatedrelationshipamongtheaforesaidshareholders | SinopharmGroupCo.,Ltd.andChinaNationalPharmaceuticalForeignTradeCorporationhavethesameactualcontroller,whichisChinaNationalPharmaceuticalGroupCorporation.ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. | |||||||
Descriptionoftheaboveshareholdersinrelationtodelegate/entrustedvotingrightsandabstentionfromvotingrights. | Notapplicable | |||||||
Particularabouttoptenshareholderswithun-lockupcommonstocksheld | ||||||||
Shareholders’name | AmountofcommonsharesheldwithoutrestrictionatPeriod-end | Typeofshares | ||||||
Type | Amount | |||||||
SinopharmGroupCo.,Ltd | 234,494,221 | RMBordinaryshares | 234,494,221 | |||||
FIRSTSENTIERINVESTORS | 11,469,644 | Domestically | 11,469,644 |
GLOBALUMBRELLAFUNDPLC-FSSACHINAGROWTHFUND | listedforeignshares | ||
HongKongSecuritiesClearingCompanyLtd | 11,033,948 | RMBordinaryshares | 11,033,948 |
ChinaNationalPharmaceuticalForeignTradeCorp. | 5,323,043 | RMBordinaryshares | 5,323,043 |
NationalSocialSecurityFund413Portfolio | 4,200,032 | RMBordinaryshares | 4,200,032 |
BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | 3,358,761 | Domesticallylistedforeignshares | 3,358,761 |
ChinaConstructionBankCorporation-ChinaEuropeValueDiscoveryEquityFund | 3,111,875 | RMBordinaryshares | 3,111,875 |
CPICFund-ChinaPacificLifeInsuranceCo.,Ltd.-with-profitinsurance-CPICFundChinaPacificLifeEquityRelativeIncome(GuaranteedDividend)singleassetsmanagementplan | 2,822,801 | RMBordinaryshares | 2,822,801 |
FidelityInvestmentManagement(HongKong)Limited-Client’sfund | 2,308,237 | RMBordinaryshares | 2,308,237 |
VANGUARDEMERGINGMARKETSSTOCKINDEXFUND | 1,756,387 | Domesticallylistedforeignshares | 1,756,387 |
Expiationonassociatedrelationshiporconsistentactorswithinthetop10un-lockupcommonshareholdersandbetweentop10un-lockupcommonshareholdersandtop10commonshareholders | SinopharmGroupCo.,Ltd.andChinaNationalPharmaceuticalForeignTradeCorporationhavethesameactualcontroller,whichisChinaNationalPharmaceuticalGroupCorporation.ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. |
Whethertoptencommonstockshareholdersortoptencommonstockshareholderswithun-lockupsharesheldhaveabuy-backagreementdealinginreportingperiod
□Yes√NoThetoptencommonstockshareholdersortoptencommonstockshareholderswithun-lockupsharesheldoftheCompanyhavenobuy-backagreementdealinginreportingperiod.IV.Changesofsharesheldbydirectors,supervisorsandseniorexecutives
□Applicable√NotapplicableSharesheldbydirectors,supervisorsandseniorexecutiveshavenochangesinreportingperiod,foundmoredetailsinAnnualReport2020.V.Changesincontrollingshareholdersoractualcontrollers
Changeofcontrollingshareholderduringthereportingperiod
□Applicable√NotapplicableTheCompanyhadnochangeofcontrollingshareholderduringthereportingperiod
Changeofactualcontrollerduringthereportingperiod
□Applicable√NotapplicableTheCompanyhadnochangeofactualcontrollerduringthereportingperiod
SectionVIII.PreferredStock
□Applicable√NotapplicableTheCompanyhadnopreferredstockinthePeriod.
SectionIX.CorporateBonds
□Applicable√Notapplicable
SectionX.FinancialReport
I.AuditreportWhetherthesemiannualreportisaudited
□Yes√NoThecompany'ssemiannualfinancialreporthasnotbeenauditedII.FinancialStatementStatementinFinancialNotesarecarriedinRMB/CNY
CONSOLIDATEDBALANCESHEET
Asat30June2021(ExpressedinRenminbiYuan)
ASSETS | NoteV | 30June2021 | 31December2020 |
Currentassets | |||
Cashandbankbalances | 1 | 5,876,638,427.56 | 5,998,204,295.87 |
Notesreceivable | 2 | 606,070,192.39 | 622,115,477.04 |
Accountsreceivable | 3 | 17,761,176,449.25 | 13,799,971,014.22 |
Receivablefinancing | 4 | 345,906,887.55 | 1,404,987,700.38 |
Advancestosuppliers | 5 | 615,602,916.31 | 480,313,574.71 |
Otherreceivables | 6 | 662,274,841.26 | 535,228,747.69 |
Incl:Dividendreceivable | - | - | |
Inventories | 7 | 7,219,658,618.62 | 6,285,010,674.46 |
ContractAssets | 8 | 17,066,105.53 | 15,177,731.64 |
Othercurrentassets | 9 | 101,585,930.05 | 121,082,863.45 |
Totalcurrentassets | 33,205,980,368.52 | 29,262,092,079.46 |
Non-currentassets | |||
Long-termequityinvestments | 10 | 2,427,605,792.21 | 2,287,019,627.99 |
Otherequityinstrumentinvestment | 11 | 99,488,340.28 | 99,488,340.28 |
Othernon-currentfinancialassets | 12 | 117,974,908.51 | 120,972,350.24 |
Investmentproperties | 13 | 123,389,130.71 | 127,444,379.94 |
Fixedassets | 14 | 840,386,519.64 | 854,191,083.27 |
Constructioninprogress | 15 | 64,636,735.93 | 46,631,190.23 |
Right-of-useassets | 16 | 2,523,874,174.71 | 2,356,952,392.99 |
Intangibleassets | 17 | 751,492,524.18 | 734,345,179.40 |
Goodwill | 18 | 2,932,001,316.63 | 2,747,375,281.11 |
Long-termprepaidexpenses | 19 | 523,192,988.98 | 457,705,276.09 |
Deferredtaxassets | 20 | 96,595,749.33 | 92,118,767.81 |
Othernon-currentassets | 21 | 484,259,854.32 | 408,197,522.84 |
Totalnon-currentassets | 10,984,898,035.43 | 10,332,441,392.19 |
Totalassets | 44,190,878,403.95 | 39,594,533,471.65 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CONSOLIDATEDBALANCESHEET(Continued)
Asat30June2021(ExpressedinRenminbiYuan)
LIABILITIESANDEQUITY | NoteV | 30June2021 | 31December2020 |
Currentliabilities | |||
Short-termborrowings | 22 | 4,632,933,904.39 | 1,612,187,020.12 |
Notespayable | 23 | 6,780,425,089.17 | 7,520,165,274.69 |
Accountspayable | 24 | 9,642,504,836.50 | 7,697,451,142.50 |
Receiptsinadvance | 25 | 14,868,097.97 | 12,352,466.64 |
Contractliabilities | 26 | 316,827,151.78 | 368,600,357.14 |
Employeebenefitspayable | 27 | 242,205,983.09 | 357,212,047.10 |
Taxpayable | 28 | 298,201,588.13 | 316,867,149.16 |
Otherpayables | 29 | 1,531,899,017.87 | 1,599,166,881.14 |
Non-currentliabilitiesduewithinoneyear | 30 | 798,170,618.10 | 748,732,059.89 |
Othercurrentliabilities | 31 | 22,432,447.97 | 24,787,078.55 |
Totalcurrentliabilities | 24,280,468,734.97 | 20,257,521,476.93 |
Non-currentliabilities | |||
Long-termborrowings | 32 | 61,633,794.44 | 31,637,173.89 |
Leaseliabilities | 33 | 1,361,131,352.80 | 1,303,054,163.90 |
Long-termpayables | 34 | 6,938,189.00 | 6,938,189.00 |
Long-termemployeebenefitspayable | 35 | 1,262,000.00 | 1,319,000.00 |
Provisions | 36 | 68,663,166.79 | 68,808,166.79 |
Deferredincome | 37 | 91,315,333.89 | 89,843,583.37 |
Deferredtaxliabilities | 20 | 200,498,143.67 | 205,921,408.66 |
Othernon-currentliabilities | 38 | 630,839,755.01 | 740,862,989.59 |
Totalnon-currentliabilities | 2,422,281,735.60 | 2,448,384,675.20 |
Totalliabilities | 26,702,750,470.57 | 22,705,906,152.13 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CONSOLIDATEDBALANCESHEET(Continued)
Asat30June2021(ExpressedinRenminbiYuan)
LIABILITIESANDEQUITY | NoteV | 30June2021 | 31December2020 |
Equity | |||
Sharecapital | 39 | 428,126,983.00 | 428,126,983.00 |
Capitalsurplus | 40 | 4,372,043,185.43 | 4,372,504,053.72 |
Othercomprehensiveincome | 41 | 38,547,872.62 | 38,483,017.72 |
Surplusreserve | 42 | 214,063,491.50 | 214,063,491.50 |
Retainedearnings | 43 | 9,294,088,533.24 | 8,895,145,106.39 |
Totalequityattributabletoownersoftheparent | 14,346,870,065.79 | 13,948,322,652.33 | |
Non-controllinginterests | 3,141,257,867.59 | 2,940,304,667.19 |
Totalequity | 17,488,127,933.38 | 16,888,627,319.52 |
Totalliabilitiesandequity | 44,190,878,403.95 | 39,594,533,471.65 |
TheaccompanyingnotesformanintegralpartofthesefinancialstatementsThefinancialstatementshavebeensignedby:
Legalrepresentative:Financialcontroller:HeadofAccountingDepartment:
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.CONSOLIDATEDINCOMESTATEMENT(Continued)
Forthesixmonthsended30June2021(ExpressedinRenminbiYuan)
NoteV | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Operatingrevenue | 44 | 33,163,091,887.39 | 27,169,940,188.52 |
Less:Operatingcosts | 44 | 29,216,837,201.07 | 23,971,029,719.44 |
Taxesandsurcharges | 45 | 75,989,854.58 | 69,505,309.32 |
Sellingexpenses | 46 | 2,307,485,529.77 | 1,728,738,818.60 |
Administrativeexpenses | 47 | 492,536,936.71 | 443,287,144.92 |
Financecosts | 48 | 107,243,003.15 | 65,313,829.62 |
Incling:Interestexpense | 147,057,897.99 | 133,350,510.68 | |
Interestincome | 38,758,729.78 | 65,512,550.22 | |
Add:Interestexpense | 49 | 47,249,616.26 | 35,855,298.32 |
Investmentincome | 50 | 156,587,066.32 | 105,206,349.26 |
Incling:Investmentincomefromassociates | 157,696,397.81 | 133,604,904.16 | |
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | (7,039,046.60) | (33,507,102.64) | |
Creditimpairmentlosses | 51 | (28,664,985.44) | (21,580,231.52) |
Impairmentlosses | 52 | (416,915.26) | (1,743,888.30) |
Gainondisposalofassets | 53 | (588,799.55) | 4,305,324.80 |
Operatingprofits | 1,137,165,344.44 | 1,014,108,219.18 | |
Add:Non-operatingincome | 54 | 12,493,320.44 | 5,219,980.22 |
Less:Non-operatingexpenses | 55 | 3,237,951.35 | 3,008,892.52 |
Totalprofit | 1,146,420,713.53 | 1,016,319,306.88 | |
Less:Incometaxexpenses | 56 | 238,426,259.04 | 210,106,764.35 |
Netprofit | 907,994,454.49 | 806,212,542.53 | |
NetProfitfromcontinuingoperations | 907,994,454.49 | 806,212,542.53 |
Netprofitattributabletoownersoftheparent | 741,445,013.25 | 643,451,580.59 |
Profitorlossofnon-controllinginterests | 166,549,441.24 | 162,760,961.94 |
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.CONSOLIDATEDINCOMESTATEMENT(Continued)
Forthesixmonthsended30June2021(ExpressedinRenminbiYuan)
NoteV | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Othercomprehensiveincome,netoftax | 64,854.90 | 122,186.89 | |
Othercomprehensiveincome,netoftax,attributabletoownersoftheparent | 64,854.90 | 122,186.89 | |
Othercomprehensiveincomethatwillbereclassifiedtoprofitorloss | 64,854.90 | 122,186.89 | |
Othercomprehensiveincomeusingtheequitymethodthatwillbereclassifiedtoprofitorloss | 64,854.90 | 122,186.89 |
Totalcomprehensiveincome | 908,059,309.39 | 806,334,729,42 |
Incl:Totalcomprehensiveincomeattributabletoownersoftheparent | 741,509,868.15 | 643,573,767.48 | |
Totalcomprehensiveincomeattributabletonon-controllinginterests | 166,549,441.24 | 162,760,961.94 |
Earningspershare | |||
Basicearningspershare | 1.73 | 1.50 | |
Dilutedearningspershare | 1.73 | 1.50 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.CONSOLIDATEDSTATEMENTOFCHANGESINEQUITY
Forthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
Forthesixmonthsended30June2021 | Attributabletoownersoftheparent | |||||||
Sharecapital | Capitalsurplus | Othercomprehensiveincome | Surplusreserves | Retainedearnings | Subtotal | Non-controllinginterests | Totalequity |
I.Balanceatendofprioryear | 428,126,983.00 | 4,372,504,053.72 | 38,483,017.72 | 214,063,491.50 | 8,895,145,106.39 | 13,948,322,652.33 | 2,940,304,667.19 | 16,888,627,319.52 |
Add:Businesscombinationinvolvingentitiesundercommoncontrol | - | - | - |
II.Balanceatbeginningofyear | 428,126,983.00 | 4,372,504,053.72 | 38,483,017.72 | 214,063,491.50 | 8,895,145,106.39 | 13,948,322,652.33 | 2,940,304,667.19 | 16,888,627,319.52 |
III.Changesfortheyear | - | (460,868.29) | 64,854.90 | - | 398,943,426.85 | 398,547,413.46 | 200,953,200.40 | 599,500,613.86 |
(1)Totalcomprehensiveincome | - | - | 64,854.90 | - | 741,445,013.25 | 741,509,868.15 | 166,549,441.24 | 908,059,309.39 |
(2)Owners’contributionsandreductionincapital | - | (460,868.29) | - | - | (460,868.29) | 58,773,146.38 | 58,312,278.09 | |
1.Capitalcontributionsbyowners | - | - | - | - | - | - | 15,680,000.00 | 15,680,000.00 |
2.Others | - | (460,868.29) | - | - | (460,868.29) | 43,093,146.38 | 42,632,278.09 | |
(3)Profitdistribution | - | - | - | (342,501,586.40)- | (342,501,586.40) | (24,369,387.22) | (366,870,973.62) | |
1.Distributiontoequityowners | - | - | - | (342,501,586.40)- | (342,501,586.40) | (24,369,387.22) | (366,870,973.62) |
IV.Balanceatendofyear | 428,126,983.00 | 4,372,043,185.43 | 38,547,872.62 | 214,063,491.50 | 9,294,088,533.24 | 14,346,870,065.79 | 3,141,257,867.59 | 17,488,127,933.38 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.CONSOLIDATEDSTATEMENTOFCHANGESINEQUITY(Continued)
Forthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
Forthesixmonthsended30June2020 | Attributabletoownersoftheparent | |||||||
Sharecapital | Capitalsurplus | Othercomprehensiveincome | Surplusreserves | Retainedearnings | Subtotal | Non-controllinginterests | Totalequity |
I.Balanceatendofprioryear | 428,126,983.00 | 4,363,007,511.57 | 45,917,342.77 | 214,063,491.50 | 7,755,295,537.08 | 12,806,410,865.92 | 2,553,426,974.31 | 15,359,837,840.23 |
Add:Businesscombinationinvolvingentitiesundercommoncontrol | - | 107,759,447.87 | - | - | (3,029,877.91) | 104,729,569.96 | 109,412,866.52 | 214,142,436.48 |
II.Balanceatbeginningofyear | 428,126,983.00 | 4,470,766,959.44 | 45,917,342.77 | 214,063,491.50 | 7,752,265,659.17 | 12,911,140,435.88 | 2,662,839,840.83 | 15,573,980,276.71 |
III.Changesfortheyear | - | (97,854,894.55) | 122,186.89 | - | 386,575,390.79 | 288,842,683.13 | 154,985,375.48 | 443,828,058.61 |
(1)Totalcomprehensiveincome | - | - | 122,186.89 | - | 643,451,580.59 | 643,573,767.48 | 162,760,961.94 | 806,334,729.42 |
(2)Owners’contributionsandreductionincapital | - | (97,854,894.55) | - | - | (97,854,894.55) | 10,931,276.73 | (86,923,617.82) | |
1.Capitalcontributionsbyowners | - | - | - | - | - | - | ||
2.Others | - | (97,854,894.55) | - | - | (97,854,894.55) | 10,931,276.73- | (86,923,617.82) | |
(3)Profitdistribution | - | - | - | - | (256,876,189.80) | (256,876,189.80) | (18,706,863.19) | (275,583,052.99) |
1.Distributiontoequityowners | - | - | - | - | (256,876,189.80) | (256,876,189.80) | (18,706,863.19) | (275,583,052.99) |
IV.Balanceatendofyear | 428,126,983.00 | 4,372,912,064.89 | 46,039,529.66 | 214,063,491.50 | 8,138,841,049.96 | 13,199,983,119.01 | 2,817,825,216.31 | 16,017,808,335.32 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CONSOLIDATEDCASHFLOWSTATEMENT
Forthesixmonthsended30June2021(ExpressedinRenminbiYuan)
NoteV | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
1.CASHFLOWSFROMOPERATINGACTIVITIESCashreceivedfromsalesofgoodandthe
renderingofservices
Cashreceivedfromsalesofgoodandtherenderingofservices | 32,800,434,055.12 | 27,735,103,033.02 | |
Receiptsoftaxesandsurchargesrefunds | 9,380,253.27 | 8,145,306.66 | |
Othercashreceiptsrelatingtooperatingactivities | 57 | 368,590,875.46 | 707,202,110.00 |
Totalcashinflowsfromoperatingactivities | 33,178,405,183.85 | 28,450,450,449.68 |
Cashpaymentsforgoodsandservices | 28,541,885,459.35 | 24,305,374,637.56 | |
Cashpaymentstoandonbehalfofemployees | 1,708,255,657.44 | 1,278,474,969.40 | |
Paymentsofalltypesoftaxesandsurcharges | 766,110,586.13 | 724,722,540.88 | |
Othercashpaymentsrelatingtooperatingactivities | 57 | 932,780,197.36 | 703,674,258.49 |
Totalcashoutflowsfromoperatingactivities | 31,949,031,900.28 | 27,012,246,406.33 | |
Netcashflowsfromoperatingactivities | 58 | 1,229,373,283.57 | 1,438,204,043.35 |
2.CASHFLOWSFROMINVESTINGACTIVITIESCashreceiptsfromreturnsofinvestments
Cashreceiptsfromreturnsofinvestments | 2,997,441.73 | 19,027,649.76 | |
Cashreceiptsfromreturnsoninvestments | 22,643,935.31 | 84,166,102.10 | |
Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 537,887.38 | 4,352,536.98 |
Othercashreceiptsrelatingtoinvestingactivities | 57 | 54,984.60 | 22,040,000.00 |
Totalcashinflowsfrominvestingactivities | 26,234,249.02 | 129,586,288.84 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.CONSOLIDATEDCASHFLOWSTATEMENT(Continued)
Forthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
NoteV | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
2.CASHFLOWSFROMINVESTINGACTIVITIES(Continued)Cashpaymentstoacquirefixedassets,intangible
assetsandotherlong-termassets
Cashpaymentstoacquirefixedassets,intangibleassetsandotherlong-termassets | 145,820,319.98 | 116,186,214.91 | |
Cashpaymentsforinvestments | 70,724,113.00 | 20,545,399.15 | |
Netcashpaymentsforacquisitionofsubsidiariesandotherbusinessunits | 100,950,637.41 | 659,201,491.65 | |
Othercashpaymentsrelatingtoinvestingactivities | - | - |
Totalcashoutflowsfrominvestingactivities | 317,495,070.39 | 795,933,105.71 |
Netcashflowsfrominvestingactivities | (291,260,821.37) | (666,346,816.87) |
3.CASHFLOWSFROMFINANCINGACTIVITIESCashproceedsfrominvestmentsbyothers
Cashproceedsfrominvestmentsbyothers | 15,680,000.00 | - | |
Incl:Cashreceiptsfromcapitalcontributionsfromnon-controllinginterestsofsubsidiaries | 15,680,000.00 | - | |
Cashreceiptsfromborrowings | 915,684,894.52 | 589,920,037.57 | |
Othercashreceiptsrelatingtofinancingactivities | 57 | 104,090,555.62 | 334,349,840.06 |
Totalcashinflowsfromfinancingactivities | 1,035,455,450.14 | 924,269,877.63 |
Cashrepaymentsfordebts | 511,076,477.58 | 284,200,000.00 | |
Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 492,345,229.08 | 432,276,651.88 | |
Incl:Dividendsorprofitpaidtonon-controllingshareholdersofsubsidiaries | 22,846,959.82 | 10,890,773.58 | |
Othercashpaymentsrelatingtofinancingactivities | 57 | 838,045,248.87 | 1,405,111,664.26 |
Totalcashoutflowsfromfinancingactivities | 1,841,466,955.53 | 2,121,588,316.14 |
Netcashflowsfromfinancingactivities | (806,011,505.39) | (1,197,318,438.51) |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.CONSOLIDATEDCASHFLOWSTATEMENT(Continued)
Forthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
NoteV | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
4.EFFECTOFFOREIGNEXCHANGERATECHANGESONCASHANDCASHEQUIVALENTS | 392,002.63 | (47,935.97) |
5.NETINCREASE/DECREASEINCASHANDCASHEQUIVALENTS | 58 | 132,492,959.44 | (425,509,148.00) |
Add:Cashandcashequivalentsatbeginningoftheyear | 5,405,113,257.99 | 8,426,071,170.16 |
6.CASHANDCASHEQUIVALENTSATENDOFYEAR | 58 | 5,537,606,217.43 | 8,000,562,022.16 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYBALANCESHEET
Asat30June2021(ExpressedinRenminbiYuan)
ASSETS | NoteXIV | 30June2021 | 31December2020 |
Currentassets | |||
Cashandbankbalances | 3,365,069,497.52 | 3,020,909,473.71 | |
Notesreceivable | 64,759,826.01 | 30,984,449.44 | |
Accountsreceivable | 1 | 701,273,128.58 | 609,575,301.13 |
Receivablesfinancing | 2,436,398.01 | 30,248,631.32 | |
Advancestosuppliers | 4,566,924.77 | 6,722,204.59 | |
Otherreceivables | 2 | 3,467,427,719.16 | 3,562,309,346.07 |
Inventories | 189,783,318.68 | 172,275,777.63 | |
CurrentAssets | 103,944.56 | 139,154.54 | |
Othercurrentassets | 39,482.38 | 39,482.38 |
Totalcurrentassets | 7,795,460,239.67 | 7,433,203,820.81 |
Non-currentassets | |||
Long-termequityinvestments | 3 | 8,014,254,485.09 | 7,873,668,245.16 |
Othernon-currentfinancialassets | 117,974,908.51 | 120,972,350.24 | |
Investmentproperties | 1,436,098.78 | 1,452,132.04 | |
Fixedassets | 12,027,831.98 | 13,279,902.76 | |
Right-of-useassets | 4,581,076.34 | 5,142,755.88 | |
Intangibleassets | 5,801,168.94 | 4,622,268.00 | |
Long-termprepaidexpenses | 4,189,589.43 | 4,335,802.92 | |
Deferredtaxassets | 9,245,324.81 | 9,025,057.52 | |
Othernon-currentassets | 36,250,241.84 | 12,967,715.50 |
Totalnon-currentassets | 8,205,760,725.72 | 8,045,466,230.02 |
Totalassets | 16,001,220,965.39 | 15,478,670,050.83 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYBALANCESHEET(Continued)
Asat30June2021(ExpressedinRenminbiYuan)
LIABILITIESANDSHAREHOLDERS’EQUITY | 30June2021 | 31December2020 |
Currentliabilities | |||
Short-termborrowings | 878,608,520.99 | 157,892,942.24 | |
Notespayable | 393,434,370.38 | 756,364,719.49 | |
Accountspayable | 507,406,947.28 | 407,275,713.49 | |
Contractliabilities | 8,566,647.98 | 1,807,562.61 | |
Employeebenefitspayable | 34,107,984.22 | 36,672,344.48 | |
Taxpayables | 16,253,302.56 | 13,975,905.04 | |
Otherpayables | 2,720,704,209.77 | 3,167,152,583.28 | |
Non-currentliabilitiesduewithinoneyear | 1,078,862.94 | 1,056,120.58 | |
Othercurrentliabilities | 1,434,414.00 | 636,200.63 |
Totalcurrentliabilities | 4,561,595,260.12 | 4,542,834,091.84 |
Non-currentliabilities | |||
Long-termborrowings | 31,633,794.44 | 31,637,173.89 | |
Leaseliabilities | 3,909,950.01 | 4,455,967.97 | |
Long-termpayables | 800,000.00 | 800,000.00 | |
Deferredincome | 603,137.94 | 827,658.18 | |
Othernon-currentliabilities | 22,866,538.58 | 11,042.52 |
Totalnon-currentliabilities | 59,813,420.97 | 37,731,842.56 |
Totalliabilities | 4,621,408,681.09 | 4,580,565,934.40 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYBALANCESHEET(Continued)
Asat30June2021(ExpressedinRenminbiYuan)
LIABILITIESANDSHAREHOLDERS’EQUITY | 30June2021 | 31December2020 |
Shareholders’equity | |||
Sharecapital | 428,126,983.00 | 428,126,983.00 | |
Capitalsurplus | 4,467,530,563.30 | 4,467,991,431.59 | |
Othercomprehensiveincome | (63,178.42) | (128,033.32) | |
Surplusreserve | 214,063,491.50 | 214,063,491.50 | |
Retainedearnings | 6,270,154,424.92 | 5,788,050,243.66 |
Totalshareholders’equity | 11,379,812,284.30 | 10,898,104,116.43 |
Totalliabilitiesandshareholders’equity | 16,001,220,965.39 | 15,478,670,050.83 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYINCOMESTATEMENTForthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
NoteXIV | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Operatingrevenue | 4 | 2,078,370,123.36 | 1,772,487,363.56 |
Less:Operatingcosts | 4 | 1,991,420,311.80 | 1,689,564,062.24 |
Taxesandsurcharges | 2,488,284.74 | 2,582,640.86 | |
Sellingexpenses | 35,959,501.73 | 31,376,377.04 | |
Administrativeexpenses | 46,619,035.09 | 43,060,479.75 | |
Financecosts | (55,486,414.78) | (43,838,117.34) | |
Incl:Interestexpense | 27,864,903.28 | 21,928,061.34 | |
Interestincome | 83,409,776.86 | 66,569,319.85 | |
Add:Otherincomes | 1,931,159.58 | 629,921.47 | |
Investmentincome | 5 | 780,364,601.71 | 749,633,760.78 |
Incl:Investmentincomefromassociates | 157,696,473.52 | 133,549,495.38 | |
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | (221,815.32) | (1,526,968.25) | |
Creditimpairmentlosses | (123,032.41) | (976,022.96) | |
Impairmentlosses | (281,770.77) | (242,731.87) | |
Gainondisposalofassets | 80,996.38 | - |
Operatingprofits | 839,341,359.27 | 798,786,848.43 | |
Add:Non-operatingincome | 408,885.12 | 1,596.77 | |
Less:Non-operatingexpenses | - | 52,122.72 |
Totalprofit | 839,750,244.39 | 798,736,322.48 | |
Less:Incometaxexpenses | 15,144,476.73 | 9,645,280.09 |
Netprofit | 824,605,767.66 | 789,091,042.39 | |
Profitorlossfromcontinuingoperations | 824,605,767.66 | 789,091,042.39 |
Othercomprehensiveincome,netoftax | 64,854.90 | 122,186.89 | |
Othercomprehensiveincomethatwillbereclassifiedtoprofitorloss | 64,854.90 | 122,186.89 | |
Othercomprehensiveincomeusingtheequitymethodthatwillbereclassifiedtoprofitorloss | 64,854.90 | 122,186.89 |
Totalcomprehensiveincome | 824,670,622.56 | 789,213,229.28 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYSTATEMENTOFCHANGESINEQUITY
Forthesixmonthsended30June2021(ExpressedinRenminbiYuan)
Forthesixmonthsended30June2021 | Sharecapital | Capitalsurplus | Othercomprehensiveincome | Surplusreserve | Retainedearnings | Totalequity |
I.Balanceatendofprioryear | 428,126,983.00 | 4,467,991,431.59 | (128,033.32) | 214,063,491.50 | 5,788,050,243.66 | 10,898,104,116.43 |
II.Changesfortheyear | - | (460,868.29) | 64,854.90 | - | 482,104,181.26 | 481,708,167.87 |
(1)Totalcomprehensiveincome | - | - | 64,854.90 | - | 824,605,767.66 | 824,670,622.56 |
(2)Owners’contributionsandreductionincapital | - | (460,868.29) | - | - | - | (460,868.29) |
1.Others | - | (460,868.29) | - | - | - | (460,868.29) |
(3)Profitdistribution | - | - | - | - | (342,501,586.40) | (342,501,586.40) |
1.Distributiontoowners | - | - | - | - | (342,501,586.40) | (342,501,586.40) |
III.Balanceatendofyear | 428,126,983.00 | 4,467,530,563.30 | (63,178.42) | 214,063,491.50 | 6,270,154,424.92 | 11,379,812,284.30 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
CHINANATIONALACCORDMEDICINESCORPORATIONLTD.COMPANYSTATEMENTOFCHANGESINEQUITY(Continued)
Forthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
Forthesixmonthsended30June2020 | Sharecapital | Capitalsurplus | Othercomprehensiveincome | Surplusreserve | Retainedearnings | Totalequity |
I.Balanceatendofprioryear | 428,126,983.00 | 4,468,385,307.32 | (133,366.19) | 214,063,491.50 | 4,996,184,257.34 | 10,106,626,672.97 |
II.Changesfortheyear | - | 14,135.44 | 122,186.89 | - | 532,214,852.59 | 532,351,174.92 |
(1)Totalcomprehensiveincome | - | - | 122,186.89 | - | 789,091,042.39 | 789,213,229.28 |
(2)Owners’contributionsandreductionincapital | - | 14,135.44 | - | - | - | 14,135.44 |
1.Others | - | 14,135.44 | - | - | - | 14,135.44 |
(3)Profitdistribution | - | - | - | - | (256,876,189.80) | (256,876,189.80) |
1.Distributiontoowners | - | - | - | - | (256,876,189.80) | (256,876,189.80) |
III.Balanceatendofyear | 428,126,983.00 | 4,468,399,442.76 | (11,179.30) | 214,063,491.50 | 5,528,399,109.93 | 10,638,977,847.89 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYCASHFLOWSTATEMENTForthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
1.CASHFLOWSFROMOPERATINGACTIVITIESCashreceivedfromsalesofgoodandthe
renderingofservices
Cashreceivedfromsalesofgoodandtherenderingofservices | 2,051,451,080.04 | 1,959,922,054.30 | |
Othercashreceiptsrelatingtooperatingactivities | 31,548,087.03 | 56,400,693.21 |
Totalcashinflowsfromoperatingactivities | 2,082,999,167.07 | 2,016,322,747.51 |
Cashpaymentsforgoodsandservices | 1,882,952,590.62 | 1,808,113,785.36 | |
Cashpaymentstoandonbehalfofemployees | 61,431,053.37 | 56,731,764.12 | |
Paymentsofalltypesoftaxesandsurcharges | 36,319,473.82 | 34,728,524.87 | |
Othercashpaymentsrelatingtooperatingactivities | 11,443,446.22 | 36,411,653.42 |
Totalcashoutflowsfromoperatingactivities | 1,992,146,564.03 | 1,935,985,727.77 |
Netcashflowsfromoperatingactivities | 90,852,603.04 | 80,337,019.74 |
2.CASHFLOWSFROMINVESTINGACTIVITIESCashreceiptsfromreturnsofinvestments
Cashreceiptsfromreturnsofinvestments | 2,997,441.73 | 32,664,096.76 | |
Cashreceiptsfromreturnsoninvestments | 214,065,210.12 | 252,042,116.93 | |
Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 339,163.00 | - | |
Othercashreceiptsrelatingtoinvestingactivities | 2,324,825,373.52 | 1,575,127,297.73 |
Totalcashinflowsfrominvestingactivities | 2,542,227,188.37 | 1,859,833,511.42 |
Cashpaymentsforacquisitionoffixedassets,intangibleassetsandotherlong-termassets | 2,302,398.23 | 10,386,641.64 | |
Othercashpaymentsrelatingtoinvestingactivities | 2,155,040,000.00 | 1,309,671,874.11 |
Totalcashoutflowsfrominvestingactivities | 2,157,342,398.23 | 1,320,058,515.75 |
Netcashflowsfrominvestingactivities | 384,884,790.14 | 539,774,995.67 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
COMPANYCASHFLOWSTATEMENT(Continued)
Forthesixmonthsended30June2021
(ExpressedinRenminbiYuan)
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
3.CASHFLOWSFROMFINANCINGACTIVITIESCashreceiptsfromborrowings
Cashreceiptsfromborrowings | 280,000,000.00 | 32,264,821.52 | |
Othercashreceiptsrelatingtofinancingactivities | 18,653,623,031.33 | 16,113,679,647.75 |
Totalcashinflowsfromfinancingactivities | 18,933,623,031.33 | 16,145,944,469.27 |
Cashrepaymentsfordebts | 30,164,821.52 | 43,700,000.00 | |
Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 363,151,913.01 | 272,655,694.83 | |
Othercashreceiptsrelatingtofinancingactivities | 18,673,121,608.99 | 15,582,101,156.66 | |
Totalcashoutflowsfromfinancingactivities | 19,066,438,343.52 | 15,898,456,851.49 |
Netcashflowsfromfinancingactivities | (132,815,312.19) | 247,487,617.78 |
4.EFFECTOFFOREIGNEXCHANGERATECHANGESONCASHANDCASHEQUIVALENTS | 392,002.63 | (47,935.97) |
5.NETINCREASEINCASHANDCASHEQUIVALENTS | 343,314,083.62 | 867,551,697.22 | |
Add:Cashandcashequivalentsatbeginningoftheyear | 3,020,909,473.71 | 2,894,333,956.38 |
6.CASHANDCASHEQUIVALENTSATENDOFYEAR | 3,364,223,557.33 | 3,761,885,653.60 |
Theaccompanyingnotesformanintegralpartofthesefinancialstatements
NotestofinancialstatementsForthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IProfileoftheCompany
(1)HistoricaldevelopmentandbasicinformationAsapprovedbythePeople’sGovernmentofShenzhen(SFBF(1993)No.356),ChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoasthe“theCompany”),formerlyknownasShenzhenHealthMineralWaterCorp.,Ltd.,wasregisteredasajointstockliabilitylimitedcompanyon1February1993throughstocktransformation.InMarch1993,withtheapprovalfromtheShenzhenBranchofthePeople’sBankofChina,theCompanyissued30millionAshares(including16.5millionpublicshares,
3.5millionemployeesharesand10millioncorporationshares)and20millionBshares.Afterthisissuance,theCompany’ssharecapitalwasRMB105million.Throughconvertcapitalsurplusintosharecapital,bonusissuesandissuanceofsharesforyears,thesharecapitaloftheCompanyincreasedtoRMB428.13millionasat30June2021InNovember2000,theCompanyenteredintoanAssetsExchangeAgreementwithShenzhenInvestmentManagementCompany,theoriginalmajorshareholderoftheCompany,toexchangealltheassetsandliabilitiesoftheCompanyasof31August2000forShenzhenInvestmentManagementCompany’s100%equityinterestsin11pharmaceuticalcompaniesandcertainpropertiesaswellas51%equityinterestsinShenzhenTefaModernComputerCo.,Ltd.TheaboveassetexchangeproposalwasapprovedbyshareholdersintheSecondExtraordinaryGeneralMeetingonDecember29,2000.Thetransactionwascompletedon8January2001.On18February2004,theCompany’soriginalmajorshareholder,ShenzhenInvestmentManagementCompany,enteredintoaStockTransferAgreementwithSinopharmGroupCo.,Ltd.(hereinafterreferredtoas“SinopharmGroup”)totransferits43.33%sharesintheCompanytoSinopharmGroup.Thelegalproceduresoftheaboveequitytransferwerecompletedon9December2004.Atthesametime,asapprovedbytheState-ownedAssetsSupervisionandAdministrationCommissionoftheStateCouncil(GZCQ(2004)No.525)andtheChinaSecuritiesRegulatoryCommission(ZJGSZ(2004)No.94),thenatureoftheseshareswaschangedfromstate-ownedstocktostate-ownedlegalentitystockandSinopharmGroupbecamethelargestshareholderoftheCompany.On14April2006,theCompany’sproposalonreformationofsegregatedstockswasapproved.TogainliquidityfortherestrictedstocksoftheCompany,theholdersoftherestrictedstocksoftheCompanyagreedtopaythefollowingconsideration:basedonthestockregistrationasof27April2006,theCompanyissuedbonusshareson28April2006attheratioof3sharestoevery10AsharestoliquidatedA-shareholderswhichwentpubliconthesameday.Afterthisbonusissue,thetotalnumberofsharesoftheCompanyremainedunchangedwithcorrespondingchangesinthecompositionofshareholdings.OnMarch142014,thecompanyissued74,482,543ordinaryshares(Ashares)throughthenon-publicoffering.ParvaluepershareisRMB1.00.Thesharesshallnotbetransferredwithin36monthssincetheissueday.ThetotalnumberofsharesoftheCompanywas362,631,943sincethedateofissue.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IProfileoftheCompany(Continued)
(1)Historicaldevelopmentandbasicinformation(Continued)TheCompanyacquiredthecompaniesundercommoncontrol,includingSinopharmHoldingGuodaDrugstoreCo.,Ltd.(“GuodaDrugstore”),FoshanNanhaiMedicineGroupCo.,Ltd.(“FoshanNanhai”),GuangdongSouthPharmaceuticalForeignTradeCo.,Ltd.(“SouthPharma&Trade”)andGuangdongDongFangUptodate&SpecialMedicinesCo.,Ltd.(“GuangdongUptodate&SpecialMedicines”)byissuingsharesandraisedsupportingfundsbyissuingsharestoPingAnAssetManagementCo.,Ltd.toacquirethenon-controllinginterestofSouthPharma&Trade.Theabovetransactionswerecompletedon31December2016,andtherelevantsharesweresuccessfullyissuedandlistedon5January2017.Afterwards,thetotalnumberofsharesoftheCompanyincreasedto428,126,983.Asof30June2021,thetotalsharecapitalwasRMB428.13million.TheCompanyisregisteredwithShenzhenAdministrationforIndustry&Commerce.ItsUniformSocialCreditCodeis91440300192186267U.TheoperationperiodoftheCompanyisfrom2August1986tothelongterm.TheregisteredcapitaloftheCompanyisRMB428.13million.ThelegalrepresentativeoftheCompanyisLinZhaoxiong.TheapprovedscopeofbusinessoftheCompanyanditssubsidiaries(together“theGroup”)includes:
thewholesaleoftraditionalChinesemedicinepreparations,bulkpharmaceuticaldrugs,chemicalpreparations,bulkantibioticdrugs,antibioticpreparations,biochemicaldrugs,biologicalproducts(includingvaccinesandinvitrodiagnosticreagentspsychotropicdrugsandpreparations,narcoticdrugs,toxicdrugsformedicaluse,proteinassimilationpreparationandpeptidehormones;tradingofdietarysupplement;research,developmentandconsultationservicesofpharmaceuticalpackagingmaterialsandpharmaceuticalindustryproducts;industrialinvestmentholding;domestictrade;materialsupplyandmarketingindustry(otherthanspeciallicensing);saleofambulances;tradeofsecond-classandthird-classmedicalequipment;projectinvestment;propertymanagementandleasingofself-ownedproperties;pharmacovigilanceandmedicalinformationconsulting;parkingoperation;logisticsandrelatedservices;packageagencybusiness;logisticdesign;importandexportservices(excludingprojectsthatareprohibitedbythecountry;andlimitedprojectshastobeapprovedbeforeoperating).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IProfileoftheCompany(Continued)
(2)TheGroup’sparentandultimateparentcompaniesareSinopharmGroupandChinaNational
PharmaceuticalGroupCorporation(“CNPGC”),respectively.
(3)ThesefinancialstatementswereauthorizedforissuebytheboardofdirectorsoftheCompany
on13August2021.
(4)Subsidiariesconsolidatedinthefinancialstatementsforthecurrentperiodandchangeinthe
consolidationscopeareshowninNoteVI.IIBasisofpreparationThefinancialstatementswerepreparedinaccordancewiththeBasicStandardandspecificstandardsofAccountingStandardsforBusinessEnterprisesissuedbytheMinistryofFinanceandthespecificaccountingstandards,applicationguidance,interpretationandotherrelevantregulationsissuedoramendedthereafter(hereaftercollectivelyreferredtoas“AccountingStandardsforBusinessEnterprises”or“CAS”).Thesefinancialstatementsarepreparedonagoingconcernbasis.Exceptforcertainfinancialinstruments,thefinancialstatementshavebeenpreparedusingthehistoricalcostastheprincipleofmeasurement.Whereassetsareimpaired,provisionsforassetimpairmentaremadeinaccordancewiththerelevantrequirements.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimatesTheGroupdeterminesthespecificaccountingpoliciesandestimatesbasedonitsfeaturesofproductionandoperation,primarilycomprisingthemethodsofprovisionforexpectedcreditlossesonreceivables,valuationofinventories,depreciationoffixedassetsandamortisationofintangibleassets,themeasurementmodelofinvestmentproperties,recognitionandmeasurementofrevenue,etc.
(1)StatementofcompliancewiththeAccountingStandardsforBusinessEnterprisesThefinancialstatementsoftheCompanyfortheyearended30June2021areincompliancewithAccountingStandardsforBusinessEnterprises,andtrulyandcompletelypresentthefinancialpositionoftheGroupandtheCompanyasof30June2021andtheoperatingresults,cashflowsandotherinformationforthesixmonthsended30June2021oftheGroupandtheCompany.
(2)AccountingyearTheCompany’saccountingyearbeginson1Januaryandendson31December.
(3)BusinesscycleTheCompany’soperatingcycleis12months.
(4)FunctionalcurrencyTheGroup’sfunctionalandpresentationcurrencyisRenminbi(RMB).ThecurrencyunitisRMBYuanunlessotherwisestated.
(5)BusinesscombinationsBusinesscombinationsareclassifiedintobusinesscombinationsinvolvingenterprisesundercommoncontrolandbusinesscombinationsnotinvolvingenterprisesundercommoncontrol.(a)BusinesscombinationsinvolvingenterprisesundercommoncontrolAbusinesscombinationinvolvingenterprisesundercommoncontrolisabusinesscombinationinwhichallofthecombiningenterprisesareultimatelycontrolledbythesamepartyorpartiesbothbeforeandafterthecombination,andthatcontrolisnottransitory.Inabusinesscombinationinvolvingenterprisesundercommoncontrol,theenterprisethat,atthecombinationdate,obtainscontrolofanothercombiningenterpriseistheabsorbingenterprise,whilethatothercombiningenterpriseistheenterprisebeingabsorbed.Thecombinationdateisthedateonwhichtheabsorbingenterpriseeffectivelyobtainscontrolontheenterprisebeingabsorbed.Theassetsandliabilities(includinggoodwillarisingfromtheultimatecontrollingparty’sacquisitionoftheenterprisebeingabsorbed)thatareobtainedbytheabsorbingenterpriseinabusinesscombinationinvolvingenterprisesundercommoncontrolshallbemeasuredonthebasisoftheircarryingamountsinthefinancialstatementsoftheultimatecontrollingpartyatthecombinationdate.Thedifferencebetweenthecarryingamountofthenetassetsobtainedandthecarryingamountoftheconsiderationpaidforthecombination(ortheaggregatefacevalueofsharesissuedasconsideration)shallbeadjustedtocapitalpremiumundercapitalreservesandthebalancetransferredfromcapitalreservesundertheoldaccountingsystem.Ifthecapitalpremiumisnotsufficienttoabsorbthedifference,anyexcessshallbeadjustedagainstretainedearnings.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(5)Businesscombinations(Continued)(b)BusinesscombinationsinvolvingenterprisesnotundercommoncontrolAbusinesscombinationnotinvolvingenterprisesundercommoncontrolisabusinesscombinationinwhichallofthecombiningenterprisesarenotultimatelycontrolledbythesamepartyorpartiesbothbeforeandafterthecombination.Inabusinesscombinationnotinvolvingenterprisesundercommoncontrol,theenterprisethat,ontheacquisitiondate,obtainscontrolofanothercombiningenterpriseistheacquirer,whilethatothercombiningenterpriseistheacquiree.Theacquisitiondateisthedateonwhichtheacquirereffectivelyobtainscontroloftheacquiree.Theacquirershallmeasuretheacquiree’sidentifiableassets,liabilitiesandcontingentliabilitiesacquiredinthebusinesscombinationattheirfairvaluesontheacquisitiondate.Goodwillisinitiallyrecognisedandmeasuredatcost,beingtheexcessoftheaggregateofthefairvalueoftheconsiderationtransferred(orthefairvalueoftheequitysecuritiesissued)andanyfairvalueoftheGroup’spreviouslyheldequityinterestintheacquireeovertheGroup’sinterestinthefairvalueoftheacquiree’snetidentifiableassets.Afterinitialrecognition,goodwillismeasuredatcostlessanyaccumulatedimpairmentlosses.Wheretheaggregateofthefairvalueoftheconsiderationtransferred(orthefairvalueoftheequitysecuritiesissued)andanyfairvalueoftheGroup’spreviouslyheldequityinterestintheacquireeislowerthantheGroup’sinterestinthefairvalueoftheacquiree’snetidentifiableassets,theGroupreassessesthemeasurementofthefairvalueoftheacquiree’sidentifiableassets,liabilitiesandcontingentliabilitiesandthefairvalueoftheconsiderationtransferred(orthefairvalueoftheequitysecuritiesissued),togetherwiththefairvalueoftheGroup’spreviouslyheldequityinterestintheacquiree.Ifafterthatreassessment,theaggregateofthefairvalueoftheconsiderationtransferred(orthefairvalueoftheequitysecuritiesissued)andtheGroup’spreviouslyheldequityinterestintheacquireeisstilllowerthantheGroup’sinterestinthefairvalueoftheacquiree’snetidentifiableassets,theGrouprecognisestheremainingdifferenceinprofitorloss.Wherethebusinesscombinationnotinvolvingenterprisesundercommoncontrolisachievedinstages,theacquirer’spreviouslyheldequityinterestsintheacquireeareremeasuredatthefairvalueontheacquisitiondate,withthedifferencebetweenthefairvalueandcarryingamountrecognisedasinvestmentincomeforthecurrentperiod.Iftheacquirer’spreviouslyheldequityinterestsoftheacquireeinvolveothercomprehensiveincome(“OCI”)undertheequitymethod,theaccountingtreatmentisconductedonthesamebasisaswouldhavebeenrequirediftheinvesteehaddirectlydisposedoftherelatedassetsorliabilities,andthechangesinshareholders’equityotherthannetprofitorloss,OCIandprofitdistributionsarechargedtoprofitorlossforthecurrentperiodontheacquisitiondate.ForfinancialassetsatfairvaluethroughOCIheldbeforetheacquisitiondate,changesinfairvaluethatwereaccumulatedthroughOCIwilltransfertoretainedearnings.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(6)PreparationofconsolidatedfinancialstatementsThescopeoftheconsolidatedfinancialstatements,whichincludethefinancialstatementsoftheCompanyandallofitssubsidiaries,isdeterminedonthebasisofcontrol.AsubsidiaryisanentitythatiscontrolledbytheCompany(suchasanenterprise,adeemedseparateentity,orastructuredentitycontrolledbytheCompany).Inthepreparationoftheconsolidatedfinancialstatements,thefinancialstatementsofsubsidiariesarepreparedforthesameaccountingyearastheCompany,usingconsistentaccountingpolicies.Allintra-groupassetsandliabilities,equity,income,expensesandcashflowsrelatingtotransactionsbetweenmembersoftheGroupareeliminatedinfullonconsolidation.Wherethelossforthecurrentperiodattributabletonon-controllinginterestsofasubsidiaryexceedsthenon-controllinginterestsoftheopeningbalanceofequityofthesubsidiary,theexcessshallstillbeallocatedagainstthenon-controllinginterests.Forsubsidiariesacquiredthroughbusinesscombinationsnotinvolvingentitiesundercommoncontrol,thefinancialperformanceandcashflowsoftheacquireeshallbeconsolidatedfromthedateonwhichtheGroupobtainscontrol,andcontinuetobeconsolidateduntilthedatesuchcontrolceases.Whilepreparingtheconsolidatedfinancialstatements,theGroupshalladjustthesubsidiary’sfinancialstatements,onthebasisofthefairvaluesoftheidentifiableassets,liabilitiesandcontingentliabilitiesrecognisedontheacquisitiondate.Forsubsidiariesacquiredthroughbusinesscombinationsinvolvingentitiesundercommoncontrol,thefinancialperformanceandcashflowsoftheentitybeingabsorbedshallbeconsolidatedfromthebeginningoftheperiodinwhichthecombinationoccurs.Whilepreparingthecomparativefinancialstatements,adjustmentsaremadetorelateditemsinthefinancialstatementsforthepriorperiodasifthereportingentityafterthecombinationhasbeeninexistencesincethedatetheultimatecontrollingpartyfirstobtainedthecontrol.TheGroupreassesseswhetherornotitcontrolsaninvesteeifanychangeinfactsandcircumstancesindicatesthattherearechangestooneormoreofthethreeelementsofcontrol.WhentheGrouplosescontrolofasubsidiaryinmultipletransactionsinwhichitdisposesofitslong-termequityinvestmentinthesubsidiaryinstages,ifeachofthemultipletransactionsdoesnotformpartofabundledtransaction,thetransactionsconductedbeforethelossofcontrolofthesubsidiaryareaccountedforinaccordancewiththeaccountingpolicyforpartialdisposaloftheequityinvestmentinsubsidiarieswherecontrolisretained.Ifeachofthemultipletransactionsformspartofabundledtransactionwhicheventuallyresultsinthelossofcontrolinthesubsidiary,thesemultipletransactionsareaccountedforasasingletransaction.Intheconsolidatedfinancialstatements,thedifferencebetweentheconsiderationreceivedandthecorrespondingproportionofthesubsidiary’snetassets(calculatedcontinuouslyfromtheacquisitiondate)ineachtransactionpriortothelossofcontrolshallberecognisedinothercomprehensiveincomeandtransferredtoprofitorlosswhentheparenteventuallylosescontrolofthesubsidiary.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(7)CashandcashequivalentsCashcomprisestheGroup’scashonhandandbankdepositsthatcanbereadilywithdrawnondemand.Cashequivalentsareshort-term,highlyliquidinvestmentsthatarereadilyconvertibleintoknownamountsofcash,andaresubjecttoaninsignificantriskofchangesinvalue.
(8)ForeigncurrencytransactionsandforeigncurrencytranslationTheGrouptranslatesforeigncurrencytransactionsintoitsfunctionalcurrency.Atthebalancesheetdate,monetaryitemsdenominatedinforeigncurrenciesaretranslatedintoRMBusingthespotexchangeratesonthebalancesheetdate.Exchangedifferencesarisingfromthesetranslationsarerecognisedinprofitorlossforthecurrentperiod,exceptforthoseattributabletoforeigncurrencyborrowingsthathavebeentakenoutspecificallyfortheacquisitionorconstructionofqualifyingassets,whicharecapitalizedaspartofthecostofthoseassets.Non-monetaryitemsdenominatedinforeigncurrenciesthataremeasuredathistoricalcostaretranslatedatthebalancesheetdateusingthespotexchangeratesatthedatesofthetransactions.Foreigncurrencycashflowsaretranslatedusingthespotexchangeratesprevailingonthedatesofcashflows.Theeffectofexchangeratechangesoncashispresentedseparatelyinthecashflowstatement.
(9)FinancialinstrumentsAfinancialinstrumentisanycontractthatgivesrisetoafinancialassetofoneentityandafinancialliabilityorequityinstrumentofanotherentity.RecognitionandderecognitionTheGrouprecognisesafinancialassetorafinancialliabilitywhenitbecomesapartytothecontractualprovisionsofafinancialinstrument.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(9)Financialinstruments(Continued)Recognitionandderecognition(Continued)Afinancialasset(or,whereapplicable,apartofafinancialassetorpartofagroupofsimilarfinancialassets)isprimarilyderecognised(i.e.,removedfromtheGroup’sconsolidatedbalancesheet)when:
(1)therightstoreceivecashflowsfromthefinancialassethaveexpired;or
(2)theGrouphastransferreditsrightstoreceivecashflowsfromthefinancialasset,orhas
assumedanobligationtopaythereceivedcashflowsinfullwithoutmaterialdelaytoathirdpartyundera“pass-through”arrangement;andeither(i)hastransferredsubstantiallyalltherisksandrewardsofthefinancialasset,or(ii)hasneithertransferrednorretainedsubstantiallyalltherisksandrewardsoftheasset,buthastransferredcontrolofthefinancialasset.Afinancialliabilityisderecognisedwhentheobligationundertheliabilityisdischargedorcancelled,orexpires.Whenanexistingfinancialliabilityisreplacedbyanotherfromthesamelenderonsubstantiallydifferentterms,orthetermsofanexistingliabilityaresubstantiallymodified,suchanexchangeormodificationistreatedasaderecognitionoftheoriginalliabilityandarecognitionofanewliability,andthedifferencebetweentherespectivecarryingamountsisrecognisedinprofitorloss.Regularwaypurchasesandsalesoffinancialassetsarerecognisedandderecognisedusingtradedateaccounting.Regularwaypurchasesorsalesarepurchasesorsalesoffinancialassetsthatrequiredeliverywithintheperiodgenerallyestablishedbyregulationorconventioninthemarketplace.ThetradedateisthedatethattheGroupcommittedtopurchaseorsellafinancialasset.ClassificationandmeasurementoffinancialassetsTheclassificationoffinancialassetsatinitialrecognitiondependsonthefinancialasset’scontractualcashflowcharacteristicsandtheGroup’sbusinessmodelformanagingthem:financialassetsatfairvaluethroughprofitorloss,financialassetsatamortisedcostandfinancialassetsatfairvaluethroughothercomprehensiveincome.AllaffectedrelatedfinancialassetswillbereclassifiedonlyiftheGroupchangesitsbusinessmodelformanagingfinancialassets.Financialassetsaremeasuredatfairvalueoninitialrecognition,butaccountsreceivableornotesreceivablearisingfromthesaleofgoodsorrenderingofservicesthatdonotcontainsignificantfinancingcomponentsorforwhichtheGrouphasappliedthepracticalexpedientofnotadjustingtheeffectofasignificantfinancingcomponentduewithinoneyear,areinitiallymeasuredatthetransactionprice.Forfinancialassetsatfairvaluethroughprofitorloss,relevanttransactioncostsaredirectlyrecognisedinprofitorloss,andtransactioncostsrelatingtootherfinancialassetsareincludedintheinitialrecognitionamounts.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(9)Financialinstruments(Continued)Classificationandmeasurementoffinancialassets(Continued)Thesubsequentmeasurementoffinancialassetsdependsontheirclassificationasfollows:
DebtinvestmentsmeasuredatamortisedcostTheGroupmeasuresfinancialassetsatamortisedcostifbothofthefollowingconditionsaremet:thefinancialassetisheldwithinabusinessmodelwiththeobjectivetoholdfinancialassetsinordertocollectcontractualcashflows;thecontractualtermsofthefinancialassetgiveriseonspecifieddatestocashflowsthataresolelypaymentsofprincipalandinterestontheprincipalamountoutstanding.Financialassetsatamortisedcostaresubsequentlymeasuredusingtheeffectiveinterestmethodandaresubjecttoimpairment.Gainsandlossesarerecognisedinprofitorlosswhentheassetisderecognised,modifiedorimpaired.DebtinvestmentsatfairvaluethroughothercomprehensiveincomeTheGroupmeasuresdebtinvestmentsatfairvaluethroughothercomprehensiveincomeifbothofthefollowingconditionsaremet:thefinancialassetisheldwithinabusinessmodelwiththeobjectiveofbothholdingtocollectcontractualcashflowsandselling;thecontractualtermsofthefinancialassetgiveriseonspecifieddatestocashflowsthataresolelypaymentsofprincipalandinterestontheprincipalamountoutstanding.Interestincomeisrecognisedusingtheeffectiveinterestmethod.Theinterestincome,impairmentlossesandforeignexchangerevaluationarerecognisedinprofitorloss.Theremainingfairvaluechangesarerecognisedinothercomprehensiveincome.Uponderecognition,thecumulativefairvaluechangerecognisedinothercomprehensiveincomeisrecycledtoprofitorloss.EquityinvestmentsatfairvaluethroughothercomprehensiveincomeTheGroupcanelecttoclassifyirrevocablyitsequityinvestmentswhicharenotheldfortradingasequityinvestmentsdesignatedatfairvaluethroughothercomprehensiveincome.Onlytherelevantdividendincome(excludingthedividendincomeexplicitlyrecoveredaspartoftheinvestmentcost)isrecognisedinprofitorloss.Subsequentchangesinthefairvalueareincludedinothercomprehensiveincome,andnoprovisionforimpairmentismade.Whenthefinancialassetisderecognised,theaccumulatedgainsorlossespreviouslyincludedinothercomprehensiveincomearetransferredfromothercomprehensiveincometoretainedearnings.FinancialassetsatfairvaluethroughprofitorlossThefinancialassetsotherthantheabovefinancialassetsmeasuredatamortisedcostandfinancialassetsatfairvaluethroughothercomprehensiveincomeareclassifiedasfinancialassetsatfairvaluethroughprofitorloss.Suchfinancialassetsaresubsequentlymeasuredatfairvaluewithnetchangesinfairvaluerecognisedinprofitorlossexceptforthederivativesdesignatedashedginginstrumentsinaneffectivehedge.Onlywhenanaccountingmismatchiseliminatedorsignificantlydecreased,financialassetsaredesignatedasfinancialassetsatfairvaluethroughprofitorlossatinitialrecognition.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(9)Financialinstruments(Continued)Classificationandmeasurementoffinancialassets(Continued)Whenanenterpriseinitiallydesignatesafinancialassetasafinancialassetatfairvaluethroughprofitorloss,itcannotbereclassifiedtootherfinancialassets;andotherfinancialassetscannotbere-designatedafterinitialrecognitionasfinancialassetsmeasuredatfairvaluethroughprofitorloss.ClassificationandmeasurementoffinancialliabilitiesTheGroup’sfinancialliabilitiesare,oninitialrecognition,classifiedintofinancialliabilitiesatfairvaluethroughprofitorloss,otherfinancialliabilitiesorderivativesdesignatedaseffectivehedginginstruments.Forfinancialliabilitiesatfairvaluethroughprofitorloss,relevanttransactioncostsaredirectlyrecognisedinprofitorloss,andtransactioncostsrelatingtootherfinancialliabilitiesareincludedintheinitialrecognitionamounts.Thesubsequentmeasurementoffinancialliabilitiesdependsontheirclassificationasfollows:
FinancialliabilitiesatfairvaluethroughprofitorlossFinancialliabilitiesatfairvaluethroughprofitorlossincludefinancialliabilitiesheldfortrading(includingderivativeinstrumentsattributabletofinancialliabilities)andfinancialliabilitiesdesignateduponinitialrecognitionasatfairvaluethroughprofitorloss.Financialliabilitiesheldfortrading(includingderivativeinstrumentsattributabletofinancialliabilities)aresubsequentlymeasuredatfairvalue.Allchangesinfairvalueofsuchfinancialliabilitiesarerecognisedinprofitorlossexceptforthederivativesdesignatedashedginginstrumentsinaneffectivehedge.Financialliabilitiesdesignatedatfairvaluethroughprofitorlossaresubsequentlymeasuredatfairvalueandgainsorlossesarerecognisedinprofitorloss,exceptforthegainsorlossesarisingfromtheGroup’sowncreditriskwhicharepresentedinothercomprehensiveincome.IfgainsorlossesarisingfromtheGroup’sowncreditriskwhicharepresentedinothercomprehensiveincomewillleadtoorexpandaccountingmismatchinprofitorloss,theGroupwillincludeallthechangesinfairvalue(includingtheamountaffectedbychangesintheGroup’sowncreditrisk)ofsuchfinancialliabilitiesinprofitorloss.Onlyifoneofthefollowingconditionsismetcanfinancialliabilitiesbedesignatedasfinancialliabilitiesatfairvaluethroughprofitorlossoninitialrecognition:
(1)Itcaneliminateorsignificantlyreducetheaccountingmismatch.
(2)Theformalwrittendocumentoftheriskmanagementorinvestmentstrategyhasstatedthattheportfoliooffinancialinstrumentsismanaged,evaluatedandreportedtokeymanagersonthebasisoffairvalue.
(3)Thefinancialliabilityisahybridinstrumentthatcontainsoneormoreembeddedderivatives,
unlesstheembeddedderivativeshavenosignificantchangeinthecashflowsofthehybridinstrument,ortheembeddedderivativesshouldobviouslynotbeseparatedfromtherelatedhybridinstruments.
(4)Mixedinstrumentscontainembeddedderivativesthatneedtobesplitbutcannotbemeasured
separatelyatthetimeofacquisitionoronsubsequentbalancesheetdays.Whenanenterprisedesignatesafinancialliabilityasafinancialliabilityatfairvaluethroughprofitorloss,itcannotbereclassifiedasotherfinancialliabilities;norcanotherfinancialliabilitiesbere-designatedasfinancialliabilitiesatfairvaluethroughprofitorlossafterinitialrecognition.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(9)Financialinstruments(Continued)Classificationandmeasurementoffinancialliabilities(Continued)OtherfinancialliabilitiesAfterinitialrecognition,suchfinancialliabilitiesaremeasuredatamortisedcostusingtheeffectiveinterestmethod.ImpairmentoffinancialassetsBasedontheexpectedcreditlosses(“ECLs”),theGrouprecognisesanallowanceforECLsforthefinancialassetsmeasuredatamortisedcost,debtinvestmentsatfairvaluethroughothercomprehensiveincome,andcontractassets.Fortradereceivablesandcontractassetsthatdonotcontainasignificantfinancingcomponent,theGroupappliesthesimplifiedapproachtorecognisealossallowancebasedonlifetimeECLs.Fortradereceivablesandcontractassetsthatcontainasignificantfinancingcomponent,theGroupchoosestoadoptthesimplifiedapproachtorecognisealossallowancebasedonlifetimeECLs.Exceptforfinancialassetswhichapplythesimplifiedapproachasmentionedaboveandotherfinancialassets,theGroupassesseswhetherthecreditriskhasincreasedsignificantlysinceinitialrecognitionateachbalancesheetdate.Ifthecreditriskhasnotincreasedsignificantlysinceinitialrecognition(stage
1),thelossallowanceismeasuredatanamountequalto12-monthECLsbytheGroupandtheinterestincomeiscalculatedaccordingtothecarryingamountandtheeffectiveinterestrate;ifthecreditriskhasincreasedsignificantlysinceinitialrecognitionbutarenotcredit-impaired(stage2),thelossallowanceismeasuredatanamountequaltolifetimeECLsbytheGroupandtheinterestincomeiscalculatedaccordingtothecarryingamountandtheeffectiveinterestrate;ifsuchfinancialassetsarecredit-impairedafterinitialrecognition(stage3),thelossallowanceismeasuredatanamountequaltolifetimeECLsbytheGroupandtheinterestincomeiscalculatedaccordingtotheamortisedcostandtheeffectiveinterestrate.Ifthecreditriskoffinancialinstrumentsislowatthebalancesheetdate,theGroupassumesthatthecreditriskhasnotincreasedsignificantlysinceinitialrecognition.TheGroupevaluatestheexpectedcreditlossesonfinancialinstrumentsonasingleandcombinedbasis.Takingintoaccountthecreditriskcharacteristicsofdifferentcustomers,theGroupevaluatestheexpectedcreditlossesonaccountsreceivablebasedontheagingportfolio.RefertoNoteX(3)forthedisclosureoftheGroup'scriteriaforjudgingthesignificantincreaseincreditrisk,thedefinitionofassetswithimpairedcreditlosses,andtheassumptionofmeasuringexpectedcreditlosses.WhentheGroupnolongerreasonablyexpectstobeabletorecoverallorpartofthecontractcashflowsofthefinancialassets,theGroupdirectlywritesdownthecarryingamountofthefinancialasset.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(9)Financialinstruments(Continued)OffsettingoffinancialinstrumentsFinancialassetsandfinancialliabilitiesareoffsetandthenetamountisreportedinthebalancesheetifthereisacurrentlyenforceablelegalrighttooffsettherecognisedamounts;andthereisanintentiontosettleonanetbasis,ortorealisetheassetsandsettletheliabilitiessimultaneously.TransferoffinancialassetsAfinancialassetisderecognisedwhentheGrouphastransferredsubstantiallyalltherisksandrewardsoftheassettothetransferee.AfinancialassetisnotderecognisedwhentheGroupretainssubstantiallyalltherisksandrewardsofthefinancialasset.WhentheGrouphasneithertransferrednorretainedsubstantiallyalltherisksandrewardsofthefinancialasset,iteither(i)derecognisesthefinancialassetandrecognisestheassetsandliabilitiescreatedinthetransferwhenithasnotretainedcontroloftheasset;or(ii)continuestorecognisethetransferredassettotheextentoftheGroup'scontinuinginvolvement,inwhichcase,theGroupalsorecognisesanassociatedliability.Continuinginvolvementthattakestheformofaguaranteeoverthetransferredfinancialassetismeasuredattheloweroftheoriginalcarryingamountofthefinancialassetandtheguaranteeamount.TheguaranteeamountisthemaximumamountofconsiderationthattheGroupcouldberequiredtorepay.
(10)NotesreceivablesFordetailsofthemethodfordeterminingtheexpectedcreditlossofnotesreceivable,pleaserefertoNoteV(9)“Financialinstruments-Impairmentoffinancialinstruments”.
(11)AccountsreceivablesFordetailsofthemethodfordeterminingtheexpectedcreditlossofaccountsreceivable,pleaserefertoNoteV(9)“Financialinstruments-Impairmentoffinancialinstruments”.
(12)ReceivablefinancingItincludesnotesreceivableandaccountsreceivablesdesignatedatfairvaluethroughothercomprehensiveincomeasatbalancesheetdate.Fordetailsofthemethodfordeterminingtheexpectedcreditlossofreceivablesfinancing,pleaserefertoNoteV(9)“Financialinstruments-Impairmentoffinancialinstruments”.
(13)OtherreceivablesFordetailsofthemethodfordeterminingtheexpectedcreditlossesofotherreceivables,pleaserefertoNoteV(9)“Financialinstruments-Impairmentoffinancialinstruments”.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(14)InventoriesInventoriesincluderawmaterials,workinprogress,finishedgoods,delegateprocessingsuppliesandturnovermaterials,andaremeasuredatthelowerofcostandnetrealizablevalue.Inventoriesareinitiallycarriedatcost.Costofinventoriescomprisesallcostsofpurchase,costsofconversionandothercosts.Costisdeterminedontheweightedaveragebasis.Turnovermaterialsincludelowvalueconsumablesandpackingmaterials,whichareontheimmediatewrite-offbasis.TheGroupadoptstheperpetualinventorysystem.Atthebalancesheetdate,inventoriesarestatedatthelowerofcostandnetrealisablevalue.Theinventoriesarewrittendownbelowcosttonetrealisablevalueandthewrite-downisrecognisedinprofitorlossifthecostishigherthanthenetrealisablevalue.Whenthecircumstancesthatpreviouslycausedtheinventoriestobewrittendownbelowcostnolongerexist,inwhichcasethenetrealisablevalueofinventoriesbecomeshigherthanthecarryingamount,theamountofthewrite-downisreversed.Thereversalislimitedtotheamountoftheoriginalwrite-down,andisrecognisedinprofitorloss.Netrealisablevalueistheestimatedsellingpriceintheordinarycourseofbusinesslesstheestimatedcostsofcompletionandtheestimatedcostsnecessarytomakethesaleandrelevanttaxes.Finishedgoodsarewrittendownitembyitem.
(15)ContractassetsTheGrouppresentscontractassetsorcontractliabilitiesdependingontherelationshipbetweenthesatisfactionofitsperformanceobligationsandthecustomer’spaymentinthebalancesheet.TheGroupoffsetsthecontractassetsandcontractliabilitiesunderthesamecontractandpresentsthenetamount.AcontractassetistherighttoconsiderationinexchangeforgoodsorservicesthattheGrouphastransferredtoacustomer,andthatrightisconditionedonsomethingotherthanthepassageoftime.FordetailsofhowtheGroupmeasuresandaccountsfortheECLsofacontractasset,refertoNoteV
(10)“Financialinstruments-Impairmentoffinancialinstruments”.
(16)AssetsrelatingtocontractcostTheGroup’scontractcostassetsincludethecoststoobtainandfulfilacontractandareclassifiedasinventories,othercurrentassetsandothernon-currentassetsbyliquidity.TheGrouprecognisesasanassettheincrementalcostsofobtainingacontractwithacustomeriftheGroupexpectstorecoverthosecosts,unlesstheamortisationperiodoftheassetisoneyearorless.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(16)Assetsrelatingtocontractcost(Continued)Otherthanthecostswhicharecapitalisedasinventories,fixedassetsandintangibleassets,etc.,costsincurredtofulfilacontractwithacustomerarecapitalisedasanassetifallofthefollowingcriteriaaremet:
(1)thecostsrelatedirectlytoacontractortoananticipatedcontract,includingdirectlabour,direct
materials,overheads(orsimilarexpenses),coststhatareexplicitlychargeabletothecustomerandothercoststhatareincurredonlybecauseanentityenteredintothecontract;
(2)thecostsgenerateorenhanceresourcesoftheGroupthatwillbeusedinsatisfying
performanceobligationsinthefuture;and
(3)thecostsareexpectedtoberecovered.Thecontractcostassetisamortisedandchargedtoprofitorlossonasystematicbasisthatisconsistentwiththepatternoftherevenuetowhichtheassetrelatedisrecognised.TheGroupaccruesprovisionsforimpairmentandrecognisesimpairmentlossestotheextentthatthecarryingamountofacontractcostassetexceeds:
(1)theremainingamountofconsiderationthattheentityexpectstoreceiveinexchangeforthe
goodsorservicestowhichtheassetrelates;less
(2)thecoststhatareexpectedtobeincurredtotransferthoserelatedgoodsorservices.TheGrouprecognisesinprofitorlossareversaloftheimpairmentlosspreviouslyrecognisedtotheextentthatthedifferencebetween(1)and(2)exceedsthecarryingamountoftheassetduetothesubsequentchangesofthefactorscausingassetimpairmentinpreviousperiods,butthecarryingamountafterthereversaldoesnotexceedthecarryingamountoftheassetatthereversaldateifnoimpairmentlossisotherwiserecognised.
(17)Long-termequityinvestmentsLong-termequityinvestmentsincludeequityinvestmentsinsubsidiaries,jointventuresandassociates.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(17)Long-termequityinvestments(Continued)Along-termequityinvestmentisinitiallymeasuredatitsinitialinvestmentcostonacquisition.Forlong-termequityinvestmentsarisingfrombusinesscombinationinvolvingenterprisesundercommoncontrol,theinitialinvestmentcostshallbetheshareofthecarryingamountofequityoftheacquireeintheconsolidatedfinancialstatementsoftheultimatecontrollingpartyasatthecombinationdate.Thedifferencebetweentheinitialinvestmentcostandbookvalueofconsiderationofcombinationisadjustedtocapitalreserves,andtoretainedearningsifcapitalreservesisinsufficient.Othercomprehensiveincomerecognisedbeforethecombinationdateisaccountedforonthesamebasisaswouldhavebeenrequirediftheinvesteehaddirectlydisposedoftherelatedassetsorliabilities.Equitypreviouslyrecognisedresultingfromtheinvestee’sequitychangesotherthanprofitorloss,othercomprehensiveincomeandprofitdistributionisreclassifiedtoprofitorloss.Equitywhichstillinvolvesalong-terminvestmentafterdisposalisreclassifiedtoprofitorlossonapro-ratabasisandequitywhichswichestoafinancialinstrumentafterdisposalisfullyreclassifiedtoprofitorloss.Forlong-termequityinvestmentsarisingfrombusinesscombinationinvolvingenterprisesnotundercommoncontrol,theinvestmentcostshallbethecombinationcost.(Forabusinesscombinationachievedinstages,theinitialinvestmentcostisdeterminedasthesumofthecarryingamountofequityoftheacquireeandtheadditionalinvestmentcostsonthecombinationdate.)Thecombinationcostinvolvestheassetspaidbytheacquirer,liabilitiesincurredandthefairvalueofequitysecurities.Othercomprehensiveincomesrecognisedusingtheequitymethodbeforethecombinationdateisaccountedforonthesamebasisaswouldhavebeenrequirediftheinvesteehaddirectlydisposedoftherelatedassetsorliabilities.Equitypreviouslyrecognisedresultingfromtheinvestee’sequitychangesotherthanprofitorloss,othercomprehensiveincomeandprofitdistributionisreclassifiedtoprofitorloss.Equitywhichstillinvolvesalong-terminvestmentafterdisposalisreclassifiedtoprofitorlossonapro-ratabasisandequitywhichswichestoafinancialinstrumentafterdisposalisfullyreclassifiedtoprofitorloss.Theaccumulatedchangesinthefairvalueoffinancialassetsatfairvaluethroughothercomprehensiveincomeisreclassifiedtoretainedearningswhenadoptingthecostmethod.Dependingonthewayofacquisitionoflong-termequityinvestments,theinitialinvestmentcostisdeterminedasfollows:Forlong-termequityinvestmentsacquiredbywayofcashpayment,theinitialinvestmentcostincludesalldirectlyassociatedexpenses,applicabletaxesandfees,andothernecessaryexpenses.Forlong-termequityinvestmentsacquiredbywayofissuingequitysecurities,theinitialinvestmentcostincludesthefairvalueofequitysecurities.Forlong-termequityinvestmentsacquiredbywayoftheswapofnon-monetaryassets,theinitialinvestmentcostshallbedeterminedinaccordancewith“ASBENo.7—SwapofNon-monetaryAssets.”Forlong-termequityinvestmentsacquiredbywayofdebtrestructuring,theinitialinvestmentcostshallbedeterminedinaccordancewith“ASBENo.12—DebtRestructuring.”Foralong-termequityinvestmentwheretheCompanycanexercisecontrolovertheinvestee,thelong-terminvestmentisaccountedforusingthecostmethodintheCompany’sindividualfinancialstatements.ControlisachievedwhentheGroupisexposed,orhasrights,tovariablereturnsfromitsinvolvementwiththeinvesteeandhastheabilitytoaffectthosereturnsthroughitspowerovertheinvestee.Underthecostmethod,thelong-termequityinvestmentismeasuredatitsinitialinvestmentcost.Whenadditionalinvestmentismadeortheinvestmentisrecouped,thecostoflong-termequityinvestmentisadjustedaccordingly.Cashdividendsorprofitdistributionsdeclaredbytheinvesteearerecognisedasinvestmentincomeinprofitorloss.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(17)Long-termequityinvestments(Continued)TheequitymethodisadoptedwhentheGrouphasjointcontrol,orexercisessignificantinfluenceovertheinvestee.Jointcontrolisthecontractuallyagreedsharingofcontrolofanarrangement,whichexistsonlywhendecisionsabouttherelevantactivitiesrequiretheunanimousconsentofthepartiessharingcontrol.Significantinfluenceisthepowertoparticipateinthefinancialandoperatingpolicydecisionsoftheinvestee,butisnotcontrolorjointcontrolwithotherpartiesoverthosepolicies.Undertheequitymethod,wheretheinitialinvestmentcostofalong-termequityinvestmentexceedstheGroup’sinterestinthefairvalueoftheinvestee’sidentifiablenetassetsattheacquisitiondate,noadjustmentismadetotheinitialinvestmentcost.WheretheinitialinvestmentcostislessthantheGroup’sinterestinthefairvaluesoftheinvestee’sidentifiablenetassetsattheacquisitiondate,thedifferenceischargedtoprofitorloss,andthecostofthelong-termequityinvestmentisadjustedaccordingly.Undertheequitymethod,afterithasacquiredalong-termequityinvestment,theGrouprecognisesitsshareoftheinvestee’sprofitorloss,aswellasitsshareoftheinvestee’sothercomprehensiveincome,asinvestmentincomeorlossandothercomprehensiveincome,andadjuststhecarryingamountoftheinvestmentaccordingly.TheGrouprecognisesitsshareoftheinvestee’sprofitorlossaftermakingappropriateadjustmentstotheinvestee’sprofitorlossbasedonthefairvalueoftheinvestee’sidentifiableassetsattheacquisitiondate,usingtheGroup’saccountingpoliciesandperiods.UnrealisedprofitsandlossesfromtransactionswithitsjointventuresandassociatesareeliminatedtotheextentoftheGroup’sinvestmentsintheassociatesorjointventures(exceptforassetsthatconstituteabusiness)(However,anylossarisingfromsuchtransactionswhichareattributabletoanimpairmentlossshallberecognisedatitsentirety).ThecarryingamountoftheinvestmentisreducedbasedontheGroup’sshareofanyprofitdistributionsorcashdividendsdeclaredbytheinvestee.TheGroup’sshareofnetlossesoftheinvesteeisrecognisedtotheextentthatthecarryingamountoftheinvestmenttogetherwithanylong-termintereststhatinsubstanceformpartofitsnetinvestmentintheinvesteeisreducedtozero,exceptthattheGrouphastheobligationstoassumefurtherlosses.TheGroup’sowner’sequitychanges,otherthanthosearisingfromtheinvestee’sprofitorloss,othercomprehensiveincomeorprofitdistribution,isrecognisedintheGroup’sequity,andthecarryingamountofthelong-termequityinvestmentisadjustedaccordingly.Upondisposalofalong-termequityinvestment,thedifferencebetweentheproceedsactuallyreceivedandthecarryingamountisrecognisedinprofitorloss.Foralong-termequityinvestmentaccountedforusingtheequitymethod,whentheGroupdiscontinuesusingtheequitymethodduetodisposal,allamountspreviouslyrecognisedinothercomprehensiveincomeareaccountedforonthesamebasisaswouldhavebeenrequirediftheinvesteehaddirectlydisposedoftherelatedassetsorliabilities.Equitypreviouslyrecognisedresultingfromtheowner’sequitychangesotherthanprofitorloss,othercomprehensiveincomeandprofitdistributionisreclassifiedtoprofitorlossinitsentirety.WhentheGroupcontinuestousetheequitymethod,theamountspreviouslyrecognisedinothercomprehensiveincomeareaccountedforonthesamebasisaswouldhavebeenrequirediftheinvesteehaddirectlydisposedoftherelatedassetsorliabilitiesandreclassifiedtoprofitorlossonapro-ratabasis.Equitypreviouslyrecognisedresultingfromtheinvestee’sequitychangesotherthanprofitorloss,othercomprehensiveincomeandprofitdistributionisreclassifiedtoprofitorlossonapro-ratabasis.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(18)InvestmentpropertiesInvestmentpropertiesarepropertiesheldtoearnrentalincomeand/orforcapitalappreciation.Investmentpropertiesincludelanduserightsleasedout,landuserightsheldfortransferuponcapitalappreciation,andbuildingsleasedout.Aninvestmentpropertyismeasuredinitiallyatcost.Iftheeconomicbenefitsrelatingtoaninvestmentpropertywillprobablyflowinandthecostcanbereliablymeasured,subsequentcostsincurredforthepropertyareincludedinthecostoftheinvestmentproperty.Otherwise,subsequentcostsarerecognisedinprofitorlossasincurred.TheGroupadoptsthecostmodelforsubsequentmeasurementofinvestmentproperties.Buildingsandlanduserightsaredepreciatedoramortizedtotheirestimatednetresidualvaluesovertheirestimatedusefullives.Theestimatedusefullives,theestimatednetresidualvaluesthatareexpressedasapercentageofcostandtheannualdepreciation(amortization)ratesofinvestmentpropertiesareasfollows:
Estimatedusefullives | Estimatedresidualvalue | Annualdepreciation(amortization)rates |
BuildingsandConstructions | 5-35years | 0-5% | 2.71-19.00% |
Landuserights | 40-50yearsorNofixedusefullife | - | 2.00-2.50% |
Whenaninvestmentpropertyistransferredtoowner-occupiedproperty,itisreclassifiedasafixedassetorintangibleassetatthedateoftransfer.Whenanowner-occupiedpropertyistransferredoutforearningrentalsorforcapitalappreciation,thefixedassetorintangibleassetisreclassifiedasaninvestmentpropertyatitscarryingamountatthedateoftransfer.Theinvestmentproperties’usefullife,netresidualvalueanddepreciation(amortization)methodappliedarereviewedandadjustedasappropriateattheendofeachyear.
(19)FixedassetsRecognitioncriteriaAfixedassetisrecognisedonlywhentheeconomicbenefitsassociatedwiththeassetwillprobablyflowintotheGroupandthecostoftheassetcanbemeasuredreliably.Subsequentexpendituresincurredforafixedassetthatmeetstherecognitioncriteriashallbeincludedinthecostofthefixedasset,andthecarryingamountofthecomponentofthefixedassetthatisreplacedshallbederecognised.Otherwise,suchexpendituresarerecognisedinprofitorlossasincurred.Fixedassetsareinitiallymeasuredatcost,bytakingintoaccounttheeffectofanyassetretirementobligations.Thecostofapurchasedfixedassetcomprisesthepurchaseprice,relevanttaxesandanydirectlyattributableexpenditureforbringingtheassettoworkingconditionforitsintendeduse.TheGroupreviewstheusefullifeandestimatednetresidualvalueofafixedassetandthedepreciationmethodappliedatleastateachyearend,andmakeadjustmentsifnecessary.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(19)Fixedassets(Continued)Depreciationmethod
EstimatedusefullivesEstimatedresidualvalueAnnualdepreciationratesBuildingsandconstructtions10-40years3-5%2.38-9.70%Machineryandequipment5-14years3-5%6.79-19.40%Motorvehicles3-10years5%9.50-31.67%Officeequipments3-10years5%9.50-31.67%Electronicequipments3-10years0-5%9.50-33.33%
(20)ConstructioninprogressThecostofconstructioninprogressisdeterminedaccordingtotheactualexpendituresincurredfortheconstruction,includingallnecessaryconstructionexpendituresincurredduringtheconstructionperiod,borrowingcoststhatshallbecapitalisedbeforetheconstructionisreadyforitsintendeduse,andotherrelevantexpenditures.Anitemofconstructioninprogressistransferredtofixedassetswhentheassetisreadyforitsintendeduse.
(21)BorrowingcostsBorrowingcostsareinterestandothercostsincurredbytheGroupinconnectionwiththeborrowingofthefunds.Borrowingcostsincludeinterest,amortisationofdiscountsorpremiumsrelatedtoborrowings,ancillarycostsincurredinconnectionwiththearrangementofborrowings,andexchangedifferencesarisingfromforeigncurrencyborrowings.Theborrowingcoststhataredirectlyattributabletotheacquisition,constructionorproductionofaqualifyingassetarecapitalised.Theamountsofotherborrowingcostsincurredarerecognisedasanexpenseintheperiodinwhichtheyareincurred.Qualifyingassetsareassets(fixedassets,investmentproperties,inventories,etc.)thatnecessarilytakeasubstantialperiodoftimeofacquisition,constructionorproductiontogetreadyfortheirintendeduseorsale.Thecapitalisationofborrowingcostscommencesonlywhenallofthefollowingconditionsaresatisfied:
(1)expendituresfortheassethavebeenincurred;
(2)borrowingcostshavebeenincurred;and
(3)activitiesthatarenecessarytoacquire,constructorproducetheassetforitsintendeduseor
salehavebeenundertaken.Capitalisationofborrowingcostsceaseswhenthequalifyingassetbeingacquired,constructedorproducedgetsreadyforitsintendeduseorsale.Anyborrowingcostssubsequentlyincurredarerecognisedinprofitorloss.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(21)Borrowingcosts(Continued)Duringthecapitalisationperiod,theamountofinteresteligibleforcapitalisationforeachaccountingperiodshallbedeterminedasfollows:
(1)wherefundsareborrowedspecificallyforthepurposeofobtainingaqualifyingasset,the
amountofinteresteligibleforcapitalisationistheactualinterestcostsincurredonthatborrowingfortheperiodlessanybankinterestearnedfromdepositingtheborrowedfundsbeforebeingusedontheassetoranyinvestmentincomeonthetemporaryinvestmentofthosefunds;or
(2)wherefundsareborrowedgenerallyforthepurposeofobtainingaqualifyingasset,theamount
ofinteresteligibleforcapitalisationisdeterminedbyapplyingaweightedaverageinterestrateonthegeneralborrowingstotheweightedaverageoftheexcessofthecumulativeexpendituresontheassetovertheexpendituresontheassetfundedbythespecificborrowings.Capitalisationofborrowingcostsissuspendedduringperiodsinwhichtheacquisition,constructionorproductionofaqualifyingassetissuspendedabnormallybyactivitiesotherthanthosenecessarytogettheassetreadyforitsintendeduseorsale,whenthesuspensionisforacontinuousperiodofmorethan3months.Borrowingcostsincurredduringtheseperiodsarerecognisedasanexpenseinprofitorlossuntiltheacquisition,constructionorproductionisresumed.
(22)Right-of-useassetsTheright-of-useassetsoftheGroupmainlyincludebuildings,machinery,vehicles,officeequipmentsandotherequipments(suchaslanduseright).Atthecommencementdateofthelease,theGrouprecognisesaright-of-useasset.Thecostoftheright-of-useassetcomprises:(i)theamountoftheinitialmeasurementoftheleaseliability;(ii)anyleasepaymentsmadeatorbeforethecommencementdateoftheleaselessanyleaseincentivesreceived;(iii)anyinitialdirectcostincurred;and(iv)anestimateofcostsincurredbythelesseeindismantlingandremovingtheunderlyingasset,restoringthesiteonwhichitislocatedorrestoringtheunderlyingassettotheconditionrequiredbythetermsandconditionsofthelease.Theright-of-useassetsaredepreciatedonastraight-linebasissubsequentlybytheGroup.IftheGroupisreasonablycertainthattheownershipoftheunderlyingassetwillbetransferredtotheGroupattheendoftheleaseterm,theGroupdepreciatestheassetfromthecommencementdatetotheendoftheusefullifeoftheasset.Otherwise,theGroupdepreciatestheassetsfromthecommencementdatetotheearlieroftheendoftheusefullifeoftheassetortheendoftheleaseterm.TheGroupremeasurestheleaseliabilityatthepresentvalueofthechangedleasepaymentsandadjuststhecarryingamountoftheright-of-useassetsaccordingly,whenthecarryingamountoftheright-of-useassetisreducedtozero,andthereisafurtherreductioninthemeasurementoftheleaseliability,theGrouprecognisestheremainingamountoftheremeasurementinprofitorloss.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(23)IntangibleassetsAnintangibleassetshallberecognisedonlywhenitisprobablethattheeconomicbenefitsassociatedwiththeassetwillflowtotheGroupandthecostoftheassetcanbemeasuredreliably.Intangibleassetsaremeasuredinitiallyatcost.However,intangibleassetsacquiredinabusinesscombinationnotinvolvingentitiesundercommoncontrolwithafairvaluethatcanbemeasuredreliablyarerecognisedseparatelyasintangibleassetsandinitiallymeasuredatthefairvalueatthedateofacquisition.TheusefullifeofanintangibleassetisdeterminedaccordingtotheperiodoverwhichitisexpectedtogenerateeconomicbenefitsfortheGroup.AnintangibleassetisregardedashavinganindefiniteusefullifewhenthereisnoforeseeablelimittotheperiodoverwhichtheassetisexpectedtogenerateeconomicbenefitsfortheGroup.Theusefullivesoftheintangibleassetsareasfollows:
Categories | Usefullives |
Landuserights | BetweentheapprovedusefulperiodandtheCompany’soperatingperiod | |
Software | 3-10years | |
TrademarksandBranduserights | 10yearsorNofixedlife | |
Distributionnetwork | 10-20years | |
Franchisingrights | 10years | |
Favorableleases | 16-20years |
LanduserightsthatarepurchasedbytheGroupareaccountedforasintangibleassets.Buildings,suchasplantsthataredevelopedandconstructedbytheGroup,andrelevantlanduserightsareaccountedforasfixedassetsandintangibleassets,respectively.Paymentsforthelandandbuildingspurchasedareallocatedbetweenthelanduserightsandthebuildings;theyareaccountedforasfixedassetsiftheycannotbereasonablyallocated.Anintangibleassetwithafiniteusefullifeisamortisedusingthestraight-linemethodoveritsusefullife.Foranintangibleassetwithafiniteusefullife,theGroupreviewstheusefullifeandamortisationmethodatleastateachyearendandmakesadjustmentifnecessary.LanduserightsallocatedbytheStateareregardedasanintangibleassetwithanindefiniteusefullifeduetoanuncertainusefullife.Theimpairmenttestshouldbeconductedfortheintangibleassetswiththeindefiniteservicelifeeveryyeartodeterminewhethertheimpairmentexists.Theintangibleassetswiththeindefiniteservicelifeshallnotbeamortized,andtheCompanyshallmakethereviewoftheservicelifeoftheintangibleassetsduringeveryaccountingperiod.Ifevidenceprovethatusefullivesarefinite,theGroupaccountsfortheintangibleassetsinaccordancewithintangibleassetswithafiniteusefullife.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(23)Intangibleassets(Continued)InternalresearchanddevelopmentprojectTheGroupclassifiestheexpensesforinternalresearchanddevelopmentasresearchcostsanddevelopmentcosts.Allresearchcostsarechargedtothecurrentprofitorlossasincurred.ExpenditureincurredonprojectstodevelopnewproductsiscapitalisedanddeferredonlywhentheGroupcandemonstratethetechnicalfeasibilityofcompletingtheintangibleassetsothatitwillbeavailableforuseorsale,itsintentiontocompleteanditsabilitytouseorselltheasset,howtheassetwillgeneratefutureeconomicbenefits(includingdemonstrationthattheproductderivedfromtheintangibleassetortheintangibleassetitselfwillbemarketableor,inthecaseofinternaluse,theusefulnessoftheintangibleassetassuch),theavailabilityoftechnicalandfinancialresourcestocompletetheprojectandprocuretheuseorsaleoftheintangibleasset,andtheabilitytomeasurereliablytheexpenditureduringthedevelopment.Productdevelopmentexpenditurewhichdoesnotmeetthesecriteriaisexpensedwhenincurred.Developmentcostspreviouslyrecognisedasexpensesarenotrecognisedasanassetinasubsequentperiod.Capitalizedexpenditureonthedevelopmentphaseispresentedasdevelopmentcostsinthebalancesheetandtransferredtointangibleassetsatthedatethattheassetisreadyforitsintendeduse.
(24)Impairmentoflong-termassetsTheGroupdeterminestheimpairmentofassets,otherthantheimpairmentofinventories,investmentpropertiesmeasuredusingthefairvaluemodel,deferredtaxassets,financialassetsandassetsclassifiedasheldforsale,usingthefollowingmethods:
TheGroupassessesatthebalancesheetdatewhetherthereisanyindicationthatanassetmaybeimpaired.Ifanyindicationexiststhatanassetmaybeimpaired,theGroupestimatestherecoverableamountoftheassetandperformsimpairmenttesting.Goodwillarisingfromabusinesscombinationandanintangibleassetwithanindefiniteusefullifearetestedforimpairmentatleastateachyearend,irrespectiveofwhetherthereisanyindicationthattheassetmaybeimpaired.Intangibleassetsthathavenotbeenreadyfortheirintendedusearetestedforimpairmenteachyear.Therecoverableamountofanassetisthehigherofitsfairvaluelesscoststosellandthepresentvalueofthefuturecashflowsexpectedtobederivedfromtheasset.TheGroupestimatestherecoverableamountonanindividualbasisunlessitisnotpossibletoestimatetherecoverableamountoftheindividualasset,inwhichcasetherecoverableamountisdeterminedfortheassetgrouptowhichtheassetbelongs.Identificationofanassetgroupisbasedonwhethermajorcashinflowsgeneratedbytheassetgrouparelargelyindependentofthecashinflowsfromotherassetsorassetgroups.Whentherecoverableamountofanassetorassetgroupislessthanitscarryingamount,thecarryingamountisreducedtotherecoverableamountbytheGroup.Thereductioninthecarryingamountistreatedasanimpairmentlossandrecognisedinprofitorloss.Aprovisionforimpairmentlossoftheassetisrecognisedaccordingly.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(24)Impairmentoflong-termassets(Continued)Forthepurposeofimpairmenttesting,thecarryingamountofgoodwillacquiredinabusinesscombinationisallocatedfromtheacquisitiondateonareasonablebasis,toeachoftherelatedassetgroupsunlessitisimpossibletoallocatetotherelatedassetgroups,inwhichcaseitisallocatedtoeachoftherelatedsetsofassetgroups.EachoftherelatedassetgroupsorsetsofassetgroupsisanassetgrouporasetofassetgroupsthatisexpectedtobenefitfromthesynergiesofthebusinesscombinationandshallnotbelargerthanareportablesegmentdeterminedbytheGroup.Whentestinganassetgroup(asetofassetgroups)towhichgoodwillhasbeenallocatedforimpairment,ifthereisanyindicationofimpairment,theGroupfirstlyteststheassetgroup(setofassetgroups),excludingtheamountofgoodwillallocated,forimpairment,i.e.,theGroupdeterminesandcomparestherecoverableamountwiththerelatedcarryingamountandrecognisesanyimpairmentloss.Afterthat,theGroupteststheassetgroup(setofassetgroups),includinggoodwill,forimpairment,thecarryingamountoftherelatedassetgroup(setofassetgroups)iscomparedtoitsrecoverableamount.Ifthecarryingamountoftheassetgroup(setofassetgroups)ishigherthanitsrecoverableamount,theamountoftheimpairmentlossisfirstlyusedtoreducethecarryingamountofthegoodwillallocatedtotheassetgroup(setofassetgroups),andthenusedtoreducethecarryingamountofotherassets(otherthanthegoodwill)withintheassetgroup(setofassetgroups),onapro-ratabasisofthecarryingamountofeachasset.Oncetheaboveimpairmentlossisrecognised,itcannotbereversedinsubsequentaccountingperiods.
(25)Long-termprepaidexpensesLong-termprepaidexpensesincludetheexpenditureforimprovementstofixedassetsunderoperatingleases,andotherexpendituresthathavebeenmadebutshouldberecognisedasexpensesovermorethanoneyearinthecurrentandsubsequentperiods.Long-termprepaidexpensesareamortizedonthestraight-linebasisovertheexpectedbeneficialperiodandarepresentedatactualexpenditurenetofaccumulatedamortization.
(26)ContractliabilitiesTheGrouppresentscontractassetsorcontractliabilitiesdependingontherelationshipbetweenthesatisfactionofitsperformanceobligationsandthecustomer’spaymentinthebalancesheet.TheGroupoffsetsthecontractassetsandcontractliabilitiesunderthesamecontractandpresentsthenetamount.AcontractliabilityistheobligationtotransfergoodsorservicestoacustomerforwhichtheGrouphasreceivedconsiderationoranamountofconsiderationisduefromthecustomer,suchasanamountofconsiderationthatanentityhasreceivedbeforethetransferofthepromisedgoodsorservices.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(27)EmployeebenefitsEmployeebenefitsrefertoallformsofconsiderationorcompensationotherthanshare-basedpaymentsgivenbytheGroupinexchangeforservicesrenderedbyemployeesorforterminationofemployment.Employeebenefitsincludeshort-termemployeebenefits,post-employmentbenefits,terminationbenefitsandotherlong-termemployeebenefits.BenefitsgivenbytheGrouptoanemployee’sspouse,childrenanddependents.Short-termemployeebenefitsTheactualoccurredshort-termemployeebenefitsarerecognizedasliabilitiesduringtheaccountingperiodinwhichtheservicehasbeenrenderedbytheemployeesandascostsofassetsorexpensestowhichevertheemployeeserviceisattributable.Post-employmentbenefits(definedcontributionplans)TheemployeesoftheGroupparticipateinapensionschemeandunemploymentinsurancemanagedbythelocalgovernment,andanenterprisepensionfund,thecorrespondingexpensesshallbeincludedinthecostofrelatedassetsorprofitorloss.Post-employmentbenefits(definedbenefitplans)TheGroupoperatesadefinedbenefitpensionplanwhichrequirescontributionstobemadetoaseparatelyadministeredfund.Thebenefitsareunfunded.Thecostofprovidingbenefitsunderthedefinedbenefitplanisdeterminedusingtheprojectedunitcreditmethod.Remeasurementsarisingfromthedefinedbenefitpensionplan,comprisingactuarialgainsandlosses,theeffectoftheassetceiling(excludingamountsincludedinnetinterestonthenetdefinedbenefitliability)andthereturnonplanassets(excludingamountsincludedinnetinterestonthenetdefinedbenefitliability),arerecognisedimmediatelyinthebalancesheetwithacorrespondingdebitorcredittoequitythroughothercomprehensiveincomeintheperiodinwhichtheyoccur.Remeasurementsarenotreclassifiedtoprofitorlossinsubsequentperiods.PastservicecostsarerecognisedinprofitorlossattheearlierofthedateoftheplanamendmentandthedatethattheGrouprecognisesrestructuring-relatedcostsorterminationbenefits.Netinterestiscalculatedbyapplyingthediscountratetothenetdefinedbenefitliabilityorasset.TheGrouprecognisesthefollowingchangesinthenetdefinedbenefitobligationunderadministrativeexpensesandfinanceexpensesintheincomestatement:servicecostscomprisingcurrentservicecosts,pastservicecosts,gainsandlossesonsettlements;netinterestcomprisinginterestincomeonplanassets,interestcostsonthedefinedbenefitobligationandinterestontheeffectoftheassetceiling.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(27)Employeebenefits(Continued)TerminationbenefitsTheGroupprovidesterminationbenefitstoemployeesandrecognisesanemployeebenefitsliabilityforterminationbenefits,withacorrespondingchargetoprofitorloss,attheearlierofwhentheGroupcannolongerwithdrawtheofferofthosebenefitsresultingfromanemploymentterminationplanoracurtailmentproposalandwhentheGrouprecognisecostsinvolvingthepaymentofterminationbenefits.TheGroupoffersterminationbenefitstotheemployeeswhoacceptinternalretirementarrangements.Terminationbenefitsreferstosalariesandsocialsecuritiespaidtotheemployeeswhovoluntarilyretireandapprovedbythemanagementbeforethelegalretirementage.TheGrouppaysterminationbenefitsfromthedateofthestartingofinternalretirementarrangementstolegalretirementage.Whenmeetingtherecognitioncriteria,terminationbenefitsarerecognisedasliabilitiesfromthedateonwhichtheemployeesstopofferingservicestothelegalretirementdateandrecognisedinprofitorlossasincurred.Thechangeofterminationbenefits’actuarialassumptionsanddifferenceincurredbytheadjustmentofwelfarestandardsarerecognisedinprofitorlossasincurred.Theterminationbenefitsexpectedtobesettledwithinoneyearsincethebalancesheetdateareclassifiedascurrentliabilities.OtherlongtermemployeebenefitsOtherlong-termemployee’benefitsprovidedtoemployeesshallberecognisedandmeasuredasnetliabilitiesornetassetswhereprovisionsregardingpost-employmentbenefitsareapplicable,providedthatchangesshallbeincludedinthecurrentprofitandlossorrelatedassetcosts.
(28)LeaseliabilityAtthecommencementdateofthelease,theGroupmeasurestheleaseliabilityatthepresentvalueoftheleasepaymentsthatarenotpaidatthatdate,exceptforshort-termleasesandleasesoflow-valueassets.Incalculatingthepresentvalueoftheleasepayments,theGroupusestheinterestrateimplicitintheleaseasthediscountrate.Ifthatratecannotbereadilydetermined,theGroupusesthelessee’sincrementalborrowingrate.TheGroupcalculatestheinterestexpensesoftheleaseliabilityineachperiodduringtheleasetermusingtheconstantperiodicrateofinterest,andrecognisessuchinterestexpensesinprofitorloss,exceptthoseinthecostsoftherelatedassetasrequired.Variableleasepaymentsthatarenotincludedinthemeasurementoftheleaseliabilitiesarerecognisedinprofitorlossasincurred,exceptthoseinthecostsoftherelatedassetasrequired.Afterthecommencementdateofthelease,theGroupremeasuresleaseliabilitieswithchangedpresentvalueoftheleasepaymentswhenfixedpayment,expectedunguaranteedresidualvaluepayable,theinterestrateimplicitintheleaseasthediscountrate,purchaseoptions,optionstoextendtheleaseordeterminationoftheleasetermchange.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(29)ProvisionsAnobligationrelatedtoacontingencyshallberecognisedbytheGroupasaprovisionwhenallofthefollowingconditionsaresatisfied,exceptforcontingentconsiderationsandcontingentliabilitiesassumedinabusinesscombinationnotinvolvingentitiesundercommoncontrol:
(1)theobligationisapresentobligationoftheGroup;
(2)itisprobablethatanoutflowofeconomicbenefitsfromtheGroupwillberequiredtosettlethe
obligation;and
(3)areliableestimatecanbemadeoftheamountoftheobligation.Aprovisionisinitiallymeasuredatthebestestimateoftheexpenditurerequiredtosettletherelatedpresentobligation,takingintoaccountfactorspertainingtoacontingencysuchastherisks,uncertaintiesandtimevalueofmoneyasawhole.Provisionsarereviewedateachbalancesheetdate.Wherethereisclearevidencethatthecarryingamountofaprovisiondoesnotreflectthecurrentbestestimate,thecarryingamountisadjustedtothecurrentbestestimate.Acontingentliabilityrecognisedinabusinesscombinationnotinvolvingentitiesundercommoncontrolisinitiallymeasuredatfairvalue.Subsequently,itismeasuredatthehigherof:(i)theamountthatwouldberecognisedinaccordancewiththegeneralpolicyforprovisionsabove;and(ii)theamountinitiallyrecognisedlesscumulativeamortisationrecognisedinaccordancewiththepolicyforrevenuerecognition.
(30)Share-basedpaymentsAshare-basedpaymentisclassifiedaseitheranequity-settledshare-basedpaymentoracash-settledshare-basedpayment.Anequity-settledshare-basedpaymentisatransactioninwhichtheGroupreceivesservicesandusessharesorotherequityinstrumentsasconsiderationforsettlement.Anequity-settledshare-basedpaymentinexchangeforservicesreceivedfromemployeesismeasuredatthefairvalueoftheequityinstrumentsgrantedtotheemployees.Ifsuchequity-settledshare-basedpaymentcouldvestimmediately,relatedcostsorexpensesatanamountequaltothefairvalueonthegrantdatearerecognised,withacorrespondingincreaseincapitalreserves;ifsuchequity-settledshare-basedpaymentcouldnotvestuntilthecompletionofservicesforavestingperiod,oruntiltheachievementofaspecifiedperformancecondition,theGroupateachbalancesheetdateduringthevestingperiodrecognisestheservicesreceivedforthecurrentperiodasrelatedcostsandexpenses,withacorrespondingincreaseincapitalreserves,atanamountequaltothefairvalueoftheequityinstrumentsatthegrantdate,basedonthebestestimateofthenumberofequityinstrumentsexpectedtovest,whichismadeonthebasisofthelatestavailableinformationsuchasthechangesinthenumberofcoveredemployeesandwhetherspecifiedperformanceconditionshavebeenmet.Thefairvalueisdeterminedusingthebinomialmodel.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(30)Share-basedpayments(Continued)Thecostofequity-settledtransactionsisrecognised,togetherwithacorrespondingincreaseincapitalreserves,overtheperiodinwhichthespecifiedperformanceorserviceconditionsarefulfilled.Thecumulativeexpenserecognisedforequity-settledtransactionsateachbalancesheetdateuntilthevestingdatereflectstheextenttowhichthevestingperiodhasexpiredandtheGroup’sbestestimateofthenumberofequityinstrumentsthatwillultimatelyvest.Forawardsthatdonotultimatelyvestbecausenon-marketperformanceand/orserviceconditionshavenotbeenmet,noexpenseisrecognised.Whereawardsincludeamarketornon-vestingcondition,thetransactionsaretreatedasvestingirrespectiveofwhetherthemarketornon-vestingconditionissatisfied,providedthatallotherperformanceand/orserviceconditionsaresatisfied.Wherethetermsofanequity-settledshare-basedawardaremodified,asaminimumanexpenseisrecognisedasifthetermshadnotbeenmodified.Inaddition,anexpenseisrecognisedforanymodificationthatincreasesthetotalfairvalueoftheshare-basedpayments,orisotherwisebeneficialtotheemployeeasmeasuredatthedateofmodification.Whereanequity-settledshare-basedawardiscancelled,itistreatedasifithadvestedonthedateofcancellation,andanyexpensenotyetrecognisedfortheawardisrecognisedimmediately.Thisincludesanyawardwherenon-vestingconditionswithinthecontrolofeithertheGrouportheemployeearenotmet.However,ifanewawardissubstitutedforthecancelledaward,andisdesignatedasareplacementonthedatethatitisgranted,thecancelledandnewawardsaretreatedasiftheywereamodificationoftheoriginalaward.Thecostofcash-settledtransactionsismeasuredatthefairvalueoftheliabilitywhichisdeterminedonthebasisofsharesorotherequityinstrumentsoftheGroup.Itisinitiallyrecognisedatthefairvalueonthegrantdateusingbinomialmodeltogetherwiththeconsiderationoftermsandconditionsonwhichtheequityinstrumentsaregranted.Iftherightsunderacash-settledshare-basedpaymentcouldvestimmediately,relatedcostsorexpensesatanamountequaltothefairvalueonthegrantdatearerecognised,withacorrespondingincreaseinliability.Iftherightsunderacash-settledshare-basedpaymentcouldnotvestuntilthecompletionofservicesforavestingperiod,oruntilachievementofaspecifiedperformancecondition,theGroupateachbalancesheetdateduringthevestingperiodrecognisestheservicesreceivedforthecurrentperiodasrelatedcostsandexpenses,withacorrespondingincreaseinliability,atanamountequaltothefairvalueoftheliabilitybasedonthebestestimateoftheoutcomeofvesting.Theliabilityismeasuredateachbalancesheetdateuptoandincludingthesettlementdate,withchangesinfairvaluerecognisedinprofitorloss.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(31)RevenuerecognitionRevenuefromcontractswithcustomersisrecognisedwhentheGrouphasfulfilleditsperformanceobligationsinthecontracts,thatis,whenthecustomerobtainscontrolofrelevantgoodsorservices.Controlofrelevantgoodsorservicesreferstotheabilitytodirecttheuseofthegoods,ortheprovisionoftheservices,andobtainsubstantiallyalloftheremainingbenefitsfromthegoodsorservices.ContractsforsaleofgoodsThecontractsforthesaleofgoodsbetweentheGroupanditscustomerusuallyonlycontaintheperformanceobligationsforthetransferofgoods.TheGroupgenerallyrecognizesrevenueatthepointoftransferringthecontrolofgoodsonthebasisofacombinationofthefollowingfactors:thecurrentrighttocollectthegoods,thetransferofmajorrisksandbenefitsintheownershipofthegoods,andthetransferofthelegalownershipofthegoods,thetransferofphysicalassetsofthegoodsandthatthecustomershaveacceptedthegoods.ServiceContractsTheservicecontractsbetweentheGroupanditscustomersusuallyconsistofperformanceobligationssuchasstorageandlogisticsandsoon.AstheGroup'sperformanceofcontractsisatthesametimewhenthecustomerobtainsandconsumestheeconomicbenefitsoftheperformanceoftheGroup,andtheGrouphastherighttocollectreceivablesfromtheperformanceofcontactsthathasbeencompletedtodate,theGroupregardsitasacontractobligationoveraperiodoftime,exceptthattheprogressofperformancecannotbereasonablydetermined.TheGroupdeterminestheprogressoftheperformanceofcontractsinaccordancewiththeinputmethod.IftheprogressofperformanceofcontractscannotbereasonablydeterminedandthecostincurredbytheGroupisexpectedtobecompensated,therevenueisrecognisedonthebasisoftheincurredcostsuntiltheprogressofperformanceofcontactscanbereasonablymeasured.VariableconsiderationSomeoftheGroup'scontractswithcustomersincludingarrangementsofsalesrebates(listitemsinaccordancewiththecustomer’sactualconditions,suchasearlycompletionawardsorothers)resultinvariableconsideration.TheGroupdeterminesthebestestimateofvariableconsiderationbyusingtheexpectedvaluemethodorthemostlikelyamountmethod.However,thetransactionpriceincludingvariableconsiderationisonlytotheextentthatitishighlyprobablethatasignificantreversalintheamountofcumulativerevenuerecognisedwillnotoccurwhentheuncertaintyassociatedwiththevariableconsiderationissubsequentlyresolved.ConsiderationpayabletocustomersWhereconsiderationispayablebytheGrouptoacustomer,suchconsiderationpayableshallbedeductedagainstthetransactionprice,andagainstcurrentrevenueupontherecognitionofrevenueorthepaymentof(orthecommitmenttopay)theconsiderationtothecustomer(whicheverislater),saveforconsiderationpayabletothecustomerforthepurposeofacquiringfromthecustomerotherclearlyseparableproducts.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(31)Revenuerecognition(Continued)ReturnclausesInconnectionwithsaleswithareturnclause,revenueisrecognisedaccordingtotheamountofconsiderationitexpectstobeentitledtoforthetransfertoacustomerwhenthecustomeracquirescontroloftherelevantproducts.Amountsexpectedtoberefundedforthereturnofsalesarerecognisedasliabilities.Atthesametime,thebalanceofthecarryingvalueoftheproductexpectedtobereturnedupontransferlessexpectedcostsfortherecallofsuchproduct(includinganimpairmentlossoftherecalledproduct)shallberecognisedasanasset(i.e.costofreturnreceivables),andthenetamountofthecarryingvalueofthetransferredproductuponthetransferlesstheaforesaidassetcostshallbetransferredtocost.Ateachbalancesheetdate,theGroupreassessesthefuturereturnofsalesandremeasurestheaboveassetsandliabilities.SignificantfinancingcomponentWhereacontractcontainsasignificantfinancingcomponent,theGroupdeterminestransactionpricesbasedonamountspayableassumedtobesettledincashbycustomersimmediatelyupontheacquisitionofcontrolovertheproducts.Thedifferencebetweensuchtransactionpriceandcontractconsiderationisamortisedoverthecontractperiodusingtheeffectiveinterestratemethodbasedonaratiothatdiscountsthenominalcontractualconsiderationtothecurrentsellingpriceoftheproducts.TheGroupshallnotgiveconsiderationtoanysignificantfinancingcomponentinacontractifthegapbetweenthecustomer’sacquisitionofcontrolovertheproductsandpaymentofconsiderationisexpectedtobelessthan1year.WarrantyclausesTheGroupprovidesqualityassuranceforproductssoldandassetsbuiltinaccordancewithcontracttermsandlawsandregulations.TheaccountingtreatmentofqualityassuranceintheformofwarrantyassuringcustomersproductssoldareincompliancewithrequiredstandardsissetoutinNoteV.36.WheretheGroupprovidesaservicewarrantyforastandaloneserviceinadditiontotheassuranceofcomplianceofproductswithrequiredstandards,suchwarrantyistreatedasastand-alonecontractualperformanceobligation,andaportionofthetransactionpriceshallbeallocatedtotheservicewarrantybasedonapercentageofthestand-alonepricefortheprovisionoftheproductandservicewarranty.Whenassessingwhetherawarrantyisrenderingastand-aloneserviceinadditiontoprovidingguaranteetocustomersthatallsoldgoodsareincompliancewithrequiredstandards,theGroupwillconsiderwhetherornotsuchwarrantyisastatutoryrequirement,thetermofthewarrantyandthenatureoftheGroup’sundertakingtoperformitsobligations.RewardpointsprogramTheGroupgrantsrewardpointstocustomerswhensellinggoods.CustomerscanuserewardpointstoredeemfreeordiscountedgoodsprovidedbytheGroup.Thisrewardpointsprogramprovidessignificantrightstocustomers,andtheGroupconsidersitasanindividualperformanceobligation,andapportionspartofthetransactionpricestorewardpointsbasedonpricingofgoodsorserviceswithwarrantyclauses.Revenueisrecognisedwhencustomersobtaingoodsredeemedorwhenrewardpointsexpire.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(31)Revenuerecognition(Continued)Principalresponsibleperson/proxyForgoodsorotherassetsobtainedfromathirdpartywhichweretransferredlatertocustomers,theGrouphastherighttodecide,independently,thepricingofgoods.ThismeansthattheGrouphasobtainedcontroloverrelatedgoodsbeforetransferringtocustomers.Therefore,theGroupistheprincipalresponsibleperson,andrevenueisrecognisedbasedonthetotalamountofconsiderationreceivedorreceivable.Otherwise,theGroupisproxy,andrevenueisrecognisedbasedonexpectedcommission.Thisamountshouldbethetotalamountofconsiderationreceivedorreceivablenetoftheamountpayabletootherparties,orbasedonthefixedamountorpercentage.
(32)GovernmentgrantsGovernmentgrantsarerecognisedwhenallattachingconditionswillbecompliedwithandthegrantswillbereceived.Ifagovernmentgrantisintheformofatransferofamonetaryasset,itismeasuredattheamountreceivedorreceivable.Ifagovernmentgrantisintheformofatransferofanon-monetaryasset,itismeasuredatfairvalue;iffairvalueisnotreliablydeterminable,itismeasuredatanominalamount.Governmentgrantsrelatedtoassetsrefertogovernmentassetswhicharegrantedtoenterprisesforthelong-termassetsformedbyacquisition,constructionorinothermanners.Governmentgrantsrelatedtoincomerefertogovernmentgrantsotherthanthoserelatedtoassets.Agovernmentgrantrelatedtoincomeisaccountedforasfollows:(i)ifthegrantisacompensationforrelatedexpensesorlossestobeincurredinsubsequentperiods,thegrantisrecognisedasdeferredincome,andreleasedinprofitorlossoroffsetagainstrelatedexpensesovertheperiodsinwhichtherelatedcostsarerecognised;or(ii)ifthegrantisacompensationforrelatedexpensesorlossesalreadyincurred,itisrecognisedimmediatelyinprofitorlossoroffsetagainstrelevantexpenses.Agovernmentgrantrelatingtoanassetshallbeoffsetagainstthecarryingamountsofrelevantassets,orrecognisedasdeferredincomeandamortisedinprofitorlossovertheusefullifeoftherelatedassetbyannualinstalmentsinasystematicandrationalway(however,agovernmentgrantmeasuredatanominalamountisrecogniseddirectlyinprofitorloss).Wheretheassetsaresold,transferred,retiredordamagedbeforetheendoftheirusefullives,therestoftheremainingdeferredincomeisreleasedtoprofitorlossfortheperiodinwhichtherelevantassetsaredisposedof.
(33)IncometaxIncometaxcomprisescurrentanddeferredtax.Incometaxisrecognisedasincomeorexpenseinprofitorloss,orrecogniseddirectlyinequityifitarisesfromabusinesscombinationorrelatestoatransactionoreventwhichisrecogniseddirectlyinequity.CurrenttaxliabilitiesorassetsarisingfromthecurrentandpriorperiodsattheamountexpectedtobepaidbytheGrouporreturnedbythetaxauthoritycalculatedaccordingtorelatedtaxlaws.Deferredtaxisprovidedusingthebalancesheetliabilitymethod,onalltemporarydifferencesatthebalancesheetdatebetweenthetaxbasesofassetsandliabilitiesandtheircarryingamounts,andtemporarydifferencesbetweenthetaxbasesandthecarryingamountsoftheitems,whichhaveataxbaseaccordingtorelatedtaxlawsbutarenotrecognisedasassetsandliabilities.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(33)Incometax(Continued)Deferredtaxliabilitiesarerecognisedforalltaxabletemporarydifferences,except:
(1)whenthetaxabletemporarydifferencearisesfromtheinitialrecognitionofgoodwill,oranasset
orliabilityinatransactionthatisnotabusinesscombinationand,atthetimeoftransaction,affectsneitheraccountingprofitnortaxableprofitorloss;and
(2)inrespectoftaxabletemporarydifferencesassociatedwithinvestmentsinsubsidiaries,
associatesandjointventures,whenthetimingofthereversalofthetemporarydifferencescanbecontrolledanditisprobablethatthetemporarydifferenceswillnotbereversedintheforeseeablefuture.Deferredtaxassetsarerecognisedforalldeductibletemporarydifferences,andthecarryforwardofunusedtaxlossesandanyunusedtaxcredits.Deferredtaxassetsarerecognisedtotheextentthatitisprobablethattaxableprofitwillbeavailableagainstwhichthedeductibletemporarydifferences,thecarryforwardofunusedtaxlossesandunusedtaxcreditscanbeutilised,except:
(1)whenthedeductibletemporarydifferencearisesfromtheinitialrecognitionofanassetor
liabilityinatransactionthatisnotabusinesscombinationand,atthetimeofthetransaction,affectsneithertheaccountingprofitnortaxableprofitorloss;and
(2)inrespectofthedeductibletemporarydifferencesassociatedwithinvestmentsinsubsidiaries,
associatesandjointventures,deferredtaxassetsareonlyrecognisedtotheextentthatitisprobablethatthetemporarydifferenceswillbereversedintheforeseeablefutureandtaxableprofitwillbeavailableagainstwhichthetemporarydifferencescanbeutilisedinthefuture.Atthebalancesheetdate,deferredtaxassetsandliabilitiesaremeasuredatthetaxratesthatareexpectedtoapplytotheperiodwhentheassetisrealisedortheliabilityissettled,inaccordancewiththerequirementsoftaxlaws.ThemeasurementofdeferredtaxassetsanddeferredtaxliabilitiesreflectsthetaxconsequencesthatwouldfollowfromthemannerinwhichtheGroupexpects,atthebalancesheetdate,torecovertheassetsorsettletheliabilities.Thecarryingamountofdeferredtaxassetsisreviewedatthebalancesheetdateandreducedtotheextentthatitisnolongerprobablethatsufficienttaxableprofitwillbeavailableinfutureperiodstoallowthedeferredtaxassetstobeutilised.Unrecogniseddeferredtaxassetsarereassessedatthebalancesheetdateandarerecognisedtotheextentthatithasbecomeprobablethatsufficienttaxableprofitwillbeavailabletoallowallorpartofthedeferredtaxassettoberecovered.DeferredtaxassetsanddeferredtaxliabilitiesareoffsetifandonlyiftheGrouphasalegallyenforceablerighttosetoffcurrenttaxassetsandcurrenttaxliabilities,andthedeferredtaxassetsanddeferredtaxliabilitiesrelatetoincometaxesleviedbythesametaxationauthorityoneitherthesametaxableentityordifferenttaxableentitieswhichintendeithertosettlecurrenttaxliabilitiesandassetsonanetbasis,ortorealisetheassetsandsettletheliabilitiessimultaneously,ineachfutureperiodinwhichsignificantamountsofdeferredtaxliabilitiesorassetsareexpectedtobesettledorrecovered.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(34)LeaseIdentificationofleasesAtinceptionofacontract,theGroupassesseswhetherthecontractis,orcontains,alease.Acontractis,orcontains,aleaseifthecontractconveystherighttocontroltheuseofanidentifiedassetforaperiodoftimeinexchangeforconsideration.Toassesswhetheracontractconveystherighttocontroltheuseofanidentifiedassetforaperiodoftime,theGroupassesseswhether,throughouttheperiodofuse,thecustomerhasbothoftherighttoobtainsubstantiallyalloftheeconomicbenefitsfromuseoftheidentifiedassetandtherighttodirecttheuseoftheidentifiedasset.IdentificationofseparateleasecomponentsForacontractthatcontainsmultipleseparateleasecomponents,theGroupseparatesthecomponentsofthecontractandaccountsforeachseparateleasecomponent.Therighttouseanunderlyingassetisaseparateleasecomponentifboth:
(1)thelesseecanbenefitfromuseoftheunderlyingasseteitheronitsownortogetherwithother
resourcesthatarereadilyavailabletothelessee;and
(2)theunderlyingassetisneitherhighlydependenton,norhighlyinterrelatedwith,theother
underlyingassetsinthecontract.Separatingleasecomponentsandnon-leasecomponentsForacontractthatcontainsleasecomponentsandnon-leasecomponents,theGroupaccountsforleasecomponentsandnon-leasecomponentsseparatelyasalessororalessee.AssessmentoftheleasetermTheleasetermisthenon-cancellableperiodofaleaseforwhichtheGrouphastherighttouseanunderlyingasset.IftheGrouphasanoptiontoextendthelease,thatis,theGrouphastherighttoextendthelease,andisreasonablycertaintoexercisethatoption,theleasetermalsoincludesperiodscoveredbyanoptiontoextendthelease.IftheGrouphasanoptiontoterminatethelease,thatis,theGrouphastherighttoterminatethelease,butisreasonablycertainnottoexercisethatoption,theleasetermincludesperiodscoveredbyanoptiontoterminatethelease.TheGroupreassesseswhetheritisreasonablycertaintoexerciseanextensionoption,purchaseoption,ornottoexerciseaterminationoption,upontheoccurrenceofeitherasignificanteventorasignificantchangeinthecircumstancesthatiswithinthecontroloftheGroupandaffectswhethertheGroupisreasonablycertaintoexerciseanoptionnotpreviouslyincludedinitsdeterminationoftheleaseterm.AsleaseeTheaccountingtreatmentoftheGroupasleasepleaserefertoNote.III.22andNoteIII.28.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(34)Leases(Continued)LeasemodificationsLeasemodificationisachangeinthescopeofalease,ortheconsiderationforalease,thatwasnotpartoftheoriginaltermsandconditionsofthelease,forexample,addingorterminatingtherighttouseoneormoreunderlyingassets,orextendingorshorteningthecontractualleaseterm.TheGroupaccountsforaleasemodificationasaseparateleaseifboth:
(1)themodificationincreasesthescopeoftheleasebyaddingtherighttouseoneormore
underlyingassets;and
(2)theconsiderationfortheleaseincreasesbyanamountcommensuratewiththestand-alone
pricefortheincreaseinscopeandanyappropriateadjustmentstothatstand-alonepricetoreflectthecircumstancesoftheparticularcontract.Foraleasemodificationthatisnotaccountedforasaseparatelease,attheeffectivedateoftheleasemodificationtheGroupremeasurestheleaseliabilitybydiscountingtherevisedleasepaymentsusingareviseddiscountrate.Thereviseddiscountrateisdeterminedastheinterestrateimplicitintheleasefortheremainderoftheleaseterm,orthelessee’sincrementalborrowingrateattheeffectivedateofthemodification,iftheinterestrateimplicitintheleasecannotbereadilydetermined.Foraleasemodificationthatisnotaccountedforasaseparatelease,theGroupaccountsfortheremeasurementoftheleaseliabilityby:
(1)decreasingthecarryingamountoftheright-of-useassettoreflectthepartialorfulltermination
oftheleaseforleasemodificationsthatdecreasethescopeofthelease,andrecognisingthegainorlossrelatingtothepartialorfullterminationoftheleaseinprofitorloss;or
(2)makingacorrespondingadjustmenttotheright-of-useassetforallotherleasemodifications.Short-termleasesandleasesoflow-valueassetsTheGroupconsidersaleasethat,atthecommencementdateofthelease,hasaleasetermof12monthsorless,anddoesnotcontainsanypurchaseoptionasashort-termlease;andaleaseforwhichthevalueoftheindividualunderlyingassetisnotmorethanRMB40,000whenitisnewasaleaseoflow-valueassets.IftheGroupsubleasesanasset,orexpectstosubleaseanasset,theheadleasedoesnotqualifyasaleaseofalow-valueasset.TheGroupdoesnotrecognisetheright-of-useassetsandleaseliabilitiesforshort-termleasesandlow-valueassets.TheGrouprecognisesleasepaymentsonshort-termleasesandleasesoflow-valueassetsinthecostsoftherelatedassetorprofitorlossonastraight-linebasisovertheleaseterm.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(34)Leases(Continued)RentconcessionsunderCOVID-19Forrentreductions,suchasrentreductions,deferredpayments,etc.,directlycausedbytheCOVID-19epidemic,theGroupandthelessorhavereachedanexistingleasecontract,andmeetthefollowingconditionsatthesametime,theGroupadoptsasimplifiedmethodforleases:
(1)Theleaseconsiderationaftertheconcessionisreducedorbasicallyunchangedfromthatbeforetheconcession;
(2)TheconcessionisonlyfortheamountofleasepaymentspayablebeforeJune30,2022;
(3)Aftercomprehensivelyconsideringqualitativeandquantitativefactors,itisdeterminedthattherearenomajorchangesinothertermsandconditionsofthelease.TheGroupdoesnotevaluatewhetherthereisaleasechange,andcontinuestocalculatetheinterestexpenseoftheleaseliabilitybasedonthesamediscountrateasbeforethereductionandincludedinthecurrentprofitandloss,andcontinuestodepreciatetheright-of-useassetinthesamewayasbeforethereduction.Forrentreductionorexemption,theGroupregardsthereducedrentasavariableleasepayment.Whenaconcessionagreementisreachedtoreleasetheoriginalrentpaymentobligation,theundiscountedcashamountwillbeusedtooffsettherelevantassetcostsorexpenses,andtheleaseliabilitywillbeadjustedaccordingly;Forthedelayedpaymentofrent,theGroupwilloffsettheleaseliabilityconfirmedinthepreviousperiodwhentheactualpaymentismade.AslessorAleaseisclassifiedasafinanceleaseifittransferssubstantiallyalltherisksandrewardsincidentaltoownershipofanunderlyingasset,exceptthataleaseisclassifiedasanoperatingleaseattheinceptiondate.TheGroup,asanintermediatelessor,classifiesthesubleasebyreferencetotheright-of-useassetarisingfromtheheadlease.AslessorofanoperatingleaseRentincomeunderanoperatingleaseisrecognisedonastraight-linebasisovertheleaseterm,throughprofitorloss.Variableleasepaymentsthatarenotincludedinthemeasurementofleasereceivablesarechargedtoprofitorlossasincurred.TheGroupaccountsforamodificationtoanoperatingleaseasanewleasefromtheeffectivedateofthemodification,consideringanyprepaidoraccruedleasepaymentsrelatingtotheoriginalleaseaspartoftheleasepaymentsforthenewlease.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(35)Othersignificantaccountingpoliciesandaccountingestimates
1)Medicalreservefundsandspeciallyapprovedreservingmaterials
MedicalreservefundsrefertothefundsappropriatedbytheStateforthereserveofmaterialsforspecifiedpurposestocopewithmajordisasters,epidemicsituations,firstaidandotheremergencies,etc.Speciallyapprovedreservingmaterialsrefertothemedicalcommoditiesrequiredbythegovernmenttodealwithemergenciessuchasepidemicsituations,firstaidandlocalcommondiseases.AccordingtotheregulationsofCNPGC,theGroup,asanenterpriseundertakingthetaskofspeciallyapprovedreservingmaterialsreserve,obtainsthemedicalreservefundsprovidedbythePRCgovernment,whichappropriatedtothelocalgovernmentandCNPGC.Themedicalreservefundsreceivedviathosepartiesarerecognisedasothernon-currentliabilities.Inthemeantime,theGovernmentofGuangdongProvinceandGuangxiProvincedesignatedSinopharmHoldingGuangzhouCo.,Ltd.(“SinopharmGuangzhou”)anditssubsidiaries,SinopharmHoldingGuangxiCo.,Ltd.(“SinopharmGuangxi”)anditssubsidiariestoundertakethestorage,allocationandsupplyofpharmaceuticalcommoditiesrequiredbymajordisasters,epidemicsituations,firstaidandotheremergenciesaswellaslocalcommondiseasesinGuangdongandGuangxiZhuangAutonomousRegion.Accordingtothereserveplan(varietyandquantity)ofthelocalgovernmentandCNPGC,theGroupreservesthecorrespondingspeciallyapprovedreservingmaterials,implementsdynamicmanagementandrecognisesthemasothernon-currentassets.
2)DividenddistributionCashdividenddistributionisrecognisedasaliabilityintheperiodinwhichitisapprovedbyshareholdersattheannualshareholders’meeting.
3)FairvaluemeasurementAteachbalancesheetdate,theGroupmeasuresthefairvalueofequityinstrumentinvestments.Fairvaluemeansthepricereceivablefromthedisposalofanassetorrequiredtobepaidforthetransferofaliabilityinanorderlytransactionincurredbymarketparticipantsonthemeasurementdate.TheGroupmeasuresassetsorliabilitiesatfairvaluewiththeassumptionthattheorderlytransactionofassetdisposalorthetransferofliabilitiestakesplaceinthemajormarketfortherelevantassetsorliabilities.Wherethereisnomajormarket,theGroupassumesthatsuchtransactiontakesplaceinthemostfavourablemarketfortherelevantassetsorliabilities.Themajormarket(ormostfavourablemarket)isatradingmarketwhichtheGrouphasaccesstoonthemeasurementdate.TheGroupadoptsassumptionsusedbymarketparticipantswhentheypricetheassetorliabilitywiththeaimofmaximisingitseconomicbenefits.Themeasurementofnon-financialassetsmeasuredatfairvalueshouldtakeintoaccounttheabilityofmarketparticipantstoutilisetheassetinthebestwayforgeneratingeconomicbenefits,ortheabilitytodisposeofsuchassettoothermarketparticipantswhoareabletoutilisetheassetinthebestwayforgeneratingeconomicbenefits.TheGroupadoptsvaluationtechniquesthatareappropriateinthecurrentcircumstancesandsupportedbysufficientusabledataandotherinformation.Observableinputwillbeusedfirstandforemost.Unobservableinputwillonlybeusedwhenitisnotpossibleorpracticabletoobtainobservableinput.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(35)Othersignificantaccountingpoliciesandaccountingestimates(Continued)
3)Fairvaluemeasurement(Continued)Thefairvaluehierarchyinwhichanassetorliabilityismeasuredordisclosedinthefinancialstatementsatfairvaluewillbedeterminedonthebasisofthelowestlevelofinputwhichissignificantforthefairvaluemeasurementasawhole.Inputatthefirstlevelrepresentsunadjustedquotedpricesinanactivemarketfortheacquisitionofthesameassetorliabilityonthemeasurementdate.Inputatthesecondlevelrepresentsdirectlyorindirectlyobservableassetsorliabilitiesapartfrominputatthefirstlevel.Inputatthethirdlevelrepresentsunobservableinputfortheassetorliability.Ateachbalancesheetdate,theGroupreassessesassetsandliabilitiesmeasuredatfairvalueonanongoingbasisrecognisedinthefinancialstatementstodeterminewhethertheleveloffairvaluemeasurementshouldbechanged.
4)SegmentinformationTheGroupidentifiesoperatingsegmentsbasedontheinternalorganizationstructure,managementrequirementsandinternalreportingsystem,anddisclosessegmentinformationofreportablesegmentswhichisdeterminedonthebasisofoperatingsegments.AnoperatingsegmentisacomponentoftheGroupthatsatisfiesallofthefollowingconditions:(1)thecomponentisabletoearnrevenuesandincurexpensesfromitsordinaryactivities;(2)thecomponent’soperatingresultsareregularlyreviewedbytheGroup’smanagementtomakedecisionsaboutresourcestobeallocatedtothesegmentandtoassessitsperformance,and(3)forwhichtheinformationonfinancialposition,operatingresultsandcashflowsisavailabletotheGroup.Iftwoormoreoperatingsegmentshavesimilareconomiccharacteristicsandsatisfycertainconditions,theyareaggregatedintoonesingleoperatingsegment.
5)SignificantaccountingjudgementsandestimatesThepreparationofthefinancialstatementsrequiresmanagementtomakejudgements,estimatesandassumptionsthataffectthereportedamountsofrevenue,expenses,assetsandliabilities,andtheiraccompanyingdisclosures,andthedisclosureofcontingentliabilitiesatthebalancesheetdate.Uncertaintyabouttheseassumptionsandestimatescouldresultinoutcomesthatcouldrequireamaterialadjustmenttothecarryingamountsoftheassetsorliabilitiesaffectedinthefuture.JudgementsIntheprocessofapplyingtheGroup'saccountingpolicies,managementhasmadethefollowingjudgementswhichhaveasignificanteffectontheamountsrecognisedinthefinancialstatements:
Operatingleases-theGroupaslessorTheGrouphasenteredintoleaseagreementsonitsinvestmentpropertyportfolio.TheGrouphasdeterminedtheseleasestobeoperatingleases,basedonanevaluationofthetermsandconditionsoftheagreements,thatitretainssubstantiallyallthesignificantrisksandrewardsofownershipoftheseproperties.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(35)Othersignificantaccountingpoliciesandaccountingestimates(Continued)
5)Significantaccountingjudgementsandestimates(Continued)Judgements(Continued)BusinessmodelsTheclassificationoffinancialassetsatinitialrecognitiondependsontheGroup'sbusinessmodelformanagingfinancialassets.Whendeterminingthebusinessmodel,theGroupconsidersthemethodstoincludeevaluationandreportfinancialassetperformancetokeymanagement,therisksaffectingtheperformanceoffinancialassetsandtheriskmanagement,andthemannerinwhichtherelevantmanagementreceivesremuneration.Whenassessingwhethertheobjectiveistocollectcontractualcashflows,theGroupneedstoanalyseandjudgethereason,timing,frequencyandvalueofthesalebeforethematuritydateofthefinancialassets.ContractualcashflowcharacteristicsTheclassificationoffinancialassetsatinitialrecognitiondependsonthefinancialasset’scontractualcashflowcharacteristics,andthejudgementsonwhetherthecontractualcashflowsaresolelypaymentsofprincipalandinterestontheprincipalamountoutstanding,includingwhenassessingthemodificationofthetimevalueofmoney,thejudgementonwhetherthereisanysignificantdifferencefromthebenchmarkcashflowandwhetherthefairvalueoftheprepaymentfeaturesisinsignificantforfinancialassetswithprepaymentfeatures,etc.EstimationuncertaintyThekeyassumptionsconcerningthefutureandotherkeysourcesofestimationuncertaintyatthebalancesheetdate,thathaveasignificantriskofcausingamaterialadjustmenttothecarryingamountsofassetsandliabilitieswithinthefutureaccountingperiods,aredescribedbelow.ImpairmentoffinancialinstrumentsTheGroupusestheexpectedcreditlossmodeltoassesstheimpairmentoffinancial.TheGroupisrequiredtoperformsignificantjudgementandestimationandtakeintoaccountallreasonableandsupportableinformation,includingforward-lookinginformation.Whenmakingsuchjudgementsandestimates,theGroupinferstheexpectedchangesinthedebtor'screditriskbasedonhistoricalrepaymentdatacombinedwitheconomicpolicies,macroeconomicindicators,industryrisksandotherfactors.Thedifferentestimatesmayimpacttheimpairmentassessment,andtheprovisionforimpairmentmayalsonotberepresentativeoftheactualimpairmentlossinthefuture.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(34)Othersignificantaccountingpoliciesandaccountingestimates(Continued)
5)Significantaccountingjudgementsandestimates(Continued)Estimationuncertainty(Continued)Impairmentofnon-currentassetsotherthanfinancialassets(otherthangoodwill)TheGroupassesseswhetherthereareanyindicationsofimpairmentforallnon-currentassetsotherthanfinancialassetsatthebalancesheetdate.Intangibleassetswithindefiniteusefullivesaretestedforimpairmentannuallyandatothertimeswhensuchanindicationexists.Othernon-currentassetsotherthanfinancialassetsaretestedforimpairmentwhenthereareindicationsthatthecarryingamountsmaynotberecoverable.Animpairmentexistswhenthecarryingamountofanassetorassetgroupexceedsitsrecoverableamount,whichisthehigherofitsfairvaluelesscostsofdisposalandthepresentvalueofthefuturecashflowsexpectedtobederivedfromit.Thecalculationofthefairvaluelesscostsofdisposalbasedonavailabledatafrombindingsalestransactionsinanarm’slengthtransactionofsimilarassetsorobservablemarketpriceslessincrementalcostsfordisposingoftheassets.Whenthecalculationsofthepresentvalueofthefuturecashflowsexpectedtobederivedfromanassetorassetgroupareundertaken,managementmustestimatetheexpectedfuturecashflowsfromtheassetorassetgroupandchooseasuitablediscountrateinordertocalculatethepresentvalueofthosecashflows.FurtherdetailsareincludedinNoteV.12/13/14/15/16.ImpairmentofgoodwillTheGroupdetermineswhethergoodwillisimpairedatleastonanannualbasis.Thisrequiresanestimationofthepresentvalueofthefuturecashflowsexpectedtobederivedfromtheassetgroups(setsofassetgroups)towhichthegoodwillisallocated.EstimatingthepresentvaluerequirestheGrouptomakeanestimateoftheexpectedfuturecashflowsfromtheassetgroups(setsofassetgroups)andalsotochooseasuitablediscountrateinordertocalculatethepresentvalueofthosecashflows.FurtherdetailsareincludedinNoteV.18.DeferredtaxassetsDeferredtaxassetsarerecognisedforallunusedtaxlossestotheextentthatitisprobablethattaxableprofitwillbeavailableagainstwhichthelossescanbeutilised.Significantmanagementjudgementisrequiredtodeterminetheamountofdeferredtaxassetsthatcanberecognised,baseduponthelikelytimingandleveloffuturetaxableprofitstogetherwithfuturetaxplanningstrategies.FairvalueofunlistedequityinvestmentsTheunlistedequityinvestmentshavebeenvaluedbasedontheexpectedcashflowsdiscountedatcurrentratesapplicableforitemswithsimilartermsandriskcharacteristics.ThisvaluationrequirestheGrouptomakeestimatesaboutexpectedfuturecashflows,creditrisk,volatilityanddiscountrates,andhencetheyaresubjecttouncertainty.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(34)Othersignificantaccountingpoliciesandaccountingestimates(Continued)
5)Significantaccountingjudgementsandestimates(Continued)Estimationuncertainty(Continued)LoyaltypointsTheGroupmakesreasonableestimateofthestand-alonesellingpriceoftheloyaltypointsbytakingintoaccountallrelevantinformation,suchasthestand-alonesellingpricesforthecustomertoacquireadditionalfreegoodsorservicesorthediscountsenjoyedbythecustomerusingtheloyaltypointsandthepossibilityforthecustomertoexercisetheredemptionright.TheGroupconsidersthelikelihoodforthecustomertoexercisetheredemptionrightbasedonthehistoricaldataofpointredemption,thecurrentpointredemptionandthefuturechangesforthecustomer,thefuturetrendofthemarketandotherfactors.TheGroupre-evaluatesthestand-alonesellingpriceofloyaltypointsatleastoneachbalancesheetdateanddeterminesthetransactionpricetobeallocatedtotheloyaltypointsbasedonthestand-alonesellingpriceofthere-evaluatedloyaltypoints.SaleswitharightofreturnTheGroupmakesreasonableestimateofagroupofcontractswithsimilarcharacteristicsaccordingtothesalesreturnhistoricaldata,thecurrentsalesreturnsituation,aswellascustomerchanges,marketchangesandotherrelevantinformation.Estimatesoftheexpectedreturnratemaynotberepresentativeoftheactualreturnsinthefuture.TheGroupre-evaluatesthereturnrateatleastoneachbalancesheetdateandupdatesthemeasurementoftherefundliabilitiesandtheright-of-returnassetsbasedonthere-evaluatedreturnrate.WarrantiesTheGroupmakesreasonableestimateofthewarrantyrateofagroupofcontractswithsimilarcharacteristicsbasedonhistoricalwarrantydata,currentwarranty,aswellasallrelevantinformationsuchasproductimprovements,marketchanges,etc.Estimatesoftheexpectedwarrantyratemaynotberepresentativeoftheactualwarrantyrateinthefuture.TheGroupre-evaluatesthewarrantyrateatleastoneachbalancesheetdateandupdatesthemeasurementoftheprovisionsbasedonthere-evaluatedwarrantyrate.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IIISummaryofsignificantaccountingpoliciesandaccountingestimates(Continued)
(34)Othersignificantaccountingpoliciesandaccountingestimates(Continued)
5)Significantaccountingjudgementsandestimates(Continued)Estimationuncertainty(Continued)AssessmentofconstrainsonvariableconsiderationTheGroupestimates,withinareasonablequantity,theamountofvariableconsiderationthatmayoccurandthelikelihoodbytakingintoaccountallreasonablyavailableinformation,includinghistoricalinformation,currentinformation,andpredictiveinformation.TheGroupincludesinthetransactionpricesomeorallofanamountofvariableconsiderationestimatedonlytotheextentthatitishighlyprobablethatasignificantreversalintheamountofcumulativerevenuerecognisedwillnotoccurwhentheuncertaintyassociatedwiththevariableconsiderationissubsequentlyresolved.Inassessingwhetheritishighlyprobablethatasignificantreversalintheamountofcumulativerevenuerecognisedwillnotoccuroncetheuncertaintyrelatedtothevariableconsiderationissubsequentlyresolved,theGroupconsidersboththelikelihoodandthemagnitudeoftherevenuereversal.Oneachbalancesheetdate,theGroupupdatestheestimatedtransactionprice(includingupdatingitsassessmentofwhetheranestimateofvariableconsiderationisconstrained)toreflectthecircumstancespresentattheendofthereportingperiodandthechangesincircumstancesduringthereportingperiod.Lessee’sincrementalborrowingrateIftheinterestrateimplicitintheleasecannotbereadilydetermined,theGroupmeasurestheleaseliabilityatthepresentvalueoftheleasepaymentsdiscountedusingthelessee’sincrementalborrowingrate.Accordingtotheeconomicenvironment,theGrouptakestheobservableinterestrateasthereferencebasisfordeterminingtheincrementalborrowingrate,thenadjuststheobservableinterestratebasedonitsowncircumstances,underlyingassets,leasetermsandamountsofleaseliabilitiestodeterminetheapplicableincrementalborrowingrate.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IVTaxation
1.Maincategoriesandratesoftaxes:
Categories | Taxbase | Taxrate |
Valueaddedtax(“VAT”) | Taxablevalueaddedamount(TaxpayableiscalculatedbyusingthetaxablesalesamountmultipliedbytheeffectivetaxratelessdeductibleVATinputofthecurrentperiod) | 1%,3%,5%,6%,9%,13% |
Citymaintenanceandconstructiontax | AmountofVAT | 5%or7% |
Corporateincometax(“CIT”) | Taxableincome | 15%,20%or25% |
Educationalsurcharge | AmountofVAT | 3% |
Localeducationalsurcharge | AmountofVAT | 2% |
2.Taxpreferences
In2021,accordingtothe"AnnouncementoftheMinistryofFinanceandtheStateAdministrationofTaxationandtheNationalDevelopmentandReformCommissionontheContinuationoftheEnterpriseIncomeTaxPolicyfortheWesternDevelopment"(AnnouncementNo.23,2020oftheMinistryofFinanceandtheStateAdministrationofTaxationandtheNationalDevelopmentandReformCommission)andthe"AnnouncementontheContinuationoftheEnterpriseIncomeTaxPolicyfortheWesternDevelopment"(MinistryofFinanceAnnouncementNo.23of2020),thecompany’ssubsidiariesthatcanenjoythepreferentialcorporateincometaxrateof15%fortheencouragedindustriesinthewesternregioninclude:SinopharmHoldingGuangxiCo.,Ltd.(SinopharmGuangxi),SinopharmHoldingGuangxiLogisticsCo.,Ltd.(“SinopharmGuangxiLogistics”),SinopharmHoldingLiuzhouCo.,Ltd.(“SinopharmLiuzhou”),SinopharmHoldingBeihaiCo.,Ltd.(“SinopharmBeihai”),SinopharmHoldingGuilinCo.,Ltd.(“SinopharmGuilin”),SinopharmHoldingGuigangCo.,Ltd.(“SinopharmGuigang”),SinopharmHoldingYulinCo.,Ltd.(“SinopharmYulin”),SinopharmHoldingBaiseCo.,Ltd.(“SinopharmBaise”),SinopharmHoldingWuzhouCo.,Ltd.(“SinopharmWuzhou”),SinopharmHoldingQinzhouCo.,Ltd.(“SinopharmQinzhou”),SinopharmHoldingHezhouCo.,Ltd.(“SinopharmHezhou”),SinopharmHoldingGuangxiMedicalSupplyChainServiceCo.,Ltd.(“SinopharmGuangxiSupplyChain”),SinopharmHoldingXinjiangNew&SpecialMedicinesChainStoreCo.,Ltd.(“XinjiangNew&SpecialMedicines”),SinopharmHoldingGuodaInnerMongoliaPharmacyChainStoreCo.,Ltd.(“InnerMongoliaGuoda”),SinopharmHoldingGuodaHulunBuirPharmacyChainStoreCo.,Ltd.(“InnerMongoliaHulunBuirGuoda”),InnerMongoliaGuodaMedicineCo.,Ltd.(“InnerMongoliaGuodaMedicine”),NingxiaGuodaPharmacyChainStoreCo.,Ltd.(“NingxiaGuoda”),SinopharmHoldingGuodaGuangxiPharmacyChainStoreCo.,Ltd.(“GuangxiGuoda”),GuodaPharmacy(Pu’er)SongmaoCo.,Ltd.(“GuodaPu’erSongmao”)andSinopharmHoldingGuodaDrugStoreManchuriaCo.,Ltd.(“ManchuriaGuoda”).
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IVTaxation(Continued)
2.Taxpreferences(Continued)Taxpreferences(Continued)In2021,accordingtothe“NoticeontheImplementationofInclusiveTaxReductionandExemptionPoliciesforSmallandMicroEnterprises”(CaiShui[2019]No.13)andthe“AnnouncementoftheMinistryofFinanceandtheStateAdministrationofTaxationontheImplementationofPreferentialIncomeTaxPoliciesforSmallandMicroEnterprisesandIndividualBusiness"(AnnouncementNo.12of2021oftheMinistryofFinanceandtheStateAdministrationofTaxation),subsidiariesoftheCompanylistedbelowqualifiedfortheconditionsofsmalllow-profitenterprises,whichthemonomertaxableincomeofthesesubsidiariesdoesnotexceedRMB3million.Hence,fortheportionofannualtaxableincomenotexceedingRMB1million,itshallbeincludedinthetaxableincomeby12.5%,andenterpriseincometaxshallbepaidattherateof20%;fortheportionofannualtaxableincomeexceedingRMB1millionbutnotexceedingRMB3million,itshallbeincludedinthetaxableincomeby50%,andenterpriseincometaxshallbepaidattherateof20%.TheCompany’ssubsidiarieswhichqualifiedfortheconditionsofsmalllow-profitenterprisesincludingShanghaiGuodaDongshengPharmacyCo.,Ltd.(“ShanghaiDongshengGuoda”),ShanghaiGuodaHaohaiPharmacyCo.,Ltd.(“ShanghaiHaohaiGuoda”),ShanghaiGuodaRuijingPharmacyCo.,Ltd.(ShanghaiRuijingGuoda”),ShanghaiGuodaDongxinPharmacyCo.,Ltd.(“ShanghaiDongxinGuoda”),SinopharmGuodaYongshengPharmacy(Shanghai)Co.,Ltd.(ShanghaiYongshengGuoda”),ZhejiangSinopharmPharmacyDongshanPharmacyCo.,Ltd.(“ZhejiangDongshanGuoda”),SinopharmHoldingGuodaPharmacyGuangzhouChainCo.,Ltd.(“GuodaGuangzhouChain”),TaishanSinopharmHoldingGuodaQunkangPharmacyChainStoreCo.,Ltd.(“TaishanQunkang”),SinopharmHoldingGuodaPharmacyYongxingtangChainStore(Chaoyang)Co.,Ltd.(”GuodaYongxingtang”),LiaoningGuodaMedicineCo.,Ltd.(“LiaoningMedicine”),ChangzhiGuodaWanminPharmacyChainStoreCo.,Ltd.(“ChangzhiWanmin”),SinopharmHoldingGuodaPharmacyBayannurCo.,Ltd.(“Bayannur”),SinopharmHoldingGuodaPharmacyUlanqabCo.,Ltd.(“InnerMongoliaWulanGuoda”),SinopharmHoldingBaiyiPharmacyGuangxiCo.,Ltd.(“SinopharmBaiyiPharmacy”),SinopharmAccord(Guangzhou)MedicineCo.,Ltd.(“GuangzhouMedicine”),ShanghaiForMeXuhuiPharmacyCo.,Ltd.(“ForMeXuhui”),BeijingGoldenElephantGuoxingPharmaceuticalCo.,Ltd.(“GoldenElephantGuoxing”),JilinYiheDrugStoreCo.,Ltd.(“JilinYihe”),GuangxiGuodaPharmaceuticalConsultingChainCo.,Ltd.(“GuangxiConsulting”),LiaoningGuodaHealthPharmacyCo.,Ltd.(“LiaoningHealthPharmacy”),LiaoningGuodaPharmacyChainCo.,Ltd.(“LiaoningGuodaPharmacy”),YanjiXiangheMedicineCo.,Ltd.(“YanjiXianghe”),InnerMongoliaChengdaFangyuanMedicineCo.,Ltd.(“InnerMongoliaChengdaFangyuanMedicine”)andJilinChengdaFangyuanMedicineCo.,Ltd.(“JilinChengdaFangyuanMedicine”).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements
1.Cashandbankbalances
30June2021 | 31December2020 |
Cashonhand | 4,898,795.54 | 6,707,125.90 | |
Cashatbanks | 5,533,553,362.08 | 5,398,406,132.09 | |
Cashandcashequivalent | 5,532,707,421.89 | 5,398,406,132.09 | |
Undueinterestreceivable(Note1) | 845,940.19 | - |
Othermonetaryfunds(Note2) | 338,186,269.94 | 593,091,037.88 |
5,876,638,427.56 | 5,998,204,295.87 |
2.Notesreceivable
Note1:Currentdepositsearninterestattheratebasedoncurrentdepositinterestrates.Maturitiesofshort-termtimedepositsrangefrom1monthto6monthsdependingonthefundarrangementsoftheGroup,andthedepositsearninterestattherespectivedepositrates.Thematuritiesofbanknoticedepositsare7daysdependingonthefundarrangementoftheGroup,andthedepositsearninterestattherespectivedepositrates.Note2:Othermonetaryfundsat30June2021include:DepositsforbankacceptancebillsRMB236,042,026.02(31December2020:RMB492,734,978.75),freezingoffundsRMB67,280,993.60(December31,2020:
RMB66,956,993.60),MedicalreservefundsRMB27,515,383.35(December31,2020:RMB27,465,331.50),fixeddepositRMB3,193,851.81(December31,2020:RMB3,167,718.14),andotherdepositsRMB4,154,015.16(December31,2020:RMB2,766,015.89).Thenotesreceivablebycategory
Thenotesreceivablebycategory30June2021
30June2021 | 31December2020 |
Commercialacceptancebills | 606,070,192.39 | 622,115,477.04 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
2.Notesreceivable(Continued)
Thecarryingamountofnotesreceivablethataffectedthechangesinprovisionthisyearisasfollows:
30June2021
30June2021 | 31December2020 | ||||||||||
Carryingamount | Baddebtprovisions | BookValue | Carryingamount | Baddebtprovisions | BookValue | ||||||
Amount | Proportion | Amount | Proportion | Amount | Proportion | Amount | Proportion |
Itemsforwhichprovisionforbaddebtsisrecognisedindividually | 10,301,666.47 | 1.70% | 585,955.98 | 5.69% | 9,715,710.49 | 27,634,855.48 | 4.43% | 1,479,520.32 | 5.35% | 26,155,335.16 | ||
Itemsforwhichprovisionforbaddebtsisrecognisedbygroup(creditriskcharacteristics) | 596,354,481.90 | 98.30% | - | - | 596,354,481.90 | 595,960,141.88 | 95.57% | - | - | 595,960,141.88 |
606,656,148.37 | 100.00% | 585,955.98 | 0.10% | 606,070,192.39 | 623,594,997.36 | 100.00% | 1,479,520.32 | 0.24% | 622,115,477.04 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
2.Notesreceivable(Continued)
On30June2021,notesreceivablethatareindividuallyassessedforprovisionsareasfollows:
Carryingamount
Carryingamount | Baddebtprovision | Expectedcreditlossrate | Assessmentforimpairment |
ClientA | 723,189.59 | 2,972.46 | 0.41% | Thedrawerhashistoricalcreditdefaults;thenotesreceivableareexpectedtobeatriskofcollection. |
ClientB | 9,578,476.88 | 582,983.52 | 6.09% | Thedrawerhashistoricalcreditdefaults;thenotesreceivableareexpectedtobeatriskofcollection. |
10,301,666.47 | 585,955.98 |
Provisionforbaddebtsinthecurrentperiodasfollows:
Currentchangeamount
Currentchangeamount | ||||||
Openingbalance | Provision | Reversalintheyear | Write-offintheyear | Others | Closingbalance | |
Individualprovisionforbaddebts | 1,479,520.32 | - | (893,564.34) | - | - | 585,955.98 |
1,479,520.32 | - | (893,564.34) | - | - | 585,955.98 |
ReceivablesfinancingendorsedordiscountedbytheGrouptootherpartieswhichwerenotyetdueat30June2021areasfollows: | |
30June2021 |
Derecognised | Notderecognised | ||
Commercialacceptancebills | - | 125,089.80 |
Attheendoftheperiod,thecompanytransferredtheacceptancenotestoaccountsreceivableduetothedrawer'sfailuretoperformthecontract:
Amounttransferredto
accountsreceivableattheendoftheperiod
Amounttransferredto
accountsreceivableattheendoftheperiodCommercialacceptancebills
Commercialacceptancebills | 2,090,087.17 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
3.Accountsreceivable
(1)Theaccountsreceivablebycategory
30June2021
30June2021 | 31December2020 | |||||||||||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingvalue | Grosscarryingamount | Provisionforbaddebt | Grosscarryingvalue | |||||||
Amount | Proportion | Amount | Proportion | Amount | Proportion | Amount | Proportion |
Itemsforwhichprovisionforbaddebtisrecognizedseparately | 1,017,692,611.96 | 5.69% | (29,993,339.31) | 2.95% | 987,699,272.65 | 674,370,776.75 | 4.85% | (29,223,931.45) | 4.33% | 645,146,845.30 | |||
Inculdes: | |||||||||||||
Itemsforwhichprovisionforbaddebtisrecognizedbygroup | 16,864,163,256.21 | 94.31% | (90,686,079.61) | 0.54% | 16,773,477,176.60 | 13,218,113,690.60 | 95.15% | (63,289,521.68) | 0.48% | 13,154,824,168.92 | |||
Includes: |
17,881,855,868.17 | 100.00% | (120,679,418.92) | 0.67% | 17,761,176,449.25 | 13,892,484,467.35 | 100.00% | (92,513,453.13) | 0.67% | 13,799,971,014.22 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
3.Accountsreceivable(Continued)
(1)TheaccountsreceivablebycategoryAccountsreceivablethatareindividuallyassessedforprovisions
Accountsreceivablethatareindividuallyassessedforprovisions | ||||
30June2021 | ||||
Carryingamount | Baddebtprovision | Proportion | Assessmentforimpairment |
Receivableofmedicalinsurance | 514,818,583.40 | (6,606,210.91) | 1.28% | Thereceivableofmedicalinsurancehaslower-tierdefaultrisk. |
ClientA | 11,559,178.29 | (11,559,178.29) | 100.00% | Debtorhadirregularoperationsofsubjecttoseriousfinancialdifficultiesandrelatedtomultiplelawsuits,iswithlower-tierrecoverability. |
ClientB | 2,447,976.74 | (2,447,976.74) | 100.00% | Debtorhadirregularoperationsofsubjecttoseriousfinancialdifficulties,andhasbeenplacedonanationallistofdefaulters,withhighlyriskofgoingbankruptcyorfinancialrestructuring. |
ClientC | 2,365,253.03 | (2,365,253.03) | 100.00% | Debtorhadirregularoperationsofsubjecttoseriousfinancialdifficulties,andhasbeenplacedonanationallistofdefaulters,withhighlyriskofgoingbankruptcyorfinancialrestructuring. |
Others | 486,501,620.50 | (7,014,720.34) | 1.44% | Partofthereceivabletakeslongerthanusualtorecover,andhasriskofrecoverability. |
1,017,692,611.96 | (29,993,339.31) | - |
Provisionforbaddebtsbyportfolio: | |
30June2021 |
Carryingamount | Baddebtprovision | Accrualproportion | |
Combinationbycreditriskcharacteristics | 16,864,163,256.21 | 90,686,079.61 | 0.54% |
Provisionforbaddebtsofaccountsreceivableaccordingtothegeneralmodelofexpectedcreditloss
30June2021
30June2021 | ||
Estimateddefaultamount | Expectedcreditlossinentirelifetime | Expectedcreditlossrate |
Within1year | 16,312,880,752.43 | (40,974,307.84) | 0.25% |
1to2years | 511,922,099.65 | (34,341,536.99) | 6.71% |
2to3years | 27,850,847.18 | (7,831,498.28) | 28.12% |
Over3years | 11,509,556.95 | (7,538,736.50) | 65.50% |
16,864,163,256.21 | (90,686,079.61) | 0.54% |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
3.Accountsreceivable(Continued)
(1)Theaccountsreceivablebycategory(Continued)Theaginganalysisofaccountsreceivables
Theaginganalysisofaccountsreceivables | |
30June2021 |
Within1year | 17,299,413,843.64 |
1to2years | 515,740,902.78 |
2to3years | 36,094,871.65 |
Over3years | 30,606,250.10 |
(2)Changesinbaddebtprovision,recoveryorreverse
Baddebtprovisionforthecurrentperiod
17,881,855,868.17
Openingbalance
Openingbalance | Amountchangesincurrentperiod | Closingbalance | ||||
Increases | Reversal | write-off | Increasesinmerger | |||
Accountsreceivablebaddebtprovision | 92,513,453.13 | 38,699,564.83 | (10,675,833.06) | (35,935.36) | 178,169.38 | 120,679,418.92 |
ImportantrecoveredorreverseditemsofprovisionforindividuallyassessedbaddebtsfromJanuarytoJune2021arelistedbelow:
Recoveredorreversedamount
Recoveredorreversedamount | Methodofrecoveryorreversion |
ClientA | 62,252.15 | Paymentcollection |
ClientB | 25,278.00 | Paymentcollection |
ClientC | 19,152.28 | Paymentcollection |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
3.Accountsreceivable(Continued)
(3)Accountsreceivableactuallywrittenoffinthecurrentperiod
Project | Writeoffamount |
ClientA | 35,935.36 |
35,935.36 |
(4)Thetopfiveaccountsreceivableanalysedbycustomer
Amount | %ofthetotalaccountsreceivable | Baddebtprovisionamount |
Top1Accountreceivable | 250,098,236.84 | 1.40% | (920,455.72) | |
Top2Accountreceivable | 248,454,363.20 | 1.39% | (1,958,560.00) | |
Top3Accountreceivable | 209,855,263.24 | 1.17% | (1,432,489.42) | |
Top4Accountreceivable | 184,205,023.09 | 1.03% | (1,592,971.29) | |
Top5Accountreceivable | 161,208,692.82 | 0.90% | (426,533.84) |
1,053,821,579.19 | 5.89% | (6,331,010.27) |
(5)Accountsreceivablederecognizedduetothefinancialassetstransferred
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
4.Receivablefinancing
30June2021 | 31December2020 |
Bankacceptancebills | 345,906,887.55 | 1,404,987,700.38 |
ReceivablefinancingendorsedordiscountedbytheGrouptootherpartieswhichwerenotyetdueat30June2021
30June2021
30June2021Derecognised
Derecognised | NotDerecognised |
Bankacceptancebills | 1,841,760,515.56 | 20,070,999.69 |
5.Advancestosuppliers
(1) | Theagingofadvancestosuppliers |
30June2021 | 31December2020 | ||
Amount | %oftotalbalance | Amount | %oftotalbalance |
Within1year | 611,349,475.09 | 99.31% | 480,215,111.42 | 99.98% |
1to2years | 4,253,441.22 | 0.69% | 42,225.29 | 0.01% |
2to3years | - | - | 56,238.00 | 0.01% |
615,602,916.31 | 100.00% | 480,313,574.71 | 100.00% |
Theillustrationofthereasonswhyadvancepaymentswithamorethanone-yearagingwhiletheamountsaresignificantnotsettledintime:
Nil.(2)
(2) | Thetopfiveadvancestosuppliersbycustomeron30June2021 |
Amount | Proportionoftotalbalance |
Totalamountoftopfiveadvancestosuppliers | 217,538,246.13 | 35.34% |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
6.Otherreceivables
30June2021 | 31December2020 |
Otherreceivables | 662,274,841.26 | 535,228,747.69 |
(1)Otherreceivables(a)Categoryofotherreceivablesbynature
(a)Categoryofotherreceivablesbynature30June2021
30June2021 | 31December2020 |
Deposits | 294,986,764.47 | 287,130,364.44 |
Receivableofpricereductioncompensationandpurchasingrebates | 141,495,787.02 | 85,263,225.16 |
Receivableofthepharmaceuticalelectronictradingplatform | 49,995,673.20 | 60,267,511.03 |
Entrustedborrowings | 46,334,222.24 | 46,334,222.24 |
Pettycashadvancetoemployees | 52,673,098.70 | 22,994,684.93 |
Receivableofequitytransactions | 8,980,000.00 | 8,980,000.00 |
Receivableduefromrelatedparties | 23,094,951.86 | 2,867,594.20 |
Others | 115,368,379.05 | 90,580,362.96 |
732,928,876.54 | 604,417,964.96 |
(b)Changesinbaddebtprovision
Stage1
Stage1 | Stage2 | Stage3 | ||
Baddebt | Expectedcreditlossesoverthenext12months | Entirelifetimeexpectedcreditlosses(Nocreditimpairmentoccurred) | Entirelifetimeexpectedcreditlosses(Creditimpairmentoccurred) | Total |
Balanceat1January2021 | - | 7,305,149.90 | 61,884,067.37 | 69,189,217.27 |
Balanceat1January2021duringtheperiod | ||||
Provisionsduringtheperiod | - | 2,441,341.87 | 171,144.99 | 2,612,486.86 |
Reversalduringtheperiod | - | (1,146,204.24) | (1,464.61) | (1,147,668.85) |
Balanceat30June2021 | - | 8,600,287.53 | 62,053,747.75 | 70,654,035.28 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
6.Otherreceivables(Continued)
Theaginganalysisofotherreceivableswasasfollows:
30June2021Within1year
Within1year | 592,791,636.86 |
1to2years | 57,692,718.34 |
2to3years | 11,332,912.33 |
Over3years | 71,111,609.01 |
732,928,876.54(c)Changesinbaddebtprovision,recoveryorreverse
(c)Changesinbaddebtprovision,recoveryorreverseProvisionforbaddebtsinthecurrentperiodasfollows:
Provisionforbaddebtsinthecurrentperiodasfollows:
Currentchangeamount
Currentchangeamount | ||||||
Openingbalance | Provision | Reversalintheyear | Write-offintheyear | Other | Closingbalance | |
Provisionforimpairmentofotherreceivables | 69,189,217.27 | 2,612,486.86 | (1,147,668.85) | - | - | 70,654,035.28 |
69,189,217.27 | 2,612,486.86 | (1,147,668.85) | - | - | 70,654,035.28 |
(d)Thetop5partiesthatowedthelargestamountsofotherreceivablebalances
Nature
Nature | Amount | Age | %oftotalamount | Provisionofbaddebt |
SinopharmGroupZhijun(Suzhou)PharmaceuticalCo.,Ltd.(Note1) | Entrustedborrowings | 46,334,222.24 | Over3years | 6.32% | 46,334,222.24 |
GuangdongPharmaceuticalelectronictradingplatform | Pharmaceuticaltradingplatformrepaymentnotyetcleared | 36,837,497.58 | Within1year | 5.03% | - |
ShenzhenAdministrationofsocialinsurancefund | Deposit | 20,029,963.00 | Within1year | 2.73% | - |
TCM-IntegratedCancerCenterofSouthernMedicalUniversity | Depositoflogisticsextensionservicesproject | 20,000,000.00 | Over3years | 2.73% | - |
BayerHealthcareCo.Ltd. | Purchaserebatesreceivableandpricereductioncompensation | 16,117,671.62 | Within1year | 2.20% | - |
139,319,354.44 | 19.01% | 46,334,222.24 |
Note1:DuetothepoormanagementofZhijunSuzhou,thesolvencydecreasedandthecreditriskincreased.Basedontheprincipleofprudence,thegroupfullyaccruedthebaddebtprovisionfortheentrustedloanofRMB46,334,222.24.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
7.Inventories
(1) | Inventoriesbycategory |
30June2021 | 31December2020 | |||||
Bookvalue | Provisionfordeclinesinvalueofinventoriesandimpairmentofcontractperformancecosts | Netbookvalue | Bookvalue | Provisionfordeclinesinvalueofinventoriesorimpairmentofcontractperformancecosts | Netbookvalue |
Rawmaterials | 890,219.51 | - | 890,219.51 | 1,959,948.73 | - | 1,959,948.73 | |
Workinprogress | 133,216.20 | - | 133,216.20 | 244,341.19 | - | 244,341.19 | |
Finishedgoods | 7,228,118,772.03 | (12,979,519.90) | 7,215,139,252.13 | 6,292,866,195.61 | (12,997,334.35) | 6,279,868,861.26 | |
Lowcostconsumables | 3,495,930.78 | - | 3,495,930.78 | 2,937,523.28 | - | 2,937,523.28 |
7,232,638,138.52 | (12,979,519.90) | 7,219,658,618.62 | 6,298,008,008.81 | (12,997,334.35) | 6,285,010,674.46 |
(2) | Provisionfordeclinesinvalueofinventoriesandimpairmentofcontractperformancecosts |
31December2020 | Increases | Decreases | 30June2021 | ||
Provision | Additionduetocombination | Reversalorwrite-off | Others |
Finishedgoods | 12,997,334.35 | 5,022,800.14 | 314,857.50 | (4,704,443.43) | (651,028.66) | 12,979,519.90 |
In2021,duetotherecoveryofthevalueofsomeinventories,theprovisionforfallingpricewasRMB4,704,443.43(2020:RMB1,975,512.44),andtheprovisionforfallingpriceofinventorieswasRMB651,028.66(2020:RMB1,458,197.19).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
8.Contractassets
9. | 31December2021 | 31December2020 | ||||||
BookValue | Provision | NetBookValue | BookValue | Provision | NetBookValue |
Medicaldevicesandequipmentguaranteefunds | 17,144,247.25 | 78,141.72 | 17,066,105.53 | 15,195,530.95- | 17,799.31 | 15,177,731.64- |
Anaginganalysisofcontractassetswithprovisionforimpairmentareasfollows:
TheGroupsellsmedicaldevicesandequipmenttocustomersandprovidesrelevantinstallationservices,whichconstitutesasingleperformanceobligation.AfterthedeliveryofmedicaldevicesandequipmentbytheGroupandacceptancebycustomers,thecontrolrightsofgoodsaretransferred.TheGrouprecognisestherelevantincomeandtransferspartofthecontractconsiderationtoreceivables,andtheotherpartsareformedascontractassets.Aftertheequipmentisinstalledandtheagreedwarrantyperiodends,thecontractassetswillformanunconditionalrightofcollectionandbetransferredintoreceivables.30June2021
30June2021 | ||
Estimateddefaultamount | Expectedcreditlossinentirelifetime | Expectedcreditlossrate |
Within1year | 17,144,247.25 | 78,141.72 | 0.46% |
Changesinprovisionforcontractassetsarepresentedasfollows:
30June2021 | ||||
Project | Provisionincurrentperiod | Reversalincurrentperiod | writeofff | Reason |
Provisionforimpairmentofcontractassets | 60,622.700 | (280.29) | - | Provisionforbaddebtsofcontractassetsshallbemadeaccordingtoexpectedcreditlosses |
9.Othercurrentassets
30June2021 | 31December2020 |
InputVATtobecredited | 95,822,907.79 | 114,251,111.76 | |
Corporateincometaxtobededucted | 5,264,487.90 | 5,981,268.15 | |
Others | 498,534.36 | 850,483.54 |
101,585,930.05 | 121,082,863.45 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
10.Long-termequityinvestments
Investee | 31December2020 | Changesincurrentperiod | 30June2021 | Provisionforimpairment | |||
Profitoflossunderequitymethod | Othercomprehensiveincomeadjustment | Otherchangesinequity | Cashdividenddeclaredbyinvestee | ||||
Associates | |||||||
ShenzhenMainLuckPharmaceuticalInc.(“MainLuckPharmaceutical”)(a) | 322,696,745.87 | 34,596,706.61 | - | - | - | 357,293,452.48 | - |
ShanghaiBeiyiGuodaPharmaceuticalCo.Ltd.(“ShanghaiBeiyi”)(b) | 11,190,188.07 | 749,788.76 | - | - | - | 11,939,976.83 | - |
ShanghaiLiyiPharmacyCo.,Ltd.(“ShanghaiLiyi”)(c) | 1,147,948.30 | - | - | - | - | 1,147,948.30 | - |
ShanghaiRenbeiPharmacyCo.,Ltd.(“ShanghaiRenbei”)(d) | 2,465,103.92 | - | - | - | - | 2,465,103.92 | - |
DongyuanAccordPharmaceuticalChainCo.,Ltd.(“DongyuanAccord”)(e) | - | - | - | - | - | 396,638.32 | |
SinopharmJienuoMedicalTreatmentServiceGuangdongCo.,Ltd.(“GuangdongJienuo”)(f) | 5,225,570.12 | (749,864.47) | - | - | - | 4,475,705.65 | - |
GuangdongJianhuiConstructionInvestmentManagementCo.,Ltd.(“GuangdongJianhui”)(g) | 8,000,000.00 | - | - | - | - | 8,000,000.00 | - |
ZhijunSuzhou(h) | - | - | - | - | - | 1,857,279.52 | |
SinopharmGroupZhijun(Shenzhen)PharmaceuticalCo.,Ltd.(“SinopharmZhijun”)(i) | 425,557,825.11 | 28,056,303.69 | - | - | - | 453,614,128.80 | - |
ShenzhenZhijunPharmaceuticalTradeCo.,Ltd.(“ZhijunTrade”)(i) | 10,408,675.18 | 64,801.68 | - | - | - | 10,473,476.86 | - |
SinopharmGroupZhijun(Shenzhen)PingShanPharmaceuticalCo.,Ltd.(“ZhijunPingshan”)(i) | 176,566,795.90 | 25,603,869.60 | - | - | - | 202,170,665.50 | - |
ShanghaiShyndecPharmaceuticalCo.,Ltd,(“SinopharmShyndec”)(i) | 1,323,760,775.52 | 69,374,791.94 | 64,854.90 | (460,868.29) | (16,714,220.20) | 1,376,025,333.87 | - |
2,287,019,627.99 | 157,696,397.81 | 64,854.90 | (460,868.29) | (16,714,220.20) | 2,427,605,792.21 | 2,253,917.84 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
10.Long-termequityinvestments(Continued)(a)On4July1990,theGroupjointlyestablishedMainLuckPharmaceuticalwithMercianKabushikiKaishaandMainLifeCo.,Ltd.,subscribing35.19%,34.15%and30.66%ofshareholdings,respectively.AccordingtotheArticlesofAssociation,theboardofdirectorsofMainLuckPharmaceuticalconsistedofsixdirectors,ofwhichtwowereappointedbytheGroup,accountingfor
33.33%ofvotingrights.Therefore,theGrouphadsignificantinfluenceoverMainLuckPharmaceutical,andthus,itwasconsideredasanassociateoftheGroup.(b)On26July1994,theGroupjointlyestablishedShanghaiBeiyiwithShanghaiBeiyi(Group)Co.,Ltd.andeightnaturalpersonsincludingFuchunZhu,withthesharepercentagesbeing26%,26%and48%,respectively.AccordingtotheArticlesofAssociation,theboardofdirectorsofShanghaiBeiyiconsistedofsevendirectors,ofwhichtwowereappointedbytheGroup,accountingfor28.57%ofvotingrights.Therefore,theGrouphadsignificantinfluenceoverShanghaiBeiyi,andthus,itwasconsideredasanassociateoftheGroup.(c)On25November2003,theGroupjointlyestablishedShanghaiLiyiwithShanghaiPudongDistrictCentralHospitalandShanghaiLiyi,withthesharepercentagesbeing35%,35%and30%,respectively.AccordingtotheArticlesofAssociation,theboardofdirectorsofShanghaiLiyiconsistedoffivedirectors,ofwhichtwowereappointedbytheGroup,accountingfor40.00%ofvotingrights.Therefore,theGrouphadsignificantinfluenceoverShanghaiLiyi,andthus,itwasconsideredasanassociateoftheGroup.(d)On5March2019,theGroupacquired30%sharesofShanghaiRenbei.AccordingtotheArticlesofAssociation,theboardofdirectorsofShanghaiRenbeiwascomposedofthreedirectors,oneofwhomwasappointedbytheGroup,accountingfor33.33%ofvotingrights.Therefore,theGrouphassignificantinfluenceoverShanghaiRenbei,andthus,itisconsideredasanassociateoftheGroup.(e)In2007,DongyuanAccord,anassociateoftheGroup,operatedinpoorconditionsanditsfutureoperationwouldbesignificantlyuncertain,sotheGroupmadeafullprovisionforimpairmentofthelong-termequityinvestmentonit.(f)On23February2016,theGroupjointlyestablishedGuangdongJienuowithSinopharmJienuoMedicalTreatmentServiceCo.,Ltd.andGuangzhouJinluoInvestmentDevelopmentCo.,Ltd.,withthesharepercentagesbeing29%,51%and20%,respectively.AccordingtotheArticlesofAssociation,theboardofdirectorsofGuangdongJienuowascomposedoffivedirectors,oneofwhomwasappointedbytheGroup,accountingfor20%ofvotingrights.Therefore,theGrouphassignificantinfluenceoverGuangdongJienuo,andthus,itisconsideredasanassociateoftheGroup.On25July2019,theGroup,togetherwiththecurrentshareholders,SinopharmJienuoMedicalTreatmentServiceCo.,Ltd.andFoshanJiejianchengfengMedicalEquipmentCo.,Ltd.,increasedthecapitalofGuangdongJienuoby29%,51%and20%accordingtotheshareholdingratiorespectively,andthetotalamountoftheincreasedcapitalwasRMB6million.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
10.Long-termequityinvestments(Continued)(g)On23November2018,theGroupjointlyestablishedGuangdongJianhuiwithGuangdongConstructionEngineeringGroupCo.,Ltd.,SuixiPeople'sHospitalandGuangdongJiankeArchitecturalDesignInstituteCo.,Ltd.,withthesharepercentagesbeing10%,79.90%,10%and0.10%,respectively.TheregisteredcapitalofthecompanywasRMB20,000thousand.On22March2019,theGroupcompletedtheinvestmentofRMB2,000thousand.AccordingtotheArticlesofAssociation,theboardofdirectorsofGuangdongJianhuiwascomposedoffivedirectors,oneofwhomwasappointedbytheGroup,accountingfor20%ofvotingrights.Therefore,theGrouphassignificantinfluenceoverGuangdongJianhui,andthus,itisconsideredasanassociateoftheGroup.On30March2020,theGroupmadeanadditionalinvestmentofRMB6millioninGuangdongJianhuiaccordingtotheshareholdingratio.(h)TheGroupdisposedofits67%equityinterestofZhijunSuzhouinApril2016.Afterthedisposal,theGrouphelda33%equityinterestofZhijunSuzhou.AccordingtotheArticlesofAssociation,theboardofdirectorsofZhijunSuzhouwascomposedoffivedirectors,oneofwhomwasappointedbytheGroup,accountingfor20%ofvotingrights.Asaresult,theGrouphassignificantinfluenceoverZhijunSuzhou,andthus,itisconsideredasanassociateoftheGroup.In2019,onaccountofmismanagement,therewassignificantuncertaintyinthefutureoperationoftheGroup'saffiliatedenterprise,ZhijunSuzhou.Thus,theGroupmadefullprovisionforimpairmentofthelong-termequityinvestmentinZhijunSuzhou.(i)TheGroupsubscribed15.56%ofnewissuedsharesofSinopharmShyndec,arelatedparty,bytransferringtheproductiveassetsinPingshanbaseandits51%equityinterestofthreepharmaceuticalcompanies(SinopharmZhijun,ZhijunTrade,ZhijunPingshan)oftheGroupin2016,respectively.Afterthecompletionofthereorganization,ShyndecPharmaholdsa51%equityinterestofeachofthethreepharmaceuticalcompanies,andtheGroupholdsa49%equityinterestofeachofthethreepharmaceuticalcompanies,andtheyhavesignificantinfluenceoverthethreepharmaceuticalcompanies.Atthesametime,afterthecompletionofthereorganization,theGroupholdsa15.56%equityinterestofSinopharmShyndec.SinceSinopharmShyndecacquiredthesharesofsubsidiarieswithshare-basedpaymentinpreviousyears,asat30June2021,theGrouphelda16.28%equityinterestofSinopharmShyndec.SinopharmShyndecsetupaboardofdirectorsthatwasresponsiblefortheshareholders'meeting,withatotalofninemembers,amongwhich,onewasappointedbytheGroup.Eachdirectorshallrepresentonevoteforresolutionsoftheboard,accountingfor11.11%ofthevotingrights.TheGrouphassignificantinfluenceoverSinopharmShyndec.TheabovethreepharmaceuticalcompaniesandSinopharmShyndecareconsideredasassociatesoftheGroup.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
11.Otherequityinstrumentinvestment
30June2021 | 31December2020 |
SinopharmHealthOnlineCo.,Ltd. | 67,056,227.40 | 67,056,227.40 | |
SinopharmGuodaHubeiCo.,Ltd. | 18,279,788.59 | 18,279,788.59 | |
ShanghaiGuodaShuguangPharmacyCo.,Ltd. | 8,242,076.02 | 8,242,076.02 | |
ShanghaiGuorenPharmacyCo.,Ltd. | 5,493,260.45 | 5,493,260.45 | |
HunanZhongbaiPharmaceuticalInvestmentCo.,Ltd. | 416,987.82 | 416,987.82 |
99,488,340.28 | 99,488,340.28 |
单位:元
Recognizeddividendincome | Accumulatedprofits | AccumulatedLoss | Amounttransferredfromothercomprehensiveincometoretainedearnings | Reasonsdesignatedtobemeasuredatfairvaluewithchangesincludedinothercomprehensiveincome | Reasonsfortransferofothercomprehensiveincometoretainedearnings | |
SinopharmHealthOnlineCo.,Ltd. | - | 55,056,227.40 | - | - | Nontradableequityinstruments | |
SinopharmGuodaHubeiCo.,Ltd. | 2,280,159.50 | 17,279,788.59 | - | - | Nontradableequityinstruments | |
ShanghaiGuodaShuguangPharmacyCo.,Ltd. | 50,000.00 | 7,971,316.02 | - | - | Nontradableequityinstruments | |
ShanghaiGuorenPharmacyCo.,Ltd. | - | 5,393,260.45 | - | - | Nontradableequityinstruments | |
HunanZhongbaiPharmaceuticalInvestmentCo.,Ltd. | - | 101,987.82 | - | - | Nontradableequityinstruments | |
2,330,159.50 | 85,802,580.28 | - | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
12.Othernon-currentfinancialassets
30June2021 | 31December2020 |
Financialassetmeasuredatfairvaluethroughcurrentprofitorloss | 117,974,908.51 | 120,972,350.24 |
.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
13.InvestmentpropertiesSubsequentmeasurementunderthecostmodel:
Buildingsandconstructions | Landuseright | Total |
Originalcost | |||
Openingbalance | 225,645,845.78 | 20,988,818.44 | 246,634,664.22 |
Increaseamountincurrentperiod | 1,137,337.42 | - | 1,137,337.42 |
Purchase | - | - | - |
Transferfrominventories\fixedassets\constructioninprogress | 1,137,337.42 | - | 1,137,337.42 |
Decreaseamountincurrentperiod | (3,881,175.93) | (841,319.61) | (4,722,495.54) |
Transfertointangibleassets | - | (841,319.61) | (841,319.61) |
Transfertofixedassets | (3,881,175.93) | - | (3,881,175.93) |
Closingbalance | 222,902,007.27 | 20,147,498.83 | 243,049,506.10 |
Accumulateddepreciationandamortization | |||
Openingbalance | (109,976,379.20) | 7,913,905.08 | (117,890,284.28) |
Increaseamountincurrentperiod | (3,206,808.84) | (88,519.70) | (3,295,328.54) |
Provision | (2,810,737.39) | (88,519.70) | (2,899,257.09) |
Transferfromfixedassets | (396,071.45) | - | (396,071.45) |
Decreaseamountincurrentperiod | 2,589,746.83 | 235,490.60 | 2,825,237.43 |
Transfertointangibleassets | - | 235,490.60 | 235,490.60 |
Transfertofixedassets | 2,589,746.83 | - | 2,589,746.83 |
Closingbalance | (110,593,441.21) | 7,766,934.18 | (118,360,375.39) |
Provisionforimpairment | |||
OpeningbalanceandClosingbalance | (1,300,000.00) | - | (1,300,000.00) |
Carryingamount | |||
Atendoftheperiod | 111,008,566.06 | 12,380,564.65 | 123,389,130.71 |
Atbeginningoftheperiod | 114,369,466.58 | 13,074,913.36 | 127,444,379.94 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
14.Fixedassets
30June2021 | 31December2020 |
Fixedassets | 840,386,519.64 | 854,191,083.27 |
(1) | Conditionoffixedassets |
Buildingsandconstructions | Machineryandequipment | Motorvehicles | Officeequipments | Electronicequipments | Total | |
Originalcost | ||||||
Openingbalance | 704,639,396.43 | 305,450,662.64 | 96,751,717.47 | 365,642,213.00 | 121,068,984.00 | 1,593,552,973.54 |
Increaseamountincurrentperiod | 4,138,624.70 | 14,781,603.50 | 10,636,685.33 | 16,626,307.17 | 25,827,199.04 | 72,010,419.74 |
Purchase | 257,448.77 | 12,411,677.50 | 9,041,665.55 | 14,689,654.35 | 23,670,703.55 | 60,071,149.72 |
Transferfromconstructioninprogress | - | 2,194,159.00 | - | - | - | 2,194,159.00 |
TransferfromInvestmentproperties | 3,881,175.93 | - | - | - | - | 3,881,175.93 |
Businesscombinations | - | 175,767.00 | 1,595,019.78 | 1,936,652.82 | 2,156,495.49 | 5,863,935.09 |
Decreaseamountincurrentperiod | (1,371,000.42) | (568,600.21) | (2,932,878.73) | (2,953,830.43) | (4,389,640.59) | (12,215,950.38) |
Transfertoinvestmentproperties | (1,137,337.42) | - | - | - | - | (1,137,337.42) |
Disposalorretirement | (233,663.00) | (568,600.21) | (2,932,878.73) | (2,953,830.43) | (4,389,640.59) | (11,078,612.96) |
Closingbalance | 707,407,020.71 | 319,663,665.93 | 104,455,524.07 | 379,314,689.74 | 142,506,542.45 | 1,653,347,442.90 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
14.Fixedassets(Continued)
(1)Conditionoffixedassets(Continued)
Buildings
Buildings | Machineryandequipment | Motorvehicles | Officeequipments | Electronicequipments | Total |
Accumulateddepreciation | ||||||
Openingbalance | (238,423,991.05) | (148,242,155.24) | (58,335,271.31) | (216,568,139.60) | (77,792,333.07) | (739,361,890.27) |
Increaseamountincurrentperiod | (16,424,080.50) | (26,413,396.62) | (4,758,056.66) | (16,722,112.14) | (16,673,703.93) | (80,991,349.85) |
Provision | (13,834,333.67) | (26,413,396.62) | (4,758,056.66) | (16,722,112.14) | (16,673,703.93) | (78,401,603.02) |
TransferfromInvestmentproperties | (2,589,746.83) | - | - | - | - | (2,589,746.83) |
Decreaseamountincurrentperiod | 418,887.13 | 427,677.74 | 2,364,303.93 | 1,555,286.72 | 2,626,161.34 | 7,392,316.86 |
Disposalorretirement | 22,815.68 | 427,677.74 | 2,364,303.93 | 1,555,286.72 | 2,626,161.34 | 6,996,245.41 |
Transfertoinvestmentproperties | 396,071.45 | - | - | - | - | 396,071.45 |
Closingbalance | (254,429,184.42) | (174,227,874.12) | (60,729,024.04) | (231,734,965.02) | (91,839,875.66) | (812,960,923.26 |
Carryingamount | ||||||
Atendofperiod | 452,977,836.29 | 145,435,791.81 | 43,726,500.03 | 147,579,724.72 | 50,666,666.79 | 840,386,519.64 |
Atbeginningoftheperiod | 466,215,405.38 | 157,208,507.40 | 38,416,446.16 | 149,074,073.40 | 43,276,650.93 | 854,191,083.27 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
14.Fixedassets(Continued)
(2)ConditionofFixedassetsfallingtoaccomplishcertificationoftitleBookvalue
Bookvalue | Reasonfornotobtainingcertificationoftitle |
Buildingsandconstructions | 25,199,513.22 | Asat30June2021,theCompanyhasnotyetobtainedthecertificationoftitleforNo.13JingxingNorthStreet,TiexiDistrict,Shenyang.Thetransferor,theState-ownedAssetsSupervisionandAdministrationCommission,wasstillprocessingthecaseandhadprovidedarelevantnotification. |
Buildingsandconstructions | 40,072,822.06 | Asat30June2021,theCompanyhasnotyetobtainedthecertificationoftitleforNo.53NanshizhongStreet,TiexiDistrict,Shenyang.Thetransferor,theState-ownedAssetsSupervisionandAdministrationCommission,wasstillprocessingthecaseandhadprovidedarelevantnotification. |
Buildingsandconstructions | 536,550.04 | Asat30June2021,theconstructionareaisgreaterthantheapprovedarea,theGroupcannothandlethehousingpropertyrightcertificatelocatedat31YiheStreet,KaiyuaninTielingCity,KaiyuanCityPlanningBureauhadprovidedaconstructionprojectcompletionplanningacceptancecertificate. |
Buildingsandconstructions | 119,844.81 | On30June2021,duetotheneedforself-usestorage,theGrouphasbuiltitsownsimplewarehouselocatedat2BaiyuRoad,SujiatunDistrict,Shenyang.TheGroupisunabletoobtainahometitlecertificateforthepropertythere.. |
15.Constructioninprogress
30June2021 | 31December2020 |
Constructioninprogress | 64,636,735.93 | 46,631,190.23 |
(1) | Conditionofconstructioninprogress |
30June2021 | 31December2020 | ||||
Carryingbalance | Impairment | Carryingamount | Carryingbalance | Impairment | Carryingamount |
Warehouseimprovementproject | 6,015,123.20 | - | 6,015,123.20 | 2,357,739.84 | - | 2,357,739.84 |
Newofficebuildingproject | 2,449,885.09 | - | 2,449,885.09 | 2,654,403.71 | - | 2,654,403.71 |
Supplychainextensionproject | 14,289,469.53 | - | 14,289,469.53 | 12,248,729.81 | - | 12,248,729.81 |
Softwareproject | 28,344,537.25 | - | 28,344,537.25 | 19,443,779.83 | - | 19,443,779.83 |
Otherconstructionprojects | 13,537,720.86 | - | 13,537,720.86 | 9,926,537.04 | - | 9,926,537.04 |
64,636,735.93 | - | 64,636,735.93 | 46,631,190.23 | - | 46,631,190.23 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
15.Constructioninprogress(Continued)
(2) | Changesofsignificantconstructioninprogressincurrentperiod |
Projectname | Budget | Openingbalance | Increase | Decrease | Closingbalance | Proportionofinvestmenttobudget | Sourceoffunds | |
Transferredtofixedassets | TransferredtoLong-termprepaidexpenses |
Warehouseimprovementproject | 13,241,063.70 | 2,357,739.84 | 9,311,593.33 | 2,194,159.00 | 3,460,050.97 | 6,015,123.20 | 93.08% | Owncapital |
NewofficebuildingProject | 3,600,282.07 | 2,654,403.71 | - | - | 204,518.62 | 2,449,885.09 | 10.54% | Owncapital |
Supplychainextensionproject | 24,311,152.00 | 12,248,729.81 | 2,040,739.72 | - | - | 14,289,469.53 | 58.22% | Owncapital |
Softwareproject | 113,000,000.00 | 19,443,779.83 | 8,900,757.42 | - | - | 28,344,537.25 | 25.08% | Owncapital |
Otherconstructionprojects | 225,408,891.74 | 9,926,537.04 | 20,559,244.54 | - | 16,948,060.72 | 13,537,720.86 | 13.17% | Owncapital |
379,561,389.51 | 46,631,190.23 | 40,812,335.01 | 2,194,159.00 | 20,612,630.31 | 64,636,735.93 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
16.Right-of-useassets
Buildingsandconstructions | Machinery,transportandofficeequipment | Others | Total |
Originalcost | ||||
Openingbalance | 3,642,726,568.57 | 6,617,052.55 | 2,418,809.35 | 3,651,762,430.47 |
Increaseamountincurrentperiod | 722,812,718.72 | 255,241.57 | - | 723,067,960.29 |
Incl:Businesscombinationsnotundercommoncontrol | 41,709,665.65 | - | - | 41,709,665.65 |
Decreaseamountincurrentperiod | (269,712,235.31) | (1,389,315.12) | - | (271,101,550.43) |
Disposal | (269,712,235.31) | (1,389,315.12) | - | (271,101,550.43) |
Closingbalance | 4,095,827,051.98 | 5,482,979.00 | 2,418,809.35 | 4,103,728,840.33 |
Accumulateddepreciation | ||||
Openingbalance | 1,289,526,014.83 | 5,092,290.96 | 191,731.69 | 1,294,810,037.48 |
Increaseamountincurrentperiod | 493,418,631.21 | 166,716.16 | 47,473.92 | 493,632,821.29 |
Provision | 493,418,631.21 | 166,716.16 | 47,473.92 | 493,632,821.29 |
Decreaseamountincurrentperiod | (207,845,002.04) | (743,191.11) | - | (208,588,193.15) |
Disposal | (207,845,002.04) | (743,191.11) | - | (208,588,193.15) |
Closingbalance | 1,575,099,644.00 | 4,515,816.01 | 239,205.61 | 1,579,854,665.62 |
Carryingamount | ||||
Atendoftheperiod | 2,520,727,407.98 | 967,162.99 | 2,179,603.74 | 2,523,874,174.71 |
Atbeginningoftheperiod | 2,353,200,553.74 | 1,524,761.59 | 2,227,077.66 | 2,356,952,392.99 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
17.Intangibleassets
Landuserights | Software | Trademarksandbrandsuserights | Favorableleases | Distributionnetwork | Franchise | Total |
Originalcost | |||||||
Openingbalance | 88,694,377.76 | 198,298,230.20 | 282,036,925.12 | 127,486,000.00 | 283,573,678.24 | 710,000.00 | 980,799,211.32 |
Increaseamountincurrentperiod | 841,319.61 | 6,604,973.46 | 40,440,000.00 | - | - | - | 47,886,293.07 |
Purchases | - | 6,383,557.95 | - | - | - | - | 6,383,557.95 |
Businesscombinationsnotundercommoncontrol | - | 221,415.51 | 40,440,000.00 | - | - | - | 40,661,415.51 |
Transferfrominvestmentproperties | 841,319.61 | - | - | - | - | - | 841,319.61 |
- | |||||||
Closingbalance | 89,535,697.37 | 204,903,203.66 | 322,476,925.12 | 127,486,000.00 | 283,573,678.24 | 710,000.00 | 1,028,685,504.39 |
- | |||||||
Accumulatedamortization | |||||||
Openingbalance | (30,664,860.97) | (111,160,831.01) | (5,060,783.81) | (37,878,526.79) | (60,979,029.34) | (710,000.00) | (246,454,031.92) |
Increaseamountincurrentperiod | (1,129,159.45) | (11,528,055.72) | (6,550,848.51) | (3,542,977.94) | (7,987,906.67) | - | (30,738,948.29) |
Provision | (893,668.85) | (11,528,055.72) | (6,550,848.51) | (3,542,977.94) | (7,987,906.67) | - | (30,503,457.69) |
Transferfrominvestmentproperties | (235,490.60) | - | - | - | - | - | (235,490.60) |
Closingbalance | (31,794,020.42) | (122,688,886.73) | (11,611,632.32) | (41,421,504.73) | (68,966,936.01) | (710,000.00) | (277,192,980.21) |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
17.Intangibleassets(Continued)
Landuserights | Software | Trademarksandbrandsuserights | Favorableleases | Distributionnetwork | Franchise | Total |
Provisionforimpairment | |||||||
Openingbalance | - | - | - | - | - | - | - |
Closingbalance | - | - | - | - | - | - | - |
Carryingamount | |||||||
Atendoftheyear | 57,741,676.95 | 82,214,316.93 | 310,865,292.80 | 86,064,495.27 | 214,606,742.23 | - | 751,492,524.18 |
- | |||||||
Atbeginningoftheyear | 58,029,516.79 | 87,137,399.19 | 276,976,141.31 | 89,607,473.21 | 222,594,648.90 | - | 734,345,179.40 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
18.Goodwill
(1)OriginalBookValueofgoodwill
Namesoftheinvesteeormattersofforminggoodwill | Openingbalance | Increaseduringthisperiod | Decreaseduringthisperiod | Closingbalance | |
Mergerofholdingsnotundercommoncontrol | Businesscombinationsnotundercommoncontrol |
SinopharmHolding(Jiangmen)MedicalCo.,Ltd.(“SinopharmJiangmen”) | 27,392,317.73 | - | - | - | 27,392,317.73 |
SinopharmHoldingShenzhenYanfengCo.,Ltd.(“SinopharmYanfeng”) | 16,868,644.87 | - | - | - | 16,868,644.87 |
SinopharmHoldingZhaoqingCo.,Ltd.(“SinopharmZhaoqing”) | 2,594,341.53 | - | - | - | 2,594,341.53 |
SinopharmHoldingShaoguanCo.,Ltd.(“SinopharmShaoguan”) | 1,686,496.80 | - | - | - | 1,686,496.80 |
SinopharmHoldingMeizhouCo.,Ltd.(“SinopharmMeizhou”) | 1,610,819.66 | - | - | - | 1,610,819.66 |
SinopharmHoldingHuizhouCo.,Ltd.(“SinopharmHuizhou”) | 923,184.67 | - | - | - | 923,184.67 |
SinopharmHoldingZhanjiangCo.,Ltd.(“SinopharmZhanjiang”) | 282,135.55 | - | - | - | 282,135.55 |
SinopharmHoldingDongguanCo.,Ltd.(“SinopharmDongguan”) | 1,499.02 | - | - | - | 1,499.02 |
SouthPharma&Trade | 2,755,680.62 | - | - | - | 2,755,680.62 |
FoshanNanhai | 88,877,850.51 | - | - | - | 88,877,850.51 |
SinopharmHoldingZhuhaiCo.,Ltd.(“SinopharmZhuhai”) | 6,772,561.47 | 6,772,561.47 | |||
SinopharmHoldingMaomingCo.,Ltd.(“SinopharmMaoming”) | 66,417.07 | - | - | - | 66,417.07 |
SinopharmHoldingGuodaForMeMedicines(Shanghai)Co.,Ltd.(“ForMeMedicines’’) | 3,033,547.53 | - | - | - | 3,033,547.53 |
SinopharmHebeiLerentangPharmacyChainStoreCo.,Ltd.(“HebeiLerentang”) | 29,482,149.57 | - | - | - | 29,482,149.57 |
XiaoyiGuodaWanminBaicaotangPharmacyChainStoreCo.,Ltd.(“XiaoyiWanmin”) | 15,866,680.00 | - | - | - | 15,866,680.00 |
ShanxiGuodaWanminPharmacyChainStoreCo.,Ltd.(“ShanxiGuodaWanmin”) | 65,025,000.00 | - | - | - | 65,025,000.00 |
SinopharmHoldingGuodaForMePharmacyChainStoreCo.,Ltd.(“ForMePharmacyChainStore”) | 19,405,450.23 | - | - | - | 19,405,450.23 |
SinopharmHoldingGuodaPharmacyChainStoreShanghaiCo.,Ltd.(“ShanghaiGuoda”) | 5,028,638.00 | - | - | - | 5,028,638.00 |
SinopharmHoldingGuodaYangzhouDadeshengPharmacyChainStoreCo.,Ltd.(“YangzhouGuoda”) | 7,979,000.00 | - | - | - | 7,979,000.00 |
ZhejiangGuodaPharmacyCo.,Ltd.(“ZhejiangGuoda”) | 3,045,183.85 | - | - | - | 3,045,183.85 |
SinopharmHoldingGuodaNanjingPharmacyChainStoreCo.,Ltd.(“NanjingGuoda”) | 11,598,341.12 | - | - | - | 11,598,341.12 |
FujianGuodaPharmacyChainStoreCo.,Ltd.(“FujianChain”) | 1,567,250.76 | - | - | - | 1,567,250.76 |
SinopharmHoldingGuodaShandongPharmacyChainStoreCo.,Ltd.(“ShandongGuoda”) | 29,110,409.46 | - | - | - | 29,110,409.46 |
SinopharmHoldingGuodaShenyangPharmacyChainStoreCo.,Ltd.(“ShenyangGuoda”) | 41,047,958.08 | - | - | - | 41,047,958.08 |
LiyangGuodaPeoplePharmacyChainStoreCo.,Ltd.(“LiyangGuoda”) | 107,275,095.74 | - | - | - | 107,275,095.74 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
18.Goodwill(Continued)
(1)OriginalBookValueofgoodwill(Continued)
Namesoftheinvesteeormattersofforminggoodwill | Openingbalance | Increaseduringthisperiod | Decreaseduringthisperiod | Closingbalance | |
Mergerofholdingsnotundercommoncontrol | Businesscombinationsnotundercommoncontrol |
SinopharmHoldingHunanGuodaMinshengtangPharmacyChainCo.,Ltd.(“HunanGuoda”) | 41,165,574.64 | - | - | - | 41,165,574.64 |
QuanzhouGuodaPharmacyChainStoreCo.,Ltd.(“QuanzhouGuoda”) | 41,298,622.59 | - | - | - | 41,298,622.59 |
SinopharmHoldingGuodaHenanPharmacyChainStoreCo.,Ltd.(“HenanGuoda”) | 22,666,179.77 | - | - | - | 22,666,179.77 |
GuodaNeimenggu | 70,485,777.00 | - | - | - | 70,485,777.00 |
SinopharmGuodaPharmacyJiangmenChainCo.,Ltd.(“JiangmenGuoda”) | 77,350,000.00 | - | - | - | 77,350,000.00 |
SinopharmHoldingGuodaShanxiYiyuanPharmacyChainStoreCo.,Ltd.(“ShanxiGuodaYiyuan”) | 9,080,100.00 | - | - | - | 9,080,100.00 |
ShenzhenGuanganliPharmacyChainStoreCo.,Ltd.‘sStoreAcquisition | 13,420,000.00 | - | - | - | 13,420,000.00 |
BeijingGoldenElephantPharmacyMedicineChainCompanyLimited(“BeijingGoldenElephant”) | 64,140,124.36 | - | - | - | 64,140,124.36 |
GuodaTaishan | 26,826,120.55 | - | - | - | 26,826,120.55 |
TaiyuanTongxinliPharmacyCo.,Ltd.(“TaiyuanTongxinli”) | 2,818,647.85 | - | - | - | 2,818,647.85 |
SinopharmHoldingGuodaYongxingtangPharmacyChainStore(Chaoyang)Co.,Ltd(“ChaoyangYongxingtang”) | 25,973,399.17 | - | - | - | 25,973,399.17 |
NeimengguTongrenBigPharmacyChainCo.,Ltd.storeacquisition. | 13,494,000.00 | - | - | - | 13,494,000.00 |
GuodaPu’er | 71,064,684.79 | - | - | - | 71,064,684.79 |
ShanghaiPudongNewAreaPharmaceuticalsCo.,Ltd.(“PudongPharmaceuticals”) | 65,978,042.61 | 65,978,042.61 | |||
ShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd. | 520,836,246.17 | - | - | - | 520,836,246.17 |
ChengDafangPharmaceuticalGroupCo.,Ltd | 1,182,443,676.11 | - | - | - | 1,182,443,676.11 |
LiaoningXianzhenPharmaceuticalChainCo.,Ltd. | 34,037,431.66 | - | - | - | 34,037,431.66 |
YunnanGuodaDishengpharmacychainCo.,Ltd(“DishengChain”)(Note1) | - | 152,157,935.52 | - | - | 152,157,935.52 |
ChinaPharmaceuticalHoldingsNantongPujiPharmacyChainCo.,Ltd.storeacquisition(Note2) | - | - | 11,498,100.00 | - | 11,498,100.00 |
ShanxiHuiminKangweiBigPharmacyChainCo.,Ltd.storeacquisition(Note3) | - | - | 20,970,000.00 | - | 20,970,000.00 |
2,772,375,281.11 | 152,157,935.52 | 32,468,100.00 | 2,957,001,316.63 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
18.Goodwill(Continued)
(2)Provisionofimpairmentloss
Namesoftheinvesteeormattersofforminggoodwill | Openingbalance | Increase | Decrease | Closingbalance |
GuodaQuanzhou | 25,000,000.00 | - | - | 25,000,000.00 |
RelevantinformationofassetgrouporcombinationofassetgroupsinwhichgoodwillislocatedExplaintheprocessofgoodwillimpairmenttest,keyparameters(suchasthegrowthrateintheforecastperiod,thegrowthrateinthestableperiod,theprofitrate,thediscountrate,theforecastperiod,etc.)andtherecognitionmethodofgoodwillimpairmentloss:
Thecarryingvalueofgoodwillisapportionedaccordingtotheproportionofeachassetgrouporcombinationofassetgroupsatfairvalueofthetotalamountofgoodwillatfairvalue.Itisshownasfollows:
30June2021 | 31December2020 |
Pharmaceuticaldistribution | 152,865,497.03 | 152,865,497.03 |
Pharmaceuticalretail | 2,779,135,819.60 | 2,594,509,784.08 |
2,932,001,316.63 | 2,747,375,281.11 |
Therecoverableamountofassetgroupandcombinationofassetgroupsiscalculatedbasedonthefive-yearperiodbudgetapprovedbythemanagementwhileusingthecashflowforecastmethod.Thecashflowsbeyondthefive-yearperiodareextrapolatedusingtheinflationrate.Keyassumptionswereusedforthecalculationofthepresentvaluesoffuturecashflowprojectionsofassetgroupandcombinationofassetgroupsconsistingofpharmaceuticaldistributionandpharmaceuticalretailasof30June2021.Keyassumptionsmadebymanagementonprojectionsofcashflowsusedinimpairmenttestingaredescribedasfollows:
Pharmaceuticaldistribution | Pharmaceuticalretail |
Revenuegrowthrateinthebudgetperiod | 1.79%-16.00% | 2.67%-16.43% |
Sustainablegrowthrate | 3.00% | 3.00% |
Grossmargin | 3.56%-6.40% | 12.40%-50.58% |
Discountrate | 12.40%-15.00% | 13.00%-15.00% |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
18.Goodwill(Continued)Thebudgetedgrossmarginandtherevenuegrowthrateinthebudgetperiodaredeterminedbasedonthepastperformanceandexpectationformarketdevelopment.Thediscountratesusedarepre-taxdiscountratesafterreflectingspecificrisksoftherelevantassetgroups.Therecoverableamountoftheassetgroupconsistingofpharmaceuticaldistributionandpharmaceuticalretailwasdeterminedaccordingtothekeyassumptions.ImpactofgoodwillimpairmenttestOtherdeclarationsNote1:TheGroupacquireda70%stakeinYunnanGuodaDishengPharmaceuticalChainCo.,Ltd.inMarch2021,andaftertheacquisition,itformedgoodwillofRMB152,157,935.52,thecalculationprocessofwhichisdetailedinNotesVI-1.Note2:TheGroupacquired15directstoresofNantongPujiPharmacyChainCo.,Ltd.inMarch2021,andaftertheacquisition,itformedgoodwillofRMB11,498,100.00,thecalculationprocessofwhichisdetailedinNotesVI-1.Note3:TheGroupacquired32directstoresofShanxiHuiminKangweiPharmaceuticalChainCo.,Ltd.inFebruary2021,andaftertheacquisitionwascompleted,itformedgoodwillofRMB20,970,000.00,thecalculationprocessofwhichisdetailedinNotesVI-1
19.Long-termprepaidexpenses
Openingbalance | Additions | Amortization | Otherdecrease | Closingbalance |
Fixedassetimprovementexpenditure | 336,895,157.13 | 73,939,831.45 | 63,049,121.27 | 1,789,848.54 | 345,996,018.77 |
Acquisitionexpendituretoobtaintherighttooperate | 95,802,321.95 | 70,780,659.86 | 10,579,442.60 | - | 156,003,539.21 |
Others | 25,007,797.01 | 1,655,150.46 | 5,469,516.47 | - | 21,193,431.00 |
457,705,276.09 | 146,375,641.77 | 79,098,080.34 | 1,789,848.54 | 523,192,988.98 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
20.Deferredtaxassets/liabilities
(1) | Deferredtaxassetsbeforeoffseting |
30June2021 | 31December2020 | ||||
Deductibletemporarydifferences | Deferredtaxassets | Deductibletemporarydifferences | Deferredtaxassets | ||
Provisionforimpairmentofassets | 196,487,679.43 | 46,536,628.81 | 170,577,875.56 | 40,697,280.41 | |
Deductibletaxloss | 32,245,677.79 | 8,061,419.46 | 30,798,485.93 | 7,699,621.49 | |
Impactofleasecriteria | 109,849,225.12 | 27,234,338.93 | 93,685,083.09 | 22,420,179.23 | |
Accruedexpenses | 108,024,144.57 | 25,409,713.77 | 113,445,282.36 | 26,095,709.73 | |
Memberbonuspoints | 61,049,011.99 | 14,722,901.75 | 59,179,220.98 | 14,575,814.61 | |
Accruedpayroll | 45,855,424.22 | 10,861,893.44 | 47,280,390.08 | 11,210,512.95 | |
Others | 20,119,732.62 | 4,832,303.97 | 21,096,550.78 | 4,641,850.41 |
573,630,895.74 | 137,659,200.13 | 536,062,888.78 | 127,340,968.83 |
(2) | Deferredtaxliabilitiesbeforeoffseting |
30June2021 | 31December2020 | |||
Taxabletemporarydifferences | Deferredtaxliabilities | Taxabletemporarydifferences | Deferredtaxliabilities |
Fairvalueadjustmentforbusinesscombinationnotinvolvingenterprisesundercommoncontrol | 716,667,762.07 | 179,197,391.85 | 713,703,864.68 | 178,425,966.17 | |
Changesinfairvalueoffinancialassetsthroughothercomprehensiveincome | 85,802,580.28 | 21,450,645.07 | 85,802,580.28 | 21,450,645.07 | |
One-timedeductionforfixedassetsunderfivemillionyuan | 123,264,042.43 | 30,816,010.64 | 126,722,799.31 | 31,679,099.86 | |
Divisionrestructuringassetstoassessvalue-addeddifferences | 16,029,854.96 | 4,007,463.74 | 17,160,546.40 | 4,290,136.60 | |
Others | 28,333,035.97 | 6,090,083.17 | 25,205,927.86 | 5,297,761.98 |
970,097,275.71 | 241,561,594.47 | 968,595,718.53 | 241,143,609.68 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
20.Deferredtaxassets/liabilities(Continued)
(3) | Deferredtaxassetsandliabilitiesarepresentedafterbeingoffsetagainsteachother: |
30June2021 | 31December2020- | ||
Deferredtaxassets/liabilities-Net | Temporarydifferencesafterset-off | Deferredtaxassets/liabilities-Net | Temporarydifferencesafterset-off |
Deferredtaxassets | 41,063,450.80 | 96,595,749.33 | 35,222,201.02 | 92,118,767.81 |
Deferredtaxliabilities | 41,063,450.80 | 200,498,143.67 | 35,222,201.02 | 205,921,408.66 |
(4) | Thedeductibletemporarydifferencesanddeductiblelossesthatwerenotrecognizedasdeferredtaxassetsarepresentedasfollows: |
30June2021 | 31December2020 |
Deductibletemporarydifferences | 11,920,797.79 | 9,435,555.39 |
Deductibleloss | 61,373,403.25 | 61,373,403.25 |
73,294,201.04 | 70,808,958.64 |
(5) | Theaforesaidunrecognizeddeductiblelosseswilldue: |
30June2021 | 31December2020 |
2021 | 2,563,056.08 | 2,563,056.08 |
2022 | 7,261,117.97 | 7,261,117.97 |
2023 | 11,977,477.56 | 11,977,477.56 |
2024 | 22,579,176.44 | 22,579,176.44 |
2025 | 16,992,575.20 | 16,992,575.20 |
61,373,403.25 | 61,373,403.25 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
21.Othernon-currentassets
30June2021 | 31December2020 | |||||
Carryingbalance | Impairment | Carryingamount | Carryingbalance | Impairment | Carryingamount | |
Physicalassetsreservespecificallyauthorized | 331,870,456.97 | - | 331,870,456.97 | 260,590,932.98 | - | 260,590,932.98 |
Securitydeposit | 100,326,250.00 | (70,000.00) | 100,256,250.00 | 114,186,431.57 | - | 114,186,431.57 |
Prepaymentforprojectandequipment | 40,757,628.00 | - | 40,757,628.00 | 24,809,091.30 | - | 24,809,091.30 |
Contractassets | 8,238,308.92 | (120,404.87) | 8,117,904.05 | 7,081,263.45 | (82,188.73) | 6,999,074.72 |
Other | 3,257,615.30 | - | 3,257,615.30 | 1,611,992.27 | - | 1,611,992.27 |
484,450,259.19 | (190,404.87) | 484,259,854.32 | 408,279,711.57 | (82,188.73) | 408,197,522.84 |
22.Short-termborrowings
30June2021 | 31December2020 |
Creditborrowings | 4,632,933,904.39 | 1,612,187,020.12 |
23.Notespayable
At30June2021,theannualinterestratefortheaboveborrowingswas2.28%((31December2020:3.49%)).At30June2021and31December2020,therewerenoshort-termborrowingsoftheGroupthatwereoverduebutnotyetpaid.30June2021
30June2021 | 31December2020 |
Commercialacceptancebills | 93,061,594.94 | 56,360,197.69 | ||
Bankacceptancebills | 6,687,363,494.23 | 7,463,805,077.00 |
6,780,425,089.17 | 7,520,165,274.69 |
At30June2021,thetotalamountofnotespayablethatwereduebutnotyetpaidwasnil(31December2020:nil).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
24.Accountspayable
30June2021 | 31December2020 |
Paymentforgoods | 9,642,504,836.50 | 7,697,451,142.50 |
At30June2021,significantaccountspayableagedoveroneyearwasanalyzedbelow:
Amount | Reason |
Paymentforgoods | 429,971,551.39 | Hasnotbeensettled |
At30June2021,accountspayableagedoveroneyear,mainlytheunsettledpaymentforgoods,wasRMB429,971,551.39(31December2020:RMB398,772,102.49).
25.Receiptsinadvance
30June2021 | 31December2020 |
Advancedleasepayment | 14,868,097.97 | 12,352,466.64 |
26.Contractliabilities
30June2021 | 31December2020 |
Contractliabilities | 316,827,151.78 | 368,600,357.14 |
TheendingbalanceofcontractliabilitiesistheadvancepaymentsreceivedbytheGroup.AftertheGroupreceivestheadvancepaymentsbythecustomerforthesalesofgoods,itwillgenerallyperformtheperformanceobligationandrecognisetherevenuewithinabout6months.
27.Employeebenefitspayable
31December2020 | Increase | Decrease | 30June2021 |
Short-termemployeebenefits(1) | 347,602,975.86 | 1,442,005,710.81 | 1,554,869,193.60 | 234,739,493.07 |
Post-employmentbenefits(definedcontributionplan)(2) | 9,216,204.49 | 135,235,733.49 | 137,243,137.06 | 7,208,800.92 |
Terminationbenefits | 392,866.75 | 560,719.50 | 695,897.15 | 257,689.10 |
357,212,047.10 | 1,577,802,163.80 | 1,692,808,227.81 | 242,205,983.09 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
27.Employeebenefitspayable(Continued)
(1) | Short-termemployeebenefits |
31December2020 | Increase | Decrease | 30June2021 |
Salaries,bonuses,allowancesandgrants | 330,233,181.61 | 1,259,235,407.05 | 1,376,555,529.89 | 212,913,058.77 |
Staffwelfare | 1,469,381.07 | 32,807,596.67 | 33,096,433.74 | 1,180,544.00 |
Socialsecuritycontribution | 2,194,328.52 | 74,031,911.08 | 74,006,336.50 | 2,219,903.10 |
Incl:Medicalinsurance | 1,531,693.95 | 68,900,758.25 | 68,513,264.14 | 1,919,188.06 |
Workinjuryinsurance | 84,285.35 | 2,846,079.32 | 2,857,214.97 | 73,149.70 |
Maternityinsurance | 578,349.22 | 2,285,073.51 | 2,635,857.39 | 227,565.34 |
Housingfunds | 1,650,393.19 | 52,281,928.06 | 52,197,609.56 | 1,734,711.69 |
Laborunionfundsandemployeeeducationfunds | 11,183,869.70 | 22,386,728.92 | 20,702,330.34 | 12,868,268.28 |
Othershort-termbenefits | 871,821.77 | 1,262,139.03 | (1,689,046.43) | 3,823,007.23 |
347,602,975.86 | 1,442,005,710.81 | 1,554,869,193.60 | 234,739,493.07 |
(2) | Definedcontributionplan |
31December2020 | Increase | Decrease | 30June2021 |
Basicpensioninsurance | 3,593,380.27 | 128,854,477.21 | 127,826,836.98 | 4,621,020.50 | |||
Unemploymentinsurance | 106,718.12 | 3,965,369.33 | 3,905,028.02 | 167,059.43 | |||
Contributiontopensionfund | 5,516,106.10 | 2,415,886.95 | 5,511,272.06 | 2,420,720.99 |
9,216,204.49 | 135,235,733.49 | 137,243,137.06 | 7,208,800.92 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
28.Taxpayable
30June2021 | 31December2020 |
Value-addedtax | 75,280,000.02 | 102,586,862.95 | |
CorporateIncometaxes | 182,236,074.48 | 173,016,908.47 | |
Individualincometax | 7,083,305.63 | 6,790,402.61 | |
Citymaintenanceandconstructionsurtax | 6,333,456.10 | 6,993,947.17 | |
Stampduty | 7,697,463.21 | 8,243,076.57 | |
Waterconservancyfund | 5,572,222.75 | 5,586,926.64 | |
Educationalsurcharge | 5,131,997.40 | 5,254,608.43 | |
Propertytax | 1,300,695.62 | 664,697.78 | |
Landusetax | 148,696.04 | 54,028.60 | |
Others | 7,417,676.88 | 7,675,689.94 |
298,201,588.13 | 316,867,149.16 |
29.Otherpayables
30June2021 | 31December2020 |
Interestpayable | 16,255,309.75 | 35,572,620.82 | |
Dividendpayable | 7,911,748.36 | 6,389,320.96 | |
Otherpayables | 1,507,731,959.76 | 1,557,204,939.36 |
1,531,899,017.87 | 1,599,166,881.14 |
(1)Interestpayable | |||
30June2021 | 31December2020 |
Factoringinterestonaccountsreceivable | 16,255,309.75 | 35,572,620.82 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
29.Otherpayables(Continued)
(2)Dividendpayable30June2021
30June2021 | 31December2020 |
ShanghaiFosunPharmaceutical(Group)Co.,Ltd. | 4,835,511.58 | 4,835,511.58 | |
DividendpayabletoZhangZhenfang | 1,389,639.31 | 1,389,639.31 | |
MeiluoPharmaceuticalCo.,Ltd. | 164,170.07 | 164,170.07 | |
LongfengDu | 526,506.14 | - | |
DongWang | 336,202.71 | - | |
HaimingLiu | 177,616.53 | - | |
GuozhuTang | 69,777.92 | - | |
XianchengLiu | 88,808.27 | - | |
ShaojunYan | 44,404.13 | - | |
HaiyuLiu | 38,060.69 | - | |
QinghuaWang | 126,868.95 | - | |
ZhanchengLiang | 114,182.06 | - |
7,911,748.36 | 6,389,320.96 |
At30June2021and31December2020,theGrouphadnosignificantdividendagedmorethanoneyearandnotyetpaid.
(3)Otherpayables30June2021
30June2021 | 31December2020 |
Deposit | 484,838,817.90 | 472,800,624.92 | |
Payablesforfactoringprograms | 325,153,045.22 | 576,523,284.81 | |
Accruedexpenses | 210,959,892.77 | 213,950,722.34 | |
Equitypayables | 207,199,828.25 | 38,702,372.01 | |
Payablesforrentals | 95,120,391.91 | 68,417,303.16 | |
Payablesforconstructioninprogressandequipment | 44,723,287.89 | 40,898,589.59 | |
Payablestoindividuals | 26,098,245.60 | 25,869,320.67 | |
Collectionofothers | 20,055,565.05 | 19,119,286.19 | |
Payablesforlandtransferpayments | 12,597,500.00 | 12,597,500.00 | |
Temporaryloans | 11,198,533.00 | 11,017,981.51 | |
Payablestorelatedparties | 5,138,862.34 | 5,093,263.36 | |
Others | 64,647,989.83 | 72,214,690.80 |
1,507,731,959.76 | 1,557,204,939.36 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
29.Otherpayables(Continued)
At30June2021,significantotherpayablesover1yearare:
Amountpayable | Reasonforoutstanding |
Equitypayable | 36,000,000.00 | Paymentconditionsnotmet | |
Deposits | 37,744,837.63 | Paymentconditionsnotmet | |
Accruedexpenses | 6,223,452.82 | Paymentconditionsnotmet | |
Payablesforlandtransferpayments | 12,597,500.00 | Paymentconditionsnotmet |
30.Non-currentliabilitiesduewithin1year
92,565,790.4530June2021
30June2021 | 31December2020 |
Leaseliabilitiesduewithin1year | 798,170,618.10 | 748,732,059.89 |
31.Othercurrentliabilities
30June2021 | 31December2020 | ||
Pre-collectedVAT | 20,997,225.61 | 24,142,106.09 | |
OutputVATtoberecognized | 1,435,222.36 | 644,972.46 |
22,432,447.97 | 24,787,078.55 |
32.Long-termborrowings
31December2021 | 31December2020 |
Creditloan | 30,000,000.00 | - | ||
Entrustedloans | 31,633,794.44 | 31,637,173.89- |
61,633,794.44 | 31,637,173.89 |
At30June2021,thetotalamountofremainingentrustedloanswasRMB31,633,794.44(31December2020:
RMB31,637,173.89).,whichwastheloanfromSinopharmGroupFinanceCo.,LtdentrustedbyCNPGCtothegroup,theweightedaverageannualinterestrateoftheentrustedloanswas3.34%(31December2020:3.41%).At30June2021,thebalanceofcreditborrowingswasRMB30,000,000.00(31December2020:None).Theannualinterestrateonthiscreditloanis4.05%(31December2020:None).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
33.Leaseliabilities
30June2021 | 31December2020 |
Leasepayment | 2,159,301,970.90 | 2,051,786,223.79 | |
Less:Leaseliabilitiesduewithin1year | 798,170,618.10 | 748,732,059.89 |
1,361,131,352.80 | 1,303,054,163.90 |
34.Long-termpayables
30June2021 | 31December2020 |
Payablesforspecificprojects | 6,938,189.00 | 6,938,189.00 |
Payablesforspecificprojects:
31December2020 | Increase | Decrease | 30June2021 | Reasonsofderredincome | ||||
Specialfundsgrantedbygovernment(1) | 800,000.00 | - | - | 800,000.00 | Fundsgrantedbygovernment | |||
Medicalreservefunds(2) | 6,138,189.00 | - | - | 6,138,189.00 |
6,938,189.00 | - | - | 6,938,189.00 |
(1)Thespecificpayablesareresearchfundsallocatedbygovernmentdepartmentsandareaccountedforthespecificpayableaccountatthetimeofallocation.
(2)ThemedicalreservefundswereallocatedbytheLiaoningProvinceDepartmentofFinancetoLiaoningChengdaFangyuanpharmaceuticalchainCo.,Ltdwhichwasincorporatedintotheconsolidationin2020.
35.Long-termemployeebenefitspayable
30June2021 | 31December2020 |
Earlyretirementbenefitspayable | 1,262,000.00 | 1,319,000.00 |
36.Provisions
30June2021 | 31December2020 |
Pendinglitigationorarbitration(1) | 68,663,166.79 | 68,808,166.79 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
37.Deferredincome
Openingbalance | Increase | Decrease | Closingbalance | Reasonsofdeferredincome | |
Governmentgrants | 89,610,262.61 | 7,520,212.93 | 5,962,539.84 | 91,167,935.70 | Governmentgrant |
VATAdditionaldeduction | 233,320.76 | 835,816.61 | 921,739.18 | 147,398.19 | VATadditionaldeduction |
89,843,583.37 | 8,356,029.54 | 6,884,279.02 | 91,315,333.89 |
Asat30June2021,deferredincomefromgovernmentgrantsareasfollows:
Governmentgrants
program
Governmentgrantsprogram | Openingbalance | Addition | Amountincludedinnon-operatingincome | Amountincludedinotherincome | Offsetcostamountincurrentperiod | Closingbalance | Assetrelated/incomerelated |
ResettlementCompensation(Note) | 70,158,624.05 | - | 1,349,204.28 | - | - | 68,809,419.77 | Assetrelated |
Fundsfortheconstructionofamodernsupplychainsysteminthecentralcirculationfieldin2018 | 4,353,019.54 | 7,450,000.00 | - | 2,143,819.53 | - | 9,659,200.01- | Assetrelated |
LogisticsprojectNanningEconomicDevelopmentZoneconstructionsupportfund | 4,846,565.87 | - | - | 93,203.22 | - | 4,753,362.65 | Assetrelated |
Guangzhoulogisticsstandardizationpilotproject | 1,722,518.87 | - | - | 273,123.42 | - | 1,449,395.45 | Assetrelated |
ShenyangTiexiGovernmenthousingsubsidies | 1,325,001.32 | - | - | 40,561.32 | - | 1,284,440.00 | Assetrelated |
Otherprojects | 7,204,532.96 | 70,212.93 | - | 2,037,129.45 | 25,498.62 | 5,212,117.82 | Asset/Incomerelated |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
38.Othernon-currentliabilities
30June2021 | 31December2020 |
Governmentalmedicalreservefunds(1) | 600,009,111.26 | 711,029,182.37 | ||
Productpromotionaccumulativepointsprogramme(2) | 30,824,503.22 | 29,815,911.17 | ||
Other | 6,140.53 | 17,896.05 |
630,839,755.01 | 740,862,989.59 | ||
(1)Governmentalmedicalreservefundsarethefundsreceivedfromthenationalandlocalgovernmentsforpurchasingreservemedicalsupplies.(2)TheProductpromotionaccumulativepointsprogrammereferstothoseproduct-originatedaccumulativepointsthatremainmorethanoneyearsurplusbeforetheexpirationdate. |
39.Sharecapital
Movementduringthecurrentyear31December2020
31December2020 | Issueofnewshare | Others | Subtotal | 30June2021 |
Shares | 428,126,983.00 | - | - | - | 428,126,983.00 |
40.Capitalsurplus
31December2020 | Increase | Decrease | 30June2021 |
Sharepremium | 2,118,174,787.27 | - | - | 2,118,174,787.27 |
Othercapitalsurplus | 2,254,329,266.45 | - | (460,868.29) | 2,253,868,398.16 |
4,372,504,053.72 | - | (460,868.29) | 4,372,043,185.43 | |
ChangesinotherequityofShyndecPharma,anassociateofthegroup,reducethebookvalueoflong-termequityinvestmentandincludeitinthecapitalreserveofRMB-460,868.29. |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
41.Othercomprehensiveincome
Amountschangesincurrentperiod | |||
31December2020 | Occurrenceamountbeforetax | Attributabletoshareholdersofownersoftheparent | 30June2021 |
Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitorloss | 38,611,051.04 | - | - | 38,611,051.04 |
Incl:Changeinthefairvalueofotherequityinvestments | 38,611,051.04 | - | - | 38,611,051.04 |
Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss | (128,033.32) | 64,854.90 | 64,854.90 | (63,178.42) |
Incl:Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | (128,033.32) | 64,854.90 | 64,854.90 | (63,178.42) |
38,483,017.72 | 64,854.90 | 64,854.90 | 38,547,872.62 |
42.Surplusreserve
31December2020 | Increase | Decrease | 30June2021 |
Statutorysurplusreserves | 214,063,491.50 | - | - | 214,063,491.50 |
43.Retainedearnings
30June2021 | 31December2020 |
Retainedearningsatbeginningofyearbeforeretrospectiveadjustmentandrestatement | 8,895,145,106.39 | 7,755,295,537.08 |
Theretrospectiveadjustmentandrestatement | - | (3,029,877.91) |
Retainedearningsatbeginningofyearafterretrospectiveadjustmentandrestatement | 8,895,145,106.39 | 7,752,265,659.17 |
Add:Netprofitattributabletotheparent | 741,445,013.25 | 1,401,892,593.23 |
Less:Dividendpayableoncommonstock | 342,501,586.40 | 256,876,189.80 |
Other | - | 2,136,956.21 |
RetainedearningsonJune30,2020 | 9,294,088,533.24 | 8,895,145,106.39 |
Adjustthedetailsofundistributedprofitsatthebeginningoftheperiod:
1).duetotheretroactiveadjustmentoftheaccountingstandardsforbusinessenterprisesanditsrelevantnewprovisions,theundistributedprofitatthebeginningoftheperiodwasaffectedby0.00yuan.
2).duetothechangeofaccountingpolicy,theundistributedprofitatthebeginningoftheperiodis0.00yuan.
3).duetothecorrectionofmajoraccountingerrors,theundistributedprofitatthebeginningoftheperiodwasaffectedby0.00yuan.
4).thechangeofconsolidationscopecausedbythesamecontrolaffectstheundistributedprofitatthebeginningoftheperiodby
0.00yuan.
5).thetotalofotheradjustmentsaffectstheundistributedprofitatthebeginningoftheperiodby0.0
VNotestotheconsolidatedfinancialstatements(Continued)
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
44.Operatingrevenueandcost
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Revenue | Cost | Revenue | Cost | |
Principaloperations | 32,841,264,479.56 | 29,156,249,513.96 | 26,944,450,698.03 | 23,953,267,481.54 |
Otheroperations | 321,827,407.83 | 60,587,687.11 | 225,489,490.49 | 17,762,237.90 |
33,163,091,887.39 | 29,216,837,201.07 | 27,169,940,188.52 | 23,971,029,719.44 |
Classification | HeadOffice | Pharmaceuticaldistribution | Pharmaceuticalretail | Eliminationbetweensegments | Total |
Byproduct | |||||
Incl: | |||||
Pharmaceuticals | - | 19,828,394,853.85 | 10,676,855,504.22 | (499,204,175.96) | 30,006,046,182.11 |
Medicaldevicesanddisposables | - | 2,076,206,193.67 | 134,724,521.61 | - | 2,210,930,715.28 |
Diagnosticreagents | - | 515,191,908.40 | - | - | 515,191,908.40 |
Medicalequipments | - | 278,181,437.86 | - | - | 278,181,437.86 |
Others | 4,532,508.37 | 111,779,259.15 | - | (5,938,298.55) | 110,373,468.97 |
Byarea | |||||
Incl: | |||||
China | 4,532,508.37 | 22,809,753,652.93 | 10,811,580,025.83 | (505,142,474.51) | 33,120,723,712.62 |
Bytypesofactivity | |||||
Incl: | |||||
Pharmaceuticaldistribution | - | 21,697,696,043.60 | 1,958,602,731.53 | (499,204,175.96) | 23,157,094,599.17 |
Retailpharmacy | - | 1,000,278,350.18 | 8,852,977,294.30 | - | 9,853,255,644.48 |
Others | 4,532,508.37 | 111,779,259.15 | - | (5,938,298.55) | 110,373,468.97 |
Bycontractduration | |||||
Incl: | |||||
Atapointintime | - | 22,697,974,393.78 | 10,811,580,025.83 | (499,204,175.96) | 33,010,350,243.65 |
Overtime | 4,532,508.37 | 111,779,259.15 | - | (5,938,298.55) | 110,373,468.97 |
4,532,508.37 | 22,809,753,652.93 | 10,811,580,025.83 | (505,142,474.51) | 33,120,723,712.62 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
44.Operatingrevenueandcost(Continued)
InformationabouttheGroup’sperformanceobligationsissummarisedbelow:
(1)Revenueisrecognisedwhencontrolofthegoodshastransferredandpaymentisgenerallyduewithin30to210days
fromdelivery;
(2)Revenueisrecognisedintheservicedurationandthepaymentisgenerallyduewithin30to210dayssincetheserviceis
completed.Informationrelatedtothesalespriceallocatedtotheremainingobligations:
TheamountofincomecorrespondingtotheobligationthathasbeensignedbuthasnotbeenfulfilledorhasnotyetfulfilledisRMB316,827,151.78,whichisexpectedtoberecognizedwithin1year.
Revenueisasfollows:
Forthesixmonthended
30June2021
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Revenuefromcontractswithcustomers | 33,120,723,712.62 | 27,139,718,273.17 | |
Rentals | 42,368,174.77 | 30,221,915.35 |
33,163,091,887.39 | 27,169,940,188.52 |
45.Taxandsurcharges
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Citymaintenanceandconstructiontax | 27,877,507.46 | 28,121,494.67 | |
Educationalsurcharge | 20,257,170.15 | 20,311,577.25 | |
Propertytax | 4,224,163.72 | 2,492,284.79 | |
Landtax | 768,836.09 | 317,162.91 | |
Vehicleandvesselusetax | 85,991.96 | 72,575.73 | |
Stampduty | 21,497,447.37 | 17,140,178.76 | |
Others | 1,278,737.83 | 1,050,035.21 |
75,989,854.58 | 69,505,309.32 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
46.Sellingexpenses
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Employeespayrollandwelfarebenefits | 1,197,067,119.97 | 904,925,594.87 | |
Depreciationexpensesofright-of-useassets | 479,540,503.22 | 387,380,924.52 | |
Rentalexpenses | 117,046,188.52 | 60,573,717.68 | |
Technicalservicefee | 84,303,596.21 | 45,620,729.98 | |
Amortizationoflong-termdeferredexpenses | 69,802,526.37 | 52,138,560.36 | |
Depreciationexpenses | 56,762,708.30 | 43,808,801.59 | |
Transportationcharges | 52,564,735.76 | 51,095,840.37 | |
Utilities | 39,863,463.73 | 34,081,779.59 | |
Officeallowances | 35,013,829.00 | 27,895,774.76 | |
Storageexpenses | 25,614,256.09 | 18,300,237.30 | |
Promotionandmarketingexpenses | 18,804,920.99 | 15,399,693.56 | |
Propertymanagementfee | 16,975,156.97 | 15,659,321.63 | |
Entertainmentexpenses | 14,061,877.53 | 9,358,003.62 | |
Marketdevelopmentfee | 8,168,582.42 | 4,517,975.19 | |
Repairingfees | 7,118,061.32 | 7,147,598.96 | |
Travelallowances | 2,939,453.78 | 1,845,288.42 | |
Conferenceexpenses | 525,946.12 | 292,483.51 | |
Others | 81,312,603.47 | 48,696,492.69 |
2,307,485,529.77 | 1,728,738,818.60 |
47.Administrativeexpenses
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Employeespayrollandwelfarebenefits | 360,049,901.79 | 325,153,640.16 | |
Depreciationexpenses | 17,675,510.90 | 16,351,496.61 | |
Rentalexpenses | 16,196,265.77 | 5,390,672.79 | |
Officeallowances | 14,281,405.19 | 12,677,148.40 | |
Depreciationexpensesofright-of-useassets | 12,957,819.94 | 10,925,364.40 | |
Amortizationofintangibleassets | 11,402,009.79 | 8,991,474.97 | |
Amortizationoflong-termdeferredexpenses | 8,283,676.96 | 6,808,445.06 | |
Entertainmentexpenses | 7,342,000.00 | 4,596,522.19 | |
Technicalservicefee | 6,691,393.49 | 11,527,561.19 | |
Propertymanagementfee | 4,749,071.86 | 3,089,556.70 | |
Vehiclemanagementexpenses | 3,659,483.25 | 3,169,051.19 | |
Travelallowances | 3,444,399.91 | 1,822,634.84 | |
Utilities | 3,107,684.09 | 1,919,161.42 | |
Repairingfees | 2,852,529.46 | 2,898,331.91 | |
Agencyservicefee | 2,841,366.73 | 3,411,279.41 | |
Promotionandmarketingexpenses | 304,402.82 | 2,180,552.03 | |
Others | 16,698,014.76 | 22,374,251.65 |
492,536,936.71 | 443,287,144.92 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
48.Financecosts
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Interestexpenses | 147,057,897.99 | 133,350,510.68 | |
Less:Interestincome | 38,758,729.78 | 65,512,550.22 | |
Cashdiscount | 18,968,417.81 | 20,153,456.44 | |
Exchangesgain/(loss) | (415,927.10) | 47,935.97 | |
Others | 18,328,179.85 | 17,581,389.63 |
107,243,003.15 | 65,313,829.62 |
Abreakdownforinterestincomeisasfollows:
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Cash | 38,758,729.78 | 65,512,550.22 |
49.Otherincomes
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Governmentgrantsrelatedtodailyoperatingactivities | 33,966,095.01 | 25,786,877.95 | |
VATreductionforsmall-scaletaxpayers | 11,566,085.35 | 8,383,678.31 | |
VATadditionaldeduction | 929,058.98 | 864,634.59 | |
Taxationservicechargerefund | 788,376.92 | 820,107.47 |
47,249,616.26 | 35,855,298.32 |
50.Investmentincome
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Long-termequityinvestmentincomeundertheequitymethod | 157,696,397.81 | 133,604,904.16 | |
Dividendincomefromotherequityinvestmentsthatarestillheld | 2,330,159.50 | - | |
Investmentincomefromfinancialassetsatfairvaluethroughprofitorloss | 3,599,555.61 | 4,109,881.90 | |
Investmentincomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | (7,039,046.60) | (33,507,102.64) | |
Others | 998,665.84 |
156,587,066.32 | 105,206,349.26 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
51.Creditimpairmentlosses
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Impairmentlossofotherreceivables | (1,464,818.01) | (1,401,731.20) | |
Impairmentlossofaccountsreceivable | (28,023,731.77) | (20,178,500.32) | |
Impairmentlossofnotesreceivables | 893,564.34 | - | |
Impairmentlossofothernon-currentfinancialassets | (70,000.00) | - |
(28,664,985.44) | (21,580,231.52) |
52.Impairmentlosses
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Lossfromwrite-downofinventories | (318,356.71) | (1,743,888.30) | |
Lossfromimpairmentofcontractassets | (60,342.41) | - | |
Lossfromimpairmentofothernon-currentassets | (38,216.14) | - |
(416,915.26) | (1,743,888.30) |
53.Gainondisposalofassets
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Gainondisposalofright-of-useassets | (505,084.56) | 3,971,813.20 | |
Gainondisposaloffixedassets | (83,714.99) | 333,511.60 |
(588,799.55) | 4,305,324.80 |
54.Non-operatingincome
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 | Amountclassifiedasnon-recurringprofitorloss |
Governmentgrants | 1,349,204.28 | 1,349,204.28 | 1,349,204.28 | |
Gainondisposalofnon-currentassets | 60,184.80 | 2,171.01 | 60,184.80 | |
Gainfromwritingofftheunnecessarypayment | 7,298,605.35 | 199,266.47 | 7,298,605.35 | |
Others | 3,785,326.01 | 3,669,338.46 | 3,789,726.01 |
12,493,320.44 | 5,219,980.22 | 12,493,320.44 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
54.Non-operatingincome(Continued)
Governmentgrantsincludedincurrentperiodprofitorloss:
ProjectName | GovernmentDepartment | ReasonsforGovernmentgrants | Type | Affectstheprofitorlossofthisyear | Specialsubsidy | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 | Relatedtoasset/income |
ResettlementCompensationofNo.7ZhongyaoRoad | NanningEconomic&TechnologicalDevelopmentAreaManagementCommittee | Subsidy | Subsidiesfromlocalgovernmentforsupportpoliciessuchasattractinginvestment | Yes | No | 1,349,204.28 | 1,349,204.28 | Assetrelated |
55.Non-operatingexpenses
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 | Amountclassifiedasnon-recurringprofitorloss |
Donationexpenses | 158,990.50 | 527,677.41 | 158,990.50 | ||
Lossesarisingfromdamageandobsolescenceofnon-currentassets | 273,414.36 | 373,790.44 | 273,414.36 | ||
Penaltyexpenses | 1,220,928.37 | 467,582.50 | 1,220,928.37 | ||
Others | 1,584,618.12 | 1,639,842.17 | 1,584,618.12 |
3,237,951.35 | 3,008,892.52 | 3,237,951.35 |
56.Incometaxexpenses
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Currentincometax | 248,326,505.55 | 213,477,221.94 | |
Deferredincometax | (9,900,246.51) | (3,370,457.59) |
238,426,259.04 | 210,106,764.35 |
Thereconciliationfromincometaxcalculatedbasedonapplicabletaxratesandtotalprofitpresentedintheconsolidatedfinancialstatementstotheincometaxesislistedbelow:
Forthesixmonthended30June2021
Forthesixmonthended30June2021Profitbeforeincometax
Profitbeforeincometax | 1,146,420,713.53 |
Taxattheapplicabletaxrate | 286,605,178.38 |
Effectofdifferenttaxratesforsomesubsidiaries | (27,341,828.05) |
Adjustmentsinrespectofcurrenttaxofpreviousperiods | 9,250,796.99 |
Incomenotsubjecttotax | (39,424,099.45) |
Expensesnotdeductiblefortax | 5,188,447.29 |
Unrecogniseddeductibletemporarydifferencesandtaxlosses | 4,147,763.88 |
Incometax | 238,426,259.04 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
57.Notestoitemsinthecashflowstatement
(1) | Othercashreceiptsrelatingtooperatingactivities |
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Receivedthespecialemergencyreservefund | - | 330,000,000.00 | |
Rentincome | 42,368,174.77 | 30,221,915.35 | |
Interestincome | 38,758,729.78 | 65,499,031.75 | |
Receivedothergovernmentgrantsexcepttaxrefund | 35,612,619.03 | 28,018,379.40 | |
Others | 251,851,351.88 | 253,462,783.50 |
368,590,875.46 | 707,202,110.00 |
(2) | Othercashpaymentsrelatingtooperatingactivities |
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Rentalexpenses | 133,233,956.70 | 65,964,390.47 | |
Transportationcharges | 52,564,735.76 | 51,095,840.37 | |
Officeexpenses | 49,295,234.19 | 40,572,923.16 | |
Utilities | 42,971,147.82 | 36,000,941.01 | |
Storageexpenses | 25,614,256.09 | 18,300,237.30 | |
Entertainmentexpenses | 21,403,877.53 | 13,954,525.81 | |
Advertisingexpenses | 19,109,323.81 | 17,580,245.59 | |
Travelexpenses | 6,383,853.69 | 3,667,923.26 | |
Others | 582,203,811.77 | 456,537,231.52 |
932,780,197.36 | 703,674,258.49 |
(3) | Othercashreceiptsrelatingtoinvestingactivities |
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Receivedfromcapitalpool(1) | - | 22,000,000.00 | |
Others | 54,984.60 | 40,000.00 |
54,984.60 | 22,040,000.00 |
(1)PudongPharmaceuticals,asubsidiaryofthemergerofenterprisesunderthecommoncontrolofGuodaPharmacyin
2020,andrecoveredthefundsoriginallycollectedtothecashpoolinthesameperiodin2020.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
57.Notestoitemsincashflowstatement(Continued)
(4) | Othercashreceiptsrelatingtofinancingactivities |
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Receivedloanprovidedbyminorityshareholders | 69,150,000.00 | 149,900,000.00 | |
Financingrestrictedmonetaryfundsreceived | 34,940,555.62 | 128,449,840.06 | |
ReceivedloanprovidedbySinmpharm | - | 56,000,000.00 |
104,090,555.62 | 334,349,840.06 |
(5) | Othercashpaymentsrelatingtofinancingactivities |
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Leasepayment | 536,275,009.28 | 466,492,796.45 | |
Bankfactoringpayable | 251,370,239.59 | 281,994,828.44 | |
Repaymentoftheloanprovidedbyminorityshareholders | 50,400,000.00 | 304,000,000.00 | |
InvestmentfundofShanghaiPudongPharmaceuticals | - | 163,115,049.98 | |
RepaymentoftheloanprovidedbySinmpharm | - | 114,000,000.00 | |
Purchaseofequityofminorityshareholders | - | 52,309,117.11 | |
Others | - | 23,199,872.28 |
838,045,248.87 | 1,405,111,664.26 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
58.Supplementaryinformationofcashflowstatement
(1) | Reconciliationofnetprofittocashflowsfromoperatingactivities |
Forthesixmonthended30June2021 | Forthesixmonthended30June2020 |
Netprofit | 907,994,454.49 | 806,212,542.53 |
Add:Provisionsforassetimpairment | 29,081,900.70 | 23,324,119.82 |
Depreciationoffixedassets | 78,401,603.02 | 61,147,847.16 |
Depreciationofright-of-useassets | 493,632,821.29 | 388,208,804.99 |
Amortizationofintangibleassets | 30,503,457.69 | 22,955,311.98 |
Amortizationoflong-termprepaidexpenses | 79,098,080.34 | 51,031,038.60 |
Gains/(losses)ondisposaloffixedassets,intangibleassetsandotherlong-termassets | 588,799.55 | (4,658,628.06) |
Lossefromobsolescenceofnon-currentassets | 213,229.56 | 371,619.43 |
Financeexpenses | 126,395,365.24 | 124,862,298.31 |
Investmentlosses | (156,587,066.32) | (105,206,349.26) |
(Increase)/decreaseindeferredtaxassets | (10,036,816.58) | (1,027,041.92) |
(Decrease)/increaseindeferredtaxliabilities | 417,984.79 | (2,343,415.67) |
Decreaseininventories | (868,988,935.78) | (85,043,215.49) |
Increaseinoperatingreceivablesitems | (3,060,847,945.57) | (2,023,296,252.84) |
(Decrease)/increaseinoperatingpayableitems | 3,561,205,596.30 | (133,395,115.40) |
Others | 18,300,754.85 | 2,315,060,479.17 |
Netcashgeneratedfromoperatingactivities | 1,229,373,283.57 | 1,438,204,043.35 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
58.Supplementaryinformationofcashflowstatement(Continued)
(2) | Movementofcash |
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Cashattheendoftheperiod | 5,537,606,217.43 | 8,000,562,022.16 |
Less:Cashatthebeginningoftheperiod | 5,405,113,257.99 | 8,426,071,170.16 |
Netincreaseincash | 132,492,959.44 | (425,509,148.00) |
(3)
Forthesixmonthsended
30June2021
Forthesixmonthsended
30June2021Cashandcashequivalentspaidforacquisitionsofsubsidiariesandotheroperatingunits
Cashandcashequivalentspaidforacquisitionsofsubsidiariesandotheroperatingunits | 129,668,139.12 |
Incl:YunnanGuodaDishengPharmaceuticalCo.,Ltd.(“DishengPharmaceutical) | 14,130,000.00 |
DishengChain. | 71,400,000.00 |
32directly-operatedstoresofShanxiHuimingkangweiPharmaceuticalChainCo.,Ltd. | 30,000,000.00 |
15directly-operatedstoresofSinopharmHoldingNantongPujiPharmacyChainCo.,Ltd. | 14,138,139.12 |
Less:Cashandcashequivalentsheldbysubsidiariesandotheroperatingunitsattheacquisitiondate | 28,717,501.71 |
Incl:DishengPharmaceutical | 7,723,702.95 |
DishengChainCo.,Ltd. | 20,993,798.76 |
Netcashoutflow/(inflow)onacquisitionofthesubsidiariesandotheroperatingunits | 100,950,637.41 |
(4) | Cashandcashequivalent |
30June2021 | 31December2020 |
Cash | 5,537,606,217.43 | 5,405,113,257.99 |
Inclue:Cashonhand | 4,898,795.54 | 6,707,125.90 |
Bankdepositsondemand | 5,532,707,421.89 | 5,398,406,132.09 |
Endingbanlancecashandcashequivalent | 5,537,606,217.43 | 5,405,113,257.99 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)
59.Assetsunderrestrictedownershiporrightofuse
Bookvalue | Reasons |
Cashandcashequivalents | 338,186,269.94 | Note1 | |
Endorsednotesreceivableandreceivablefinancing | 20,196,089.49 | Note2 |
Note1:Asat30June2021,thetheGroup’scashandcashequivalentswithabookvalueofRMB338,186,269.94(December31,2020:RMB593,091,037.88)aremainlydepositsforbankacceptancebills,freezingoffundsandmedicalreservefunds,etc.Note2:Asat30June2021,theGrouphadreceivablesfinancingofRMB20,070,999.69andnotesreceivableofRMB125,089.80,endorsedbutnotdue(31December2020:receivablesfinancingofRMB23,843,867.66andnotesreceivableofRMB4,095,283.92)
60.Governmentgrants
358,382,359.43Type
Type | Amount | Itemsoffinancialstatements | Theamountrecordedintoprofitorlossforthecurrentperiod |
Taxreturn | 12,016,071.91 | Otherincome | 12,016,071.91 |
Stabilitationallowances | 11,572,570.54 | Otherincome/Deferredincome | 11,572,570.54 |
Constructionfundofthemodernsupplychainsysteminthecentralcirculationfieldin2018 | 2,143,819.51 | Otherincome/Deferredincome | 2,143,819.51 |
SubsidiesfromfoodandstrategicreservesadministrationofGuangdongprovince | 1,946,573.87 | Otherincome | 1,946,573.87 |
MedicalReserveSubsidiesfromShenzhenmunicipalhealthcommission | 1,437,149.37 | Otherincome | 1,437,149.37 |
Governmentsupportfund | 1,361,117.00 | Otherincome | 1,361,117.00 |
ResettlementCompensationofNo.7ZhongyuRoad | 1,349,204.28 | Non-operatingincome/Deferredincome | 1,349,204.28 |
EnterpriseEconomicReward | 733,317.46 | Otherincome/Deferredincome | 733,317.46 |
GovernmentgrantsforCOVID-19 | 422,595.35 | Otherincome | 422,595.35 |
VATreductionorexemptionforself-employmentretiredsoldiers | 300,870.00 | Otherincome | 300,870.00 |
Guangzhoulogisticsstandardizationpilotprojectallowance | 273,123.42 | Otherincome/Deferredincome | 273,123.42 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VNotestotheconsolidatedfinancialstatements(Continued)60Governmentgrants(Continued)
Type | Amount | Itemsoffinancialstatements | Theamountrecordedintoprofitorlossforthecurrentperiod |
Specialfundsforindustrialtransformationandupgradingindualizedintegrationprojects | 224,520.24 | Otherincome/Deferredincome | 224,520.24 |
RentsubsidyfromGuangzhouHigh-techIndustrialDevelopmentZone | 216,700.85 | Otherincome | 216,700.85 |
ServiceIndustryEnterpriseMarketDevelopmentSubsidyProjectinNanning | 200,000.00 | Otherincome | 200,000.00 |
SubsidyfundformedicinereserveinFoshan | 150,000.00 | Otherincome | 150,000.00 |
Comprehensiveexperimentalmodernserviceindustrysubsidies | 150,000.00 | Otherincome/Deferredincome | 150,000.00 |
LogisticsprojectconstructionsupportfundfromNanningeconomicdevelopmentcommittee | 93,203.22 | Otherincome/Deferredincome | 93,203.22 |
Fundsforthelogisticsinformationplatformprojectofthepharmaceuticalstoragecentre | 71,428.56 | Otherincome/Deferredincome | 71,428.56 |
Guangzhouspecialsubsidyforcommerceandtradecirculationindustry | 50,000.04 | Otherincome/Deferredincome | 50,000.04 |
SpecialFundfortheconstructionofEnterpriseResearchanddevelopmentInstitutionsinGuangzhou | 44,705.94 | Otherincome/Deferredincome | 44,705.94 |
HousepurchasesubsidyfromthegovernmentofTiexiDistrict,Shenyang | 40,561.32 | Otherincome/Deferredincome | 40,561.32 |
SubsidyforindustrializationapplicationprojectofpharmaceuticalcoldchainpatentincubatorfromGuangzhouliwandistrict | 12,499.98 | Otherincome/Deferredincome | 12,499.98 |
Medicalintelligentsupplychaine-commerceserviceplatformtechnologyprojectsubsidyfromGuangzhouliwandistrict | 9,861.24 | Otherincome/Deferredincome | 9,861.24 |
Othergovernmentgrants | 543,447.58 | Otherincome/Financecosts/Administrative/Sellingexpenses/Deferredincome | 543,447.58 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VI.Changesinscopeofconsolidation
1.Businesscombinationnotinvolvingenterprisesundercommoncontrol
1.1AcquiringDishengPharmaceutical.AndDishengchain
Acquiree | Thedateofacquiringtheright | Acquistioncostoftheright | ProportionofrightsownedbytheGroup | Methodsofacquisitiontheright | Acquisitiondate | Thebasisfordeterminingthedateofpurchase | Incomeearnedfromtheacquisitiondateto30June2021 | Netprofitearnedfromtheacquisitiondateto30June2021 |
DishengPharmaceutical(a) | 15March2021 | 14,130,000.00 | 70.00% | Acquisition | 15March2021 | Thepurchaseractuallyacquirescontrolovertheacquiredcompany | 88,507,060.89 | 964,797.79 |
DishengchainCo.,Ltd.(b) | 15March2021 | 238,000,000.00 | 70.00% | Acquisition | 15March2021 | Thepurchaseractuallyacquirescontrolovertheacquiredcompany | 116,656,427.71 | 12,161,419.65 |
Additionalclarification:
(a)GuodaPharmacy,asubsidiaryoftheCompany,acquired70%sharesofDishengPharmaceuticalfromXishuangbannaDishengPharmaceuticalCo.,LtdbyRMB14,130,000.00.Theacquisitionwascompletedon15March2021.(b)GuodaPharmacy,asubsidiaryoftheCompany,acquired70%sharesofDishengchainfromXishuangbannaDishengPharmaceuticalCo.,LtdbyRMB238,000,000.00.Theacquisitionwascompletedon15March2021.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VI.Changesinscopeofconsolidation(Continued)
1.Businesscombinationsnotinvolvingenterprisesundercommoncontrol(Continued)
1.2Acquisitioncostsandgoodwillarisingfromacquisition
Acquisitioncosts | DishengPharmaceutical | Dishengchain |
Cash | 14,130,000.00 | 238,000,000.00 |
Acquisitioncosts | 14,130,000.00 | 238,000,000.00 |
Less:thefairvaluesofacquiredidentifiablenetassets | 14,708,610.41 | 85,842,064.48 |
Goodwillarisingfromacquisition/Acquisitioncostsexceedingthefairvaluesofacquiredidentifiablenetassets | (578,610.41) | 152,157,935.52 |
Thefairvalueofthecostofacquisitionisrecognizedaccordingtothepriceactuallypaid.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VI.Changesinscopeofconsolidation(Continued)
1.Businesscombinationsnotinvolvingenterprisesundercommoncontrol(Continued)
1.3Thefairvaluesofacquiredidentifiableassetsandliabilitiesontheacquisitiondate
DishengPharmaceutical | Dishengchain | ||
Fairvalue | Carryingamount | Fairvalue | Carryingamount |
Cashandbankbalances | 7,723,702.95 | 7,723,702.95 | 20,993,798.76 | 20,993,798.76 |
Accountsreceivable | 30,471,781.24 | 30,471,781.24 | 23,414,107.18 | 23,414,107.18 |
Inventories | 19,829,957.32 | 19,829,957.32 | 45,829,051.06 | 45,829,051.06 |
Fixedassets | 1,335,373.90 | 1,335,373.90 | 2,000,261.19 | 2,000,261.19 |
Intangibleassets | - | - | 40,661,415.51 | 221,415.51 |
Advancestosuppliers | 2,318,717.10 | 2,318,717.10 | 91,212.94 | 91,212.94 |
Otherreceivables | 2,129,844.69 | 2,129,844.69 | 3,414,254.84 | 3,414,254.84 |
Othercurrentassets | 5,329,820.93 | 5,329,820.93 | 4,627,358.05 | 4,627,358.05 |
Long-termprepaidexpenses | 724,925.12 | 724,925.12 | 7,783,811.55 | 7,783,811.55 |
Right-of-useassets | - | - | 41,047,873.29 | 41,047,873.29 |
Deferredtaxassets | 31,947.59 | 31,947.59 | 249,467.13 | 249,467.13 |
Accountspayable | 47,041,828.70 | 47,041,828.70 | 13,321,430.50 | 13,321,430.50 |
Deferredtaxliabilities | - | - | 6,066,000.00 | - |
Contractliabilities | 123,430.92 | 123,430.92 | 1,818,156.15 | 1,818,156.15 |
Employeebenefitspayable | 490,428.65 | 490,428.65 | 5,316,750.15 | 5,316,750.15 |
Taxpayable | 408,921.64 | 408,921.64 | 5,707,308.60 | 5,707,308.60 |
Otherpayables | 819,160.34 | 819,160.34 | 7,477,165.09 | 7,477,165.09 |
Non-currentliabilitiesduewithinoneyear | - | - | 15,482,505.32 | 15,482,505.32 |
Leaseliabilities | - | - | 12,291,775.00 | 12,291,775.00 |
Netassets | 21,012,300.59 | 21,012,300.59 | 122,631,520.69 | 88,257,520.69 |
Less:equityofminorityshareholders | 6,303,690.18 | 6,303,690.18 | 36,789,456.21 | 26,477,256.21 |
Netassetsacquired | 14,708,610.41 | 14,708,610.41 | 85,842,064.48 | 61,780,264.48 |
Methodsfordeterminingthefairvalueofidentifiableassetsandliabilities:
Itisrecognizedaccordingtotheappraisal.
VI.Changesinscopeofconsolidation(Continued)
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
2.Others
2.1Acquisitionofthemanagementrightof15directly-managedstoresofSinopharmholding
NantongPujipharmacychainCo.,Ltd.(hereafterreferdas“NantongPuji”)YangzhouGuoda,asubsidiaryoftheCompany,obtained15directly-managedstoresofNantongPujiwithcashofRMB14,138,139.12.Theacquisitiondateisdeterminedas2March2021.Aftertheacquisition,goodwillofRMB11,498,100.00wasformed.Thefairvaluesandcarryingamountsofidentifiableassetsandliabilitiesof15directly-managedstoresofNantongPujiontheacquisitiondatearepresentedasfollows:
NantongPuji | 2March2021 | 2March2021 | |
Fairvalue | Carryingamount |
Fixedassets | 788,300.00 | 788,300.00 | |
Inventories | 1,751,439.12 | 1,751,439.12 | |
Long-termprepaidexpenses | 100,300.00 | 100,300.00 | |
Total | 2,640,039.12 | 2,640,039.12 | |
Pricepaid | 14,138,139.12 | 14,138,139.12 | |
Goodwillarisingfromacquisition | 11,498,100.00 | 11,498,100.00 |
Operatingresultsandcashflowsof15directly-managedstoresofNantongPujifortheperiodfromtheacquisitiondatetotheendoftheJunearepresentedasfollows:
2March2021to30June2021Operatingrevenue
Operatingrevenue | 7,016,410.53 | |
Netprofit | 303,795.13 | |
cashflowsfromoperatingactivities | 871,784.36 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VI.Changesinscopeofconsolidation(Continued)
2.Others(Continued)
2.2Acquisitionofthemanagementrightof32directly-managedstoresofShanxiHuiminKangwei
pharmacychainCo.,Ltd.(hereafterreferdas“ShanxiHuiminKangweipharmacy”)GuodaWanminHuiminKangweipharmacyLuliangCo.,Ltd.(hereafterreferdas“HuiminLvliang”),asubsidiaryoftheCompany,obtained32directly-managedstoresofShanxiHuiminKangweipharmacywithcashofRMB30,000,000.00.Theacquisitiondateisdeterminedas8February2021.Aftertheacquisition,goodwillofRMB20,970,000.00wasformed.Thefairvaluesandcarryingamountsofidentifiableassetsandliabilitiesof32directly-managedstoresofShanxiHuiminKangweipharmacyontheacquisitiondatearepresentedasfollows:
ShanxiHuiminKangweipharmacy | 8February2021 | 8February2021 | |
Fairvalue | Carryingamount |
Fixedassets | 1,740,000.00 | 1,740,000.00 | |
Inventories | 7,290,000.00 | 7,290,000.00 | |
Total | 9,030,000.00 | 9,030,000.00 | |
Pricepaid | 30,000,000.00 | 30,000,000.00 | |
Goodwillarisingfromacquisition | 20,970,000.00 | 20,970,000.00 |
Operatingresultsandcashflowsof32directly-managedstoresofShanxiHuiminKangweipharmacyfortheperiodfromtheacquisitiondatetotheendoftheJunearepresentedasfollows:
8February2021to30June2021Operatingrevenue
Operatingrevenue | 15,240,595.69 | |
Netprofit | 292,600.01 | |
cashflowsfromoperatingactivities | 209,519.17 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIInterestsinotherentities
1.Interestsininsubsidiaries
(1) | ThecompositionoftheGroup: |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect |
SinopharmGuilin | Guilin | Guilin | Commercial | - | 100.00% | Establishment |
SinopharmBaise | Baise | Baise | Commercial | - | 100.00% | Establishment |
SinopharmHoldingZhongshanCo.,Ltd. | Zhongshan | Zhongshan | Commercial | - | 100.00% | Establishment |
SinopharmGuigang | Guigang | Guigang | Commercial | - | 100.00% | Establishment |
SinopharmBeihai | Beihai | Beihai | Commercial | - | 100.00% | Establishment |
SinopharmHoldingGuangzhouMedicalTreatment | Guangzhou | Guangzhou | Commercial | - | 51.00% | Establishment |
SinopharmHoldingShenzhenJianminCo.,Ltd.(hereafterreferedas"SinopharmShenzhenJianmin") | Shenzhen | Shenzhen | Commercial | 100.00% | - | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmHoldingShenzhenTraditional&HerbalMedicineCo.,Ltd.(hereafterreferdas“SinopharmTraditional&HerbalMedicine") | Shenzhen | Shenzhen | Commercial | 100.00% | - | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmHoldingShenzhenLogisticsCo.,Ltd.(hereafterreferedas“SinopharmShenzhenLogistics") | Shenzhen | Shenzhen | Services | 100.00% | - | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmGuangzhou | Guangzhou | Guangzhou | Commercial | 100.00% | - | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmHoldingGuangdongHengxingCo.,Ltd. | Guangzhou | Guangzhou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmYulin | Yulin | Yulin | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect | |||||
SinopharmLiuzhou | Liuzhou | Liuzhou | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
GuangdongHuixinInvestmentCo.,Ltd. | Guangzhou | Guangzhou | Service | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
SinopharmHoldingFoshanCo.,Ltd. | Foshan | Foshan | Commercial | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
SinopharmHoldingGuangdongYuexingCo.,Ltd.(hereafterreferedas“SinopharmGuangdongYuexing”) | Guangzhou | Guangzhou | Commercial | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
SinopharmHoldingGuangdongLogisticsCo.,Ltd. | Guangzhou | Guangzhou | Service | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
SinopharmGuangxi | Nanning | Nanning | Commercial | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
GuangxiLogistic | Nanning | Nanning | Service | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
SinopharmWuzhou | Wuzhou | Wuzhou | Commercial | 99.90% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
SinopharmDongguan | Dongguan | Dongguan | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmZhanjiang | Zhanjiang | Zhanjiang | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmYanfeng | Shenzhen | Shenzhen | Commercial | 51.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmMeizhou | Meizhou | Meizhou | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmHuizhou | Huizhou | Huizhou | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmZhaoqing | Zhaoqing | Zhaoqing | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
SinopharmJiangmen | Jiangmen | Jiangmen | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
SinopharmShaoguan | Shaoguan | Shaoguan | Commercial | - | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
SinopharmHoldingShantouCo.,Ltd | Shantou | Shantou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
FoshanNanhai | Foshan | Foshan | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
FoshanNanhaiUptodate&SpecialMedicinesCo.,Ltd. | Foshan | Foshan | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
FoshanNanhaiMedicineCo.,Ltd. | Foshan | Foshan | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmHoldingGuangdongDongFangUptodate&SpecialMedicinesCo.,Ltd.(a) | Guangzhou | Guangzhou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SouthPharma&Trade | Guangzhou | Guangzhou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmZhuhai | Zhuhai | Zhuhai | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
SinopharmMaoming | Maoming | Maoming | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect | |||||
SinopharmHoldingGZMedicalTechnologyCo.,Ltd. | Guangzhou | Guangzhou | Commercial | - | 51.00% | Establishment |
SinopharmHoldingGZMedicalSupplyChainServiceCo.,Ltd. | Guangzhou | Guangzhou | Commercial | - | 51.00% | Establishment |
SinopharmHoldingHeyuanCo.,Ltd. | Heyuan | Heyuan | Commercial | - | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
GuodaPharmacy | Shanghai | Shanghai | Commercial | 60.00% | - | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiGuoda. | Shanghai | Shanghai | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
BeijingGuodaPharmacyChainStoreCo.,Ltd. | Beijing | Beijing | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
TianjinGuodaPharmacyChainStoreCo.,Ltd. | Tianjin | Tianjin | Commercial | - | 80.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
GuangxiConsulting | Nanning | Nanning | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmHoldingGuodaPharmacyGuangdongCo.,Ltd. | Shenzhen | Shenzhen | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
GuangxiGuoda | Liuzhou | Liuzhou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ZhejiangGuoda | Hangzhou | Hangzhou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
YangzhouGuoda | Yangzhou | Yangzhou | Commercial | - | 93.68% | Businesscombinationsinvolvingentitiesundercommoncontrol |
NingxiaGuoda | Yinchuan | Yinchuan | Commercial | - | 70.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
NanjingGuoda | Nanjing | Nanjing | Commercial | - | 60.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShandongGuoda | Linyi | Linyi | Commercial | - | 55.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShenyangGuoda | Shenyang | Shenyang | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
FujianChain | Xiamen | Xiamen | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
AnhuiGuodaPharmacyChainStoreCo.,Ltd. | Hefei | Hefei | Commercial | - | 60.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
QuanzhouGuoda | Quanzhou | Quanzhou | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanxiGuodaWanmin | Taiyuan | Taiyuan | Commercial | - | 85.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
HunanGuoda | Hengyang | Hengyang | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
LiyangGuoda | Liyang | Liyang | Commercial | - | 80.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
HenanGuoda | Pingdingshan | Pingdingshan | Commercial | - | 60.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
InnerMongoliaGuoda | Hohhot | Hohhot | Commercial | - | 96.70% | Businesscombinationsinvolvingentitiesundercommoncontrol |
HebeiLerentang | Shijiazhuang | Shijiazhuang | Commercial | - | 60.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect | |||||
JiangmenGuoda | Jiangmen | Jiangmen | Commercial | - | 65.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanxiGuodaYiyuan | Taiyuan | Taiyuan | Commercial | - | 80.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
XinjiangGuoda | Urumqi | Urumqi | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ForMeMedicines | Shanghai | Shanghai | Commercial | - | 97.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiForMeYiXingPharmacyChainStoreCo.,Ltd. | Shanghai | Shanghai | Commercial | - | 99.76% | Businesscombinationsinvolvingentitiesundercommoncontrol |
BeijingGoldenElephant | Beijing | Beijing | Commercial | - | 53.13% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanxiTongfengPharmacyLogisticsCo.,Ltd. | Taiyuan | Taiyuan | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ChangzhiWanmin | Changzhi | Changzhi | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanxiGuodaWanminClinicManagementChainCo.,Ltd. | Taiyuan | Taiyuan | Medicalservices | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiGuodaShanghongQibaoPharmacyCo.,Ltd. | Shanghai | Shanghai | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ZhejiangIntlmedicinePharmacyDongshanCo.,Ltd. | Hangzhou | Hangzhou | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiDongshengGuoda | Shanghai | Shanghai | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmGuodaDrugStore(Shenzhen)ChainCo.,Ltd. | Shenzhen | Shenzhen | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
GuodaGuangzhouChain | Guangzhou | Guangzhou | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiGuodongChineseTraditionalMedicineClinicCo.,Ltd. | Shanghai | Shanghai | Medicalclinic | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiGuodaDongxinPharmacyChainStoreCo.,Ltd. | Shanghai | Shanghai | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ShanghaiYutaitangChineseTraditionalMedicineClinicCo.,Ltd. | Shanghai | Shanghai | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SanheLiyangGoldenElephantPharmacyCo.,Ltd. | Langfang | Langfang | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
XiaoyiWanmin | Xiaoyi | Xiaoyi | Commercial | - | 70.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
InnerMongoliaHulunBuirGuoda | HulunBuir | HulunBuir | Commercial | - | 51.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ForMeXuhui | Shanghai | Shanghai | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
InnerMongoliaUlanqabGuoda. | Ulanqab | Ulanqab | Commercial | - | 60.00% | Establishment |
TaishanGuoda | Taishan | Taishan | Commercial | - | 70.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
SinopharmLerentangShijiazhuangPharmaceutical | Shijiazhuang | Shijiazhuang | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol |
ManchuriaGuoda | Manchuria | Manchuria | Commercial | - | 51.00% | Establishment |
SinopharmGuodaDrugStoreAnshanChainCo.,Ltd. | Anshan | Anshan | Commercial | - | 51.00% | Establishment |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect | |||||
SinopharmHoldingGuodaYongshengDrugStore(Shanghai)Co.,Ltd. | Shanghai | Shanghai | Commercial | - | 55.00% | Establishment |
SinopharmHoldingFoshanMedicalConsumablesSupplyChainCo.,Ltd. | Foshan | Foshan | Commercial | - | 70.00% | Establishment |
SinopharmGuangxiSupplyChain | Nanning | Nanning | Commercial | - | 30.60% | Establishment |
ShanghaiHaohaiGuoda | Shanghai | Shanghai | Commercial | - | 51.00% | Establishment |
SinopharmBaiyiPharmacy | Nanning | Nanning | Commercial | - | 51.00% | Establishment |
SinopharmHezhou | Hezhou | Hezhou | Commercial | - | 100.00% | Establishment |
SinopharmHoldingNationalPharmacyZhengzhouChainCo.,Ltd. | Zhengzhou | Zhengzhou | Commercial | - | 60.00% | Establishment |
ShanghaiRuijingGuoda | Shanghai | Shanghai | Commercial | - | 55.00% | Establishment |
FujianGuodaPharmaceuticalCo.,Ltd. | Xiamen | Xiamen | Commercial | - | 100.00% | Establishment |
SinopharmQinzhou | Qinzhou | Qinzhou | Commercial | - | 100.00% | Establishment |
SinopharmHechi | Hechi | Hechi | Commercial | - | 100.00% | Establishment |
SinopharmHoldingGuangzhouHuaduCo.,Ltd. | Guangzhou | Guangzhou | Commercial | - | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
SinopharmHoldingGuodaShanxiPharmaceuticalCo.,Ltd. | Taiyuan | Taiyuan | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
TaiyuanTongxinliGuodaPharmacyCo.,Ltd. | Taiyuan | Taiyuan | Commercial | - | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
Bayannaoer | Bayannaoer | Bayannaoer | Commercial | - | 80.00% | Establishment |
GuodaInnerMongoliaPharmaceutical | Hohhot | Hohhot | Commercial | - | 100.00% | Establishment |
SinopharmHoldingGuodaYongxingtangChain(Chaoyang)Co.,Ltd. | Chaoyang | Chaoyang | Commercial | - | 51.00% | Establishment |
SinopharmAccordMedicalDevices(Shenzhen)Co.,Ltd(b)(“AccordDevices”) | Shenzhen | Shenzhen | Commercial | 60.00% | Establishment | |
SinopharmHoldingGuozhiPharmacy(Heyuan)Co.,Ltd. | Heyuan | Heyuan | Commercial | 70.00% | Establishment | |
LiaoningGuodaPharmaceuticalCo.,Ltd. | Shenyang | Shenyang | Commercial | 100.00% | Establishment | |
SinopharmHoldingGuangyiHealthManagement(Zhanjiang)Co.,Ltd. | Zhanjiang | Zhanjiang | Commercial | 60.00% | Establishment | |
GuangzhouMedicine | Guangzhou | Guangzhou | Commercial | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
Guodapharmacy(Chaoyang)RenaiCo.,Ltd. | Chaoyang | Chaoyang | Commercial | 51.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
GuodaPu’erSongmao | Puer | Puer | Commercial | 60.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
ShanghaiDingqun | Shanghai | Shanghai | Medicalservices | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmHoldingTianheJilinPharmaceuticalCo.,Ltd. | Changchun | Changchun | Commercial | 85.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
JilinYihe | Changchun | Changchun | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
JilinDonglongMedicalLogistisdistributionCo.,Ltd. | Changchun | Changchun | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
YushuDingheMedicalTechnologyCo.,Ltd. | Changchun | Changchun | Commercial | 51.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect | |||||
GuodapharmacyJilinCo.,Ltd.(c) | Changchun | Changchun | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
YanjiXiangheMedicalCo.,Ltd. | Yanji | Yanji | Commercial | 51.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
PudongPharmaceuticals | Shanghai | Shanghai | Commercial | 75.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
ShanghaiYanghetangPharmaceuticalChainManagementCo.,Ltd. | Shanghai | Shanghai | Commercial | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
ShanghaiPudongYanghetangTCMClinicCo.,Ltd. | Shanghai | Shanghai | Commercial | 100.00% | Businesscombinationsinvolvingentitiesundercommoncontrol | |
GuodaPharmacy(Rizhao)Co.,Ltd. | Rizhao | Rizhao | Commercial | 100.00% | Establishment | |
LiaoningHealthPharmacy | Shenyang | Shenyang | Commercial | 100.00% | Establishment | |
BeijingJinxiangGuoxingpharmaceuticalchainCo.,Ltd. | Beijing | Beijing | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
SinopharmAccord(Yangjiang)MedicineCo.,Ltd. | Yangjiang | Yangjiang | Commercial | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
LiaoningGuodapharmacy | Dalian | Dalian | Commercial | 100.00% | Establishment | |
LiaoningHuludaoGuodapharmacyCo.,Ltd(d) | Huludao | Huludao | Commercial | 100.00% | Establishment | |
JinzhongYuciGuodaWanminclinicCo.,Ltd | Jinzhong | Jinzhong | Commercial | 100.00% | Establishment | |
GuodaJianfeng(Jiangmen)pharmaceuticalchainCo.,Ltd | Jiangmen | Jiangmen | Commercial | 51.00% | Establishment | |
ChengdaFangyuanPharmaceuticalGroupCo.,Ltd | Shenyang | Shenyang | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
ShandongChengdaFangyuanpharmaceuticalchainCo.,Ltd | Qingdao | Qingdao | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
LiaoningChengdaFangyuanpharmaceuticalchainCo.,Ltd | Shenyang | Shenyang | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
LiaoningZhichengXingdaadvertisingmediaCo.,Ltd | Benxi | Benxi | Medicalservices | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
ChengdaFangyuan(Liaoning)newdrugspecialdrugchainCo.,Ltd | Shenyang | Shenyang | Commercial | 80.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
LiaoningChengdaFangyuanvocationalandtechnicaltrainingschool | Shenyang | Shenyang | Medicalservices | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Subsidiaries | Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding | Waysofacquisition | |
Direct | Indirect | |||||
LiaoningChengdaFangyuanPharmaceuticalCo.,Ltd | Shenyang | Shenyang | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
DalianZhengdaPharmaceuticalCo.,Ltd | Dalian | Dalian | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
HebeiChengdaFangyuanpharmaceuticalchainCo.,Ltd | Qnghuangdao | Qnghuangdao | Commercial | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
LiaoningChengdaFangyuanPharmaceuticalLogisticsCo.,Ltd | Shenyang | Shenyang | Medicalservices | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
LiaoningChengdaFangyuanLogisticsCo.,Ltd | Shenyang | Shenyang | Medicalservices | 100.00% | Businesscombinationsinvolvingentitiesnotundercommoncontrol | |
JilinChengdaFangyuanPharmaceuticalCo.,Ltd | Changchun | Changchun | Commercial | 80.00% | Businesscombinationsinvolvingentitiesnotundercommoncontro | |
JilinChengdaFangyuanpharmaceuticalchainCo.,Ltd | Changchun | Changchun | Commercial | 99.00% | Businesscombinationsinvolvingentitiesnotundercommoncontro | |
InnerMongoliaChengdaFangyuanMedicine | Chifeng | Chifeng | Commercial | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontro | |
InnerMongoliaChengdaFangyuanpharmaceuticalchainCo.,Ltd | Chifeng | Chifeng | Commercial | 99.00% | Businesscombinationsinvolvingentitiesnotundercommoncontro | |
HuiminLuliang(e) | Lvliang | Lvliang | Commercial | 51.00% | Establishment | |
DishengPharmaceutical(f) | Xishuangbanna | Xishuangbanna | Commercial | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontro | |
Dishengchain(g) | Xishuangbanna | Xishuangbanna | Commercial | 70.00% | Businesscombinationsinvolvingentitiesnotundercommoncontro |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(1) | ThecompositionoftheGroup(Continued): |
Descriptionofshareholdingratioinsubsidiariesdifferentfromvotingratio:
OnJanuary4,2018,thegroup,Guorunmedicalsupplychainservice(Shanghai)Co.,Ltd.(hereafterreferredtoas"Guorunmedical")andGuangxideyiyuanMedicalInvestmentCenter(limitedpartnership)jointlyfundedtheestablishmentofSinopharmholdingmedicalsupplychainservice(Guangxi)Co.,Ltd.,withcontributionsofRMB6.12million,RMB5.88millionandRMB8millionrespectively.Guorunmedicalentrustsitsvotingrighttothecompany,andthecompanyholds60%ofthevotingrightofSinopharmholdingmedicalsupplychainservices(Guangxi)Co.,Ltd.
a.On20April2021,GuangdongDongFangUptodate&SpecialMedicinesCo.,Ltd.wasrenamedasSinopharmHolding
GuangdongDongFangUptodate&SpecialMedicinesCo.,Ltd.
b.On12July2021,SinopharmAccordMedicalSupplyChain(Shenzhen)Co.,Ltd.wasrenamedasSinopharmAccord
MedicalDevices(Shenzhen)Co.,Ltd.c.On5July2021,GuodapharmacyJilinCo.,Ltd.hascompletedtheindustrialandcommercialcancellation,andthecancellationannouncementperiodisfromJune10,2021toJune30,2021.
d.On14December2020,theGroupinvestedRMB1,000.00thousandtosetupLiaoningHuludaoGuodapharmacyCo.,Ltd.
Asat30June2021,RMB500.00thousandwaspaid.
e.On28December2020,theGroupandWenshuiWeikangTradingCo.,Ltd.investedRMB16,320.00thousandand
RMB15,680.00thousandtosetupGuodaWanminHuiminKangweipharmacyLuliangCo.,Ltd,thegroupholds51%ofits
equity.Asat30June2021,paymenthasbeencompleted.
f.On15March2021,theGroupacquired70%equityinDishengPharmaceuticafromXishuangbannaDishengPharmaceutical
Co.,Ltd.forRMB14,130.00thousand,whichformedabusinesscombinationnotinvolvingenterprisesundercommoncontrol.
Theacquisitionwascompletedon15March2021andwasincludedinthescopeofconsolidation.
g.On15March2021,theGroupacquired70%equityinDishengchainfromXishuangbannaDishengPharmaceuticalCo.,Ltd.
forRMB238,000.00thousand,whichformedabusinesscombinationnotinvolvingenterprisesundercommoncontrol.The
acquisitionwascompletedon15March2021andwasincludedinthescopeofconsolidation.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII | Interestsinotherentities(Continued) |
1. | Interestsinsubsidiaries(Continued) |
(2)Importantnon-whollyownedsubsidiary
Subsidiaries | Minorityshareholdingratio | Profitorlossattributabletominorityshareholdersinthecurrentperiod | Dispatchofdividendstominorityshareholdersinthecurrentperiod | Minorityshareholders'equity |
GuodaPharmacy | 40.00% | 79,549,416.99 | - | 2,028,470,458.01 |
(3)Keyfinancialinformationofimportantnon-whollyownedsubsidiaries
Subsidiaries | 30June2021 | 31December2020 | ||||||||||
Currentassets | Non-currentassets | Totalassets | Currentliabilities | Non-currentliabilities | Totalliabilities | Currentassets | Non-currentassets | Totalassets | Currentliabilities | Non-currentliabilities | Totalliabilities | |
GuodaPharmacy | 9,335,400,322.92 | 7,008,855,001.21 | 16,344,255,324.13 | 9,037,608,731.16 | 1,459,822,617.08 | 10,497,431,348.24 | 8,886,545,970.79 | 6,570,327,751.04 | 15,456,873,721.83 | 8,541,421,518.15 | 1,375,989,559.14 | 9,917,411,077.29 |
Subsidiaries | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 | ||||||
Operatingrevenue | Netprofit | Totalcomprehensiveincome | Cashflowfromoperatingactivities | Operatingrevenue | Netprofit | Totalcomprehensiveincome | Cashflowfromoperatingactivities | |
GuodaPharmacy | 10,841,326,194.08 | 263,262,365.37 | 263,262,365.37 | 786,526,215.87 | 8,613,020,309.15 | 248,037,573.90 | 248,037,573.90 | 470,794,143.55 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII.Interestsinotherentities(Continued)
2.Interestsinassociates
Principalplaceofbusiness | Placeofincorporation | Natureofbusiness | Shareholding(%) | Accounting | ||
Direct | Indirect | |||||
Associates |
MainLuckPharmaceutical | Shenzhen | Shenzhen | Manufacturing | 35.19% | - | Equity |
ZhijunSuzhou | Suzhou | Suzhou | Manufacturing | 33.00% | - | Equity |
SinopharmZhijun | Shenzhen | Shenzhen | Manufacturing | 49.00% | - | Equity |
ZhijunTrade | Shenzhen | Shenzhen | Commercial | 49.00% | - | Equity |
ZhijunPingshan | Shenzhen | Shenzhen | Manufacturing | 49.00% | - | Equity |
SinopharmShyndec | Shanghai | Shanghai | Businessserviceindustry | 16.28% | - | Equity |
ShanghaiBeiyi | Shanghai | Shanghai | Commercial | - | 26.00% | Equity |
ShanghaiLiyi | Shanghai | Shanghai | Commercial | - | 35.00% | Equity |
GuangdongJienuo | Guangzhou | Guangzhou | Commercial | - | 29.00% | Equity |
Dongyuanaccord | Heyuan | Heyuan | Commercial | - | 45.00% | Equity |
ShanghaiRenbei | Shanghai | Shanghai | Commercial | - | 30.00% | Equity |
GuangdongJianhui | Zhanjiang | Zhanjiang | Public-Private-Partnership | - | 10.00% | Equity |
Explicationoftheshareholdingratioofajointventurediffersfromtheproportionofvotingrights:
AccordingtothearticlesofassociationofGuangdongJianhuicompany,theboardofdirectorsiscomposedoffivedirectors,oneofwhomisappointedbythecompany,accountingfor20%ofthevotingrights.Therefore,thegrouphasasignificantimpactonGuangdongJianhui,whichisanassociateofthegroup.Basisforholdinglessthan20%ofthevotingrightsbuthavingsignificantinfluence,orholding20%ormoreofthevotingrightsbutnothavingsignificantinfluence:
SinopharmShyndechasestablishedaboardofdirectors,whichisresponsibletotheshareholders'meeting.Ithasnine
members,ofwhichthegroupappointsonedirector.Theresolutionoftheboardofdirectorsisoneperson,onevote,accountingfor11.11%ofitsvotingrights.TheGrouphasasignificantinfluenceonSinopharmShyndec.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII.Interestsinotherentities(Continued)
2.Interestsinassociates(Continued)
Mainfinancialinformationofimportantassociates:
30June2021/Forthesixmonthsended30June2021 | 1January2020/Forthesixmonthsended30June2020 | ||||
SinopharmShyndec | ZhijunMedicine | MainLuckPharmaceutical | SinopharmShyndec | ZhijunMedicine | MainLuckPharmaceutical |
Currentassets | 11,543,472,621.58 | 1,310,424,165.50 | 1,150,192,274.24 | 10,162,475,190.65 | 1,176,812,039.37 | 1,076,146,345.00 |
Non-currentassets | 8,262,496,257.36 | 241,317,313.08 | 120,177,914.28 | 8,087,979,595.07 | 238,613,242.87 | 124,495,504.04 |
Totalassets | 19,805,968,878.94 | 1,551,741,478.58 | 1,270,370,188.52 | 18,250,454,785.72 | 1,415,425,282.24 | 1,200,641,849.04 |
Currentliabilities | 7,742,313,859.56 | 621,599,563.08 | 246,923,526.16 | 6,194,362,158.11 | 541,117,019.88 | 275,509,215.17 |
Non-currentliabilities | 1,879,414,378.30 | 4,398,795.45 | 8,120,000.00 | 2,236,726,740.99 | 5,822,904.95 | 8,120,000.00 |
Totalliabilities | 9,621,728,237.86 | 625,998,358.53 | 255,043,526.16 | 8,431,088,899.10 | 546,939,924.83 | 283,629,215.17 |
Non-controllinginterests | 1,731,996,575.52 | - | - | 1,688,157,191.81 | - | - |
Shareholders’equityattributabletoshareholdersoftheparent | 8,452,244,065.56 | 925,743,120.05 | 1,015,326,662.36 | 8,131,208,694.81 | 868,485,357.41 | 917,012,633.87 |
Portionofnetassetscalculatedbyshareholdingratio | 1,376,025,333.87 | 453,614,128.80 | 357,293,452.48 | 1,323,760,775.52 | 425,557,825.11 | 322,696,745.87 |
Carryingvalueofequityinvestmentinjointventures | 1,376,025,333.87 | 453,614,128.80 | 357,293,452.48 | 1,323,760,775.52 | 425,557,825.11 | 322,696,745.87 |
Operatingrevenue | 7,632,136,688.61 | 746,410,222.02 | 476,292,028.69 | 6,211,855,587.54 | 659,730,341.51 | 475,122,136.41 |
Netprofit | 541,049,057.92 | 57,257,762.64 | 98,308,111.37 | 427,914,866.04 | 35,512,234.88 | 98,199,603.82 |
Totalcomprehensiveincome | 541,447,429.53 | 57,257,762.64 | 98,308,111.37 | 428,665,399.75 | 35,512,234.88 | 98,199,603.82 |
Dividendsreceivedfromjointventuresthisperiod | 16,714,220.20 | - | - | 16,714,220.20 | - | 63,342,000.00 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VII.Interestsinotherentities(Continued)
2.Interestsinassociates(Continued)
Summaryfinancialinformationofunimportantjointventuresandassociatedenterprises:
Excesslossesincurredbyjointventuresorassociates:
Accumulatedunrecognizedlossesinthepreviousperiod | Unrecognizedlossinthecurrentperiod(ornetprofitsharedinthecurrentperiod) | Accumulatedunrecognizedlossesattheendoftheperiod | |
SinopharmGroupZhijun(Suzhou)PharmaceuticalCo.,Ltd | (11,193,619.06) | - | (11,193,619.06) |
On11May2021,thecourtruledthatSinopharmGroupZhijun(Suzhou)PharmaceuticalCo.,Ltd.wasbankruptanddesignatedthelocalgovernmentasthebankruptcyadministrator.Atpresent,itisinthestageofcreditor'srightdeclaration.
30June2021/Forthesixmonthsended30June2021 | 1January2020/Forthesixmonthsended30June2020 | |
associatedenterprises: | ||
Carryingvalueofequityinvestment | 240,672,877.06 | 215,004,281.49 |
Netprofit | 25,668,595.57 | 28,478,625.69 |
Totalcomprehensiveincome | 25,668,595.57 | 28,478,625.69 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments
1.Classificationoffinancialinstruments
30June2021:
Financialassets | Financialassetsatfairvaluethroughprofitorloss | Financialassetsatamortisedcost | Financialassetsatfairvaluethroughothercomprehensiveincome | Total | |
Mandatorilyrequired | Mandatorilyrequired | Designated |
Cashandbankbalances | - | 5,876,638,427.56 | - | - | 5,876,638,427.56 |
Notesreceivable | - | 606,070,192.39 | - | - | 606,070,192.39 |
Accountsreceivable | - | 17,761,176,449.25 | - | - | 17,761,176,449.25 |
Receivablefinancing | - | - | 345,906,887.55 | - | 345,906,887.55 |
Otherreceivables | - | 661,339,404.62 | - | - | 661,339,404.62 |
Othernon-currentfinancialassets | 117,974,908.51 | - | - | - | 117,974,908.51 |
Otherequityinstrumentinvestment | - | - | - | 99,488,340.28 | 99,488,340.28 |
117,974,908.51 | 24,905,224,473.82 | 345,906,887.55 | 99,488,340.28 | 25,468,594,610.16 |
Financialliabilities | Financialliabilitiesatamortisedcost |
Short-termborrowings | 4,632,933,904.39 | |
Notespayable | 6,780,425,089.17 | |
Accountspayable | 9,642,504,836.50 | |
Otherpayables | 1,530,963,581.23 | |
Non-currentliabilitiesduewithin1year | 798,170,618.10 | |
Leaseliabilities | 1,361,131,352.80 | |
Long-termborrowings | 61,633,794.44 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
1.Classificationoffinancialinstruments(Continued)31December2021:
Financialassets | Financialassetsatfairvaluethroughprofitorloss | Financialassetsatamortisedcost | Financialassetsatfairvaluethroughothercomprehensiveincome | Total | |
Mandatorilyrequired | Mandatorilyrequired | Designated |
Cashandbankbalances | - | 5,998,204,295.87 | - | - | 5,998,204,295.87 |
Notesreceivable | - | 622,115,477.04 | - | - | 622,115,477.04 |
Accountsreceivable | - | 13,799,971,014.22 | - | - | 13,799,971,014.22 |
Receivablefinancing | - | - | 1,404,987,700.38 | - | 1,404,987,700.38 |
Otherreceivables | - | 535,228,747.69 | - | - | 535,228,747.69 |
Othernon-currentfinancialassets | 120,972,350.24 | - | - | - | 120,972,350.24 |
Otherequityinstrumentinvestment | - | - | - | 99,488,340.28 | 99,488,340.28 |
120,972,350.24 | 20,955,519,534.82 | 1,404,987,700.38 | 99,488,340.28 | 22,580,967,925.72 |
Financialliabilities | Financialliabilitiesatamortisedcost |
Short-termborrowings | 1,612,187,020.12 | |
Notespayable | 7,520,165,274.69 | |
Accountspayable | 7,697,451,142.50 | |
Otherpayables | 1,599,166,881.14 | |
Non-currentliabilitiesduewithin1year | 748,732,059.89 | |
Leaseliabilities | 1,303,054,163.90 | |
Long-termborrowings | 31,637,173.89 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
2.Transferoffinancialassets
TransferredfinancialassetsthatarenotderecognisedintheirentiretyAsat30June2021,theGrouphadendorsedcommercialacceptancebills(the"EndorsedBills")withacarryingamountofRMB125,089.80(30June2020:4,095,283.92)tocertainofitssupplierstosettleaccountspayableduetosuchsuppliersandtheGrouphadendorsedbankacceptancebillswithacarryingamountofRMB20,070,999.69(30June2020:23,843,867.66)tocertainofitssupplierstosettleaccountspayableduetosuchsuppliers.IntheopinionoftheGroup,theGrouphasretainedsubstantiallyalltherisksandrewards,whichincludedefaultrisksrelatingtosuchEndorsedBillsandDiscountedBills.Accordingly,itcontinuedtorecognisethefullcarryingamountsofthoseBillsandtheassociatedaccountspayablesettled.SubsequenttotheEndorsementandDiscount,theGroupdidnotretainanyrightsontheuseofthoseBills,includingthesale,transferorpledgeofthoseBillstoanyotherthirdparties.Asat30June2021,thetotalcarryingvalueofaccountspayablesettledbytheGroupwasRMB20,196,089.49(31December2020:RMB27,939,151.58).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
2.Transferoffinancialassets(Continued)
TransferredfinancialassetsthatarederecognisedintheirentiretyinwhichcontinuinginvolvementexistsAsat30June2021,theGrouphadendorsedbankacceptancebills(the"EndorsedBills")withacarryingamountofRMB754,753,155.51(31December2020:RMB1,283,369,787.75)tocertainofitssupplierstosettleaccountspayableduetosuchsuppliers.Asat30June2021,theGrouphaddiscountedbankacceptancebills(the"DiscountedBills")withacarryingamountofRMB1,067,286,554.94(31December2020:RMB330,472,883.05)tobanks.Asat30June2021,thoseBillshadamaturityof1to12monthsattheendofthereportingperiod.InaccordancewiththeLawofNegotiableInstruments,theholdersofthederecognisedbillshavearightofrecourseagainsttheGroupiftheacceptingbanksdefault(the"ContinuingInvolvement").IntheopinionoftheGroup,theGrouphastransferredsubstantiallyallrisksandrewardsrelatingtothoseBills.Accordingly,ithasderecognisedthefullcarryingamountsofthoseBillsandtheassociatedaccountspayable.ThemaximumexposuretolossfromtheGroup'sContinuingInvolvementinthederecognisedbillsandtheundiscountedcashflowstorepurchasethesederecognisedbillsisequaltotheircarryingamounts.IntheopinionoftheGroup,thefairvaluesoftheGroup’sContinuingInvolvementinthederecognisedbillsarenotsignificant.During2021,theGrouphasnotrecognisedanygainorlossonthedateoftransfer.NogainorlosswasrecognisedfromderecognisedfinancialassetsinwhichtheContinuingInvolvementexists,bothduringtheyearorcumulatively.During2021,theGrouphasnotrecognisedanygainorlossonthedateoftransferofthederecognisedbills.NogainsorlosseswererecognisedfromtheContinuingInvolvement,bothduringtheyearorcumulatively.Aspartofitsnormalbusiness,theGroupenteredintoanaccountsreceivablefactoringwithoutrecoursewithbanksandtransferredcertainaccountsreceivabletobanks.Intheopinionofthedirectors,theGrouphastransferredsubstantiallyallrisksandrewardsunderthearrangement.Accordingly,ithasderecognisedthefullcarryingamountsoftheassociatedaccountsreceivable.TheoriginalcarryingvalueofthederecognisedaccountsreceivabletransferredundertheArrangementthathavenotbeensettledasat30June2021amountedtoRMB695,181,891.24(31December2020:RMB1,409,768,709.18).
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
3.Risksoffinancialinstruments
ThemainrisksarisingfromtheGroup'sfinancialinstrumentsarecreditrisk,liquidityriskandmarketrisk(includingcurrencyriskandinterestraterisk).TheGroup'sprincipalfinancialinstrumentscomprisecashandbankbalances,equityinvestments,debtinvestments,borrowings,notesreceivable,accountsreceivable,notespayableandaccountspayable.RisksthatrelatedtothesefinancialinstrumentsandtheGroup'sriskmanagementstrategiesforreducingtheserisksareasfollows.TheCompany’sboardofdirectorsisresponsibleforplanningandestablishingtheriskmanagementframeworkoftheGroup,formulatingriskmanagementpoliciesandrelatedguidelinesoftheGroupandsupervisingtheimplementationofriskmanagementmeasures.TheGrouphasalreadydevelopedriskmanagementpoliciestoidentifyandanalysetherisksfacedbytheGroup,whichhaveclearlyidentifiedspecificrisks,coveringalotofaspectssuchasmarketrisk,creditriskandliquidityriskmanagement.TheGroupregularlyassessesthemarketenvironmentandchangesintheGroup’sbusinessactivitiestodeterminewhetherornottoupdatetheriskmanagementpoliciesandsystems.TheriskmanagementoftheGroupshallbeconductedbytheoperationandmanagementdepartmentaccordingtothepolicyapprovedbytheCompany’smanagement.Theoperationandmanagementdepartmentidentifies,evaluatesandavoidsrelatedrisksbymeansofclosecooperationwithotherbusinessunitsoftheGroup.Toavoidtheriskconcentratingonasingleindustry,aspecificareaoraspecificcounterparty,theGroupspreadsfinancialinstrumentsriskwithdiversifiedinvestmentsandbusinessportfolio.CreditriskTheGrouponlytradeswithrecognisedandcreditworthythirdparties.ItistheGroup’spolicythatallcustomerswhowishtotradeoncredittermsaresubjecttocreditverificationprocedures.Inaddition,receivablebalancesaremonitoredonanongoingbasisandtheGroup’sexposuretobaddebtsisnotsignificant.Fortransactionsthatarenotdenominatedinthefunctionalcurrencyoftherelevantoperatingunit,theGroupdoesnotoffercredittermswithoutthespecialapprovalofthecreditcontroldepartmentoftheGroup.Sincecashandbankbalances,bankacceptancebillsreceivableandderivativefinancialinstrumentsareplacedinthewell-establishedbankswithhighcreditratings,thecreditriskofthesefinancialinstrumentsislower.TheotherfinancialinstrumentsoftheGroupincludecashandbankbalancesandotherreceivables.Thecreditriskofthesefinancialassetsresultsfromdefaultofcounterparty.Themaximumcreditexposureequalstothebookvalueoftheseinstruments.ThemaximumexposuretocreditriskoftheGroupateachbalancesheetdateisthetotalamountchargedtothecustomerslesstheamountoftheimpairmentprovision.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
3.Risksoffinancialinstruments(Continued)
Creditrisk(Continued)SincetheGrouptradesonlywithrecognisedandcreditworthythirdparties,thereisnorequirementforcollateral.Creditrisksaremanagedbycustomer/counterparty,bygeographicalregionandbyindustrysector.TherearenosignificantconcentrationsofcreditriskwithintheGroupasthecustomerbasesoftheGroup’saccountsreceivablearewidelydispersedindifferentsectorsandindustries.TheGroupdoesnotholdanycollateralorothercreditenhancementsoveritsaccountsreceivablebalancesDeterminationofsignificantincreaseincreditriskAteachreportingdate,theGroupdetermineswhetherthecreditriskofafinancialassethasincreasedsignificantlysinceinitialrecognition.Whendeterminingwhetherthecreditriskofafinancialassethasincreasedsignificantlysinceinitialrecognition,theGroupconsidersreasonableandsupportableinformationthatisrelevantandavailablewithoutunduecostoreffort.Thisincludesbothquantitativeandqualitativeinformationanalysis,basedontheGroup’shistoricalexperienceandinformedcreditassessmentandincludingforward-lookinginformation.Inordertodeterminethechangeofexpecteddefaultriskduringthefinancialinstrument’sentirelifetime,theGroupcomparesthedefaultriskoffinancialinstrumentonthebalancesheetdateandontheinitialrecognitiondatebasedonsinglefinancialinstrumentorfinancialinstrumentportfoliowithsimilardefaultrisk.TheGroupdeterminesthatthecreditriskoffinancialassetshassignificantlyincreasedwhenoneormorequantitativeorqualitativecriteriaaremet:
(1)Quantitativecriteriaaremainlyprobabilityofdefaultincreasingmorethanagiven%since
initialrecognition;
(2)Qualitativecriteriaaremainlysignificantdetrimentalchangesintheborrower’soperatingorfinancialconditionsandearlywarningcustomerlists.
(3)Theuppercriterionisabove30daysoftheborrowersdefault(includingprincipalandinterests).
Definitionofcredit-impairedfinancialassets
Inassessingwhetherafinancialassetiscredit-impaired,theGroupconsidersbothquantitative
andqualitativeinformationinlinewithinternalcreditriskmanagement.TheGroupassesses
whetherafinancialassetiscredit-impairedbyconsideringthefollowingfactors:
(1)Significantfinancialdifficultyoftheborrowerorissuer;
(2)Abreachofcontractsuchasadefaultorpastdueevent;
(3)Thelender(s)oftheborrower,foreconomicorcontractualreasonsrelatingtotheborrower’s
financialdifficulty,havinggrantedtotheborrowerconcession(s)thatthelender(s)wouldnot
otherwiseconsider;
(4)Itisbecomingprobablethattheborrowerwillenterbankruptcyorotherfinancialreorganisation;
(5)Thedisappearanceofanactivemarketforsecuritybecauseoffinancialdifficulties;and
(6)Financialassetspurchasedorsourcedatlargediscountsindicatingthatcreditlosseshaveoccurred.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
3.Risksoffinancialinstruments(Continued)
Creditrisk(Continued)Theimpairmentoffinancialassetsmaynotbenecessarilyduetoasingledisparateevent.Thecombinedeffectsofmultipleeventsmayresultinfinancialassetsbeingcredit-impaired.ParameteroftheexpectedcreditlossmodelBasedonwhetherthereisasignificantincreaseincreditriskandwhetherthefinancialassetsarecredit-impaired,theGrouprecognizesimpairmentallowancefordifferentassetsusingeither12-monthexpectedcreditlossesorlifetimeexpectedcreditlosses.ThemeasurementoftheECLmodelisafunctionoftheprobabilityofdefault,thelossgivendefault(i.e.themagnitudeofthelossifthereisadefault)andtheexposureatdefault.TheGroupestablishesthemodelbyconsideringthequantitativeanalysisofhistoricalstatisticssuchasthecounterpartyrating,theguaranteemethod,thecollateralcategory,therepaymentmethod,andalsoforward-lookinginformation.Definitions:
(1)Theprobabilityofdefaultistheprobabilitythatthedebtorwillnotbeabletomeetitsrepaymentobligationswithinthefollowing12monthsorthroughouttheremainingduration.Toreflectthemacro-economicenvironmentconditions,theGroup’sassessmentoftheprobabilityofdefaultisbasedonthecalculationoftheECLmodeladjustedbyforward-lookinginformation.
(2)Thelossgivendefault(i.e.themagnitudeofthelossifthereisadefault)referstotheGroup'sexpectationoftheextentofthelossofdefaultriskexposure.Thelossgivendefaultvariesdependingonthetypeofcounterparty,thewayandpriorityofrecourse,andthetypeofcollateral.Thelossgivendefaultisthepercentageoftheriskexposurelossatthetimeofdefault,calculatedonthebasisofthenext12monthsortheentireduration.
(3)TheexposureatdefaultreferstotheamountthattheGroupshouldrepayintheeventofdefaultinthenext12monthsorthroughouttheremainingperiod.BoththeassessmentofasignificantincreaseincreditriskandthecalculationoftheECLinvolveforward-lookinginformation.TheGrouprecogniseskeyeconomicratiosthatinfluencecreditriskandtheECLbyhistoricaldataanalysis.Asat30June2021,therewasnoevidenceofasignificantincreaseincreditrisk.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
3.Risksoffinancialinstruments(Continued)
LiquidityriskThematurityanalysisoftheGroup'sfinancialliabilitiesasattheendofthereportingperiod,basedonthecontractualundiscountedcashflows,isasfollows:
30June2021 | ||||||||
Within1year | 1to2years | 2to5years | Above5years | Total |
Short-termborrowings | 4,709,466,709.01 | - | - | - | 4,709,466,709.01 | |||||
Long-termborrowings | - | 2,431,600.00 | 62,818,460.27 | - | 65,250,060.27 | |||||
Notespayable | 6,780,425,089.17 | - | - | - | 6,780,425,089.17 | |||||
Accountspayable | 9,642,504,836.50 | - | - | - | 9,642,504,836.50 | |||||
Otherpayables | 1,530,963,581.23 | - | - | - | 1,530,963,581.23 | |||||
Non-currentliabilitiesduewithin1year | 875,756,920.06 | - | - | - | 875,756,920.06 | |||||
Leaseliabilities | - | 647,956,518.10 | 715,415,984.31 | 96,740,307.76 | 1,460,112,810.17 |
23,539,117,135.97 | 650,388,118.10 | 778,234,444.58 | 96,740,307.76 | 25,064,480,006.41 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
3.Risksoffinancialinstruments(Continued)
Liquidityrisk(Continued)ThematurityanalysisoftheGroup'sfinancialliabilitiesasattheendofthereportingperiod,basedonthecontractualundiscountedcashflows,isasfollows:
31December2020 | ||||||||
Within1year | 1to2years | 2to5years | Above5years | Total |
Short-termborrowings | 1,630,237,831.47 | - | - | - | 1,630,237,831.47 | |||||
Long-termborrowings | - | 1,216,600.00 | 32,313,062.78 | - | 33,529,662.78 | |||||
Notespayable | 7,520,165,274.69 | - | - | - | 7,520,165,274.69 | |||||
Accountspayable | 7,697,451,142.50 | - | - | - | 7,697,451,142.50 | |||||
Otherpayables | 1,599,166,881.14 | - | - | - | 1,599,166,881.14 | |||||
Non-currentliabilitiesduewithin1year | 866,553,230.12 | - | - | - | 866,553,230.12 | |||||
Leaseliabilities | - | 607,074,838.58 | 682,420,061.05 | 86,860,654.77 | 1,376,355,554.40 |
19,313,574,359.92 | 608,291,438.58 | 714,733,123.83 | 86,860,654.77 | 20,723,459,577.10 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
3.Risksoffinancialinstruments(Continued)
MarketriskInterestrateriskTheGroup'sinterestrateriskarisesfromlong-termborrowingsfrombanks.FinancialliabilitiesissuedatfloatingratesexposetheGrouptocashflowinterestraterisk.FinancialliabilitiesissuedatfixedratesexposetheGrouptofairvalueinterestraterisk.TheGroupdeterminestherelativeproportionsofitsfixedrateandfloatingratecontractsdependingontheprevailingmarketconditions.Asat30June2021,ifthefloatinginterestratesofthelong-terminterest-bearingborrowingsincreasedordecreasedby50basepoints,whileotherfactorsdidnotchange,theGroup’snetincomewoulddecreaseorincreasebyRMB59,087.67(31December2020:ifthefloatinginterestratesofthelong-terminterest-bearingborrowingsincreasedordecreasedby50basepoints,whileotherfactorsdidnotchange,theGroup’snetincomewouldincreaseordecreasebyRMB97,072.60).TheGroup’sfinancedepartmentatitsheadquarterscontinuouslymonitorstheinterestratepositionoftheGroup.IncreasesininterestrateswillincreasethecostofnewborrowingsandtheinterestexpenseswithrespecttotheGroup’soutstandingfloatingrateborrowingsand,therefore,couldhaveamaterialadverseeffectontheGroup’sfinancialposition.TheGroup’smanagementlayerwouldmakeadjustmentswithreferencetothelatestmarketconditionswhichareinterestrateswapagreementstomitigateitsexposuretointerestraterisk.During2021and2020,theGrouphadnotenteredintoanyinterestrateswapagreements.Fortheyearended30June2021,theGrouphaslong-terminterest-bearingborrowingswithfloatinginterestratesamountingtoRMB31,600,000.00(31December2020:RMB31,600,000.00).Andlong-terminterest-bearingborrowingswithfixedinterestratesamountingtoRMB30,000,000.00(31December2020:nil).CurrencyriskTheGroup’smajoroperationalactivitiesarecarriedoutinMainlandChinaandamajorityofthetransactionsaredenominatedinRMB.TheGroupisexposedtoforeignexchangeriskarisingfromtherecognisedassetsandliabilitiesaswellasfuturetransactions(denominatedinforeigncurrencies,primarilywithrespecttoUnitedStatesdollarsandHongKongdollars).TheGroup’sfinancedepartmentatitsheadquartersisresponsibleformonitoringtheamountsofassetsandliabilities,andtransactionsdenominatedinforeigncurrenciesaimatmitigatingthepotentialforeignexchangerisktoalargeextent.
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
VIIIRisksrelatedtofinancialinstruments(Continued)
4.Capitalmanagement
TheCompany’sprimaryobjectiveformanagingcapitalistoensurethatitmaintainsastrongcreditratingandahealthycapitalratioinordertosupportitsbusiness,bringshareholdersinvestingreturnsandbenefitrelatedparties.Managementalsoaimstomaintainacapitalstructurethatensuresthatthelowestcostofcapitalisavailabletotheentity.Managementadjuststhecapitalstructurethroughadjustingdividendpaymentstoshareholders,returningcapitaltoshareholders,issuingnewsharesorsellingassetstoreducedebts.TheGroup’stotalcapitalisthetotalshareholders’equityinthebalancesheet.TheGroupdoesnotadoptanassetratioasacompulsoryfactortogoverncapitalinvestment.ThegearingratiosoftheGroupasattheendofthereportingperiodsareasfollows:
30June2021 | 31December2020 |
Gearingratio | 60.43% | 57.35% |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IX.Disclosureoffairvalue
1.Assetsandliabilitiesatfairvalue30June2021:
Inputappliedinthemeasurementoffairvalue | ||||
Quotedpricesinactivemarkets | Significantobservableinputs | Significantunobservableinputs | Total | |
Level1 | Level2 | Level3 |
Continuousmeasurementoffairvalue | |||||
Receivablefinancing | - | 345,906,887.55 | - | 345,906,887.55 | |
Otherinvestmentinequityinstruments | - | 99,488,340.28 | - | 99,488,340.28 | |
Othernon-currentfinancialassets | - | - | 117,974,908.51 | 117,974,908.51 |
- | 445,395,227.83 | 117,974,908.51 | 563,370,136.34 |
31December2020
Inputappliedinthemeasurementoffairvalue | ||||
Quotedpricesinactivemarkets | Significantobservableinputs | Significantunobservableinputs | Total | |
Level1 | Level2 | Level3 |
Continuousmeasurementoffairvalue | |||||
Receivablefinancing | - | 1,404,987,700.38 | - | 1,404,987,700.38 | |
Otherinvestmentinequityinstruments | - | 99,488,340.28 | - | 99,488,340.28 | |
Othernon-currentfinancialassets | - | - | 120,972,350.24 | 120,972,350.24 |
- | 1,504,476,040.66 | 120,972,350.24 | 1,625,448,390.90 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IX.Disclosureoffairvalue(Continued)
2.Assetsandliabilitiesdisclosedatfairvalue30June2021:
Inputappliedinthemeasurementoffairvalue | |||
Quotedpricesinactivemarkets | Significantobservableinputs | Significantunobservableinputs | Total |
Level1 | Level2 | Level3 |
Long-termborrowings | - | 61,633,794.44 | - | 61,633,794.44 |
3.Estimationoffairvalue
ThefollowingarethebookvalueandfairvalueoffinancialinstrumentsoftheGroup,excludingthosethathaveimmaterialdifferenceinbookvalueandfairvalue:
Carryingamount | Fairvalue | ||
30June2021 | 31December2020 | 30June2021 | 31December2020 |
Financialliabilities | - | - | - | - |
Long-termborrowings | 61,633,794.44 | 31,637,173.89 | 61,633,794.44 | 31,637,173.89 |
Managementhasassessedthatthefairvaluesofcashandcashequivalents,tradereceivables,receivablefinancing,otherreceivables,short-termborrowings,notespayable,tradepayables,otherpayables,non-currentliabilitiesduewithin1yearaswellasothershort-termfinancialassetsandliabilities.Duetotheshortremainingmaturitiesoftheseinstruments,thefairvalueapproximatedtothecarryingamount.ThefinancialcontrolleroftheGrouptakestheresponsibilitytoformulatepoliciesandproceduresrelatedtofinancialinstrumentfairvaluemeasurementsanddirectlyreportstotheCFOandtheauditcommittee.Oneachbalancesheetdate,thefinancialdepartmentanalysesthevariationofthefairvalueoffinancialinstrumentsanddeterminestheinputsapplicabletovaluation.ThevaluationisrequiredtobeapprovedbytheCFO.Thefairvaluesoffinancialassetsandliabilitiesaretheamountsatwhichtheinstrumentcouldbeexchangedordebtscouldbesettledinanarm’slengthtransactionbetweenknowledgeableandwillingparties,otherthaninaforcedorliquidationsale.Thefollowingmethodsandassumptionswereusedtoestimatethefairvalues.Thefairvaluesofshort-termandlong-termborrowings,andlong-termpayableshavebeencalculatedbydiscountingtheexpectedfuturecashflowsusingmarketratesofreturncurrentlyavailableforotherfinancialinstrumentswithsimilarterms,creditriskandremainingmaturities.Asat30June2021,theGroup’sownnon-performanceriskforshort-termandlong-termborrowingswasassessedtobeinsignificant.Foranequityinstrumentoflistedentities,themarketpriceisusedtodeterminefairvalue.Foranequityinstrumentofnon-listedentities,therecentequitytransactionconsiderationorthemarketcomparablecompanymodelisusedtoestimatefairvalue.TheGroupbelievesthattheestimatedfairvaluebythevaluationmethodisrational,andalsothemostsufficientvalueatthebalancesheetdate.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
IX.Disclosureoffairvalue(Continued)
4.Unobservableinputs
Othernon-currentfinancialassetswerethefundsharesofQiruiPortInvestmentCenterLPofNingboMeishanBondedPortsubscribedbytheGroup.Forthedeterminationofthefairvalueoftheinvestment,afterreferringtothenetassetsofQiruiPortInvestmentCenterLPofNingboMeishanBondedPorton30June2021,whichhasimplementedthenewfinancialinstrumentstandards,theresultwascalculatedanddeterminedaccordingtothefundshareproportionownedbythecompany.Afinancialinstrumentthatismeasuredatfairvaluewithmeasurementoflevel3isinsensitivetoreasonablefluctuationoftheunobservableinputs.
5.TransfersbetweenlevelsoffairvaluemeasurementAt30June2021and31December2020,therewerenotransfersoffairvaluemeasurementsbetweenLevel1andLevel2.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions
1.Parent
Parent’sname | Registeredaddress | Natureofbusiness | Sharecapital | ProportionofownershipinterestintheCompany | ProportionofvotingpowerintheCompany |
SinopharmGroupCo.,Ltd. | Shanghai | Industrialinvestmentholding,trusteeofapharmaceuticalenterprise,assetsreorganization,distributionandretailofmedicinesandpharmaceuticalproducts,etc. | 3,120,656,191.00 | 56.06% | 56.06% |
TheultimatecontrollingpartyoftheCompanyisCNPGC.
2.SubsidiariesRefertoNoteVII1fordetailsofsubsidiaries.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
3.Associates
RefertoNoteVII2fordetailsofassociates.Thesituationofotherjointventuresorassociatesthathaverelatedpartytransactionswiththecompanyduringthecurrentperiodorthebalanceoftherelatedpartytransactionswiththecompanyinthepreviousperiodisasfollows:
PleaserefertoNoteX5fordetails.
4.Otherrelatedparties
Companyname | Relatedpartyrelationships |
LanzhouBiotechnologyDevelopmentCo.,Ltd. | ControlledbyCNPGC |
ShanghaiShyndecPharmaceuticalMarketingCo.,Ltd. | ControlledbyCNPGC |
ChinaNationalPharmaceuticalForeignTradeCorporation | ControlledbyCNPGC |
SinopharmYixinPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
FoshanWinteamPharmaceuticalGroupLtd. | ControlledbyCNPGC |
SouthwestPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
ChengduRongshengPharmacyCo.,Ltd. | ControlledbyCNPGC |
TaijiGroupChongqingFulingPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
BeijingHuashengPharmaceuticalBiotechnologyDevelopmentCo.,Ltd. | ControlledbyCNPGC |
TaijiGroupChongqingTongjungePharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmFengliaoxing(Foshan)PharmaceuticalDrugsCo.,Ltd. | ControlledbyCNPGC |
ShanghaiShangshengBiologicalProductsCo.,Ltd. | ControlledbyCNPGC |
SinopharmGroupRongshengPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmZhonglianPharmaceuticalGroupCo.,Ltd. | ControlledbyCNPGC |
ChinaNationalPharmaceuticalIndustryCo.,Ltd. | ControlledbyCNPGC |
ShanghaiModernHasen(Shangqiu)PharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmLuya(Shandong)PharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmTongjitang(Guizhou)PharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmChuanKangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
HuayiPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmShantouJinshiPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmWeiqidaPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
ChengduInstituteofBiologicalProductsCo.,Ltd. | ControlledbyCNPGC |
SinopharmGroupYibinPharmaceuticalsCo.,Ltd. | ControlledbyCNPGC |
YunnanTianjiangYifangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
WuhanZhongshengYujinBiologicalMedicineCo.,Ltd. | ControlledbyCNPGC |
ShantouJinshiPowderInjectionCo.,Ltd. | ControlledbyCNPGC |
SinopharmXinjiangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmWuhanBloodProductsCo.,Ltd. | ControlledbyCNPGC |
TaijiGroup | ControlledbyCNPGC |
SichuanJiangyouZhongbaAconitiScienceandTechnologyDevelopmentCo.,Ltd. | ControlledbyCNPGC |
SinopharmWuhanZhonglianSiyaoPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
TaijiGroupZhejiangDongfangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
TaijiGroupSichuanMianyangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmSanyiMedicine(Wuhu)Co.,Ltd. | ControlledbyCNPGC |
Sinopharm(Anhui)JingfangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
TaijiGroupSichuanNanchongPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
ShanghaiZenoBiotechnologyCo.,Ltd. | ControlledbyCNPGC |
SinopharmGuangdongGlobalPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
FujianChentianJinlingPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmDezhong(Foshan)PharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmForeignTrade(Beijing)Co.,Ltd. | ControlledbyCNPGC |
FoshanChengnanFengliaoxingMedicalHospitalCo.,Ltd. | ControlledbyCNPGC |
SinopharmFengliaoxingMedicalHospitalCo.,Ltd. | ControlledbyCNPGC |
ChongqingTongjungeCo.,Ltd. | ControlledbyCNPGC |
SichuanTaijiPharmacyChainCo.,Ltd. | ControlledbyCNPGC |
SinopharmGroupFengliaoxingMedicalHospital(FoshanNanhai)Co.,Ltd. | ControlledbyCNPGC |
ChinaSinopharmInternationalCorporation | ControlledbyCNPGC |
GuangdongYifangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmFengliaoxing(Foshan)MedicinesCo.,Ltd. | ControlledbyCNPGC |
SinopharmGroupFengliaoxingPharmacy(Foshan)Co.,Ltd. | ControlledbyCNPGC |
GuangxiYifangTianjiangPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
SinopharmGroupFinancialCo.,Ltd. | ControlledbyCNPGC |
InnostarBiotechnologyNantongCo.,Ltd | ControlledbyCNPGC |
HubeiSinopharmZhonglianMedicineCo.,Ltd. | ControlledbyCNPGC |
TaijiGroupGansuTianshuiXihuangEjiaoCo.,Ltd. | ControlledbyCNPGC |
SinopharmBeijingHuamiaoPharmaceuticalCo.,Ltd. | ControlledbyCNPGC |
ChinaNationalofTraditional&HerbalMedicineCo.,Ltd. | ControlledbyCNPGC |
SinopharmHoldingSubMarketingCenterCo.,Ltd. | ControlledbySinopharmGroup |
ChinaNationalMedicinesCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShenyangCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingYangzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinjiangSpecialDrugsWesternPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingLunanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingInnerMongoliaCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJilinCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingFujianCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHenanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShandongCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingLerentangHebeiPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupGuangdongMedicineDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBeijingCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinjiangXinteShenrongPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJiangsuCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingTongliaoCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupGuoruiMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHunanCo.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingPingdingshanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXiamenCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChangzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmXingshaPharmaceuticals(Xiamen)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangShijiazhuangMedicineCo.,Ltd. | ControlledbySinopharmGroup |
YunnanSinopharmHoldingDongchangMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJinzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingNingxiaCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingAnshanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupShanxiMedicalDevicesCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiZhongjianMedicalDeviceChainCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJinanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiDajiuzhouMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmJiankun(Beijing)MedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingDonghongMedical(Shanghai)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmAdvanced(Shanghai)MedicalDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanghaiLikangPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
ShanghaiInternationalPharmaceuticalTradeCo.,Ltd. | ControlledbySinopharmGroup |
ChinaNationalMedicalDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHeilongjiangCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHuaideju(Xiamen)PharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingWuxiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHulunBuirCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBeijingKangchenBio-PharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupSouthwestMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingTianjinCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingLinfenNinglePharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinjiangXinteKaramayPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingDalianCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLiaoningMedicalEquipmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBeijingTianxingPuxinBiologicalMedicalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingYanchengCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangQinhuangdaoPharmaceuticalTradingCo.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingFuzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLingyunBiopharmaceutical(Shanghai)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingYunnanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingAnhuiHuaningMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinjiangSpecialDrugsKashgarPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHuixinqinyuan(Beijing)TechnologyDevelopmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingNantongCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBiopharmaceutical(Tianjin)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingQuanzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingSpecialDrugsShiheziPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBenxiCo.,Ltd. | ControlledbySinopharmGroup |
ShanghaiMerroPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHubeiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingsBeijingHuahongco.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanghaiBiomedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingYangzhouMedicalTreatmentEquipmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChifengCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingZhejiangCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingPu’erCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingZhihuiminsheng(Tianjin)PharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHubeiLikangPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHainanHongyiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingPutianCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmSichuanPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBayannurCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingAnhuiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHunanPharmaceuticalDevelopmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiMingdikangMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingNanpingNewforceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinye(Hubei)MedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChangshaCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinjiangSpecialDrugsYiliPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingKunmingCo.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingChangdeCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingOrdosCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmInnerMongoliaMedicalEquipmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingDalianHechengCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHainanCo.,Ltd. | ControlledbySinopharmGroup |
ChinaNationalMedicalDevice(HuiZhou)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupMedicineLogisticCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChangshaGaoxinMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingNanjingWendePharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupLinfenCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmDevice(Guangdong)MedicalTechnologyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLiaoningMedicalEquipmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingZhangzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingYangzhouBiologicalProductsCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmShenzhenMedicineDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHubeiGuodaPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
ChinaNationalScientificInstruments&MaterialsI&EShenzhenCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChongqingCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmMedicalInstrument(Hainan)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingWuhanHongshenMedicineCo.,Ltd. | ControlledbySinopharmGroup |
Sinopharm(Dalian)MedicalDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingLinyiMedicalDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHebeiMedicalInstrumentCo.,Ltd. | ControlledbySinopharmGroup |
LiaoningPilotFreeTradeZoneChinaMedicalDeviceTechnologyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiJinzhongCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiRunheMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupMed-TechCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingRizhaoCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJiangxiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChengduCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShiyanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingUlanqabCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiJinchengCo.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingLianyungangCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChangzhouMedicalLogisticsCenterCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingBaotouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupShanghaiMedicineDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingDezhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingTaizhouCo.,Ltd. | ControlledbySinopharmGroup |
ChinaMedicalEquipmentShandongCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingGuang’anCo.,Ltd.. | ControlledbySinopharmGroup |
ShanghaiTongyuInformationTechnologyCo.,Ltd. | ControlledbySinopharmGroup |
GuorunMedicalSupplyChainService(Shanghai)Co.,Ltd. | ControlledbySinopharmGroup |
XinjiangBaitongPropertyServiceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmPharmaceuticalLogisticsCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLogisticsBeijingCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingWenzhouCo.,Ltd. | ControlledbySinopharmGroup |
HandanSinopharmLerentangPharmacyChainCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroup(Tianjin)EasternBokangPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentang(Langfang)PharmaceuticalTradeCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangTangshanMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangXingtaiPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingGuizhouMedicalDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangBaodingTradingCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangBaodingHongkangPharmaceuticalChainCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangHengshuiMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHolding(Hubei)HankouPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingAnhuiPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXuzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShangqiuCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingGansuCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingGuizhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChongqingTaiminPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingAnshunCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingTongrenCo.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingGuizhou(Zunyi)MedicalEquipmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingZunyiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingWuhuCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangCangzhouMedicineCo.,Ltd. | ControlledbySinopharmGroup |
ShanghaiShengxinPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangQinhuangdaoMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangTangshanMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmBaiseDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingQinghaiCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHongheCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangXingtaiMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJiaozuoCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingAnhuiPharmaceuticalChainCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChuxiongCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangShijiazhuangMedicalManagementCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingTianjinNorthMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangCangzhouPharmaceuticalTradingCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGuangdongMedicalExaminationCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangChengdeMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangZhangjiakouMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangLangfangPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingLongyanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHubeiHongyuanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmMedicalInstrumentGuizhouQiannanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangHandanMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingWuhanGuodaPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangBaodingMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangZhangjiakouMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingProfessionalPharmacy(Hainan)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangHealthcareShijiazhuangPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHongrunMedicalBusinessService(Shanghai)Co.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingZhuanyePharmacy(Dongfang)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHunanWeianPharmacyMedicineChainCompanyLimited | ControlledbySinopharmGroup |
SinopharmHoldingNingdeCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingChangxingProfessionalPharmacy(Haikou)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingPharmacy(Shanghai)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmGuanaiYuankangPharmacy(Haikou)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingDalianSpecialDrugsPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiMedicalDevicesCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHolding(Shandong)MedicineDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingProfessionalPharmacySongyuanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmMedicalInstrument(Jiangmen)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingXinyuCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingSuzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmZhuhaiMedicalInstrumentCo.,Ltd. | ControlledbySinopharmGroup |
YuxiSinopharmMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHunanProv.MedicalEquipmentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingQianxi’nanCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingFuzhouCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingKunmingPharmacyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGuanaiJikunPharmacy(Haikou)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmLerentangLangfangMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingZhenjiangCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingGuizhouMedicalChainCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiHejinPharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJilinChainStoreCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGuangdongMedicineDeviceSupplyChainCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmMedicalInstrumentGuangxiMedicalTechnologyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmMedicalInstrument(Foshan)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmDevice(Guangdong)MedicalTechnologyCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmGroupShanghaiCo.,Ltd. | ControlledbySinopharmGroup |
BeijingSinopharmTianyuanRealEstate&PropertyManagementCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingGuizhouYitongMedicineCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingShanxiLinfenCo.,Ltd. | ControlledbySinopharmGroup |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
SinopharmHoldingHuaidejuPharmaceutical(Xiamen)Co.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingLiaochengCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingJilinMedicineDeviceCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHolding(TianjinBinhai)PharmaceuticalCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmChemicalReagentCo.,Ltd. | ControlledbySinopharmGroup |
SinopharmHoldingHuaianCo.,Ltd. | ControlledbySinopharmGroup |
FreseniusKabiHuaruiPharmaceuticalsCo.,Ltd. | AssociateofCNPGC |
ChinaOtsukaPharmaceuticalCo.,Ltd. | AssociateofCNPGC |
SinopharmGroupShanxiRuifulaiCo.,Ltd. | AssociateofCNPGC |
SINO-TCMShanghaiMedicine&MedicinalMaterialsCo.,Ltd. | AssociateofCNPGC |
ChangchunChangshengGenePharmaceuticalCo.,Ltd. | AssociateofCNPGC |
YichangHumanwellPharmaceuticalCo.,Ltd. | AssociateofSinopharmGroup |
HutchisonWhampoaSinopharmPharmaceuticals(Shanghai)Co.,Ltd. | AssociateofSinopharmGroup |
SinopharmHoldingChuangkeMedicalTechnology(Guangxi)Co.,Ltd. | AssociateofSinopharmGroup |
SinopharmHoldingChuangkeYuanzheMedicalTechnology(Shanghai)Co.,Ltd. | AssociateofSinopharmGroup |
SinopharmHealthOnlineCo.,Ltd. | AssociateofSinopharmGroup |
ShanghaiGuodaLingyunPharmacyCo.,Ltd. | AssociateofSinopharmGroup |
SinopharmHolding(China)FinancingLeaseCo.,Ltd. | AssociateofSinopharmGroup |
SinopharmNutraceuticals(Shanghai)Co.,Ltd. | AssociateofSinopharmGroup |
SinopharmAnhuiGreatHealthIndustryCo.,Ltd. | AssociateofSinopharmGroup |
BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | Minorityshareholdersofasubsidiary |
JiangmenXinhuiDistrictJianfengPharmaceuticalCo.,Ltd. | Minorityshareholdersofasubsidiary |
LerentangInvestmentGroupCo.,Ltd. | Minorityshareholdersofasubsidiary |
ShenyangPharmaceuticalCo.,Ltd. | Minorityshareholdersofasubsidiary |
HunanMinshengtangBiotechnologyCo.,Ltd. | Minorityshareholdersofasubsidiary |
GuangdongJiyuantangDevelopmentCo.,Ltd. | Minorityshareholdersofasubsidiary |
XishuangbannaDishengPharmaceuticalCo.,Ltd. | Minorityshareholdersofasubsidiary |
BeijingHuafangInvestmentCo.,Ltd. | Minorityshareholdersofasubsidiary |
GuHaiqun | Minorityshareholdersofasubsidiary |
ShenzhenJiufengInvestmentCo.,Ltd. | Minorityshareholdersofasubsidiary |
ZhangHaiyan | Minorityshareholdersofasubsidiary |
TaishanQunkangPharmacyCo.,Ltd. | Minorityshareholdersofasubsidiary |
Pu'erSongmaoMedicineGroupCo.,Ltd. | Minorityshareholdersofasubsidiary |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
4.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
HangzhouXihuDistrictCommercialCo.,Ltd. | Minorityshareholdersofasubsidiary |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | Minorityshareholdersofasubsidiary |
DuLongfeng | Minorityshareholdersofasubsidiary |
LiHuichun | Minorityshareholdersofasubsidiary |
ZhangZhenfang | Minorityshareholdersofasubsidiary |
PingdingshanPushengPharmaceuticalCo.,Ltd. | Minorityshareholdersofasubsidiary |
XiongXinyuan | Minorityshareholdersofasubsidiary |
ShenyangShengdiouTradingCo.,Ltd. | Minorityshareholdersofasubsidiary |
ShanghaiBaizhongBusinessDevelopment(Group)Co.,Ltd. | Minorityshareholdersofasubsidiary |
ZhangYechuan | Familymembersoftheactualcontrollerofminorityshareholdersofasubsidiary |
WangYang | Familymembersoftheactualcontrollerofminorityshareholdersofasubsidiary |
LiFang | Theactualcontrollerofminorityshareholdersofasubsidiary |
GuJinhua | Theactualcontrollerofminorityshareholdersofasubsidiary |
NanjingYuanguangTradingCo.,Ltd. | Companiesownedbyminorityshareholdersofasubsidiary |
ShaoguanWujiangDistrictMuyangMedicineInformationConsultantCo.,Ltd. | Companiesownedbyminorityshareholdersofasubsidiary |
TaishanXiangranhuiTradeCo.,Ltd. | Companiesownedbyminorityshareholdersofasubsidiary |
Southeast(Quanzhou)BiotechnologyPharmaceuticalCo.,Ltd. | Companiesownedbyminorityshareholdersofasubsidiary |
ShenzhenWanweiMedicineTradingCo.,Ltd. | SubsidiaryofMainLuckPharmaceutical |
JiangsuWanbangPharmacyMarketingCo.,Ltd. | SubsidiaryofFosunPharm |
ChongqingYaoyouPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
ShanghaiHenliusBiopharmaceuticalsCo.,Ltd. | SubsidiaryofFosunPharm |
TibetYaoyouMedicinesCo.,Ltd. | SubsidiaryofFosunPharm |
JinzhouAvancPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
ShanghaiChaohuiPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
JiangxiEryeMedicineMarketingCo.,Ltd. | SubsidiaryofFosunPharm |
FosunPharmaceuticalDistributionJiangsuCo.,Ltd. | SubsidiaryofFosunPharm |
SichuanHexinPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
SuzhouEryePharmaceuticalLimitedCompany | SubsidiaryofFosunPharm |
HunanDongtingPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.Otherrelatedparties(Continued)
Companyname | Relatedpartyrelationships |
GlaxoSmithKlinePharmaceuticals(Suzhou)Co.,Ltd. | SubsidiaryofFosunPharm |
ShanghaiTransfusionTechnologyCo.,Ltd. | SubsidiaryofFosunPharm |
ShenyangHongqiPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
GuilinPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
JinzhouAvancMedicineCo.,Ltd. | SubsidiaryofFosunPharm |
JiangsuHuanghePharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
HunanYaoyouMedicinesCo.,Ltd. | SubsidiaryofFosunPharm |
SuzhouLaishiTransfusionEquipment | SubsidiaryofFosunPharm |
ChengduListPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
ChongqingHaisimanPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
FoshanChanchengPharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
ShenzhenHengshengHospital | SubsidiaryofFosunPharm |
FoshanChanchengCentralHospitalCo.,Ltd. | SubsidiaryofFosunPharm |
FoshanChanyixingMedicineDevelopmentCo.,Ltd. | SubsidiaryofFosunPharm |
ShenzhenChindexMedicalBeautyClinic | SubsidiaryofFosunPharm |
LecongSupplyandMarketGroupShunketangMedicineCo.,Ltd. | SubsidiaryofFosunPharm |
ChindexShanghaiInternationalTradingCo.,Ltd. | SubsidiaryofFosunPharm |
DalianYalifengBiopharmaceuticalCo.,Ltd. | SubsidiaryofFosunPharm |
ChindexShanghaiInternationalTradingCo.,Ltd. | SubsidiaryofFosunPharm |
NatonBiotechnology(Beijing)Co.,Ltd. | SubsidiaryofFosunNaton |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties
(1)Relatedpartytransactions-goodsandservices
Purchaseofgoodsandreceivingofservicesfromrelatedparties
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmHoldingSubMarketingCenterCo.,Ltd. | Purchaseofgoods | 567,957,995.48 | 8,910,000,000.00 | NO | 548,051,256.56 |
ChinaNationalMedicinesCo.,Ltd. | Purchaseofgoods | 378,976,943.17 | NO | 309,588,426.46 | |
SinopharmHoldingShanxiCo.,Ltd. | Purchaseofgoods | 291,169,816.86 | NO | 302,659,086.81 | |
SinopharmHoldingShenyangCo.,Ltd. | Purchaseofgoods | 218,687,438.90 | NO | 91,252,243.44 | |
SinopharmLerentangMedicineCo.,Ltd. | Purchaseofgoods | 212,774,916.08 | NO | 144,033,107.71 | |
SinopharmHoldingShanxiCo.,Ltd. | Purchaseofgoods | 204,598,556.55 | NO | 168,218,597.08 | |
SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | Purchaseofgoods | 132,068,068.87 | NO | 76,699,225.00 | |
SinopharmGroupCo.,Ltd. | Purchaseofgoods | 130,357,912.20 | NO | 101,625,946.62 | |
FreseniusKabiHuaruiPharmaceuticalsCo.,Ltd. | Purchaseofgoods | 83,397,212.70 | NO | 60,511,824.27 | |
JiangsuWanbangPharmacyMarketingCo.,Ltd. | Purchaseofgoods | 80,954,984.16 | NO | 97,184,029.57 | |
LanzhouBiotechnologyDevelopmentCo.,Ltd. | Purchaseofgoods | 68,090,371.68 | NO | 48,840,600.00 | |
SinopharmHoldingYangzhouCo.,Ltd. | Purchaseofgoods | 51,592,777.55 | NO | 38,126,655.70 | |
SinopharmHoldingXinjiangSpecialDrugsWesternPharmaceuticalCo.,Ltd. | Purchaseofgoods | 45,696,541.00 | NO | 34,152,784.08 | |
SinopharmHoldingLunanCo.,Ltd. | Purchaseofgoods | 40,999,864.55 | NO | 26,448,807.82 | |
SinopharmHoldingInnerMongoliaCo.,Ltd. | Purchaseofgoods | 40,632,946.46 | NO | 35,570,487.58 | |
ChongqingYaoyouPharmaceuticalCo.,Ltd. | Purchaseofgoods | 37,011,667.64 | NO | 26,949,678.43 | |
ShanghaiShyndecPharmaceuticalMarketingCo.,Ltd. | Purchaseofgoods | 36,421,939.26 | NO | 82,302.92 | |
ChinaNationalPharmaceuticalForeignTradeCorporation | Purchaseofgoods | 31,428,461.51 | NO | 8,156,658.48 | |
SinopharmHoldingJilinCo.,Ltd. | Purchaseofgoods | 30,157,192.13 | NO | 11,181,666.83 | |
SinopharmYixinPharmaceuticalCo.,Ltd. | Purchaseofgoods | 28,345,022.18 | NO | 8,249,563.42 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
ShanghaiHenliusBiopharmaceuticalsCo.,Ltd. | Purchaseofgoods | 26,663,502.35 | 8,910,000,000.00 | NO | - |
SinopharmHoldingFujianCo.,Ltd. | Purchaseofgoods | 26,242,880.93 | NO | 21,032,808.12 | |
MainLuckPharmaceutical | Purchaseofgoods | 25,917,861.73 | NO | 16,716,318.29 | |
FoshanWinteamPharmaceuticalGroupLtd. | Purchaseofgoods | 23,659,412.81 | NO | 11,624,754.37 | |
SinopharmHoldingHenanCo.,Ltd. | Purchaseofgoods | 22,693,352.04 | NO | 22,896,338.50 | |
SinopharmHoldingShandongCo.,Ltd. | Purchaseofgoods | 22,619,090.27 | NO | 9,870,222.38 | |
SinopharmHoldingLerentangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 19,472,073.81 | NO | 16,213,399.66 | |
SinopharmGroupGuangdongMedicineDeviceCo.,Ltd. | Purchaseofgoods | 19,340,530.98 | NO | - | |
SouthwestPharmaceuticalCo.,Ltd. | Purchaseofgoods | 17,542,194.64 | NO | - | |
SinopharmHoldingBeijingCo.,Ltd. | Purchaseofgoods | 17,360,821.15 | NO | 32,520,572.80 | |
SinopharmHoldingXinjiangXinteShenrongPharmaceuticalCo.,Ltd. | Purchaseofgoods | 17,310,598.75 | NO | - | |
SinopharmHoldingJiangsuCo.,Ltd. | Purchaseofgoods | 16,730,745.30 | NO | 10,137,097.99 | |
SinopharmHoldingTongliaoCo.,Ltd. | Purchaseofgoods | 16,039,594.19 | NO | 5,810,230.35 | |
SinopharmZhijun | Purchaseofgoods | 15,931,558.84 | NO | 12,126,208.66 | |
SinopharmGroupGuoruiMedicineCo.,Ltd. | Purchaseofgoods | 15,180,518.65 | NO | 2,675,445.41 | |
SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | Purchaseofgoods | 14,889,163.04 | NO | 4,168,839.16 | |
ChengduRongshengPharmacyCo.,Ltd. | Purchaseofgoods | 14,584,099.03 | NO | 8,518,290.00 | |
TibetYaoyouMedicinesCo.,Ltd. | Purchaseofgoods | 14,011,950.98 | NO | 10,576,537.72 | |
SinopharmHoldingHunanCo.,Ltd. | Purchaseofgoods | 13,204,231.22 | NO | 8,970,281.71 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
ShenzhenWanweiMedicineTradingCo.,Ltd. | Purchaseofgoods | 13,151,952.24 | 8,910,000,000.00 | NO | 11,467,474.49 |
YichangHumanwellPharmaceuticalCo.,Ltd. | Purchaseofgoods | 12,457,905.62 | NO | 7,649,748.62 | |
SinopharmPharmaceuticals(Shanghai)Co.,Ltd. | Purchaseofgoods | 12,051,455.59 | NO | 3,507,017.31 | |
SinopharmHoldingPingdingshanCo.,Ltd. | Purchaseofgoods | 11,979,529.78 | NO | 15,984,508.75 | |
SinopharmHoldingXiamenCo.,Ltd. | Purchaseofgoods | 11,957,608.14 | NO | 8,217,598.96 | |
JinzhouAvancPharmaceuticalCo.,Ltd. | Purchaseofgoods | 11,829,570.34 | NO | 7,185,929.54 | |
ChinaOtsukaPharmaceuticalCo.,Ltd. | Purchaseofgoods | 11,763,554.47 | NO | 6,256,674.56 | |
ZhijunPingshan | Purchaseofgoods | 10,838,947.13 | NO | 11,851,634.26 | |
SinopharmHoldingChangzhouCo.,Ltd. | Purchaseofgoods | 10,160,654.93 | NO | 11,126,503.85 | |
SinopharmXingshaPharmaceuticals(Xiamen)Co.,Ltd. | Purchaseofgoods | 9,851,650.37 | NO | 5,872,922.23 | |
SinopharmLerentangShijiazhuangMedicineCo.,Ltd. | Purchaseofgoods | 9,697,409.23 | NO | 7,471,038.17 | |
YunnanSinopharmHoldingDongchangMedicineCo.,Ltd. | Purchaseofgoods | 9,191,104.74 | NO | 989,799.95 | |
SinopharmHoldingJinzhouCo.,Ltd. | Purchaseofgoods | 8,931,064.40 | NO | 3,117,332.78 | |
ShanghaiChaohuiPharmaceuticalCo.,Ltd. | Purchaseofgoods | 7,770,056.47 | NO | 3,912,114.41 | |
SinopharmHoldingNingxiaCo.,Ltd. | Purchaseofgoods | 7,527,437.99 | NO | 12,243,904.08 | |
SinopharmHoldingAnshanCo.,Ltd. | Purchaseofgoods | 7,386,999.04 | NO | 584,206.98 | |
SinopharmGroupShanxiMedicalDevicesCo.,Ltd. | Purchaseofgoods | 6,568,011.43 | NO | 4,980,871.81 | |
JiangxiEryeMedicineMarketingCo.,Ltd. | Purchaseofgoods | 6,315,288.30 | NO | 6,456,636.49 | |
SinopharmHoldingShanxiZhongjianMedicialDeviceChainCo.,Ltd. | Purchaseofgoods | 6,180,889.71 | NO | 7,522,898.44 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
FosunPharmaceuticalDistributionJiangsuCo.,Ltd. | Purchaseofgoods | 5,932,515.36 | 8,910,000,000.00 | NO | 2,481,349.10 |
SinopharmHoldingJinanCo.,Ltd. | Purchaseofgoods | 5,593,031.01 | NO | 3,208,390.44 | |
SinopharmHoldingShanxiDajiuzhouMedicineCo.,Ltd. | Purchaseofgoods | 5,438,916.55 | NO | 4,606,542.22 | |
TaijiGroupChongqingFulingPharmaceuticalCo.,Ltd. | Purchaseofgoods | 5,323,305.69 | NO | - | |
SinopharmJiankun(Beijing)MedicineCo.,Ltd. | Purchaseofgoods | 4,529,929.13 | NO | 1,444,828.32 | |
SinopharmHoldingDonghongMedical(Shanghai)Co.,Ltd. | Purchaseofgoods | 4,477,305.68 | NO | 1,124,358.11 | |
SinopharmAdvanced(Shanghai)MedicineDeviceCo.,Ltd. | Purchaseofgoods | 4,359,697.01 | NO | 649,215.02 | |
BeijingHuashengPharmaceuticalBiotechnologyDevelopmentCo.,Ltd. | Purchaseofgoods | 4,230,984.00 | NO | 1,450,504.18 | |
SinopharmHoldingShanghaiLikangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 4,051,307.75 | NO | 2,283,462.26 | |
TaijiGroupChongqingTongjungePharmaceuticalCo.,Ltd. | Purchaseofgoods | 3,955,453.47 | NO | - | |
SinopharmFengliaoxing(Foshan)PharmaceuticalDrugsCo.,Ltd. | Purchaseofgoods | 3,765,974.30 | NO | 2,745,736.27 | |
ShanghaiShangshengBiologicalProductsCo.,Ltd. | Purchaseofgoods | 3,748,316.28 | NO | 1,506,116.50 | |
SinopharmHoldingChuangkeMedicialTechnology(Guangxi)Co.,Ltd. | Purchaseofgoods | 3,741,777.16 | NO | 796,460.19 | |
ShanghaiInternationalPharmaceuticalTradeCo.,Ltd. | Purchaseofgoods | 3,215,831.81 | NO | 3,897,527.05 | |
SinopharmGroupRongshengPharmaceuticalCo.,Ltd. | Purchaseofgoods | 2,917,177.22 | NO | 1,911,884.91 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
ChinaNationalMedicalDeviceCo.,Ltd. | Purchaseofgoods | 2,866,958.60 | 8,910,000,000.00 | NO | 26,548.67 |
SinopharmHoldingHeilongjiangCo.,Ltd. | Purchaseofgoods | 2,700,433.59 | NO | 2,533,432.31 | |
SinopharmHoldingHuaidejuPharmaceutical(Xiamen)Co.,Ltd. | Purchaseofgoods | 2,654,950.93 | NO | - | |
SichuanHexinPharmaceuticalCo.,Ltd. | Purchaseofgoods | 3,903,635.62 | NO | 2,257,987.38 | |
SinopharmHoldingWuxiCo.,Ltd. | Purchaseofgoods | 2,439,252.13 | NO | 8,550,202.41 | |
SinopharmHoldingHulunBuirCo.,Ltd. | Purchaseofgoods | 2,425,267.22 | NO | 1,564,568.11 | |
SinopharmZhonglianPharmaceuticalGroupCo.,Ltd. | Purchaseofgoods | 2,350,922.70 | NO | 907,465.81 | |
SinopharmHoldingBeijingKangchenBio-PharmaceuticalCo.,Ltd. | Purchaseofgoods | 2,321,886.33 | NO | (550,607.22) | |
SinopharmGroupSouthwestMedicineCo.,Ltd. | Purchaseofgoods | 2,313,721.29 | NO | 372,966.72 | |
SinopharmHoldingTianjinCo.,Ltd. | Purchaseofgoods | 2,113,934.18 | NO | 2,168,770.41 | |
SuzhouEryePharmaceuticalLimitedCompany | Purchaseofgoods | 1,942,102.86 | NO | 1,489,545.90 | |
SinopharmHoldingLinfenNinglePharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,922,967.49 | NO | 160,565.02 | |
SinopharmHoldingXinjiangSpecialDrugsKaramayPharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,801,633.72 | NO | 2,704,084.84 | |
HunanDongtingPharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,673,060.75 | NO | 1,885,047.92 | |
ChinaNationalPharmaceuticalIndustryCo.,Ltd. | Purchaseofgoods | 1,658,893.69 | NO | 1,509,682.80 | |
SinopharmHoldingDalianCo.,Ltd. | Purchaseofgoods | 1,618,603.64 | NO | 1,450,198.00 | |
SinopharmLiaoningMedicalEquipmentCo.,Ltd. | Purchaseofgoods | 1,610,762.20 | NO | 3,970,884.24 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmHoldingBeijingTianxingPuxinBiologicalMedicalCo.,Ltd. | Purchaseofgoods | 1,591,292.21 | 8,910,000,000.00 | NO | 34,820,929.08 |
ShanghaiModernHasen(Shangqiu)PharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,553,305.70 | NO | 506,283.18 | |
SinopharmLuya(Shandong)PharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,537,349.20 | NO | 2,381,688.57 | |
SinopharmHoldingYanchengCo.,Ltd. | Purchaseofgoods | 1,355,193.79 | NO | 1,623,042.70 | |
SinopharmTongjitang(Guizhou)PharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,342,043.34 | NO | 2,616,939.67 | |
GlaxosmithklinePharmaceuticals(Suzhou)Co.,Ltd. | Purchaseofgoods | 1,312,782.80 | NO | 6,570,287.55 | |
SinopharmChuankangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,292,333.10 | NO | 1,699,176.97 | |
HuayiPharmaceuticalCo.,Ltd. | Purchaseofgoods | 1,266,831.84 | NO | 176,144.72 | |
SinopharmLerentangQinhuangdaoPharmaceuticalTradingCo.,Ltd | Purchaseofgoods | 1,156,691.29 | NO | - | |
SinopharmHoldingFuzhouCo.,Ltd. | Purchaseofgoods | 1,152,589.16 | NO | 2,117,865.83 | |
SinopharmLingyunBiopharmaceutical(Shanghai)Co.,Ltd. | Purchaseofgoods | 1,017,142.82 | NO | 1,717,968.13 | |
BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | Purchaseofgoods | 984,816.68 | NO | 2,391,565.82 | |
SinopharmHoldingYunnanCo.,Ltd. | Purchaseofgoods | 805,065.42 | NO | 143,973.45 | |
SinopharmShantouJinshiPharmaceuticalCo.,Ltd. | Purchaseofgoods | 781,581.70 | NO | 1,077,980.94 | |
SinopharmHoldingAnhuiHuaningMedicineCo.,Ltd. | Purchaseofgoods | 781,575.58 | NO | 1,434,252.18 | |
SinopharmHoldingXinjiangSpecialDrugsKashgarPharmaceuticalCo.,Ltd. | Purchaseofgoods | 773,057.14 | NO | 627,174.03 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmHuixinqinyuan(Beijing)TechnologyDevelopmentCo.,Ltd. | Purchaseofgoods | 753,274.35 | 8,910,000,000.00 | NO | 1,300,658.82 |
SinopharmHoldingNantongCo.,Ltd. | Purchaseofgoods | 697,002.20 | NO | - | |
SinopharmWeiqidaPharmaceuticalCo.,Ltd. | Purchaseofgoods | 690,157.52 | NO | 668,790.52 | |
SinopharmHoldingBiopharmaceutical(Tianjin)Co.,Ltd. | Purchaseofgoods | 682,560.86 | NO | 414,430.28 | |
ShanghaiTransfusionTechnologyCo.,Ltd. | Purchaseofgoods | 667,699.12 | NO | 712,212.39 | |
SinopharmHoldingQuanzhouCo.,Ltd. | Purchaseofgoods | 662,423.54 | NO | 880,856.56 | |
ShenyangHongqiPharmaceuticalCo.,Ltd. | Purchaseofgoods | 653,104.18 | NO | 359,010.73 | |
SinopharmHoldingSpecialDrugsShiheziPharmaceuticalCo.,Ltd. | Purchaseofgoods | 607,344.52 | NO | 132,136.11 | |
ChengduInstituteofBiologicalProductsCo.,Ltd. | Purchaseofgoods | 562,767.00 | NO | 475,738.80 | |
SinopharmHoldingBenxiCo.,Ltd. | Purchaseofgoods | 559,188.59 | NO | - | |
ShanghaiMerroPharmaceuticalCo.,Ltd. | Purchaseofgoods | 542,162.94 | NO | 749,178.23 | |
SinopharmGroupYibinPharmaceuticalsCo.,Ltd. | Purchaseofgoods | 536,821.03 | NO | 433,524.84 | |
SinopharmholdingsHubeiCo.,Ltd. | Purchaseofgoods | 531,440.87 | NO | 58,060,607.87 | |
YunnanTianjiangYifangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 497,209.07 | NO | - | |
GuilinPharmaceuticalCo.,Ltd. | Purchaseofgoods | 491,568.15 | NO | 351,228.30 | |
SinopharmholdingsBeijingHuahongCo.,Ltd. | Purchaseofgoods | 471,946.23 | NO | 2,856,735.70 | |
SinopharmHoldingShanghaiBiomedicineCo.,Ltd. | Purchaseofgoods | 408,296.15 | NO | 282,209.74 | |
SinopharmGroupShanxiRuifulaiCo.,Ltd. | Purchaseofgoods | 404,922.04 | NO | - | |
SinopharmHoldingYangzhouMedicalTreatmentEquipmentCo.,Ltd. | Purchaseofgoods | 371,264.92 | NO | 1,209,038.66 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2010 |
WuhanZhongshengYujinBiologicalMedicineCo.,Ltd. | Purchaseofgoods | 354,016.00 | 8,910,000,000.00 | NO | - |
ShantouJinshiPowderInjectionCo.,Ltd. | Purchaseofgoods | 351,589.74 | NO | 300,803.34 | |
SinopharmHoldingChifengCo.,Ltd. | Purchaseofgoods | 347,527.93 | NO | - | |
SinopharmXinjiangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 341,818.02 | NO | 368,206.57 | |
SinopharmHoldingZhejiangCo.,Ltd. | Purchaseofgoods | 317,534.11 | NO | 194,238.02 | |
SinopharmHoldingPuerCo.,Ltd. | Purchaseofgoods | 296,085.02 | NO | 446,396.77 | |
SinopharmHoldingZhihuiminsheng(Tianjin)PharmaceuticalCo.,Ltd. | Purchaseofgoods | 295,539.81 | NO | 2,181,662.15 | |
SinopharmWuhanBloodProductsCo.,Ltd. | Purchaseofgoods | 281,200.00 | NO | 24,800.00 | |
JinzhouAvancMedicineCo.,Ltd. | Purchaseofgoods | 265,412.37 | NO | 2,780,545.99 | |
SinopharmHoldingHubeiLikangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 260,747.00 | NO | - | |
SinopharmHoldingHainanHongyiCo.,Ltd. | Purchaseofgoods | 258,280.38 | NO | 17,043.48 | |
SinopharmHoldingPutianCo.,Ltd. | Purchaseofgoods | 257,643.78 | NO | 466,764.43 | |
SinopharmSichuanPharmaceuticalCo.,Ltd. | Purchaseofgoods | 253,894.16 | NO | 144,648.00 | |
SinopharmHoldingBayannurCo.,Ltd. | Purchaseofgoods | 234,878.49 | NO | 667,045.83 | |
SinopharmHoldingAnhuiCo.,Ltd. | Purchaseofgoods | 180,725.82 | NO | 2,398,623.06 | |
TaijiGroup | Purchaseofgoods | 166,678.24 | NO | - | |
JiangsuHuanghePharmaceuticalCo.,Ltd. | Purchaseofgoods | 162,782.30 | NO | - | |
SichuanJiangyouZhongbaAconitiScienceandTechnologyDevelopmentCo.,Ltd. | Purchaseofgoods | 142,201.82 | NO | - | |
SinopharmHoldingHunanPharmaceuticalDevelopmentCo.,Ltd. | Purchaseofgoods | 136,860.13 | NO | 157,222.35 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
TheFourthPharmaceuticalCo.,Ltd.ofZhonglianGroup | Purchaseofgoods | 124,447.86 | 8,910,000,000.00 | NO | (1,875.00) |
HunanYaoyouMedicinesCo.,Ltd. | Purchaseofgoods | 121,513.28 | NO | - | |
SinopharmHoldingShanxiMingdikangMedicineCo.,Ltd. | Purchaseofgoods | 110,206.77 | NO | 42,957.42 | |
SinopharmHoldingNanpingNewforceCo.,Ltd | Purchaseofgoods | 105,027.03 | NO | 122,980.30 | |
SinopharmHoldingXinye(Hubei)MedicineCo.,Ltd. | Purchaseofgoods | 101,222.21 | NO | 56,646.03 | |
SinopharmHoldingChangshaCo.,Ltd. | Purchaseofgoods | 84,558.36 | NO | 1,783,867.44 | |
TaijiGroupZhejiangDongfangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 79,709.72 | NO | - | |
SinopharmHoldingXinjiangSpecialDrugsYiliPharmaceuticalCo.,Ltd. | Purchaseofgoods | 68,861.47 | NO | - | |
SinopharmHoldingKunmingCo.,Ltd. | Purchaseofgoods | 58,396.46 | NO | - | |
TaijiGroupSichuanMianyangPharmaceuticalCo.,Ltd. | Purchaseofgoods | 48,842.47 | NO | - | |
SinopharmHoldingChangdeCo.,Ltd. | Purchaseofgoods | 48,318.59 | NO | - | |
SinopharmHoldingSanyiMedicine(Wuhu)Co.,Ltd. | Purchaseofgoods | 37,095.80 | NO | 46,347.42 | |
SinopharmShyndec | Purchaseofgoods | 36,180.53 | NO | 9,493,936.28 | |
SinopharmHoldingOrdosCo.,Ltd. | Purchaseofgoods | 35,001.77 | NO | - | |
SinopharmInnerMongoliaMedicalEquipmentCo.,Ltd. | Purchaseofgoods | 35,000.88 | NO | - | |
SinopharmJingfang(Anhui)PharmaceuticalCo.,Ltd. | Purchaseofgoods | 20,306.19 | NO | 766,468.52 | |
TaijiGroupSichuanNanchongPharmaceuticalCo.,Ltd. | Purchaseofgoods | 18,751.86 | NO | - | |
SinopharmHoldingDalianHechengCo.,Ltd. | Purchaseofgoods | 17,404.47 | NO | 48,749.02 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmHoldingHainanCo.,Ltd. | Purchaseofgoods | 13,042.99 | 8,910,000,000.00 | NO | 111,398.23 |
SinopharmMedicalInstrument(Huizhou)Co.,Ltd. | Purchaseofgoods | 10,618.77 | NO | - | |
SinopharmGroupMedicineLogisticCo.,Ltd. | Purchaseofgoods | 9,450.54 | NO | 11,161.53 | |
SinopharmHoldingChangshaGaoxinMedicineCo.,Ltd. | Purchaseofgoods | 9,380.53 | NO | 32,964.60 | |
SinopharmHoldingNanjingWendePharmaceuticalCo.,Ltd. | Purchaseofgoods | 9,026.54 | NO | 9,026.54 | |
SinopharmGroupLinfenCo.,Ltd. | Purchaseofgoods | 8,257.25 | NO | 107,014.36 | |
SinopharmDevice(Guangdong)MedicalTechnologyCo.,Ltd. | Purchaseofgoods | 6,578.33 | NO | 52,672.56 | |
SinopharmLiaoningMedicalEquipmentCo.,Ltd. | Purchaseofgoods | 4,424.78 | NO | - | |
SinopharmHoldingZhangzhouCo.,Ltd. | Purchaseofgoods | 2,835.40 | NO | 73,228.32 | |
SinopharmHoldingYangzhouBiologicalProductsCo.,Ltd. | Purchaseofgoods | 1,850.00 | NO | 49,400.00 | |
SuzhouLaishiTransfusionEquipment | Purchaseofgoods | 1,019.47 | NO | - | |
NatonBiotechnology(Beijing)Co.,Ltd. | Purchaseofgoods | 63.72 | NO | - | |
SinopharmShenzhenMedicineDeviceCo.,Ltd. | Purchaseofgoods | - | NO | 4,689,458.43 | |
ShanghaiZenoBiotechnologyCo.,Ltd. | Purchaseofgoods | - | NO | 4,424,779.00 | |
SinopharmHoldingHubeiGuodaPharmacyCo.,Ltd. | Purchaseofgoods | - | NO | 3,749,173.52 | |
ChinaNationalScientificInstruments&MaterialsI&EShenzhenCo.,Ltd. | Purchaseofgoods | - | NO | 3,716,814.16 | |
SinopharmHoldingChongqingCo.,Ltd. | Purchaseofgoods | - | NO | 3,106,188.00 | |
SinopharmMedicalInstrumentHainanCo.,Ltd. | Purchaseofgoods | - | NO | 2,109,734.51 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmHoldingWuhanHongshenMedicineCo.,Ltd. | Purchaseofgoods | - | 8,910,000,000.00 | NO | 1,415,929.21 |
Sinopharm(Dalian)MedicialDeviceCo.,Ltd. | Purchaseofgoods | - | NO | 928,255.76 | |
SinopharmHoldingChuangkeYuanzheMedicialTechnology(Shanghai)Co.,Ltd. | Purchaseofgoods | - | NO | 672,566.40 | |
SinopharmHoldingLinyiMedicialDeviceCo.,Ltd. | Purchaseofgoods | - | NO | 633,769.93 | |
SinopharmHebeiMedicalInstrumentCo.,Ltd. | Purchaseofgoods | - | NO | 607,424.77 | |
SinopharmGuangdongGlobalPharmaceuticalCo.,Ltd. | Purchaseofgoods | - | NO | 581,499.90 | |
LiaoningPilotFreeTradeZoneChinaMedicalDeviceTechnologyCo.,Ltd. | Purchaseofgoods | - | NO | 260,176.99 | |
ChengduListPharmaceuticalCo.,Ltd. | Purchaseofgoods | - | NO | 204,849.56 | |
FujianChentianJinlingPharmaceuticalCo.,Ltd. | Purchaseofgoods | - | NO | 138,669.72 | |
SinopharmHoldingShanxiJinzhongCo.,Ltd. | Purchaseofgoods | - | NO | 119,470.72 | |
SinopharmHoldingShanxiRunheMedicineCo.,Ltd. | Purchaseofgoods | - | NO | 93,171.55 | |
SinopharmGroupMed-TechCo.,Ltd. | Purchaseofgoods | - | NO | 92,920.35 | |
SinopharmDezhong(Foshan)PharmaceuticalCo.,Ltd. | Purchaseofgoods | - | NO | 53,734.51 | |
SinopharmHoldingRizhaoCo.,Ltd. | Purchaseofgoods | - | NO | 34,498.69 | |
SinopharmHoldingJiangxiCo.,Ltd. | Purchaseofgoods | - | NO | 28,244.60 | |
SinopharmHoldingChengduPharmaceuticalCo.,Ltd. | Purchaseofgoods | - | NO | 11,307.62 | |
SinopharmHoldingShiyanCo.,Ltd. | Purchaseofgoods | - | NO | 2,088.50 | |
SinopharmHoldingUlanqabCo.,Ltd. | Purchaseofgoods | - | NO | 2,043.91 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmHoldingShanxiJinchengCo.,Ltd. | Purchaseofgoods | - | 8,910,000,000.00 | NO | 171.81 |
SinopharmHoldingLianyungangCo.,Ltd. | Purchaseofgoods | - | NO | (478.47) | |
ChongqingHaisimanPharmaceuticalCo.,Ltd. | Purchaseofgoods | - | NO | (3,514.34) | |
SINO-TCMShanghaiMedicine&MedicinalMaterialsCo.,Ltd. | Purchaseofgoods | - | NO | (10,888.69) | |
SinopharmHoldingChangzhouMedicalLogisticsCenterCo.,Ltd. | Purchaseofgoods | - | NO | (191,787.19) | |
SinopharmHoldingBaotouCo.,Ltd. | Purchaseofgoods | (88.50) | NO | 126,066.66 | |
SinopharmGroupShanghaiMedicineDeviceCo.,Ltd. | Purchaseofgoods | (209.96) | NO | 308,584.08 | |
SinopharmHoldingDezhouCo.,Ltd. | Purchaseofgoods | (223.18) | NO | 108,484.59 | |
SinopharmHoldingTaizhouCo.,Ltd. | Purchaseofgoods | (350.45) | NO | 81,224.26 | |
ChinaMedicalEquipmentShandongCo.,Ltd. | Purchaseofgoods | (2,177.00) | NO | 14,427.65 | |
SinopharmHoldingGuang’anCo.,Ltd. | Purchaseofgoods | (6,594.69) | NO | - | |
SinopharmGroupMedicineLogisticCo.,Ltd. | Storageandtransportcost,informationsystemaccessfee | 9,631,686.33 | 80,000,000.00 | NO | 8,264,849.06 |
SinopharmGroup | Consultingservicefee | 2,269,577.44 | NO | - | |
SinopharmHuixinqinyuan(Beijing)TechnologyDevelopmentCo.,Ltd. | Consultingservicefee | 658,831.86 | NO | - | |
SinopharmHoldingZhihuiminsheng(Tianjin)PharmaceuticalCo.,Ltd. | Storageandtransportcost;Consultingservicefee | 518,400.00 | NO | - | |
ShanghaiTongyuInformationTechnologyCo.,Ltd. | Consultingservicefee,informationsystemaccessfee | 476,169.82 | NO | 187,905.67 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Purchaseofgoodsandreceivingofservicesfromrelatedparties(Continued)
Relatedparty | Typeoftransaction | Forthesixmonthsended30June2021 | Approvedtradingquota | whetherthetransactionlimitisexceeded | Forthesixmonthsended30June2020 |
SinopharmForeignTrade(Beijing)Co.,Ltd. | Equipmentmaintenancefee | 141,592.92 | 80,000,000.00 | NO | - |
SinopharmHoldingHenanCo.,Ltd. | Consultingservicefee | 106,046.95 | NO | - | |
ChinaNationalPharmaceuticalForeignTradeCorporation | Equipmentmaintenancefee | 68,938.05 | NO | - | |
GuorunMedicalSupplyChainService(Shanghai)Co.,Ltd. | Informationsystemaccessfee | 49,056.60 | NO | 12,264.15 | |
SinopharmGroupGuangdongMedicineDeviceCo.,Ltd. | Operationservicefee | 34,651.32 | NO | - | |
XinjiangBaitongPropertyServiceCo.,Ltd. | Propertyfee | 1,150.44 | NO | - | |
SinopharmHoldingJilinCo.,Ltd. | Consultingservicefee | 109.23 | NO | - | |
SinopharmHealthOnlineCo.,Ltd. | Consultingservicefee | - | NO | 7,008,590.59 | |
ShanghaiBeiyiGuodaPharmaceuticalCo.Ltd. | Consultingservicefee | - | NO | 1,492,677.11 | |
SinopharmPharmaceuticalLogisticsCo.,Ltd. | Storageandtransportcost;Consultingservicefee | - | NO | 93,635.83 | |
SinopharmLogisticsBeijingCo.,Ltd. | Storageandtransportcost;Consultingservicefee | - | NO | 54,060.78 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmGroup | Saleofgoods | 139,234,971.54 | 110,426,213.05 |
FoshanChanchengPharmaceuticalCo.,Ltd. | Saleofgoods | 68,883,280.00 | 49,079,098.20 |
SinopharmHoldingHainanCo.,Ltd. | Saleofgoods | 56,647,385.55 | 60,158,578.46 |
ShanghaiBeiyiGuodaPharmaceuticalCo.Ltd. | Saleofgoods | 51,633,689.10 | 61,896,587.65 |
SinopharmLerentangMedicineCo.,Ltd. | Saleofgoods | 30,299,085.61 | 22,566,166.73 |
SinopharmHoldingBeijingCo.,Ltd. | Saleofgoods | 20,211,375.98 | 12,909,717.52 |
SinopharmHoldingHainanHongyiCo.,Ltd. | Saleofgoods | 19,732,331.43 | 13,367,342.74 |
SinopharmHoldingWenzhouCo.,Ltd. | Saleofgoods | 16,294,606.34 | 14,794,703.17 |
SinopharmLingyunBiopharmaceutical(Shanghai)Co.,Ltd. | Saleofgoods | 15,169,815.63 | 10,455,648.05 |
SinopharmHoldingShandongCo.,Ltd. | Saleofgoods | 14,001,108.69 | 6,925,017.46 |
HandanSinopharmLerentangPharmacyChainCo.,Ltd. | Saleofgoods | 13,521,643.14 | 1,075,458.43 |
ShenzhenHengshengHospital | Saleofgoods | 13,376,757.25 | 10,629,421.43 |
SinopharmHoldingHenanCo.,Ltd. | Saleofgoods | 12,870,576.33 | 9,642,957.94 |
FoshanChanchengCentralHospitalCo.,Ltd. | Saleofgoods | 12,092,528.87 | 7,665,327.44 |
BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | Saleofgoods | 10,239,238.49 | 10,679,779.77 |
SinopharmholdingsBeijingHuahongCo.,Ltd. | Saleofgoods | 10,138,011.45 | 5,763,714.05 |
SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | Saleofgoods | 8,887,736.05 | 1,587,426.88 |
SinopharmHoldingNantongCo.,Ltd. | Saleofgoods | 8,373,035.18 | 7,861,952.62 |
SinopharmHoldingJinzhouCo.,Ltd. | Saleofgoods | 7,182,756.92 | 72,477.87 |
SinopharmHoldingSubMarketingCenterCo.,Ltd. | Saleofgoods | 6,713,774.05 | 5,584,808.87 |
SinopharmHoldingDonghongMedical(Shanghai)Co.,Ltd. | Saleofgoods | 6,709,036.12 | 784,084.53 |
SinopharmHoldingShanxiCo.,Ltd. | Saleofgoods | 6,114,523.08 | 2,812,873.37 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmGroup(Tianjin)EasternBokangPharmaceuticalCo.,Ltd. | Saleofgoods | 5,801,373.68 | 4,803,387.32 |
SinopharmHoldingHubeiCo.,Ltd. | Saleofgoods | 5,725,139.41 | 18,913,611.09 |
SinopharmHoldingYangzhouCo.,Ltd. | Saleofgoods | 5,243,275.79 | 3,233,686.62 |
SinopharmLerentang(Langfang)PharmaceuticalTradeCo.,Ltd. | Saleofgoods | 4,540,492.31 | 18,101.77 |
FoshanChanyixingMedicineDevelopmentCoLtd. | Saleofgoods | 4,356,266.82 | 3,705,867.85 |
SinopharmLerentangTangshanMedicineCo.,Ltd. | Saleofgoods | 3,561,044.84 | 661,960.55 |
SinopharmLerentangXingtaiPharmaceuticalCo.,Ltd. | Saleofgoods | 3,311,038.77 | - |
SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | Saleofgoods | 3,187,482.23 | 492,572.13 |
SinopharmHoldingShanghaiLikangPharmaceuticalCo.,Ltd. | Saleofgoods | 2,986,283.70 | 3,680,499.78 |
SinopharmHoldingJilinCo.,Ltd. | Saleofgoods | 2,942,030.47 | 1,599,917.79 |
SinopharmHoldingTianjinCo.,Ltd. | Saleofgoods | 2,941,625.35 | 1,822,107.93 |
ShanghaiMerroPharmaceuticalCo.,Ltd. | Saleofgoods | 2,858,507.18 | 3,312,398.44 |
SinopharmLerentangQinhuangdaoPharmaceuticalTradingCo.,Ltd | Saleofgoods | 2,637,455.35 | 16,467.26 |
SinopharmHoldingShanxiCo.,Ltd. | Saleofgoods | 2,569,451.46 | 3,053,010.35 |
SinopharmHoldingGuizhouMedicalDeviceCo.,Ltd. | Saleofgoods | 2,506,974.27 | 255,175.71 |
SinopharmLerentangBaodingTradingCo.,Ltd. | Saleofgoods | 2,386,692.15 | - |
SinopharmLerentangBaodingHongkangPharmaceuticalChainCo.,Ltd. | Saleofgoods | 2,371,766.36 | 1,716,599.10 |
HutchisonWhampoaSinopharmPharmaceuticals(Shanghai)Co.,Ltd. | Saleofgoods | 2,280,410.62 | 1,724,205.31 |
SinopharmSichuanPharmaceuticalCo.,Ltd. | Saleofgoods | 2,270,896.31 | 5,574,204.53 |
SinopharmHoldingYunnanCo.,Ltd. | Saleofgoods | 2,197,412.02 | 1,875,892.22 |
SinopharmHoldingHunanCo.,Ltd. | Saleofgoods | 2,170,058.36 | 1,594,378.72 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmHoldingShanxiCo.,Ltd. | Saleofgoods | 1,759,444.55 | 190,595.28 |
SinopharmHoldingXinjiangSpecialDrugsWesternPharmaceuticalCo.,Ltd. | Saleofgoods | 1,732,284.48 | 2,349,651.28 |
SinopharmHoldingAnhuiCo.,Ltd. | Saleofgoods | 1,714,909.94 | 3,490,356.70 |
SinopharmGroupSouthwestMedicineCo.,Ltd. | Saleofgoods | 1,686,783.92 | 1,891,076.22 |
SinopharmLerentangHengshuiMedicineCo.,Ltd. | Saleofgoods | 1,541,096.39 | 158,792.13 |
SinopharmHoldingDalianCo.,Ltd. | Saleofgoods | 1,505,999.43 | 1,320,364.57 |
ShanghaiGuodaLingyunPharmacyCo.,Ltd. | Saleofgoods | 1,444,193.49 | 786,887.13 |
SinopharmHoldingAnshanCo.,Ltd. | Saleofgoods | 1,410,135.08 | - |
ChinaNationalMedicinesCo.,Ltd. | Saleofgoods | 1,269,341.13 | 2,178,096.79 |
SinopharmHoldingJiangxiCo.,Ltd. | Saleofgoods | 1,230,819.17 | 499,633.43 |
SinopharmHolding(Hubei)HankouPharmacyCo.,Ltd. | Saleofgoods | 1,164,258.24 | - |
SinopharmHoldingAnhuiPharmaceuticalCo.,Ltd. | Saleofgoods | 1,152,047.45 | 693,361.90 |
SinopharmHoldingXuzhouCo.,Ltd. | Saleofgoods | 1,108,631.54 | 1,271,612.79 |
ShanghaiLiyiPharmacyCo.,Ltd | Saleofgoods | 1,102,980.44 | 690,837.84 |
SinopharmHoldingShangqiuCo.,Ltd. | Saleofgoods | 1,039,646.02 | - |
SinopharmHoldingFujianCo.,Ltd. | Saleofgoods | 992,070.43 | 51,109,674.50 |
SinopharmHoldingGansuCo.,Ltd. | Saleofgoods | 863,189.43 | 662,808.94 |
SinopharmHoldingGuizhouCo.,Ltd. | Saleofgoods | 836,038.24 | 749,381.57 |
SinopharmHoldingNingxiaCo.,Ltd. | Saleofgoods | 766,385.82 | 607,397.50 |
SinopharmHoldingChongqingTaiminPharmaceuticalCo.,Ltd. | Saleofgoods | 675,555.69 | 174,838.95 |
SinopharmHoldingWuxiCo.,Ltd. | Saleofgoods | 651,490.72 | 545,114.34 |
SinopharmHoldingAnshunCo.,Ltd. | Saleofgoods | 637,336.24 | 626,960.18 |
SinopharmHoldingTongrenCo.,Ltd. | Saleofgoods | 608,054.18 | 347,824.70 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmHoldingLerentangHebeiPharmaceuticalCo.,Ltd. | Saleofgoods | 585,023.94 | 477,391.38 |
SinopharmHoldingGuizhou(Zunyi)MedicalEquimentCo.,Ltd. | Saleofgoods | 551,323.97 | 722,382.88 |
SinopharmHoldingJiangsuCo.,Ltd. | Saleofgoods | 526,573.72 | 578,180.26 |
SinopharmHoldingZunyiCo.,Ltd. | Saleofgoods | 497,385.52 | 1,078,617.62 |
SinopharmHoldingWuhuCo.,Ltd. | Saleofgoods | 483,333.34 | 421,019.02 |
SinopharmLerentangCangzhouMedicineCo.,Ltd. | Saleofgoods | 441,107.97 | 27,143.36 |
SinopharmHoldingDalianHechengCo.,Ltd. | Saleofgoods | 440,610.07 | 39,122.93 |
ShenzhenChindexMedicalBeautyClinic | Saleofgoods | 388,613.67 | 97,277.83 |
SinopharmHoldingShanghaiBiomedicineCo.,Ltd. | Saleofgoods | 367,752.21 | 282,212.28 |
ShanghaiShengxinPharmacyCo.,Ltd. | Saleofgoods | 352,446.68 | - |
SinopharmLerentangQinhuangdaoMedicineCo.,Ltd. | Saleofgoods | 352,417.43 | 107,256.67 |
SinopharmLerentangTangshanMedicineCo.,Ltd. | Saleofgoods | 330,239.40 | - |
SinopharmBaiseDeviceCo.,Ltd. | Saleofgoods | 328,663.72 | 102,654.87 |
SinopharmHoldingShanxiPharmacyCo.,Ltd. | Saleofgoods | 274,021.65 | - |
SinopharmHoldingQinghaiCo.,Ltd. | Saleofgoods | 262,068.06 | 253,282.77 |
JiangmenXinhuiDistrictJianfengPharmaceuticalCo.,Ltd. | Saleofgoods | 253,856.26 | - |
SinopharmHoldingHongheCo.,Ltd. | Saleofgoods | 233,627.39 | 411,978.99 |
SinopharmLerentangXingtaiMedicineCo.,Ltd. | Saleofgoods | 224,344.53 | 178,966.16 |
SinopharmHoldingJiaozuoCo.,Ltd. | Saleofgoods | 220,106.10 | 183,421.75 |
SinopharmHoldingAnhuiPharmaceuticalChainCo.,Ltd. | Saleofgoods | 190,577.18 | - |
SinopharmHoldingChuxiongCo.,Ltd. | Saleofgoods | 185,415.94 | 83,585.92 |
SinopharmHoldingNanjingWendePharmaceuticalCo.,Ltd. | Saleofgoods | 175,046.02 | 79,064.60 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
GuoyaoLerentangShijiazhuangMedicalManagementCo.,Ltd. | Saleofgoods | 169,490.24 | 55,743.09 |
SinopharmHoldingTianjinNorthMedicineCo.,Ltd. | Saleofgoods | 165,577.13 | 237,608.84 |
SinopharmHoldingChongqingCo.,Ltd. | Saleofgoods | 157,390.71 | 98,396.45 |
SinopharmHoldingInnerMongoliaCo.,Ltd. | Saleofgoods | 150,193.67 | 159,586.47 |
SinopharmLerentangCangzhouPharmaceuticalTradingCo.,Ltd. | Saleofgoods | 143,767.71 | - |
SinopharmLerentangShijiazhuangMedicineCo.,Ltd. | Saleofgoods | 135,104.03 | 8,730.28 |
SinopharmGuangdongMedicalExaminationCo.,Ltd. | Saleofgoods | 134,910.79 | 163,965.18 |
FoshanChengnanFengliaoxingMedicialHospitalCo.,Ltd. | Saleofgoods | 134,895.13 | 87,322.13 |
SinopharmHoldingBenxiCo.,Ltd. | Saleofgoods | 134,235.92 | - |
SinopharmLerentangChengdeMedicineCo.,Ltd. | Saleofgoods | 129,707.75 | 63,193.63 |
SinopharmFengliaoxingMedicalHospitalCo.,Ltd. | Saleofgoods | 123,210.38 | 75,159.98 |
SinopharmHoldingPingdingshanCo.,Ltd. | Saleofgoods | 121,061.94 | - |
SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | Saleofgoods | 110,309.74 | 113,097.35 |
SinopharmLerentangZhangjiakouMedicineCo.,Ltd. | Saleofgoods | 107,351.54 | - |
SinopharmAdvanced(Shanghai)MedicalDeviceCo.,Ltd. | Saleofgoods | 107,011.95 | - |
SinopharmHoldingFuzhouCo.,Ltd. | Saleofgoods | 93,210.07 | 131,345.42 |
SinopharmLerentangLangfangPharmaceuticalCo.,Ltd. | Saleofgoods | 88,799.03 | 55,538.93 |
SinopharmHoldingLongyanCo.,Ltd. | Saleofgoods | 87,410.63 | 57,138.07 |
SinopharmHoldingHubeiHongyuanCo.,Ltd. | Saleofgoods | 74,265.48 | 133,587.47 |
SinopharmMedicalInstrumentGuizhouQiannanCo.,Ltd. | Saleofgoods | 70,346.37 | 16,276.77 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)
Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmLerentangHandanMedicineCo.,Ltd. | Saleofgoods | 69,991.28 | 18,101.77 |
SinopharmHoldingWuhanGuodaPharmacyCo.,Ltd. | Saleofgoods | 66,101.95 | - |
SinopharmLerentangBaodingMedicineCo.,Ltd. | Saleofgoods | 57,943.93 | 32,999.89 |
SinopharmLerentangZhangjiakouMedicineCo.,Ltd. | Saleofgoods | 55,499.70 | 84,353.70 |
SinopharmZhijun | Saleofgoods | 54,493.27 | 3,922.08 |
SinopharmGroupGuangdongMedicineDeviceCo.,Ltd. | Saleofgoods | 48,348.50 | 8,494.51 |
SinopharmHoldingProfessionalPharmacy(Hainan)Co.,Ltd. | Saleofgoods | 40,146.37 | - |
SinopharmLerentangHealthcareShijiazhuangPharmacyCo.,Ltd. | Saleofgoods | 35,758.14 | 41,262.69 |
SinopharmHoldingPutianCo.,Ltd. | Saleofgoods | 26,888.49 | 53,777.00 |
SinopharmHoldingYanchengCo.,Ltd. | Saleofgoods | 25,340.97 | 556,583.59 |
ChinaNationalScientificInstruments&MaterialsI&EShenzhenCo.,Ltd. | Saleofgoods | 25,022.45 | 11,412.30 |
SinopharmHoldingChangzhouCo.,Ltd. | Saleofgoods | 21,218.05 | 110,397.17 |
ChongqingTongjungeCo.,Ltd. | Saleofgoods | 19,289.52 | - |
SichuanTaijiPharmacyChainCo.,Ltd. | Saleofgoods | 18,141.59 | - |
SinopharmHoldingHongrunMedicalBusinessService(Shanghai)Co.,Ltd. | Saleofgoods | 16,629.61 | 5,383.97 |
SinopharmHoldingZhuanyePharmacy(Dongfang)Co.,Ltd. | Saleofgoods | 14,607.52 | 8,438.69 |
SinopharmHoldingHunanWeianPharmacyMedicineChainCompanyLimited | Saleofgoods | 13,825.24 | - |
SinopharmHoldingNingdeCo.,Ltd. | Saleofgoods | 10,083.19 | 30,249.56 |
SinopharmHoldingChangxingProfessionalPharmacy(Haikou)Co.,Ltd. | Saleofgoods | 6,978.32 | 12,993.87 |
SinopharmHoldingTaizhouCo.,Ltd. | Saleofgoods | 5,834.87 | 68,810.53 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmHoldingPharmacy(Shanghai)Co.,Ltd. | Saleofgoods | 4,862.18 | - |
SinopharmGroupFengliaoxingMedicalHospital(FoshanNanhai)Co.,Ltd. | Saleofgoods | 3,939.20 | 2,261.97 |
SinopharmGuanaiYuankangPharmacy(Haikou)Co.,Ltd. | Saleofgoods | 2,902.65 | 34,988.29 |
SinopharmHoldingDalianSpecialDrugsPharmaceuticalCo.,Ltd. | Saleofgoods | 2,831.86 | - |
SinopharmGroupShanxiMedicalDevicesCo.,Ltd. | Saleofgoods | 2,795.57 | - |
SinopharmHolding(Shandong)MedicineDeviceCo.,Ltd. | Saleofgoods | 2,492.03 | - |
SinopharmHoldingProfessionalPharmacySongyuanCo.,Ltd. | Saleofgoods | 1,231.86 | - |
SinopharmMedicalInstrument(Jiangmen)Co.,Ltd. | Saleofgoods | 884.96 | - |
SinopharmHoldingShenyangCo.,Ltd. | Saleofgoods | 839.65 | 92,078.76 |
SinopharmHoldingXinyuCo.,Ltd. | Saleofgoods | 632.94 | - |
LecongSupplyandMarketGroupShunketangMedicineCo.,Ltd. | Saleofgoods | 58.41 | - |
SinopharmHoldingTongliaoCo.,Ltd. | Saleofgoods | 45.14 | - |
SinopharmHoldingSuzhouCo.,Ltd. | Saleofgoods | 3.54 | - |
SinopharmZhuhaiMedicalInstrumentCo.,Ltd. | Saleofgoods | - | 7,446,238.57 |
ChindexInternationalTrading(Shanghai)Co.,Ltd. | Saleofgoods | - | 3,037,167.60 |
ChinaSinopharmInternationalCorporation | Saleofgoods | - | 2,988,690.22 |
SinopharmHoldingQuanzhouCo.,Ltd. | Saleofgoods | - | 1,628,615.99 |
ZhijunPingshan | Saleofgoods | - | 297,706.43 |
DongyuanAccord | Saleofgoods | - | 230,559.29 |
YuxiSinopharmMedicineCo.,Ltd. | Saleofgoods | - | 226,147.04 |
FoshanChanchengDistrictShiwanTownChengnanCommunityHealthServiceCenter | Saleofgoods | - | 207,388.60 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmHunanProv.MedicalEquipmentCo.,Ltd. | Saleofgoods | - | 142,300.88 |
FreseniusKabiHuaruiPharmaceuticalsCo.,Ltd. | Saleofgoods | - | 84,955.75 |
SinopharmHoldingQianxi’nanCo.,Ltd. | Saleofgoods | - | 47,058.57 |
SinopharmHoldingFuzhouCo.,Ltd. | Saleofgoods | - | 36,927.44 |
GuangdongYifangPharmaceuticalCo.,Ltd. | Saleofgoods | - | 27,079.65 |
SinopharmHoldingKunmingPharmacyCo.,Ltd. | Saleofgoods | - | 26,664.78 |
SinopharmHoldingBeijingTianxingPuxinBiologicalMedicalCo.,Ltd. | Saleofgoods | - | 25,300.89 |
SinopharmGuanaiJikunPharmacy(Haikou)Co.,Ltd. | Saleofgoods | - | 17,838.67 |
SinopharmFengliaoxing(Foshan)MedicinesCo.,Ltd. | Saleofgoods | - | 12,682.56 |
SinopharmLerentangLangfangMedicineCo.,Ltd. | Saleofgoods | - | 7,323.36 |
MainLuckPharmaceutical | Saleofgoods | - | 6,610.62 |
SinopharmHoldingXiamenCo.,Ltd. | Saleofgoods | - | 5,889.38 |
SinopharmHoldingZhenjiangCo.,Ltd. | Saleofgoods | - | 5,614.16 |
GuangdongJienuo | Saleofgoods | - | 2,657.08 |
SinopharmMedicalInstrument(Hainan)Co.,Ltd. | Saleofgoods | - | 1,805.31 |
SinopharmHoldingGuizhouMedicialChainCo.,Ltd. | Saleofgoods | - | 1,340.53 |
SinopharmHoldingShanxiHejinPharmaceuticalCo.,Ltd. | Saleofgoods | - | 1,187.61 |
SinopharmHoldingUlanqabCo.,Ltd. | Saleofgoods | - | (555.14) |
SinopharmHoldingJilinChainStoreCo.,Ltd. | Saleofgoods | - | (16,556.17) |
SinopharmGroupFengliaoxingPharmacy(Foshan)Co.,Ltd. | Saleofgoods | - | (26,464.91) |
SinopharmHoldingChengduCo.,Ltd. | Saleofgoods | (20,800.88) | 238,592.93 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmGroupMedicineLogisticCo.,Ltd. | Transportandstorageincome | 4,729,519.50 | 3,176,727.67 |
ChinaNationalMedicinesCo.,Ltd. | Subleaseincome,transportandstorageincome | 1,658,616.64 | 3,116,205.52 |
SinopharmZhijun | Subleaseincome,canteenincome | 1,299,722.86 | 1,250,273.36 |
SinopharmGuangdongMedicineDeviceSupplyChainCo.,Ltd. | Consultingserviceincome | 498,556.31 | 82,325.73 |
SinopharmHoldingSubMarketingCenterCo.,Ltd. | Consultingserviceincome | 404,513.64 | 1,253,573.97 |
GuangdongJienuo | Transportandstorageincome | 252,229.35 | - |
ZhijunTrade | Subleaseincome | 157,142.88 | 285,714.30 |
SinopharmMedicalInstrumentGuangxiMedicalTechnologyCo.,Ltd. | SPDserviceincome | 135,813.29 | - |
SinopharmBaiseDeviceCo.,Ltd. | SPDserviceincome | 104,923.15 | - |
SinopharmHoldingHunanWeianPharmacyMedicineChainCompanyLimited | Subleaseincome | 102,102.49 | 97,240.50 |
SinopharmMedicalInstrument(Foshan)Co.,Ltd. | SPDserviceincome | 89,941.38 | - |
ZhijunPingshan | Transportandstorageincome | 83,186.24 | 129,797.90 |
SinopharmGroupSouthwestMedicineCo.,Ltd. | Transportandstorageincome | 79,480.00 | - |
SinopharmHoldingShanxiZhongjianMedicalDeviceChainCo.,Lt | Businesspromotionincome | 51,415.10 | - |
SinopharmHoldingLerentangHebeiPharmaceuticalCo.,Ltd. | Businesspromotionincome | 50,471.71 | - |
SinopharmHoldingShanxiCo.,Ltd. | Businesspromotionincome | 31,886.79 | 1,886.79 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(1)Relatedpartytransactions-goodsandservices(Continued)Saleofgoodsandrenderingofservices(Continued)
RelatedParty | Typeoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmHoldingJilinCo.,Ltd. | Transportandstorageincome | 26,000.00 | - |
SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | SPDserviceincome | 25,173.94 | - |
SinopharmDevice(Guangdong)MedicalTechnologyCo.,Ltd. | SPDserviceincome | 19,777.54 | - |
SinopharmHoldingShanxiDajiuzhouMedicineCo.,Ltd. | Businesspromotionincome | 15,377.36 | - |
SinopharmHoldingShenyangCo.,Ltd. | Consultingserviceincome | 2,452.83 | - |
SinopharmGroupGuangdongMedicineDeviceCo.,Ltd. | Consultingserviceincome | 1,523.21 | - |
SinopharmMedicalInstrument(Huizhou)Co.,Ltd. | Consultingserviceincome | 173.96 | - |
SinopharmHoldingHubeiCo.,Ltd. | Transportandstorageincome | - | 81,773.22 |
SinopharmHuixinqinyuan(Beijing)TechnologyDevelopmentCo.,Ltd. | Consultingserviceincome | - | 17,169.81 |
ChinaNationalScientificInstruments&MaterialsI&EShenzhenCo.,Ltd. | Consultingserviceincome | - | 2.64 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(2)Relatedpartytransactions-leases
(a)Asthelessor | |||
Typeofassetsunderleases | IncomefromleasesForthesixmonthsended30June2021 | IncomefromleasesForthesixmonthsended30June2020 |
SinopharmZhijun | Building | 957,142.86 | 957,142.86 |
ZhijunTrade | Building | 157,142.88 | 285,714.30 |
SinopharmHoldingHunanWeianPharmacyMedicineChainCompanyLimited | Building | 102,102.49 | 97,240.50 |
BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | Building | 66,666.66 | - |
ChinaNationalMedicinesCo.,Ltd. | Building | 52,554.86 | 52,554.86 |
(b)Asthelessee | |||
Typeofassetsunderleases | ExpensefromleasesForthesixmonthsended30June2021 | ExpensefromleasesForthesixmonthsended30June2020 | |
HunanMinshengtangBiotechnologyCo.,Ltd. | Building | 7,317,209.70 | - |
SinopharmGroup | Building | 5,406,057.00 | - |
SinopharmGroupMedicineLogisticCo.,Ltd. | Equipment | 3,749,999.99 | 3,750,000.00 |
SinopharmGroupMedicineLogisticCo.,Ltd. | Building | 3,539,999.99 | 3,540,000.00 |
BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | Building | 5,536,320.75 | 5,296,226.44 |
LerentangInvestmentGroupCo.,Ltd. | Building | 4,361,467.88 | 3,224,047.60 |
ShenyangPharmaceuticalCo.,Ltd. | Building | 3,543,964.78 | 3,571,428.61 |
SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | Building | 2,748,595.47 | 3,786,173.34 |
SinopharmHoldingYangzhouCo.,Ltd. | Building | 1,866,023.82 | - |
NanjingYuanguangTradingCo.,Ltd. | Building | 1,077,247.29 | 1,923,809.52 |
GuangdongJiyuantangDevelopmentCo.,Ltd. | Building | 921,180.26 | 978,504.36 |
SinopharmHoldingShanxiJinchengCo.,Ltd. | Building | 600,000.00 | - |
SinopharmGroupShanghaiCo.,Ltd. | Building | 586,365.00 | 2,031,905.96 |
ShaoguanWujiangDistrictMuyangMedicineInformationConsultantCo.,Ltd. | Building | 508,827.42 | 478,984.74 |
XishuangbannaDishengPharmaceuticalCo.,Ltd. | Building | 405,799.98 | - |
SinopharmHolding(China)FinancingLeaseCo.,Ltd. | Building | 360,000.00 | - |
TaishanXiangranhuiTradeCo.,Ltd. | Equipment | 462,670.01 | 389,625.00 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(2)Relatedpartytransactions-leases(Continued)
(b)Asthelessee(Continued) | |||
Typeofassetsunderleases | ExpensefromleasesForthesixmonthsended30June2021 | ExpensefromleasesForthesixmonthsended30June2020 | |
ZhangYechuan | Building | 333,046.64 | - |
WangYang | Building | 312,305.70 | 295,868.56 |
LiFang | Building | 269,047.62 | 254,761.90 |
SinopharmHoldingBeijingCo.,Ltd. | Building | 272,400.00 | - |
GuangxiYifangTianjiangPharmaceuticalCo.,Ltd. | Building | 257,389.00 | - |
BeijingSinopharmTianyuanRealEstate&PropertyManagementCo.,Ltd. | Building | 242,857.14 | 181,428.58 |
SinopharmHoldingXinjiangSpecialDrugsKashgarPharmaceuticalCo.,Ltd. | Building | 216,191.74 | - |
SinopharmHoldingXinjiangXinteKaramayPharmaceuticalCo.,Ltd. | Building | 215,968.52 | - |
GuJinhua | Building | 187,740.00 | 178,800.00 |
SinopharmXinjiangPharmaceuticalCo.,Ltd. | Building | 177,233.88 | - |
BeijingHuafangInvestmentCo.,Ltd. | Building | 119,004.08 | 120,934.28 |
Southeast(Quanzhou)BiotechnologyPharmaceuticalCo.,Ltd. | Building | 118,025.28 | - |
GuHaiqun | Building | 104,099.04 | 99,143.81 |
ShenzhenJiufengInvestmentCo.,Ltd. | Building | 92,279.59 | - |
ZhangHaiyan | Building | 85,714.26 | - |
ZhijunPingshan | Building | 50,917.44 | - |
ZhangGuitang | Building | 49,714.26 | |
TaishanQunkangPharmacyCo.,Ltd. | Equipment | 11,258.41 | - |
SinopharmHolding(China)FinancingLeaseCo.,Ltd. | Building | - | 2,971,727.14 |
Pu'erSongmaoMedicineGroupCo.,Ltd. | Building | - | 1,984,761.90 |
SinopharmHoldingRizhaoCo.,Ltd. | Building | - | 436,785.87 |
HangzhouXihuDistrictCommercialCo.,Ltd. | Building | - | 146,438.10 |
ChinaNationalMedicinesCo.,Ltd. | Building | - | 142,857.14 |
TaishanQunkangPharmacyCo.,Ltd. | Building | - | 70,850.46 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 71,629,923.57 | 25February2021 | 25August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 54,707,698.10 | 25February2021 | 25May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 94,787,926.58 | 6May2021 | 6August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 50,462,024.83 | 17May2021 | 17August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 48,621,724.23 | 26February2021 | 26May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 47,123,809.11 | 30April2021 | 30October2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 30,698,840.96 | 29January2021 | 29July2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 13,237,656.55 | 29January2021 | 29April2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 41,035,658.40 | 5February2021 | 5May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 36,462,587.66 | 10May2021 | 30June2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 19,867,578.99 | 19May2021 | 19August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 15,663,049.52 | 19May2021 | 19September2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 34,614,169.13 | 30June2021 | 30December2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 33,675,870.87 | 26May2021 | 26August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 26,570,964.00 | 10February2021 | 10May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 19,998,663.88 | 20May2021 | 20August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 5,650,549.88 | 20May2021 | 27August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 25,471,272.13 | 31May2021 | 31August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 25,123,710.36 | 3June2021 | 3September2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 24,991,580.40 | 23June2021 | 23September2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 24,272,643.76 | 8February2021 | 8May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 22,224,875.91 | 28January2021 | 28April2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 20,712,214.94 | 7May2021 | 7August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 20,341,265.01 | 4February2021 | 4May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 19,215,568.92 | 24February2021 | 24May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 18,756,773.39 | 22February2021 | 22May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 17,331,983.85 | 15April2021 | 30June2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 9,569,134.14 | 17June2021 | 29October2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 6,424,446.52 | 17June2021 | 8October2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 15,853,329.24 | 25May2021 | 27August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 12,201,711.11 | 1April2021 | 30June2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 11,497,531.01 | 12May2021 | 12August2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 8,830,838.40 | 09June2021 | 08October2021 | Short-termborrowings |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 8,222,169.28 | 7February2021 | 7May2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 5,876,451.19 | 27April2021 | 30June2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 5,042,535.17 | 25June2021 | 25December2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 4,283,314.86 | 10June2021 | 10September2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 4,060,815.23 | 18June2021 | 26October2021 | Short-termborrowings |
SinopharmGroupFinanceCo.,Ltd. | 44,296,134.90 | 20January2021 | 29April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 36,495,375.70 | 20January2021 | 29March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 20,957,120.78 | 20January2021 | 5July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 13,865,920.44 | 20January2021 | 23February2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 12,428,990.00 | 20January2021 | 17May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 10,882,062.53 | 20January2021 | 23March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 10,214,229.97 | 20January2021 | 24March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 10,000,000.00 | 20January2021 | 6May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 9,565,723.90 | 20January2021 | 30March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 7,799,879.19 | 20January2021 | 7July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 7,590,732.63 | 20January2021 | 16March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 7,042,747.95 | 20January2021 | 7April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,537,002.78 | 20January2021 | 12February2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,026,702.20 | 20January2021 | 14July2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 4,926,793.36 | 20January2021 | 26February2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,907,195.62 | 20January2021 | 30June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,506,000.00 | 20January2021 | 27July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,888,241.63 | 20January2021 | 25February2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,398,007.79 | 20January2021 | 30September2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,058,953.56 | 20January2021 | 28March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,740,000.00 | 20January2021 | 3April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,396,451.40 | 20January2021 | 27February2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,200,000.00 | 20January2021 | 28April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,000,000.00 | 20January2021 | 6July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,822,498.07 | 20January2021 | 31March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,448,834.11 | 20January2021 | 23April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,157,784.94 | 20January2021 | 30April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,108,342.37 | 20January2021 | 14April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,017,440.00 | 20January2021 | 4March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,000,000.00 | 20January2021 | 9February2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 54,801,891.65 | 13January2021 | 28May2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 38,986,447.03 | 13January2021 | 30June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 30,000,000.00 | 13January2021 | 27August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 22,265,381.78 | 13January2021 | 23June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 19,674,402.16 | 13January2021 | 25June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,835,167.48 | 13January2021 | 29June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,783,483.59 | 13January2021 | 21March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,519,239.80 | 13January2021 | 19November2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,471,900.80 | 13January2021 | 11May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,164,873.99 | 13January2021 | 5May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,858,045.62 | 13January2021 | 8September2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,000,000.00 | 13January2021 | 28June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,523,993.34 | 13January2021 | 7June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,500,000.00 | 13January2021 | 19May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,292,152.37 | 13January2021 | 12August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 18,680,231.59 | 17May2021 | 26July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 15,883,376.88 | 17May2021 | 27July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 14,286,605.28 | 17May2021 | 28July2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 13,480,000.00 | 17May2021 | 25July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,796,478.52 | 17May2021 | 10August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,273,537.35 | 17May2021 | 30July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,378,924.20 | 17May2021 | 30June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,960,609.75 | 17May2021 | 23July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,703,388.49 | 17May2021 | 22June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,595,598.82 | 17May2021 | 29October2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,182,401.59 | 17May2021 | 3August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,008,800.00 | 17May2021 | 11November2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,700,944.91 | 17May2021 | 29July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,488,466.57 | 17May2021 | 7August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,361,657.30 | 17May2021 | 8July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,038,005.12 | 17May2021 | 10June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,035,276.72 | 17May2021 | 2July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 997,255.88 | 17May2021 | 16June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 616,725.82 | 17May2021 | 22July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 561,672.80 | 17May2021 | 14July2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 10,459,326.96 | 9February2021 | 25April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 9,152,110.07 | 9February2021 | 27April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 7,677,033.25 | 9February2021 | 29April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,880,000.00 | 9February2021 | 26April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,659,793.42 | 9February2021 | 28March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,000,000.00 | 9February2021 | 22July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,262,169.90 | 9February2021 | 24March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,168,433.40 | 9February2021 | 30April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,000,000.00 | 9February2021 | 21July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,000,000.00 | 9February2021 | 20July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,958,612.59 | 9February2021 | 22April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,741,698.80 | 9February2021 | 30March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,602,467.58 | 9February2021 | 24June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,065,088.90 | 9February2021 | 28June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 900,094.07 | 9February2021 | 25June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 848,393.16 | 9February2021 | 2March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 753,663.52 | 9February2021 | 4March2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 710,000.00 | 9February2021 | 11March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 637,104.40 | 9February2021 | 25March2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 564,197.26 | 9February2021 | 14April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 500,000.00 | 9February2021 | 13April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 500,000.00 | 9February2021 | 16April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 25,075,659.76 | 20February2021 | 25July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 8,060,000.00 | 20February2021 | 26April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 6,309,241.36 | 20February2021 | 27July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 5,467,954.90 | 20February2021 | 27April2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,358,800.90 | 20February2021 | 30June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,873,122.00 | 20February2021 | 5July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,500,000.00 | 20February2021 | 28July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 18,000,000.00 | 22February2021 | 22June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 17,139,076.55 | 22February2021 | 28June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,013,193.00 | 22February2021 | 25June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,337,172.57 | 22February2021 | 24July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,211,874.00 | 22February2021 | 5July2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 14,670,958.74 | 4March2021 | 22August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 5,617,316.39 | 4March2021 | 29July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 5,321,515.08 | 4March2021 | 25May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,147,744.22 | 4March2021 | 26August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,044,614.59 | 4March2021 | 28August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,900,000.00 | 4March2021 | 24August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,189,149.82 | 4March2021 | 23May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 371,529.55 | 4March2021 | 24May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 13,008,065.85 | 5March2021 | 27November2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 4,593,633.89 | 5March2021 | 31May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,274,404.52 | 5March2021 | 27July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 3,000,000.00 | 5March2021 | 30June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,275,132.93 | 5March2021 | 26August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,812,568.88 | 5March2021 | 20May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,642,356.60 | 5March2021 | 18May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,638,360.00 | 5March2021 | 25January2022 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,379,729.57 | 5March2021 | 23July2021 | Discountonbankacceptancebill |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
SinopharmGroupFinanceCo.,Ltd. | 1,000,000.00 | 5March2021 | 26May2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 883,068.00 | 5March2021 | 5July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 751,251.30 | 5March2021 | 9July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 10,000,000.00 | 20April2021 | 24September2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 9,055,204.07 | 20April2021 | 22August2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 5,819,577.00 | 20April2021 | 24June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 5,000,000.00 | 20April2021 | 13October2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,000,000.00 | 20April2021 | 30June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 1,370,000.00 | 20April2021 | 26June2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 23,539,009.32 | 29April2021 | 27July2021 | Discountonbankacceptancebill |
SinopharmGroupFinanceCo.,Ltd. | 2,000,000.00 | 29April2021 | 21July2021 | Discountonbankacceptancebill |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 33,000,000.00 | 22April2021 | 21April2022 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 1,500,000.00 | 22April2021 | 20August2021 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 1,500,000.00 | 22April2021 | 21October2021 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 9,900,000.00 | 14May2021 | 13May2022 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 4,500,000.00 | 30March2021 | 29March2022 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 1,500,000.00 | 30March2021 | 29September2021 | Short-termborrowings |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(3)Relatedpartytransactions-Financing(Continued)
RelatedParty | Amount | InceptionDate | MaturityDate | Note |
Borrowfrom | ||||
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 4,500,000.00 | 21June2021 | 20June2022 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 4,500,000.00 | 19April2021 | 18June2021 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 4,500,000.00 | 15January2021 | 14April2022 | Short-termborrowings |
JilinProvinceYiheInvestmentConsultingCo.,Ltd. | 3,750,000.00 | 18May2021 | 17May2022 | Short-termborrowings |
(4)Relatedpartyassettransfer
Relatedparty | Typesoftransaction | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
ShanghaiTongyuInformationTechnologyCo.,Ltd. | Purchaseofanintangibleasset | 161,045.25 | - |
ShanghaiTongyuInformationTechnologyCo.,Ltd. | Purchaseofaconstructioninprogress | 103,797.89 | - |
(5)Remunerationforkeymanagementpersonnel
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Remunerationforkeymanagementpersonnel | 3,729,169.00 | 4,375,318.00 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
5.MajortransactionsbetweentheGroupanditsrelatedparties(Continued)
(6)Otherrelatedpartytransactions
Interestexpense | |||
Relatedparty | Typesoftransactions | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmGroupFinanceCo.,Ltd. | Paymentofnotesdiscountinterest | 8,036,560.44 | 3,199,207.88 |
SinopharmGroupFinanceCo.,Ltd. | Paymentoffinancecompaniesloaninterest | 5,933,752.64 | 1,882,094.57 |
JilinYiheInvestmentConsultingCo.,Ltd | Paymentofentrustedloaninterest | 1,289,047.50 | - |
ChinaPharmaceuticalGroupCo.,Ltd | Paymentofentrustedloaninterest | 611,679.44 | 513,884.11 |
SinopharmGroupFinanceCo.,Ltd. | Paymentofrelatedpartiesloaninterest | - | 1,311,742.70 |
SinopharmHoldingCo.,Ltd | Paymentofentrustedloaninterest | - | 1,035,984.12 |
SinopharmHolding(China)FinancingLeaseCo.,Ltd. | Paymentofrelatedpartiesloaninterest | - | 44,007.71 |
15,871,040.02 | 7,986,921.09 |
Interestincome | |||
Relatedparty | Typesoftransactions | Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
SinopharmGroupFinanceCo.,Ltd. | Depositinterest | 190,537.17 | 17,036.24 |
190,537.17 | 17,036.24 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties
(1).AccountsReceivable
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Accountsreceivable | SinopharmGroup | 59,684,699.84 | - | 51,044,738.77 | - |
Accountsreceivable | FoshanChanchengPharmaceuticalCo.,Ltd. | 55,897,388.44 | 382,518.20 | 50,457,076.93 | 331,221.14 |
Accountsreceivable | SinopharmLerentangMedicineCo.,Ltd. | 17,212,247.23 | - | 11,339,926.55 | - |
Accountsreceivable | SinopharmHealthOnlineCo.,Ltd. | 16,591,484.79 | - | 5,961,622.28 | - |
Accountsreceivable | SinopharmHoldingHainanCo.,Ltd. | 16,079,241.71 | - | 9,263,188.55 | - |
Accountsreceivable | ShanghaiBeiyi | 12,620,973.07 | - | 26,066,542.88 | - |
Accountsreceivable | HandanSinopharmLerentangPharmacyChainCo.,Ltd. | 9,594,611.38 | - | 832,391.06 | - |
Accountsreceivable | SinopharmHoldingBeijingCo.,Ltd. | 8,097,092.09 | - | 9,329,174.72 | - |
Accountsreceivable | FoshanChanchengCentralHospitalCo.,Ltd. | 7,747,869.21 | 50,335.53 | 6,199,898.17 | 38,953.63 |
Accountsreceivable | SinopharmHoldingHainanHongyiCo.,Ltd. | 6,678,714.03 | - | 5,347,075.47 | - |
Accountsreceivable | ShenzhenHengshengHospital | 6,589,721.27 | - | 5,376,978.17 | - |
Accountsreceivable | SinopharmLingyunBiopharmaceutical(Shanghai)Co.,Ltd. | 4,880,354.02 | - | 4,380,633.00 | - |
Accountsreceivable | SinopharmLerentangBaodingHongkangPharmaceuticalChainCo.,Ltd. | 4,540,010.19 | - | 3,464,166.50 | - |
Accountsreceivable | BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | 4,289,053.68 | - | 4,397,286.71 | - |
Accountsreceivable | SinopharmHoldingHenanCo.,Ltd. | 4,139,688.62 | - | 2,144,155.36 | - |
Accountsreceivable | SinopharmHoldingWenzhouCo.,Ltd. | 4,048,268.69 | - | 3,142,596.82 | - |
Accountsreceivable | SinopharmHoldingDonghongMedical(Shanghai)Co.,Ltd. | 3,834,188.90 | - | 2,049,971.85 | - |
Accountsreceivable | SinopharmHoldingsBeijingHuahongco.,Ltd. | 3,673,535.53 | - | 1,811,083.32 | - |
Accountsreceivable | SinopharmHoldingShandongCo.,Ltd. | 2,831,043.88 | - | 76,095.93 | - |
Accountsreceivable | SinopharmHoldingShanxiCo.,Ltd. | 2,816,264.17 | - | 771,816.12 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Accountsreceivable | SinopharmHoldingJilinCo.,Ltd. | 2,528,223.55 | - | 208,589.40 | - |
Accountsreceivable | FoshanChanyixingMedicineDevelopmentCo.,Ltd. | 2,509,939.17 | 13,136.36 | 3,445,722.95 | 17,975.48 |
Accountsreceivable | SinopharmHoldingSubMarketingCenterCo.,Ltd. | 2,432,642.59 | - | 2,237,094.40 | - |
Accountsreceivable | SinopharmHoldingNantongCo.,Ltd. | 2,304,018.16 | - | 62,224.62 | - |
Accountsreceivable | SinopharmLerentangBaodingTradingCo.,Ltd. | 2,035,819.17 | - | 1,645,313.00 | - |
Accountsreceivable | SinopharmGroup(Tianjin)EasternBokangPharmaceuticalCo.,Ltd. | 1,997,891.99 | - | 943,539.89 | - |
Accountsreceivable | SinopharmLerentangQinhuangdaoPharmaceuticalTradingCo.,Ltd. | 1,889,841.32 | - | 1,067,964.98 | - |
Accountsreceivable | SinopharmLerentangTangshanMedicineCo.,Ltd. | 1,860,045.69 | - | 997,312.62 | - |
Accountsreceivable | SinopharmHoldingShanxiCo.,Ltd. | 1,846,421.01 | - | 94,929.87 | - |
Accountsreceivable | SinopharmHoldingHubeiCo.,Ltd. | 1,554,241.15 | - | 1,252,860.26 | - |
Accountsreceivable | SinopharmHoldingYangzhouCo.,Ltd. | 1,462,063.19 | - | 1,092,414.55 | - |
Accountsreceivable | SinopharmLerentang(Langfang)PharmaceuticalTradeCo.,Ltd. | 1,401,228.87 | - | 1,294,279.54 | - |
Accountsreceivable | HutchisonWhampoaSinopharmPharmaceuticals(Shanghai)Co.,Ltd. | 1,348,814.00 | - | 1,814,506.00 | - |
Accountsreceivable | SinopharmHoldingDalianCo.,Ltd. | 1,183,889.64 | - | 657,906.20 | - |
Accountsreceivable | ShanghaiMerroPharmaceuticalCo.,Ltd. | 1,127,455.20 | - | 1,648,042.00 | - |
Accountsreceivable | SinopharmHoldingShanghaiLikangPharmaceuticalCo.,Ltd. | 1,125,141.84 | - | 1,337,124.28 | - |
Accountsreceivable | SinopharmHoldingShanxiCo.,Ltd. | 1,009,330.58 | - | 63,447.29 | - |
Accountsreceivable | SinopharmHoldingTianjinCo.,Ltd. | 837,878.00 | - | 568,733.37 | - |
Accountsreceivable | ShanghaiGuodaLingyunPharmacyCo.,Ltd. | 824,587.38 | - | 664,836.26 | - |
Accountsreceivable | SinopharmHoldingAnhuiPharmaceuticalCo.,Ltd. | 790,661.48 | - | 225,394.20 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Accountsreceivable | SinopharmHoldingHunanCo.,Ltd. | 665,593.65 | - | 476,299.62 | - |
Accountsreceivable | SinopharmHoldingWuxiCo.,Ltd. | 648,747.00 | - | 129,862.00 | - |
Accountsreceivable | SinopharmLerentangHengshuiMedicineCo.,Ltd. | 627,902.87 | - | 1,197,573.36 | - |
Accountsreceivable | SinopharmHoldingXinjiangSpecialDrugsWesternPharmaceuticalCo.,Ltd. | 623,234.72 | - | 1,385,097.14 | - |
Accountsreceivable | SinopharmLerentangXingtaiPharmaceuticalCo.,Ltd. | 577,711.40 | - | 82,171.75 | - |
Accountsreceivable | SinopharmSichuanPharmaceuticalCo.,Ltd. | 510,242.85 | - | 1,437,709.48 | - |
Accountsreceivable | SinopharmHoldingXuzhouCo.,Ltd. | 483,736.52 | - | 227,353.60 | - |
Accountsreceivable | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 482,610.48 | - | 1,257,499.80 | - |
Accountsreceivable | SinopharmHoldingYunnanCo.,Ltd. | 425,758.31 | - | 139,122.62 | - |
Accountsreceivable | ChinaNationalMedicinesCo.,Ltd. | 409,622.43 | - | 333,566.22 | - |
Accountsreceivable | SinopharmHoldingGansuCo.,Ltd. | 396,351.02 | - | 14,543.96 | - |
Accountsreceivable | SinopharmHoldingAnhuiCo.,Ltd. | 387,196.36 | - | 74,455.49 | - |
Accountsreceivable | SinopharmHoldingJinzhouCo.,Ltd. | 376,206.03 | - | 587,192.90 | - |
Accountsreceivable | SinopharmHoldingAnshanCo.,Ltd. | 341,765.32 | - | 81,120.00 | - |
Accountsreceivable | SinopharmGroupSouthwestMedicineCo.,Ltd. | 339,980.82 | - | 192,876.72 | - |
Accountsreceivable | SinopharmHoldingJiangxiCo.,Ltd. | 327,835.60 | - | 114,697.32 | - |
Accountsreceivable | SinopharmHoldingNingxiaCo.,Ltd. | 240,560.00 | - | 50,448.00 | - |
Accountsreceivable | SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | 237,868.93 | - | 921,543.58 | - |
Accountsreceivable | SinopharmHoldingShanghaiBiomedicineCo.,Ltd. | 207,780.00 | - | 169,080.04 | - |
Accountsreceivable | SinopharmHoldingLerentangHebeiPharmaceuticalCo.,Ltd. | 200,134.47 | - | 120,058.61 | - |
Accountsreceivable | SinopharmHoldingShanxiPharmacyCo.,Ltd. | 161,494.00 | - | - | - |
Accountsreceivable | SinopharmHoldingGuizhouCo.,Ltd. | 145,406.38 | - | 79,571.94 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Accountsreceivable | SinopharmLerentangShijiazhuangMedicineCo.,Ltd. | 140,111.40 | - | 62,413.00 | - |
Accountsreceivable | SinopharmLerentangQinhuangdaoMedicineCo.,Ltd. | 139,548.04 | - | 10,333.92 | - |
Accountsreceivable | SinopharmHolding(Hubei)HankouPharmacyCo.,Ltd. | 130,741.00 | - | - | - |
Accountsreceivable | SinopharmHoldingJiangsuCo.,Ltd. | 122,527.35 | - | 138,015.90 | - |
Accountsreceivable | SinopharmLerentangTangshanMedicineCo.,Ltd. | 112,190.04 | - | - | - |
Accountsreceivable | SinopharmHoldingFujianCo.,Ltd. | 106,344.00 | - | 258,264.00 | - |
Accountsreceivable | ShanghaiLiyi | 106,314.44 | - | 237,727.36 | - |
Accountsreceivable | SinopharmLerentangLangfangPharmaceuticalCo.,Ltd. | 100,342.90 | - | 102,413.00 | - |
Accountsreceivable | SinopharmHoldingDalianHechengCo.,Ltd. | 99,164.02 | - | 16,766.22 | - |
Accountsreceivable | SinopharmMedicalInstrument(Foshan)Co.,Ltd. | 95,337.86 | - | - | - |
Accountsreceivable | SinopharmHoldingQinghaiCo.,Ltd. | 83,207.22 | - | 57,312.76 | - |
Accountsreceivable | SinopharmLerentangZhangjiakouMedicineCo.,Ltd. | 71,875.21 | - | - | - |
Accountsreceivable | SinopharmHoldingWuhanGuodaPharmacyCo.,Ltd. | 68,085.00 | - | - | - |
Accountsreceivable | SinopharmLerentangChengdeMedicineCo.,Ltd. | 65,785.14 | - | - | - |
Accountsreceivable | SinopharmHoldingChuxiongCo.,Ltd. | 61,759.70 | - | - | - |
Accountsreceivable | SinopharmHoldingHongheCo.,Ltd. | 55,179.48 | - | - | - |
Accountsreceivable | SinopharmHoldingBenxiCo.,Ltd. | 52,679.28 | - | - | - |
Accountsreceivable | SinopharmZhijun | 50,503.75 | - | 41,533.50 | - |
Accountsreceivable | SinopharmHoldingProfessionalPharmacy(Hainan)Co.,Ltd. | 45,365.40 | - | - | - |
Accountsreceivable | SinopharmHoldingInnerMongoliaCo.,Ltd. | 45,137.28 | - | 16.00 | - |
Accountsreceivable | ShanghaiShengxinPharmacyCo.,Ltd. | 42,289.16 | - | 217,507.20 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Accountsreceivable | SinopharmMedicalInstrumentGuangxiMedicalTechnologyCo.,Ltd. | 42,276.91 | - | - | - |
Accountsreceivable | SinopharmLerentangZhangjiakouMedicineCo.,Ltd. | 40,042.75 | - | - | - |
Accountsreceivable | SinopharmLerentangShijiazhuangMedicalManagementCo.,Ltd. | 38,872.60 | - | 74,424.44 | - |
Accountsreceivable | SinopharmLerentangHandanMedicineCo.,Ltd. | 37,771.71 | - | 11,012.40 | - |
Accountsreceivable | SinopharmLerentangCangzhouPharmaceuticalTradingCo.,Ltd. | 37,491.28 | - | 470,726.50 | - |
Accountsreceivable | SinopharmHoldingAnshunCo.,Ltd. | 37,206.55 | - | 20,656.00 | - |
Accountsreceivable | SinopharmLerentangBaodingMedicineCo.,Ltd. | 35,216.00 | - | 13,056.35 | - |
Accountsreceivable | SinopharmLerentangCangzhouMedicineCo.,Ltd. | 30,282.41 | - | 39,136.40 | - |
Accountsreceivable | FoshanChengnanFengliaoxingMedicalHospitalCo.,Ltd. | 28,152.70 | 3.53 | 37,151.74 | 10.36 |
Accountsreceivable | SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | 26,684.38 | - | - | - |
Accountsreceivable | SinopharmHoldingTianjinNorthMedicineCo.,Ltd. | 25,316.96 | - | 68,180.00 | - |
Accountsreceivable | SinopharmHoldingFuzhouCo.,Ltd. | 24,627.20 | - | 88.00 | - |
Accountsreceivable | SinopharmFengliaoxingMedicalHospitalCo.,Ltd. | 18,658.86 | 164.15 | 15,505.90 | 131.93 |
Accountsreceivable | SinopharmHoldingZunyiCo.,Ltd. | 17,159.10 | - | - | - |
Accountsreceivable | SinopharmLerentangXintaiMedicineCo.,Ltd. | 12,579.33 | - | 34,154.44 | - |
Accountsreceivable | SinopharmHoldingZhuanyePharmacy(Dongfang)Co.,Ltd. | 11,282.50 | - | 3,560.10 | - |
Accountsreceivable | SinopharmHoldingChengduCo.,Ltd. | 10,563.41 | - | 34,068.41 | - |
Accountsreceivable | SinopharmHoldingChangxingProfessionalPharmacy(Haikou)Co.,Ltd. | 6,667.50 | - | - | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Accountsreceivable | SinopharmLerentangHealthcareShijiazhuangPharmacyCo.,Ltd. | 4,415.33 | - | 1,491.33 | - |
Accountsreceivable | SinopharmGroupShanxiMedicalDevicesCo.,Ltd. | 3,159.00 | - | - | - |
Accountsreceivable | SinopharmHoldingHongrunMedicalBusinessService(Shanghai)Co.,Ltd. | 3,081.60 | - | 5,602.42 | - |
Accountsreceivable | ShanghaiHenliusBiopharmaceuticalsCo.,Ltd. | 1,798.00 | - | - | - |
Accountsreceivable | SinopharmMedicalInstrument(Jiangmen)Co.,Ltd. | 1,000.00 | - | - | - |
Accountsreceivable | SinopharmHoldingPharmacy(Shanghai)Co.,Ltd. | 768.70 | - | - | - |
Accountsreceivable | SinopharmGroupFengliaoxingMedicalHospital(FoshanNanhai)Co.,Ltd. | 56.74 | 0.57 | 916.62 | 9.17 |
Accountsreceivable | SinopharmHoldingTongliaoCo.,Ltd. | 9.60 | - | - | - |
Accountsreceivable | ChinaNationalPharmaceuticalForeignTradeCorporation | - | - | 299,402.99 | - |
Accountsreceivable | FoshanChanchengDistrictShiwanTownChengnanCommunityHealthServiceCenter | - | - | 160,285.82 | 396.20 |
Accountsreceivable | SinopharmHoldingYanchengCo.,Ltd. | - | - | 65,635.20 | - |
Accountsreceivable | SinopharmHoldingChangzhouCo.,Ltd. | - | - | 14,975.52 | - |
Accountsreceivable | JiangmenXinhuiDistrictJianfengPharmaceuticalCo.,Ltd. | - | - | 3,652.00 | - |
Accountsreceivable | SinopharmFengliaoxing(Foshan)PharmaceuticalDrugsCo.,Ltd. | - | - | 3,456.00 | - |
Accountsreceivable | SinopharmGuanaiYuankangPharmacy(Haikou)Co.,Ltd. | - | - | 2,301.60 | - |
Accountsreceivable | SinopharmHoldingShenyangCo.,Ltd. | - | - | 440.00 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Notereceivable | SinopharmHoldingHainanCo.,Ltd. | 7,790,377.25 | - | 48,549,280.19 | - |
Notereceivable | SinopharmHoldingHainanHongyiCo.,Ltd. | 3,648,399.46 | - | 9,445,722.78 | - |
Notereceivable | SinopharmHoldingBeijingCo.,Ltd. | 2,752,320.00 | - | 2,795,361.96 | - |
Notereceivable | SinopharmHoldingShanxiCo.,Ltd. | 927,668.77 | - | 650,373.76 | - |
Notereceivable | InnostarBiotechnologyNantongCo.,Ltd | 15,550.30 | - | - | - |
Notereceivable | SinopharmHoldingShandongCo.,Ltd. | - | - | 1,355,084.16 | - |
Notereceivable | SinopharmLerentangMedicineCo.,Ltd. | - | - | 909,517.66 | - |
Notereceivable | SinopharmHoldingZunyiCo.,Ltd. | - | - | 803,004.11 | - |
Notereceivable | SinopharmHoldingGuizhouYitongMedicineCo.,Ltd. | - | - | 357,540.60 | - |
Notereceivable | SinopharmHoldingAnshanCo.,Ltd. | - | - | 313,535.20 | - |
Notereceivable | SinopharmHoldingJinzhouCo.,Ltd. | - | - | 300,000.00 | - |
Notereceivable | SinopharmHoldingGansuCo.,Ltd. | - | - | 175,281.40 | - |
Notereceivable | SinopharmHoldingGuizhouCo.,Ltd. | - | - | 158,268.10 | - |
Notereceivable | SinopharmHoldingAnhuiCo.,Ltd. | - | - | 140,856.05 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Otherreceivable | ZhijunSuzhou | 46,334,222.24 | 46,334,222.24 | 46,334,222.24 | ZhijunSuzhou |
Otherreceivable | XishuangbannaDishengPharmaceuticalCo.,Ltd. | 16,046,032.95 | - | - | - |
Otherreceivable | SinopharmGroupMedicineLogisticCo.,Ltd. | 3,662,451.54 | - | 2,559,772.89 | - |
Otherreceivable | JiangsuWanbangPharmacyMarketingCo.,Ltd. | 1,106,077.40 | - | 220,000.00 | - |
Otherreceivable | SinopharmShyndec | 983,940.00 | - | 983,940.00 | - |
Otherreceivable | SinopharmHolding(China)FinancingLeaseCo.,Ltd. | 938,513.78 | - | 570,000.00 | - |
Otherreceivable | SinopharmHoldingFujianCo.,Ltd. | 753,015.80 | - | 1,158,302.52 | - |
Otherreceivable | SinopharmZhijun | 421,976.49 | - | 204,351.29 | - |
Otherreceivable | SinopharmHoldingSubMarketingCenterCo.,Ltd. | 414,904.45 | - | - | - |
Otherreceivable | SinopharmHoldingShanghaiBiomedicineCo.,Ltd. | 400,000.00 | - | 400,000.00 | - |
Otherreceivable | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 398,842.11 | - | - | - |
Otherreceivable | GuangdongJienuo | 274,930.00 | - | - | - |
Otherreceivable | DalianYalifengBiopharmaceuticalCo.,Ltd. | 180,900.74 | - | 1.00 | - |
Otherreceivable | SinopharmHoldingXinjiangSpecialDrugsKashgarPharmaceuticalCo.,Ltd. | 170,025.29 | - | 7,174.98 | - |
Otherreceivable | SinopharmHoldingInnerMongoliaCo.,Ltd. | 142,500.00 | - | 256,500.00 | - |
Otherreceivable | SinopharmHoldingXinjiangXinteKaramayPharmaceuticalCo.,Ltd. | 58,582.65 | - | - | - |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Otherreceivable | ZhijunPingshan | 41,684.00 | - | 18,500.00 | - |
Otherreceivable | ZhijunTrade | 31,573.40 | - | 10,779.42 | - |
Otherreceivable | ZhangHaiyan | 30,000.00 | - | 30,000.00 | - |
Otherreceivable | InnostarBiotechnologyNantongCo.,Ltd | 15,550.30 | - | - | - |
Otherreceivable | SinopharmMedicalInstrumentGuangxiMedicalTechnologyCo.,Ltd. | 12,276.81 | - | - | - |
Otherreceivable | ChinaNationalScientificInstruments&MaterialsI&EShenzhenCo.,Ltd. | 10,036.80 | - | - | - |
Otherreceivable | SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | 3,060.93 | - | - | - |
Otherreceivable | SinopharmGroupGuangdongMedicineDeviceCo.,Ltd. | 1,000.00 | - | 60.00 | - |
Otherreceivable | ChinaNationalMedicalDevice(HuiZhou)Co.,Ltd. | 184.40 | - | - | - |
Otherreceivable | DuLongfeng | - | - | 2,057,281.04 | - |
Otherreceivable | LiHuichun | - | - | 2,057,281.04 | - |
Otherreceivable | SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | - | - | 48,493.16 | - |
Otherreceivable | SinopharmGuangdongMedicineDeviceSupplyChainCo.,Ltd. | - | - | 17,397.44 | - |
Otherreceivable | SinopharmZhonglianPharmaceuticalGroupCo.,Ltd. | - | - | 5,000.00 | 1,000.00 |
Otherreceivable | XinjiangBaitongPropertyServiceCo.,Ltd. | - | - | 1,300.00 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Advancestosuppliers | SouthwestPharmaceuticalCo.,Ltd. | 2,675,229.26 | - | - | - |
Advancestosuppliers | NanjingYuanguangTradingCo.,Ltd. | 1,170,978.86 | - | - | - |
Advancestosuppliers | SichuanHexinPharmaceuticalCo.,Ltd. | 710,539.19 | - | - | - |
Advancestosuppliers | ShanghaiShyndecPharmaceuticalMarketingCo.,Ltd. | 440,791.78 | - | 475,673.07 | - |
Advancestosuppliers | SinopharmGroupGuoruiMedicineCo.,Ltd. | 264,040.41 | - | 307,838.82 | - |
Advancestosuppliers | TaijiGroupChongqingFulingPharmaceuticalCo.,Ltd. | 249,048.67 | - | - | - |
Advancestosuppliers | HunanDongtingPharmaceuticalCo.,Ltd. | 166,924.76 | - | 176,257.86 | - |
Advancestosuppliers | ChinaNationalPharmaceuticalIndustryCo.,Ltd. | 149,990.40 | - | - | - |
Advancestosuppliers | ShanghaiTongyuInformationTechnologyCo.,Ltd. | 132,743.36 | - | - | - |
Advancestosuppliers | SinopharmHoldingHubeiCo.,Ltd. | 127,076.65 | - | - | - |
Advancestosuppliers | SinopharmHoldingsBeijingHuahongco.,Ltd. | 104,156.85 | - | 10,984.33 | - |
Advancestosuppliers | SuzhouEryePharmaceuticalLimitedCompany | 91,135.03 | - | 121,669.23 | - |
Advancestosuppliers | SinopharmWeiqidaPharmaceuticalCo.,Ltd. | 81,416.71 | - | - | - |
Advancestosuppliers | ChongqingYaoyouPharmaceuticalCo.,Ltd. | 55,637.49 | - | 408,984.97 | - |
Advancestosuppliers | SinopharmHoldingSubMarketingCenterCo.,Ltd. | 45,683.18 | - | 44,662.50 | - |
Advancestosuppliers | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 34,469.49 | - | - | - |
Advancestosuppliers | HunanYaoyouMedicinesCo.,Ltd. | 26,721.82 | - | - | - |
Advancestosuppliers | SinopharmXingshaPharmaceuticals(Xiamen)Co.,Ltd. | 21,057.70 | - | 137,280.00 | - |
Advancestosuppliers | SinopharmYixinPharmaceuticalCo.,Ltd. | 20,757.00 | - | - | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Advancestosuppliers | TaijiGroupChongqingTongjungePharmaceuticalCo.,Ltd. | 14,901.57 | - | - | - |
Advancestosuppliers | FoshanWinteamPharmaceuticalGroupLtd. | 13,972.00 | - | - | - |
Advancestosuppliers | TaijiGroupGansuTianshuiXihuangEjiaoCo.,Ltd. | 13,648.00 | - | - | - |
Advancestosuppliers | HubeiSinopharmZhonglianMedicineCo.,Ltd. | 13,529.23 | - | 13,529.23 | - |
Advancestosuppliers | TaishanXiangranhuiTradeCo.,Ltd. | 13,150.03 | - | - | - |
Advancestosuppliers | SinopharmTongjitang(Guizhou)PharmaceuticalCo.,Ltd. | 8,956.01 | - | 8,956.01 | - |
Advancestosuppliers | SinopharmGuangdongGlobalPharmaceuticalCo.,Ltd. | 4,708.38 | - | - | - |
Advancestosuppliers | SinopharmGroupRongshengPharmaceuticalCo.,Ltd. | 2,833.81 | - | 12,393.12 | - |
Advancestosuppliers | SinopharmHoldingDalianHechengCo.,Ltd. | 2,444.10 | - | - | - |
Advancestosuppliers | SinopharmHoldingShanxiJinchengCo.,Ltd. | 1,837.72 | - | - | - |
Advancestosuppliers | Zhanghaiyan | 714.29 | - | - | - |
Advancestosuppliers | SinopharmGroup | 594.95 | - | 59,577.44 | - |
Advancestosuppliers | ShanghaiModernHasen(Shangqiu)PharmaceuticalCo.,Ltd. | 457.48 | - | - | - |
Advancestosuppliers | SinopharmShyndec | 61.20 | - | 84.97 | - |
Advancestosuppliers | SinopharmHoldingHubeiLikangPharmaceuticalCo.,Ltd. | 35.08 | - | - | - |
Advancestosuppliers | SinopharmLerentangHebeiMedicineCo.,Ltd. | 0.01 | - | 0.01 | - |
Advancestosuppliers | SinopharmHoldingShanxiCo.,Ltd. | - | - | 17,747,100.00 | - |
Advancestosuppliers | SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | - | - | 1,850,000.00 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(1).AccountsReceivable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 | ||
Grosscarryingamount | Provisionforbaddebt | Grosscarryingamount | Provisionforbaddebt | ||
Advancestosuppliers | FreseniusKabiHuaruiPharmaceuticalsCo.,Ltd. | - | - | 260,846.15 | - |
Advancestosuppliers | ChengduRongshengPharmacyCo.,Ltd. | - | - | 217,055.13 | - |
Advancestosuppliers | LanzhouBiotechnologyDevelopmentCo.,Ltd. | - | - | 180,000.00 | - |
Advancestosuppliers | SinopharmShantouJinshiPharmaceuticalCo.,Ltd. | - | - | 79,332.33 | - |
Advancestosuppliers | GuilinPharmaceuticalCo.,Ltd. | - | - | 74,560.00 | - |
Advancestosuppliers | SinopharmZhijun | - | - | 41,928.00 | - |
Advancestosuppliers | JiangsuWanbangPharmacyMarketingCo.,Ltd. | - | - | 28,796.22 | - |
Advancestosuppliers | SinopharmHoldingBeijingCo.,Ltd. | - | - | 14,878.90 | - |
Advancestosuppliers | JinzhouAvancPharmaceuticalCo.,Ltd. | - | - | 8,351.85 | - |
Advancestosuppliers | SinopharmHoldingChangshaCo.,Ltd. | - | - | 4,476.56 | - |
Advancestosuppliers | SinopharmDevice(Guangdong)MedicalTechnologyCo.,Ltd. | - | - | 4,021.05 | - |
Advancestosuppliers | SinopharmGroupYibinPharmaceuticalsCo.,Ltd. | - | - | 1,377.08 | - |
Advancestosuppliers | SinopharmHoldingYanchengCo.,Ltd. | - | - | 703.62 | - |
Advancestosuppliers | FosunPharmaceuticalDistributionJiangsuCo.,Ltd. | - | - | 81.08 | - |
Advancestosuppliers | SinopharmHoldingNanpingNewforceCo.,Ltd | - | - | 20.46 | - |
Advancestosuppliers | SinopharmHoldingXinye(Hubei)MedicineCo.,Ltd. | - | - | 3.40 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmHoldingSubMarketingCenterCo.,Ltd. | 136,420,774.52 | 100,597,889.85 |
AccountsPayable | ChinaNationalMedicinesCo.,Ltd. | 94,328,048.04 | 53,510,089.86 |
AccountsPayable | SinopharmLerentangMedicineCo.,Ltd. | 92,347,900.63 | - |
AccountsPayable | SinopharmHoldingShanxiCo.,Ltd. | 79,515,178.71 | 8,706,339.43 |
AccountsPayable | SinopharmHoldingShanxiCo.,Ltd. | 50,047,053.30 | 698,931.88 |
AccountsPayable | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 46,826,354.95 | 44,967,413.32 |
AccountsPayable | FreseniusKabiHuaruiPharmaceuticalsCo.,Ltd. | 46,680,139.27 | 31,372,881.57 |
AccountsPayable | SinopharmHoldingShenyangCo.,Ltd. | 42,512,516.24 | 17,044,758.52 |
AccountsPayable | SinopharmGroupCo.,Ltd. | 38,594,822.49 | 30,169,144.90 |
AccountsPayable | JiangsuWanbangPharmacyMarketingCo.,Ltd. | 23,252,792.65 | 14,299,613.79 |
AccountsPayable | LanzhouBiotechnologyDevelopmentCo.,Ltd. | 17,238,914.69 | - |
AccountsPayable | SinopharmHoldingXinjiangSpecialDrugsWesternPharmaceuticalCo.,Ltd. | 15,460,751.55 | 6,926,143.50 |
AccountsPayable | SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | 15,071,393.38 | 13,211,593.60 |
AccountsPayable | SinopharmYixinPharmaceuticalCo.,Ltd. | 12,922,894.16 | 5,223,703.27 |
Accountspayable | SinopharmHoldingLerentangHebeiPharmaceuticalCo.,Ltd. | 12,538,440.66 | 11,917,795.97 |
AccountsPayable | SinopharmHoldingJilinCo.,Ltd. | 12,238,802.76 | 4,774,676.38 |
AccountsPayable | SinopharmHoldingLunanCo.,Ltd. | 10,975,399.71 | - |
AccountsPayable | ChongqingYaoyouPharmaceuticalCo.,Ltd. | 10,259,242.11 | 3,319,845.70 |
AccountsPayable | SinopharmHoldingTongliaoCo.,Ltd. | 9,464,045.96 | 802,269.56 |
AccountsPayable | ShanghaiHenliusBiopharmaceuticalsCo.,Ltd. | 9,349,231.90 | 3,489,402.52 |
AccountsPayable | SinopharmHoldingYangzhouCo.,Ltd. | 9,270,870.65 | 6,056,767.80 |
AccountsPayable | SinopharmHoldingFujianCo.,Ltd. | 8,787,141.12 | 5,306,468.57 |
AccountsPayable | MainLuckPharmaceutical | 8,563,894.25 | 5,586,186.27 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmHoldingShanxiZhongjianMedicalDeviceChainCo.,Ltd. | 8,116,781.92 | 4,873,657.16 |
AccountsPayable | SinopharmHoldingInnerMongoliaCo.,Ltd. | 7,811,861.15 | 2,761,321.64 |
AccountsPayable | SinopharmLerentangShijiazhuangMedicineCo.,Ltd. | 7,687,260.65 | 3,588,817.09 |
AccountsPayable | SinopharmHoldingXinjiangXinteShenrongPharmaceuticalCo.,Ltd. | 7,418,455.79 | 3,753,212.37 |
AccountsPayable | SinopharmHoldingJiangsuCo.,Ltd. | 6,986,215.82 | 6,211,219.22 |
AccountsPayable | SinopharmGroupShanxiMedicalDevicesCo.,Ltd. | 6,366,021.31 | 6,105,947.86 |
AccountsPayable | SinopharmHoldingShandongCo.,Ltd. | 6,124,476.27 | 793,417.76 |
AccountsPayable | YunnanSinopharmHoldingDongchangMedicineCo.,Ltd. | 5,922,302.36 | 1,660,475.22 |
AccountsPayable | FoshanWinteamPharmaceuticalGroupLtd. | 5,488,616.17 | 5,032,327.78 |
AccountsPayable | SinopharmHoldingHunanCo.,Ltd. | 4,923,319.80 | 407,092.81 |
AccountsPayable | ShenzhenWanweiMedicineTradingCo.,Ltd. | 4,869,268.33 | 883,982.13 |
AccountsPayable | SinopharmHoldingBeijingCo.,Ltd. | 4,868,848.38 | 2,391,873.73 |
AccountsPayable | HutchisonWhampoaSinopharmPharmaceuticals(Shanghai)Co.,Ltd. | 4,559,628.22 | 626,104.94 |
AccountsPayable | YichangHumanwellPharmaceuticalCo.,Ltd. | 4,470,996.08 | 702,352.60 |
AccountsPayable | JinzhouAvancPharmaceuticalCo.,Ltd. | 4,411,339.82 | 4,977,249.88 |
AccountsPayable | SinopharmHoldingHenanCo.,Ltd. | 4,396,344.31 | 3,206,888.96 |
AccountsPayable | ZhijunPingshan | 4,272,258.25 | 3,854,209.10 |
AccountsPayable | ChinaOtsukaPharmaceuticalCo.,Ltd. | 3,739,214.15 | 2,677,852.24 |
AccountsPayable | SinopharmHoldingXiamenCo.,Ltd. | 3,388,026.93 | 551,570.55 |
AccountsPayable | ChinaNationalPharmaceuticalForeignTradeCorporation | 3,183,468.89 | 1,264,206.58 |
AccountsPayable | SinopharmHoldingNingxiaCo.,Ltd. | 3,139,723.50 | 2,414,511.01 |
AccountsPayable | SinopharmHoldingJinzhouCo.,Ltd. | 3,002,980.96 | 1,176,931.82 |
AccountsPayable | SinopharmHoldingChangzhouCo.,Ltd. | 2,986,094.33 | 4,061,240.62 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | TibetYaoyouMedicinesCo.,Ltd. | 2,766,861.56 | 5,599,734.54 |
AccountsPayable | SinopharmZhijun | 2,752,553.26 | 2,204,850.71 |
AccountsPayable | TaijiGroupChongqingLinglingPharmaceuticalFactoryCo.,Ltd | 2,678,260.95 | - |
AccountsPayable | SinopharmFengliaoxing(Foshan)PharmaceuticalDrugsCo.,Ltd. | 2,635,957.97 | 2,029,331.09 |
AccountsPayable | SinopharmHoldingShanxiDajiuzhouMedicineCo.,Ltd. | 2,503,237.00 | 206,174.46 |
AccountsPayable | SinopharmHoldingPingdingshanCo.,Ltd. | 2,334,135.94 | 3,110,222.71 |
AccountsPayable | SinopharmHoldingBeijingKangchenBio-PharmaceuticalCo.,Ltd. | 2,297,132.34 | 1,402,636.20 |
AccountsPayable | ShanghaiInternationalPharmaceuticalTradeCo.,Ltd. | 2,268,132.84 | 2,140,826.76 |
AccountsPayable | TaijiGroupChongqingJungePharmaceuticalCo.,Ltd | 2,209,845.30 | - |
AccountsPayable | SinopharmXingshaPharmaceuticals(Xiamen)Co.,Ltd. | 2,169,689.83 | 1,345,750.22 |
AccountsPayable | SinopharmAdvanced(Shanghai)MedicalDeviceCo.,Ltd. | 2,018,301.45 | 474.35 |
AccountsPayable | SinopharmHoldingAnshanCo.,Ltd. | 1,921,040.94 | 210,514.52 |
AccountsPayable | SinopharmHoldingHulunBuirCo.,Ltd. | 1,723,560.47 | 862,728.46 |
AccountsPayable | SinopharmHoldingShanghaiLikangPharmaceuticalCo.,Ltd. | 1,664,002.07 | 1,179,431.76 |
AccountsPayable | SinopharmJiankun(Beijing)MedicineCo.,Ltd. | 1,558,885.49 | 236,040.00 |
AccountsPayable | SinopharmZhonglianPharmaceuticalGroupCo.,Ltd. | 1,528,102.51 | 450,506.71 |
AccountsPayable | SinopharmHoldingWuxiCo.,Ltd. | 1,475,312.09 | 839,716.25 |
AccountsPayable | SinopharmHuixinqinyuan(Beijing)TechnologyDevelopmentCo.,Ltd. | 1,406,460.00 | 1,315,880.00 |
AccountsPayable | FosunPharmaceuticalDistributionJiangsuCo.,Ltd. | 1,396,404.21 | 1,404,453.04 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmHoldingJinanCo.,Ltd. | 1,378,772.68 | 5,044.24 |
AccountsPayable | SinopharmLiaoningMedicalEquipmentCo.,Ltd. | 1,332,215.59 | 801,190.96 |
AccountsPayable | BeijingHuashengPharmaceuticalBiotechnologyDevelopmentCo.,Ltd. | 1,210,637.01 | 275,637.01 |
AccountsPayable | SinopharmHoldingDonghongMedical(Shanghai)Co.,Ltd. | 1,191,544.83 | 189,625.02 |
AccountsPayable | ShanghaiShyndecPharmaceuticalMarketingCo.,Ltd. | 1,120,294.14 | 1,198,963.22 |
AccountsPayable | SinopharmGroup,SouthwestPharmaceuticalCo.,Ltd. | 889,435.22 | - |
AccountsPayable | SinopharmHoldingBeijingTianxingPuxinBiologicalMedicalCo.,Ltd. | 878,317.60 | 1,495,702.47 |
AccountsPayable | SinopharmGroupGuoruiMedicineCo.,Ltd. | 847,231.99 | 1,029,635.96 |
AccountsPayable | JinzhouAvancMedicineCo.,Ltd. | 774,228.85 | 2,251,486.36 |
AccountsPayable | SinopharmLuya(Shandong)PharmaceuticalCo.,Ltd. | 717,286.31 | 1,728,265.11 |
AccountsPayable | SinopharmHoldingHeilongjiangCo.,Ltd. | 709,357.70 | 811,310.59 |
AccountsPayable | SinopharmHoldingLinfenNinglePharmaceuticalCo.,Ltd. | 702,647.45 | 7,414.31 |
AccountsPayable | SinopharmTongjitang(Guizhou)PharmaceuticalCo.,Ltd. | 661,183.36 | 560,063.40 |
AccountsPayable | SinopharmHoldingXinjiangSpecialDrugsKaramayPharmaceuticalCo.,Ltd. | 651,582.93 | 659,567.18 |
AccountsPayable | BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | 641,043.63 | 714,642.68 |
AccountsPayable | FujianChentianJinlingPharmaceuticalCo.,Ltd. | 639,896.10 | 639,896.10 |
AccountsPayable | HuayiPharmaceuticalCo.,Ltd. | 622,400.00 | 110,159.29 |
AccountsPayable | ChinaNationalPharmaceuticalIndustryCo.,Ltd. | 563,196.30 | 614,940.77 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SouthwestPharmaceuticalCo.,Ltd | 498,114.40 | - |
AccountsPayable | SinopharmHoldingZhihuiminsheng(Tianjin)PharmaceuticalCo.,Ltd. | 483,577.38 | 763,894.30 |
AccountsPayable | SinopharmChuanKangPharmaceuticalCo.,Ltd. | 483,468.40 | 228,071.04 |
AccountsPayable | YunnanTianjiangYifangPharmaceuticalCo.,Ltd. | 475,579.30 | 792,663.67 |
AccountsPayable | ShanghaiTransfusionTechnologyCo.,Ltd. | 452,700.00 | 301,800.00 |
AccountsPayable | SinopharmLingyunBiopharmaceutical(Shanghai)Co.,Ltd. | 451,033.67 | 553,653.19 |
AccountsPayable | JiangxiEryeMedicineMarketingCo.,Ltd. | 437,250.19 | 134,268.38 |
AccountsPayable | SichuanHexinPharmaceuticalCo.,Ltd. | 414,600.00 | 1,164,727.22 |
AccountsPayable | SinopharmHoldingsChuangkeMedicalTechnology(Guangxi)Co.,Ltd | 405,660.80 | - |
AccountsPayable | SinopharmHoldingsBenxiCo.,LTD | 356,397.10 | - |
AccountsPayable | SinopharmHoldingTianjinCo.,Ltd. | 352,357.23 | 95,084.93 |
AccountsPayable | SinopharmHoldingYanchengCo.,Ltd. | 344,929.57 | - |
AccountsPayable | SinopharmHoldingXinjiangSpecialDrugsKashgarPharmaceuticalCo.,Ltd. | 338,359.74 | 390,349.10 |
AccountsPayable | SinopharmHoldingSpecialDrugsShiheziPharmaceuticalCo.,Ltd. | 337,497.87 | 126,985.40 |
AccountsPayable | HunanDongtingPharmaceuticalCo.,Ltd. | 335,196.57 | 667,433.56 |
AccountsPayable | JiangsuHuanghePharmaceuticalCo.,Ltd. | 334,470.96 | 229,932.46 |
AccountsPayable | SuzhouEryePharmaceuticalLimitedCompany | 332,911.50 | 350,413.20 |
AccountsPayable | SinopharmLerentangQinhuangdaoPharmaceuticalTradingCo.,Ltd. | 325,253.73 | 355,710.50 |
AccountsPayable | SinopharmHoldingHubeiCo.,Ltd. | 325,147.65 | 706,495.38 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmHoldingFuzhouCo.,Ltd. | 294,318.62 | 655,028.77 |
AccountsPayable | SinopharmHoldingAnhuiHuaningMedicineCo.,Ltd. | 292,609.10 | 248,701.04 |
AccountsPayable | GlaxoSmithKlinePharmaceuticals(Suzhou)Co.,Ltd. | 286,776.33 | 156,960.48 |
AccountsPayable | TaijiGroupSichuanMianyangPharmaceuticalCo.,Ltd | 284,788.67 | - |
AccountsPayable | SinopharmGroupYibinPharmaceuticalsCo.,Ltd. | 281,130.03 | 286,441.67 |
AccountsPayable | SinopharmHoldingYangzhouMedicalTreatmentEquipmentCo.,Ltd. | 280,247.31 | 347,738.10 |
AccountsPayable | SinopharmHoldingPu’erCo.,Ltd. | 267,364.71 | 126,457.83 |
AccountsPayable | SinopharmHoldingDalianCo.,Ltd. | 260,998.30 | 372,970.88 |
AccountsPayable | SinopharmGroupRongshengPharmaceuticalCo.,Ltd. | 246,191.00 | 412,372.07 |
AccountsPayable | ShanghaiMerroPharmaceuticalCo.,Ltd. | 243,184.50 | 196,678.40 |
AccountsPayable | SinopharmHoldingYunnanCo.,Ltd. | 239,684.27 | 128,094.48 |
AccountsPayable | SinopharmHoldingShanghaiBiomedicineCo.,Ltd. | 198,359.00 | 182,202.00 |
AccountsPayable | SinopharmXinjiangPharmaceuticalCo.,Ltd. | 191,183.73 | 94,780.05 |
AccountsPayable | SinopharmShanxiruifulaiPharmaceuticalCo.,Ltd | 163,015.43 | - |
AccountsPayable | SinopharmHoldingPutianCo.,Ltd. | 160,656.67 | 224,611.58 |
AccountsPayable | ShanghaiShangshengBiologicalProductsCo.,Ltd. | 153,756.00 | 194,400.00 |
AccountsPayable | SichuanJiangyouZhongbaFuziTechnologyDevelopmentCo.,Ltd | 148,143.06 | - |
AccountsPayable | ChengduInstituteofBiologicalProductsCo.,Ltd. | 140,400.00 | 374,400.00 |
AccountsPayable | SinopharmHoldingsBeijingHuahongco.,Ltd. | 139,337.70 | 68,274.07 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmHoldingHunanPharmaceuticalDevelopmentCo.,Ltd. | 136,890.18 | 105,438.07 |
AccountsPayable | SinopharmHoldingShanxiMingdikangMedicineCo.,Ltd. | 113,139.81 | 47,953.27 |
AccountsPayable | SinopharmHoldingBiopharmaceutical(Tianjin)Co.,Ltd. | 106,718.02 | 106,918.61 |
AccountsPayable | ChengduRongshengPharmacyCo.,Ltd. | 100,794.89 | 100,000.02 |
AccountsPayable | SinopharmHoldingZhejiangCo.,Ltd. | 100,418.02 | 30,316.89 |
AccountsPayable | SinopharmHoldingBayannurCo.,Ltd. | 96,966.40 | 69,930.10 |
AccountsPayable | WuhanZhongshengYujinbiomedicalCo.,Ltd | 88,504.00 | - |
AccountsPayable | SinopharmShantouJinshiPharmaceuticalCo.,Ltd. | 88,254.41 | 135,961.28 |
AccountsPayable | SinopharmHoldingQuanzhouCo.,Ltd. | 81,315.39 | 203,348.93 |
AccountsPayable | ShanghaiChaohuiPharmaceuticalCo.,Ltd. | 77,054.61 | 1,020,709.97 |
AccountsPayable | SinopharmHoldingHuaideju(Xiamen)PharmacyCo.,Ltd. | 76,448.34 | 84.48 |
AccountsPayable | SinopharmholdingXinteYiliPharmaceuticalCo.,Ltd | 68,861.47 | - |
AccountsPayable | ShenyangHongqiPharmaceuticalCo.,Ltd. | 65,372.23 | 165,983.07 |
AccountsPayable | SinopharmHoldingNantongCo.,Ltd | 61,946.90 | - |
AccountsPayable | ShantouJinshiPowderInjectionCo.,Ltd. | 61,662.00 | 72,590.24 |
AccountsPayable | SinopharmDevice(Guangdong)MedicalTechnologyCo.,Ltd. | 58,450.50 | 76,078.94 |
AccountsPayable | TaijiGroupLtd | 47,123.91 | - |
AccountsPayable | SinopharmHoldingChifengCo.,Ltd | 46,663.80 | - |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmInnerMongoliaMedicalInstrumentCo.,Ltd | 39,551.00 | - |
AccountsPayable | SinopharmHoldingNanpingNewPowerCo.,Ltd | 38,961.61 | - |
AccountsPayable | SinopharmHoldingDezhouCo.,Ltd. | 37,534.02 | 45,750.41 |
AccountsPayable | SinopharmSanyiMedicine(Wuhu)Co.,Ltd. | 35,199.94 | 26,646.40 |
AccountsPayable | SinopharmHoldingAnhuiCo.,Ltd. | 34,219.90 | - |
AccountsPayable | SinopharmHoldingChangzhouMedicalLogisticsCenterCo.,Ltd. | 32,872.49 | 32,872.49 |
AccountsPayable | Sinopharm(Anhui)JingfangPharmaceuticalCo.,Ltd. | 32,814.69 | 59,773.89 |
AccountsPayable | SinopharmholdingShanxiLinfenCo.,Ltd | 31,242.18 | - |
AccountsPayable | ShanghaiModernHasen(Shangqiu)PharmaceuticalCo.,Ltd. | 30,432.28 | 31,024.85 |
AccountsPayable | SinopharmHoldingChangshaCo.,Ltd. | 30,339.75 | - |
AccountsPayable | TaijiGroupZhejiangDongfangPharmaceuticalCo.,Ltd | 30,277.66 | - |
AccountsPayable | SinopharmBeijingHuamiaoPharmaceuticalCo.,Ltd. | 26,862.15 | 131,751.68 |
AccountsPayable | SinopharmGuangdongGlobalPharmaceuticalCo.,Ltd. | 25,018.25 | 28,464.87 |
AccountsPayable | SinopharmWuhanZhonglianSiyaoPharmaceuticalCo.,Ltd. | 19,500.56 | 147,224.95 |
AccountsPayable | ChongqingHaisimanPharmaceuticalCo.,Ltd. | 18,488.82 | 18,488.82 |
AccountsPayable | SinopharmHoldingUlanqabCo.,Ltd. | 16,092.20 | 36,092.20 |
AccountsPayable | SinopharmHoldingNanjingWendePharmaceuticalCo.,Ltd. | 15,958.84 | 10,858.84 |
AccountsPayable | SinopharmHoldingTaizhouCo.,Ltd. | 11,239.87 | 17,598.01 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | ChinaNationalMedicalDevice(HuiZhou)Co.,Ltd. | 8,950.00 | 805.31 |
AccountsPayable | ChinaMedicalEquipmentShandongCo.,Ltd. | 7,303.36 | 29,843.36 |
AccountsPayable | SinopharmHoldingChangshaGaoxinMedicineCo.,Ltd. | 5,825.00 | 12,900.00 |
AccountsPayable | SinopharmholdingHainanHongyiCo.,Ltd | 4,960.00 | - |
AccountsPayable | ChangchunChangshengGenePharmaceuticalCo.,Ltd. | 3,017.25 | 3,807.25 |
AccountsPayable | SinopharmHoldingYangzhouBiologicalProductsCo.,Ltd. | 2,378.07 | 149,183.90 |
AccountsPayable | SinopharmholdingXinye(Hubei)PharmaceuticalCo.,Ltd | 2,170.00 | - |
AccountsPayable | SinopharmHoldingOrdosCo.,Ltd. | 1,771.20 | 1,771.20 |
AccountsPayable | SinopharmNutraceuticals(Shanghai)Co.,Ltd. | 1,461.55 | 1,461.56 |
AccountsPayable | SinopharmDezhong(Foshan)PharmaceuticalCo.,Ltd. | 1,244.76 | 5,453.55 |
AccountsPayable | SinopharmHoldingHuaidejuPharmaceutical(Xiamen)Co.,Ltd. | 1,113.85 | 2,229.36 |
AccountsPayable | SinopharmholdingGuang'anCo.,Ltd | 857.31 | - |
AccountsPayable | GuilinPharmaceuticalCo.,Ltd. | 627.25 | 627.25 |
AccountsPayable | SinopharmAnhuiGreatHealthIndustryCo.,Ltd | 504.00 | - |
AccountsPayable | SinopharmHoldingZhangzhouCo.,Ltd. | 468.00 | 2,119.78 |
AccountsPayable | SinopharmHoldingLiaochengCo.,Ltd. | 174.00 | 174.00 |
AccountsPayable | SinopharmFengliaoxing(Foshan)MedicinesCo.,Ltd. | 127.72 | 127.72 |
AccountsPayable | ChengduListPharmaceuticalCo.,Ltd. | 72.89 | 1,756.39 |
AccountsPayable | NatongBiotechnology(Beijing)Co.,Ltd | 63.72 | - |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
AccountsPayable | SinopharmholdingJilinMedicalInstrumentCo.,Ltd | 47.50 | 47.50 |
AccountsPayable | SinopharmholdingChongqingCo.,Ltd | 45.00 | - |
AccountsPayable | SinopharmShyndec | 15.61 | 612.78 |
AccountsPayable | SinopharmHoldingSuzhouCo.,Ltd. | 13.09 | 13.09 |
AccountsPayable | SinopharmHoldingLinfenCo.,Ltd | 5.00 | 5.30 |
AccountsPayable | SinopharmHoldingXinyuCo.,Ltd | 0.01 | 0.01 |
AccountsPayable | SinopharmGroupGuangxiMedicalDeviceCo.,Ltd. | - | 1,637,168.14 |
AccountsPayable | SinopharmHoldingShanxiJinzhongCo.,Ltd. | - | 304,455.20 |
AccountsPayable | SinopharmHoldingBaotouCo.,Ltd. | - | 16,443.00 |
AccountsPayable | SinopharmHoldingDalianHechengCo.,Ltd. | - | 3,169.55 |
AccountsPayable | SinopharmHoldingShanxiJinchengCo.,Ltd. | - | 2,233.33 |
AccountsPayable | SinopharmGroupShanghaiMedicineDeviceCo.,Ltd. | - | 209.96 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
NotesPayable | SinopharmLerentangMedicineCo.,Ltd. | 178,726,114.00 | 133,513,118.91 |
NotesPayable | SinopharmHoldingSubMarketingCenterCo.,Ltd. | 98,532,398.98 | 145,007,748.49 |
NotesPayable | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 86,581,666.40 | 34,904,620.08 |
NotesPayable | ChinaNationalMedicinesCo.,Ltd. | 46,854,819.69 | 21,240,547.39 |
NotesPayable | SinopharmHoldingShanxiCo.,Ltd. | 37,255,237.87 | 96,475,832.70 |
NotesPayable | SinopharmHoldingShanxiCo.,Ltd. | 29,956,295.04 | 147,484,839.36 |
NotesPayable | SinopharmHoldingShenyangCo.,Ltd. | 27,343,806.55 | 23,666,333.81 |
NotesPayable | JiangsuWanbangPharmacyMarketingCo.,Ltd. | 19,093,642.80 | 42,481,785.07 |
NotesPayable | SinopharmHoldingLunanCo.,Ltd. | 15,322,762.00 | 4,500,000.00 |
NotesPayable | SinopharmHoldingYangzhouCo.,Ltd. | 13,766,896.93 | 4,300,000.00 |
NotesPayable | ChengduRongshengPharmacyCo.,Ltd. | 12,003,000.00 | 10,368,750.00 |
NotesPayable | SinopharmHoldingInnerMongoliaCo.,Ltd. | 11,789,525.01 | 20,429,758.48 |
NotesPayable | SinopharmHoldingFujianCo.,Ltd. | 9,086,169.43 | 15,606,964.31 |
NotesPayable | SinopharmHoldingTongliaoCo.,Ltd. | 8,146,891.51 | - |
NotesPayable | SinopharmHoldingJilinCo.,Ltd. | 7,870,548.03 | 430,080.28 |
NotesPayable | SinopharmLerentangHebeiMedicalInstrumentTradeCo.,Ltd. | 7,734,939.35 | 5,681,012.75 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
NotesPayable | LanzhouBiotechnologyDevelopmentCo.,Ltd | 6,720,000.00 | 34,920,000.00 |
NotesPayable | SinopharmHoldingXiamenCo.,Ltd. | 6,189,287.86 | 3,173,200.37 |
NotesPayable | ChongqingYaoyouPharmaceuticalCo.,Ltd. | 5,683,557.40 | 2,693,445.70 |
NotesPayable | SinopharmHoldingPingdingshanCo.,Ltd. | 5,644,930.05 | 3,000,000.00 |
NotesPayable | SinopharmXingshaPharmaceuticals(Xiamen)Co.,Ltd. | 5,339,586.09 | 1,978,218.04 |
NotesPayable | SinopharmHoldingHenanCo.,Ltd. | 4,804,061.33 | - |
NotesPayable | SinopharmHoldingXinjiangSpecialDrugsWesternPharmaceuticalCo.,Ltd. | 4,226,969.98 | 2,840,425.46 |
NotesPayable | SinopharmGroup | 3,360,257.39 | 15,665,754.04 |
NotesPayable | SinopharmHoldingHunanCo.,Ltd. | 3,296,556.25 | 769,724.44 |
NotesPayable | FoshanWinteamPharmaceuticalGroupLtd. | 2,988,970.44 | 1,047,709.72 |
NotesPayable | MainLuckPharmaceutical | 2,505,357.14 | 1,274,104.80 |
NotesPayable | SinopharmHoldingHuaideju(Xiamen)PharmacyCo.,Ltd. | 2,400,044.48 | 4,755,780.00 |
NotesPayable | ChinaOtsukaPharmaceuticalCo.,Ltd. | 1,571,497.60 | 2,321,674.00 |
NotesPayable | SinopharmHoldingHulunBuirCo.,Ltd. | 1,278,836.38 | - |
NotesPayable | SinopharmHoldingNingxiaCo.,Ltd. | 1,268,500.30 | 2,139,620.00 |
NotesPayable | SinopharmJiankun(Beijing)MedicineCo.,Ltd. | 1,213,920.00 | 1,911,680.00 |
NotesPayable | SinopharmHoldingDalianCo.,Ltd. | 1,180,305.76 | 1,269,329.00 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
NotesPayable | SinopharmHoldingJinanCo.,Ltd. | 1,107,000.00 | 650,000.00 |
NotesPayable | SinopharmHoldingHeilongjiangCo.,Ltd. | 1,031,283.29 | - |
NotesPayable | SinopharmHoldingLerentangHebeiPharmaceuticalCo.,Ltd. | 913,177.02 | 1,777,689.35 |
NotesPayable | SinopharmFengliaoxing(Foshan)PharmaceuticalDrugsCo.,Ltd. | 865,606.40 | 715,196.92 |
NotesPayable | ShanghaiShyndecPharmaceuticalMarketingCo.,Ltd. | 743,698.80 | 267,514.80 |
NotesPayable | FosunPharmaceuticalDistributionJiangsuCo.,Ltd. | 740,537.68 | 754,075.83 |
NotesPayable | JinzhouAvancMedicineCo.,Ltd. | 609,930.00 | 655,110.00 |
NotesPayable | SinopharmHoldingYanchengCo.,Ltd. | 563,801.29 | 967,264.56 |
NotesPayable | ShenzhenWanweiMedicineTradingCo.,Ltd. | 521,432.00 | 597,769.76 |
NotesPayable | SinopharmZhijun | 471,834.29 | 636,206.80 |
NotesPayable | TaijiGroupChongqingLinglingPharmaceuticalFactoryCo.,Ltd | 427,400.50 | - |
NotesPayable | ShanghaiTransfusionTechnologyCo.,Ltd. | 402,400.00 | 251,500.00 |
NotesPayable | SinopharmZhonglianPharmaceuticalGroupCo.,Ltd. | 330,347.20 | 116,747.00 |
NotesPayable | SinopharmWuhanBloodProductsCo.,Ltd. | 281,200.00 | 420,000.00 |
NotesPayable | WuhanZhongshengJinBiopharmaceuticalCo.,Ltd | 265,512.00 | - |
NotesPayable | SinopharmHoldingBayannurCo.,Ltd. | 221,930.30 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
NotesPayable | SinopharmHoldingQuanzhouCo.,Ltd. | 212,549.38 | 1,347,279.74 |
NotesPayable | SinopharmHoldingAnshanCo.,Ltd. | 199,777.75 | 63,415.75 |
NotesPayable | SinopharmGroupRongshengPharmaceuticalCo.,Ltd. | 112,420.00 | 278,588.10 |
NotesPayable | SinopharmHoldingNanpingNewPowerCo.,Ltd | 97,439.62 | 100,557.27 |
NotesPayable | SinopharmWuhanZhonglianSiyaoPharmaceuticalCo.,Ltd. | 50,000.00 | - |
NotesPayable | SinopharmHoldingChangshaCo.,Ltd. | 46,237.84 | 29,765.60 |
NotesPayable | SinopharmYixinPharmaceuticalCo.,Ltd. | - | 14,416,290.57 |
NotesPayable | SinopharmLerentangShijiazhuangMedicineCo.,Ltd. | - | 2,946,186.04 |
NotesPayable | SinopharmHoldingTianjinCo.,Ltd. | - | 2,365,453.12 |
NotesPayable | ChinaMedicalDevicesCo.,Ltd | - | 1,743,360.00 |
NotesPayable | SinopharmGroupShanxiMedicalDevicesCo.,Ltd. | - | 1,431,000.00 |
NotesPayable | SinopharmHoldingJinzhouCo.,Ltd. | - | 1,222,139.83 |
NotesPayable | SinopharmHoldingLinfenNinglePharmaceuticalCo.,Ltd. | - | 564,116.00 |
NotesPayable | SinopharmHoldingShanxiDajiuzhouMedicineCo.,Ltd. | - | 537,224.53 |
NotesPayable | SinopharmHoldingShanxiJinzhongCo.,Ltd. | - | 102,211.00 |
NotesPayable | FujianChentianJinlingPharmaceuticalCo.,Ltd. | - | 71,204.00 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
OtherPayable | SinopharmGroup | 5,313,664.01 | 4,146,496.53 |
OtherPayable | NationalPharmaceuticalGroupPharmaceuticalLogisticsCo.,Ltd | 4,715,402.44 | 2,825,718.21 |
OtherPayable | ZhenfangZhang | 4,322,499.97 | 3,919,999.95 |
OtherPayable | ChinaPharmaceuticalGroupShanghaiCo.,Ltd | 1,660,431.38 | 3,619,450.06 |
OtherPayable | ChinaTraditionalChineseMedicineCo.,Ltd | 1,300,000.00 | 1,300,000.00 |
OtherPayable | SinopharmHoldingZhihuiminsheng(Tianjin)PharmaceuticalCo.,Ltd. | 518,400.00 | 165,906.00 |
OtherPayable | NationalPharmaceuticalHealthOnlineCo.,Ltd | 414,492.64 | 185,980.18 |
OtherPayable | ShanghaiNorthWingGuodaPharmaceuticalCo.,Ltd | 286,498.20 | 364,905.28 |
OtherPayable | SinopharmHoldings(TianjinBinhai)PharmaceuticalCo.,Ltd | 241,760.00 | - |
OtherPayable | ShanghaiTongyuInformationTechnologyCo.,Ltd | 180,338.49 | 249,892.49 |
OtherPayable | SinopharmholdingHunanWei'anpharmacychainCo.,Ltd | 104,625.76 | 104,626.65 |
OtherPayable | SinopharmHoldingsBeijingHuahongco.,Ltd. | 104,156.84 | - |
OtherPayable | SinopharmHoldingSubMarketingCenterCo.,Ltd. | 37,817.38 | 37,871.38 |
OtherPayable | ZhijunPingshan | 25,458.72 | - |
OtherPayable | FoshanWinteamPharmaceuticalGroupLtd. | 7,280.00 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
OtherPayable | SinopharmGroupChemicalReagentCo.,Ltd | 6,980.00 | - |
OtherPayable | JiangsuWanbangPharmacyMarketingCo.,Ltd. | 2,800.00 | - |
OtherPayable | FreseniusKabiHuaruiPharmaceuticalsCo.,Ltd. | 6.28 | 6.28 |
OtherPayable | PingdingshanPushengPharmaceuticalCo.,Ltd | - | 515,857.96 |
OtherPayable | SinopharmHoldingYangzhouCo.,Ltd. | - | 372,571.40 |
OtherPayable | FujianChentianJinlingPharmaceuticalCo.,Ltd. | - | 50,000.00 |
OtherPayable | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 22,401.28 | |
OtherPayable | HaiyanZhang | - | 1,422.03 |
OtherPayable | ChengduInstituteofBiologicalProductsCo.,Ltd. | - | 327.60 |
OtherPayable | SinopharmGuangdongGlobalPharmaceuticalCo.,Ltd. | - | 126.63 |
OtherPayable | ShenzhenWanweiMedicineTradingCo.,Ltd. | - | 123.46 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
Contractliability | SinopharmlerentangQinhuangdaoPharmaceuticalCo.,Ltd | 72,666.90 | 97,625.80 |
Contractliability | SinopharmHoldingShenyangCo.,Ltd. | 64,281.72 | 64,395.72 |
Contractliability | SinopharmHoldingYunnanCo.,Ltd. | 64,039.40 | 186,666.45 |
Contractliability | SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 50,924.30 | - |
Contractliability | SinopharmHoldingQianxinanCo.,Ltd | 30,905.31 | - |
Contractliability | SinopharmHoldingWuhuCo.,Ltd | 30,384.00 | 30,384.00 |
Contractliability | SinopharmlerentangCangzhouPharmaceuticalCo.,Ltd | 25,691.00 | 25,691.00 |
Contractliability | SinopharmHoldingHulunBuirCo.,Ltd. | 21,177.25 | 21,177.25 |
Contractliability | SinopharmHoldingGansuCo.,Ltd | 21,960.00 | 21,960.00 |
Contractliability | SinopharmGroupGuizhou(Zunyi)MedicalInstrumentCo.,Ltd | 5,743.36 | - |
Contractliability | SinopharmlerentangShijiazhuangmedicalmanagementCo.,Ltd | 5,134.40 | - |
Contractliability | SinopharmHoldingGuizhoumedicaldeviceCo.,Ltd | 2,929.38 | 1,140.71 |
Contractliability | SinopharmlerentangTangshanPharmaceuticalCo.,Ltd | 1,734.36 | - |
Contractliability | JiangmenXinhuiJianfengPharmaceuticalCo.,Ltd | 1,368.00 | - |
Contractliability | SinopharmHoldingChongqingCo.,Ltd | 755.62 | 3,523.35 |
Contractliability | SinopharmInstrumentGuizhouQiannanCo.,Ltd | 524.51 | - |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
6.Amountsduefrom/torelatedparties(Continued)
(2).AccountsPayable(Continued)
Item | RelatedParty | 30June2021 | 31December2020 |
Contractliability | SinopharmHoldingTongrenCo.,Ltd | 438.00 | - |
Contractliability | SinopharmHoldingInnerMongoliaCo.,Ltd. | 83.60 | 83.60 |
Contractliability | Sinopharmholding(Shandong)medicaldeviceCo.,Ltd | 64.00 | - |
Contractliability | SinopharmHoldingHuai'anCo.,Ltd | 19.40 | 19.40 |
Contractliability | SinopharmHoldingNantongCo.,Ltd | - | 1,074,470.38 |
Contractliability | Qiandainternationaltrade(Shanghai)Co.,Ltd | - | 783,640.00 |
Contractliability | SinopharmHoldingAnhuiCo.,Ltd. | - | 154,870.80 |
Contractliability | SinopharmHoldingNanjingWendePharmaceuticalCo.,Ltd. | - | 98,901.00 |
Contractliability | SinopharmLerentangMedicineCo.,Ltd. | - | 40,366.72 |
Contractliability | SinopharmHoldingJilinCo.,Ltd. | - | 23,017.49 |
Contractliability | SinopharmHoldingShaanxiCo.,Ltd | - | 14,791.76 |
Contractliability | SinopharmlerentangChengdePharmaceuticalCo.,Ltd | - | 10,976.96 |
Contractliability | SinopharmlerentangHengshuiPharmaceuticalCo.,Ltd | - | 10,276.41 |
Contractliability | SinopharmHoldingTaizhouCo.,Ltd. | - | 6,593.40 |
Contractliability | DongyuanAccord | - | 855.00 |
Contractliability | SinopharmHoldingJiangxiCo.,Ltd. | - | 190.98 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
7.CommitmentsofRelatedPartyLeasecommitmentRent-out
RelatedParty | 30June2021 | 31December2020 |
BeijingGoldenElephantFosunPharmaceuticalCo.,Ltd. | 199,999.99 | 266,666.66 |
SinopharmHoldingHunanWeianPharmacyMedicineChainCompanyLimited | 85,085.99 | 187,187.99 |
Rent-in
RelatedParty | 30June2021 | 31December2020 |
SinopharmHoldingYangzhouCo.,Ltd. | 16,794,214.38 | 19,560,000.00 |
ZhangYechuan | 8,910,988.61 | 5,777,181.67 |
SinopharmGroupMedicineLogisticCo.,Ltd. | 7,290,000.00 | - |
ShaoguanWujiangDistrictMuyangMedicineInformationConsultantCo.,Ltd. | 7,208,388.45 | 7,717,215.87 |
ShenyangPharmaceuticalCo.,Ltd. | 7,142,857.14 | 2,976,190.55 |
SinopharmGroup | 6,631,429.92 | - |
LerentangInvestmentGroupCo.,Ltd. | 5,617,201.82 | 10,178,669.70 |
SinopharmGroupXinjiangSpecialDrugsNationalPharmaceuticalCo.,Ltd. | 2,748,595.47 | - |
GuangxiYifangTianjiangPharmaceuticalCo.,Ltd. | 2,723,965.98 | 3,974,949.26 |
Xiongxinyuan | 2,582,102.83 | - |
GuangdongJiyuantangDevelopmentCo.,Ltd. | 1,990,209.48 | 3,180,113.86 |
LiFang | 1,906,800.00 | 2,179,200.00 |
SinopharmHoldingBeijingCo.,Ltd. | 1,557,142.84 | 123,809.52 |
ShenyangShengdiouTradingCo.,Ltd. | 1,499,269.22 | - |
BeijingSinopharmTianyuanRealEstate&PropertyManagementCo.,Ltd. | 1,385,714.26 | 1,628,571.40 |
SinopharmHoldingShanxiJinchengCo.,Ltd | 1,200,000.00 | - |
WangYang | 936,917.10 | - |
ZhangZhenfang | 805,000.00 | 805,000.00 |
NanjingYuanguangTradingCo.,Ltd. | 750,000.00 | 571,488.75 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
7.CommitmentsofRelatedParty(Continued)Leasecommitment(Continued)Rent-in(Continued)
RelatedParty | 30June2021 | 31December2020 |
TaishanXiangranhuiTradeCo.,Ltd. | 479,468.57 | 843,949.00 |
ZhangHaiyan | 451,530.48 | 537,244.90 |
SinopharmHolding(China)FinancingLeaseCo.,Ltd. | 415,363.22 | 870,588.42 |
SinopharmXinjiangPharmaceuticalCo.,Ltd. | 388,571.43 | 777,142.86 |
GuJinhua | 344,190.00 | 378,609.00 |
GuHaiqun | 342,774.31 | 446,873.35 |
ZhijunPingshan | 313,990.88 | 364,908.32 |
ZhangGuitang | 240,285.59 | - |
SinopharmHoldingXinjiangSpecialDrugsKashgarPharmaceuticalCo.,Ltd. | 216,191.74 | - |
SinopharmHoldingXinjiangXinteKaramayPharmaceuticalCo.,Ltd. | 215,968.52 | - |
ShanghaiBaizhongBusinessDevelopment(Group)Co.,Ltd. | 151,568.54 | - |
Southeast(Quanzhou)BiotechnologyPharmaceuticalCo.,Ltd. | 118,025.28 | - |
BeijingHuafangInvestmentCo.,Ltd. | 91,428.57 | 345,908.56 |
HunanMinshengtangInvestmentCo.,Ltd. | - | 1,097,581.46 |
ShenzhenJiufengInvestmentCo.,Ltd. | - | 166,666.67 |
Pu'erSongmaoMedicineGroupCo.,Ltd. | - | 37,335.24 |
TaishanQunkangPharmacyCo.,Ltd. | - | 11,258.41 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
8.Others
RelatedParty | 30June2021 | 31December2020 |
Short-termBorrowing | ||
SinopharmGroupFinanceCo.,Ltd. | 581,796,571.46 | 14,338,732.53 |
Entrustedloan | ||
CNPGC(1) | 31,633,794.44 | 31,637,173.89 |
JilinProvinceYiheInvestmentConsultingCo.,Ltd.(2) | 75,450,000.00 | 56,700,000.00 |
(1)CNPGCentrustedSinopharmGroupFinanceCo.,Ltd.withthisborrowingtotheGroup.TheentrustedborrowingincludestheprincipalofRMB31,600.00thousandandtheoutstandinginterestreceivableofRMB33.79thousand. |
(2)TheloanisabankloanentrustedbyJilinYiheInvestmentConsultingCo.,Ltd.tothegroup. |
Othernon-currentliabilities | ||
SinopharmGroupCo.,Ltd. | 35,061,743.31 | 35,061,743.31 |
Cashdepositewithinarelatedparty | ||
SinopharmGroupFinanceCo.,Ltd. | 1,636,830.68 | 101,779,861.57 |
Forthesixmonthsended30June2021,theannualinterestratesoftheabovedepositsare0.35%to1.15%.(Inyear2020,theannualinterestratesoftheabovedepositsare0.35%to1.89%.) |
Leaseliability | ||
SinopharmHoldingYangzhouCo.,Ltd. | 15,391,588.00 | |
ShaoguanWujiangDistrictMuyangMedicineInformationConsultantCo.,Ltd. | 6,252,122.18 | 6,628,838.10 |
LerentangInvestmentGroupCo.,Ltd. | 5,489,599.52 | 6,112,542.74 |
ZhangYechuan | 4,527,961.17 | 5,201,907.68 |
GuangxiYifangTianjiangPharmaceuticalCo.,Ltd. | 3,243,616.53 | 3,434,525.25 |
XiongXinyuan | 2,582,102.83 | 2,873,340.76 |
GuangdongJiyuantangDevelopmentCo.,Ltd. | 1,743,569.88 | 3,085,854.50 |
ShenyangShengdiouTradingCo.,Ltd. | 1,499,269.22 | 1,468,641.78 |
SinopharmHoldingBeijingCo.,Ltd. | 1,494,302.29 | 130,936.97 |
BeijingSinopharmTianyuanRealEstate&PropertyManagementCo.,Ltd. | 1,313,142.67 | |
LiFang | 1,293,405.86 | |
WangYang | 936,917.10 | |
SinopharmHoldingShanxiJinchengCo.,Ltd. | 587,475.03 | |
ZhangHaiyan | 427,589.17 | 503,526.40 |
SinopharmXinjiangPharmaceuticalCo.,Ltd. | 387,110.55 | 378,950.29 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
X.Relatedpartyrelationshipsandtransactions(Continued)
8.Others(Continued)
RelatedParty | 30June2021 | 31December2020 |
Leaseliability(Continued) | ||
GuHaiqun | 331,772.12 | 427,942.87 |
ZhijunPingshan | 294,545.87 | 338,800.77 |
ZhangGuitang | 228,947.93 | |
BeijingHuafangInvestmentCo.,Ltd. | 216,830.68 | 336,640.65 |
ShanghaiBaizhongBusinessDevelopment(Group)Co.,Ltd. | 151,568.54 | 300,058.00 |
Southeast(Quanzhou)BiotechnologyPharmaceuticalCo.,Ltd. | 116,951.13 | |
SinopharmHolding(China)FinancingLeaseCo.,Ltd. | 91,512.93 | 388,839.95 |
SinopharmGroup | 172,342.31 | |
Pu'erSongmaoMedicineGroupCo.,Ltd. | 37,330.98 | |
Total | 48,601,901.20 | 31,821,020.00 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XICommitmentsandcontingencies
1.Commitments
(1) | Capitalcommitments |
Capitalexpenditurescontractedforatthebalancesheetdatebutnotrecognizedinbalancesheetareanalyzedasfollows:
30June2021
30June2021 | 31December2020 |
RMB‘0,000 | RMB‘0,000 |
Buildings,machineryandequipment | 42.16 | 42.16 |
2.Contingencies
Asofthebalancesheetdate,therewerenocontingenciesthattheGroupwasrequiredtodisclose.
XIIOthersignificantevents
1.SegmentreportingOperatingsegments
Formanagementpurposes,theGroupisorganizedintobusinessunitsbasedonitsproductsandservicesandhasthreereportableoperatingsegmentsasfollows:
(1)TheHeadOffice,whichismainlyengagedintheinvestmentandmanagementofbusinesses;
(2)Pharmaceuticaldistributionsegment,whichismainlyengagedinthedistributionofmedicineandpharmaceuticalproductstocustomers;
(3)Retailpharmacysegment,whichisthemanagementoftheoperationofGuodaPharmacy.ManagementmonitorstheresultsoftheGroup’soperatingsegmentsseparatelyforthepurposeofmakingdecisionsaboutresourceallocationandperformanceassessment.Segmentperformanceisevaluatedbasedonreportablesegmentprofit,whichismeasuredconsistentlywiththeGroup’sprofitbeforetax.Inter-segmentsalesandtransfersaretransactedwithreferencetothesellingpricesusedinthetransactionscarriedoutwiththirdpartiesatthethenprevailingmarketprices.
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIOthersignificantevents(Continued)
1.Segmentreporting(Continued)
Operatingsegments(Continued)
Operatingsegmentinformationasatandforthesemiyearended
HeadOffice | Pharmaceuticaldistribution | Pharmaceuticalretail | Eliminationbetweensegments | Total |
Principaloperationsincome | - | 22,714,878,520.83 | 10,625,590,134.69 | (499,204,175.96) | 32,841,264,479.56 |
Principalcostofsales | - | (21,415,481,154.82) | (8,237,771,652.36) | 497,003,293.22 | (29,156,249,513.96) |
Incomefrominvestmentsinassociates | 157,696,473.52 | (749,864.47) | 749,788.76 | - | 157,696,397.81 |
Netprofit | 804,194,136.76 | 462,450,144.61 | 263,262,365.37 | (621,912,192.25) | 907,994,454.49 |
Totalassets | 14,935,672,415.11 | 25,483,335,796.44 | 16,344,255,324.13 | (12,572,385,131.73) | 44,190,878,403.95 |
Totalliabilities | (3,580,219,319.14) | (19,600,657,390.32) | (10,497,431,348.24) | 6,975,557,587.13 | (26,702,750,470.57) |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements
1.Accountsreceivable
Theaccountsreceivablebycategoryareanalyzedbelow:
30June2021
30June2021 | 31December2020 | |||||||||||
Grosscarryingamount | Provisionforbaddebt | Bookvalue | Grosscarryingamount | Provisionforbaddebt | Bookvalue | |||||||
Amount | Proportion | Amount | Proportion | Amount | Proportion | Amount | Proportion |
Itemsforwhichprovisionforbaddebtisrecognisedseparately | 25,150,432.16 | 3.58% | (334,294.70) | 1.33% | 24,816,137.46 | 18,549,524.82 | 3.04% | (334,294.70) | 1.80% | 18,215,230.12 | |||
Itemsforwhichprovisionforbaddebtisrecognizedbygroup(creditriskcharacteristics) | 676,458,655.12 | 96.42% | (1,664.00) | - | 676,456,991.12 | 591,360,071.01 | 96.96% | - | - | 591,360,071.01 |
701,609,087.28 | 100.00% | (335,958.70) | 0.05% | 701,273,128.58 | 609,909,595.83 | 100.00% | (334,294.70) | 0.05% | 609,575,301.13 |
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
1.Accountsreceivable(Continued)
At30June2021,accountsreceivablethatareindividuallyassessedforprovisionsareasfollows:
Debtor’sname
Debtor’sname | Carryingamount | Baddebtprovision | Rate | Assessmentforimpairment |
ReceivablesfromsubsidiariesoftheGroup | 24,816,137.46 | - | - | Internalrelatedparties,withlower-tierrecoveryrisk |
ClientA | 323,044.50 | (323,044.50) | 100.00% | Debtorhadmismanagement,subjecttoseriousfinancialdifficulties,andtheexpectedrecoverabilityisverylow |
ClientB | 11,250.20 | (11,250.20) | 100.00% | Debtorhadmismanagement,subjecttoseriousfinancialdifficulties,andtheexpectedrecoverabilityisverylow |
25,150,432.16 | (334,294.70) |
Provisionforbaddebtsofaccountsreceivableaccordingtothegeneralmodelofexpectedcreditloss:
30June2021
30June2021 | |||||
Estimateddefaultamount | Expectedcreditlossinentirelifetime | Expectedcreditlossrate | |||
Within1year | 676,425,237.12 | - | - | ||
1to2years | 33,418.00 | (1,664.00) | 4.98% |
676,458,655.12 | (1,664.00) | - |
TheaccountsreceivableforwhichtheCompanyrecognisedprovisionforbaddebtsusingtheaginganalysismethodarepresentedasfollows:
30June2021
30June2021Within1year
Within1year | 701,241,374.58 | ||||
1to2years | 33,418.00 | ||||
2to3years | - | - | 334,294.70 |
- | 701,609,087.28 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
1.Accountsreceivable(Continued)
Baddebtprovisionforthecurrentperiodasfollows:
Openingbalance | Increasesduringtheperiod | Reversalduringtheperiod | Write-offduringtheperiod | Other | Closingbalance |
Baddebtprovision | 334,294.70 | 1,664.00 | - | - | - | 335,958.70 |
Asat30June2021,thetopfiveaccountsreceivablebycustomerareasfollows:
Amount
Amount | %ofthetotalaccountsreceivable | Baddebtprovisionamount |
Top1Accountreceivable | 75,221,487.68 | 10.72% | - | |
Top2Accountreceivable | 40,139,214.96 | 5.72% | - | |
Top3Accountreceivable | 39,234,570.32 | 5.59% | - | |
Top4Accountreceivable | 24,895,974.53 | 3.55% | - | |
Top5Accountreceivable | 24,378,296.97 | 3.47% | - |
203,869,544.46 | 29.05% | - |
Accountsreceivablederecognisedduetotransferoffinancialassetswasasfollows:
FromJanuarytoJune2021,theCompanyfactoredasmallportionofaccountsreceivableatamortisedcosttofinancialinstitutions.TheamountofaccountsreceivablederecognisedwasRMB26,097,254.38(fromJanuarytoJune2020:
RMB156,689,648.43),andtheamountoflossrecognisedthroughInvestmentincomewasRMB221,815.32(fromJanuarytoJune2020:RMB1,526,968.25).
Notestofinancialstatements(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
2.Otherreceivables
30June2021 | 31December2020 |
Otherreceivables | 3,467,427,719.16 | 3,562,309,346.07 |
Categoryofotherreceivablesbynatureisasfollows:
Nature
Nature | 30June2021 | 31December2020 |
Amountsduefromsubsidiaries | 3,442,240,233.02 | 3,539,822,609.73 |
Receivableofequitytransactions | 8,980,000.00 | 8,980,000.00 |
Deposit | 331,867.02 | 343,834.42 |
Others | 71,367,604.27 | 68,533,518.66 |
3,522,919,704.31 | 3,617,679,962.81 |
Changesinbaddebtprovisionforthe12-monthexpectedcreditlossesandlifetimeexpectedcreditlossesonotherreceivablesareasfollows:
Stage1 | Stage2 | Stage3 | ||
Baddebt | Expectedcreditlossesoverthenext12months | Entirelifetimeexpectedcreditlosses(Nocreditimpairmentoccurred) | Entirelifetimeexpectedcreditlosses(Creditimpairmentoccurred) | Total |
Balanceat1January2021 | - | 56,394.50 | 55,314,222.24 | 55,370,616.74 |
Balanceat1January2021duringtheperiod | ||||
Provisionsduringtheperiod | - | 4,709.88 | 127,901.60 | 132,611.48 |
Reversalduringtheperiod | - | (11,243.07) | - | (11,243.07) |
Balanceat30June2021 | - | 49,861.31 | 55,442,123.84 | 55,491,985.15 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
2.Otherreceivables(Continued)
Theaginganalysisofotherreceivableswasasfollows:
30June2021Within1year
Within1year | 3,465,946,636.42 |
1to2years | 2,490,521.42 |
2to3years | 436,281.36 |
Over3years | 54,046,265.11 |
Total | 3,522,919,704.31 |
Baddebtprovisionforthecurrentperiodasfollows:
Openingbalance | Increasesduringtheperied | Reversalduringtheperiod | Write-offduringtheperiod | Other | Closingbalance |
Baddebtprovision | 55,370,616.74 | 132,611.48 | (11,243.07) | - | - | 55,491,985.15 |
Asat30June2021,theaccumulatedtopfiveotherreceivablesareanalysedbelow:
Nature
Nature | Amount | Age | %oftotalamount | Baddebtprovision |
SinopharmGuangzhou | Entrustedborrowings | 950,965,833.42 | Within1year | 26.99% | - |
SinopharmGuangxi | Entrustedborrowings | 566,090,705.45 | Within1year | 16.07% | - |
SouthPharma&Trade | Entrustedborrowings | 200,193,333.25 | Within1year | 5.68% | - |
SinopharmGuangdongYuexing | Entrustedborrowings | 173,834,848.77 | Within1year | 4.93% | - |
SinopharmDongguan | Entrustedborrowings | 161,153,558.44 | Within1year | 4.57% | - |
2,052,238,279.33 | 58.24% | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
3.Long-termequityinvestments
30June2021 | 31December2020 | ||||
Originalvalue | Baddebtprovision | Carryingamount | Originalvalue | Baddebtprovision | Carryingamount |
Investmentsinsubsidiaries | 5,614,677,427.58 | - | 5,614,677,427.58 | 5,614,677,427.58 | - | 5,614,677,427.58 |
Investmentsinassociates | 2,439,507,057.51 | 39,930,000.00 | 2,399,577,057.51 | 2,298,920,817.58 | 39,930,000.00 | 2,258,990,817.58 |
8,054,184,485.09 | 39,930,000.00 | 8,014,254,485.09 | 7,913,598,245.16 | 39,930,000.00 | 7,873,668,245.16 |
(1) | Subsidiaries |
31December2020 | Increases | Decrease | 30June2021 | Amountofprovisionforimpairment |
SinopharmShenzhenJianmin | 60,054,911.04 | - | - | 60,054,911.04 | - | ||||
SinopharmShenzhenMaterial | 15,450,875.93 | - | - | 15,450,875.93 | - | ||||
SinopharmShenzhenLogistics | 5,019,062.68 | - | - | 5,019,062.68 | - | ||||
SinopharmGuangzhou | 3,588,689,716.80 | - | - | 3,588,689,716.80 | - | ||||
SinopharmGuangxi | 525,456,951.07 | - | - | 525,456,951.07 | - | ||||
SinopharmYanfeng | 38,207,800.00 | - | - | 38,207,800.00 | - | ||||
GuodaPharmacy | 1,361,800,110.06 | - | - | 1,361,800,110.06 | - | ||||
AccordDevices | 19,998,000.00 | - | - | 19,998,000.00 | - | ||||
- | - | ||||||||
5,614,677,427.58 | - | - | 5,614,677,427.58 | - |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
3.Long-termequityinvestments(Continued)
(2) | Associates | ||||||||
Changesintheperiod | |||||||||
Openingbalance | Profitorlossundertheequitymethod | Adjustmentinothercomprehensiveincome | Otherchangesinequity | Cashdividendorprofitsdeclared | Closingbalance | Provisionofimpairment | |||
MainLuckPharmaceutical | 322,696,745.87 | 34,596,706.61 | - | - | - | 357,293,452.48 | - | ||
ZhijunSuzhou | - | - | - | - | - | - | 39,930,000.00 | ||
SinopharmZhijun | 425,557,825.11 | 28,056,303.69 | - | - | - | 453,614,128.80 | - | ||
ZhijunTrade | 10,408,675.18 | 64,801.68 | - | - | - | 10,473,476.86 | - | ||
ZhijunPingshan | 176,566,795.90 | 25,603,869.60 | - | - | - | 202,170,665.50 | - | ||
SinopharmShyndec | 1,323,760,775.52 | 69,374,791.94 | 64,854.90 | (460,868.29) | (16,714,220.20) | 1,376,025,333.87 | - |
2,258,990,817.58 | 157,696,473.52 | 64,854.90 | (460,868.29) | (16,714,220.20) | 2,399,577,057.51 | 39,930,000.00 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
4.Operatingrevenueandcost
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 | |||
Revenue | Cost | Revenue | Cost | |
Principaloperations | 2,062,334,204.15 | 1,982,274,379.60 | 1,750,454,957.66 | 1,679,162,910.91 |
Otheroperations | 16,035,919.21 | 9,145,932.20 | 22,032,405.90 | 10,401,151.33 |
2,078,370,123.36 | 1,991,420,311.80 | 1,772,487,363.56 | 1,689,564,062.24 |
Classification | Forthesixmonthsended30June2021 |
Byproduct | |
Include: | |
Pharmaceuticals | 1,971,490,771.22 |
Medicaldevicesanddisposables | 86,143,203.37 |
Diagnosticreagents | 4,700,229.56 |
Other | 11,402,530.41 |
Byarea | |
Include: | |
China | 2,073,736,734.56 |
Bymajoractivities | |
Include: | |
Pharmaceuticaldistribution | 2,062,334,204.15 |
Others | 11,402,530.41 |
Bycontractduration | |
Include: | |
Atapointintime | 2,062,334,204.15 |
Overtime | 11,402,530.41 |
Notestofinancialstatements(Continued)
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIIINotestokeyitemsofthecompanyfinancialstatements(Continued)
4.Operatingrevenueandcost(Continued)
InformationabouttheCompany’sobligationsisasfollows:
(1)Revenueisrecognisedwhencontrolofthegoodshastransferredandpaymentisgenerallyduewithin30to210daysfromdelivery; |
(2)Revenueisrecognisedintheservicedurationandthepaymentisgenerallyduewithin30to210dayssincetheserviceiscompleted. |
Informationrelatedtothesalespriceallocatedtotheremainingobligations:
TheamountofincomecorrespondingtotheobligationthathasbeensignedbuthasnotbeenfulfilledorhasnotyetfulfilledisRMB8,566,647.98,whichisexpectedtoberecognizedwithin1year.
Revenueisasfollows:
30June2021
30June2021 | 30June2020 |
Revenuefromcontractswithcustomers | 2,073,736,734.56 | 1,768,294,423.43 | |
Rentals | 4,633,388.80 | 4,192,940.13 |
2,078,370,123.36 | 1,772,487,363.56 |
5.Investmentincome
Forthesixmonthsended30June2021 | Forthesixmonthsended30June2020 |
Gainonlong-termequityinvestmentsunderthecostmethod | 619,290,387.90 | 612,502,685.91 | |
Gainonlong-termequityinvestmentsundertheequitymethod | 157,696,473.52 | 133,549,495.38 | |
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcostmeasuredatamortisedcost | (221,815.32) | (1,526,968.25) | |
?Dividendsfromotherfinancialassets | 3,599,555.61 | 4,109,881.90 | |
?Others | - | 998,665.84 |
780,364,601.71 | 749,633,760.78 |
Supplementaryinformationtofinancialstatements
Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIVSupplementaryinformationtofinancialstatements
1.Scheduleofnon-recurringprofitorloss
Amountfor30June2021 | Illustration |
Gainsandlossesfromdisposalofnon-currentassets | (802,029.11) | Mainlyprobabilityofgainandlossesfromtheendoflease |
Governmentgrantsrecognizedinincomestatementforthecurrentyear,exceptforthosecloselyrelatedtotheordinaryoperationoftheCompanywhichtheGroupenjoyedconstantlyaccordingtotheallotmentstandardsorquantitativecriteriaofthecountry | 35,363,341.68 | MainlyprobabilityofexemptionandothergovernmentgrantsforspecialpurposeandfinanceDiscount |
Theinvestmentcostofanenterprisetoacquireasubsidiary,anassociateandajointventure,whichislessthanprofitsderivedfromthefairvalueoftheidentifiablenetassetsoftheinvestedunitwheninvesting | 578,610.41 | |
Reversalofbaddebtprovisionforaccountsreceivableandcontractassetsthatweretestedforimpairmentindividually | 88,994.76 | |
Non-operatingincomeandexpensesotherthantheaforesaiditems | 7,540,783.96 | Mainlyprobabilityofthenonoperatingincomegeneratedfromthewriteoffoffundsthatdonotneedtobepaidinthecurrentperiod |
Other | 1,717,435.90 | |
Less:Impactofincometax | 12,962,326.01 | |
Impactofnon-controllinginterestsaftertax | 11,034,206.56 |
20,490,605.03Basisforpreparationofdetailedlistofnon-recurringprofitorlossitems:
TheGroup'srecognitionofnon-recurringprofitorlossitemsisinaccordancewiththeprovisionsofExplanatoryannouncementNo.1oninformationdisclosurebycompaniesofferingsecuritiestothepublic-non-recurringprofitorloss.
Appendix(Continued)Forthesixmonthsended30June2021(AllamountsinRenminbi“RMB”unlessotherwisestated)
XIVSupplementaryinformationtofinancialstatements(Continued)
2.Returnonequity(“ROE”)andearningspershare(“EPS”)
WeightedaverageROE(%) | BasicEPS(RMB/Share) | |
BasicEPS(RMB/Share) | DilutedEPS(RMB/Share) |
Netprofitattributabletoordinaryshareholdersoftheparent | 5.22% | 1.73 | 1.73 |
Netprofitafterdeductingnon-recurringprofitorlossattributabletotheCompany’sordinaryshareholdersoftheparent | 5.08% | 1.68 | 1.68 |